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Upon responding to cellular stress, p53 protein becomes stabilised and acts 
as a transcription factor mainly resulting from phosphorylation and 
acetylation of the protein. Nitration of p53 protein is poorly characterised by 
comparison with phosphorylation and acetylation. The main aim of this work 
was to study the effects of nitration on p53 functional activities and on p53-
MDM2 protein-protein interactions. Preliminary work was to characterise the 
nitration of p53 protein over-expressed in E. coli BL21(DE3) which was then 
purified by a series of column chromatography. GST-MDM2 protein along 
with control GST protein were also overexpressed in BL21 which were 
subsequently purified by a single step batch purification before subjected to 
nitration. Peroxynitrite, a nitrating agent used in this study, was generated in 
vitro. Preliminary nitration work was carried out using BSA as a model 
protein as it is easily nitrated owing to its high number of tyrosine residues 
(19 residues). The present results showed that p53 and GST-MDM2 proteins 
were hardly nitrated as no strong nitro-tyrosine signals were obtained. This 
might be due to these proteins, being overexpressed in E. coli, were not 
properly folded resulting in hidden/cryptic tyrosine residues of which making 
nitration difficult to achieve. Peroxynitrite was shown to have a degrading 
property, reducing protein levels of peroxynitrite-treated p53, GST-MDM2 
and GST proteins. Immunoprecipitation studies of cancer cell lysates with 
different p53 status treated with peroxynitrite showed very weak signals of 
nitro-p53 protein in mutant p53 cells whereby no nitro-p53 protein signal in 
wild-type p53 MCF7 cells. In addition, NO donor GSNO-treated MCF7 cells 
showed weak nitro-p53 protein signals. 
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CHAPTER 1 
INTRODUCTION 
 
Cancer is a genetic disease resulting from oncogene activation and/or 
inactivation of tumour suppressor genes. Furthermore, cancer is now 
appreciated to arise from epigenetic alterations that link environmental and 
dietary exposures and disease (Virani et al., 2012), however it is not the 
theme of this thesis. Changes in key genes, namely oncogenes and tumour 
suppressors, lead to the formation of cancer from a single progenitor cell. 
The most widely studied tumour suppressor gene in cancer is p53. p53’s 
main role as a transcription factor transcribing its target genes upon 
exposure to cellular stresses is important for its tumour suppressor activities. 
p53 acts as a cellular gatekeeper to safeguard the integrity of the genome by 
preventing the propagation of cells with mutated DNA mainly through cell 
cycle arrest and/or apoptosis. This also led p53 to be coined as the Guardian 
of the Genome by Lane (1992). p53 has several other newer activities mainly 
its role in cellular metabolism, anti-oxidant defence and autophagy. 
. 
In normal cells, p53 regulates cell growth by controlling cell 
proliferation and cell death. The p53 tumour suppressor protein exerts anti-
proliferative effects, including cell cycle arrest, repair of damaged DNA, and 
apoptosis in response to various types of cellular stress. These cellular 
functions of p53 protein are activated in response to cellular stress by 
enzymes that covalently modify p53 protein in direct response to DNA 
damage. Widely known post-translational modifications of p53 protein 
include phosphorylation, acetylation and ubiquitination and lesser 
characterised modifications include sumoylation, neddylation and 
methylation. It has emerged that p53 protein is also covalently modified by 
nitration (Calmels et al., 1997; Chazotte-Aubert et al., 2000). This thesis 
focuses on the nitration events of p53 protein and its impact on the p53 
tumour suppressive activities. 
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1.1  The p53 gene and its protein product 
The p53 gene was discovered over 30 years ago by the finding that its 
protein product p53 formed a complex with the large T-antigen in Simian 
Virus 40 (SV40) transformed cells (Lane & Crawford, 1979; Linzer & Levine, 
1979). The gene was first thought to behave as an oncogene as evidenced 
by its ability to increase the plating efficiency in primary cultures transfected 
with p53 cDNA  (Jenkin et al., 1984) and transfection of p53 in cooperation 
with the ras oncogene, could transform primary rat embryo fibroblasts 
(Eliyahu et al., 1984). However, it was later discovered that it is in fact a 
tumour suppressor gene, i.e., its activity stops the formation of tumours, as 
shown by Eliyahu et al. (1989) where the WT p53 protein has an anti-
proliferative effect by blocking the ability of oncogenes, such as H-ras, to 
promote cancer. Further evidence that supports p53 as a tumour suppressor 
protein is by a study by Chen et al. (1990) which found that the transfection 
of the wild-type p53 gene in human osteosarcoma cells lacking endogenous 
p53 stopped the neoplastic growth by reducing cell growth and division. 
cDNA clones of murine and human p53 were isolated in the early 1980’s 
(Zakut-Houri et al., 1985). The p53 gene is located on the short arm of 
Chromosome 17 (17p13.1) and spans 20 kb with 11 exons, the first of which 
is a non-coding exon (Oren et al., 1985). The gene encodes a protein of 393 
amino acids with an apparent molecular weight of 53 kDa, hence the name. 
In normal cells, the p53 protein is located in the cell nucleus and is very 
labile. The p53 protein is maintained at very low levels or almost 
undetectable under normal conditions of cells and tissues and it has an 
extremely short half-life of around 20 minutes (reviewed in Levine, 1997). It 
coordinates cellular response to DNA damage and is a multi-functional 
protein. The p53 protein is activated in response to a number of cellular 
stresses, including DNA damage, hypoxia, ionizing radiation, oncogene 
activation, metabolic changes, viral infection, etc. The activation of p53 
protein leads to the rapid elevation of p53 protein levels along with its 
increased half-life (Kastan et al., 1992; Lu and Lane, 1993; Zhan et al., 
1993), due in part to increased mRNA translation (Fu et al., 1996), but mainly 
due to stabilisation of the protein by a post-translational mechanism 
(Maltzman and Czyzyk, 1984) and this also increases the ability of p53 to 
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bind DNA and mediate transcriptional activation (Kastan et al., 1992). This 
then activates a number of genes whose products mainly trigger cell cycle 
arrest, or apoptosis. It is now known that p53 upregulates ~5000 genes and 
downregulates ~50 genes (Dr Picksley’s personal communication). Figure 
1.3 shows several p53 target genes. Cell cycle arrest and apoptosis are two 
discreet functions of p53 protein as a tumour suppressor, both in response to 
cellular stress (Kastan et al., 1991; Yonish-Rouach et al., 1991). When the 
extent of DNA damage is not severe, the p53 protein mediates cell cycle 
arrest during G1 to give cells time to repair their DNA before entry into S 
phase. Extensive, irrepairable DNA damage leads to programmed cell death, 
a process termed apoptosis. Activated p53 protein also mediates cellular 
senescence and differentiation depending on particular cellular conditions. 
 
The p53 gene is the most commonly mutated or lost gene in a wide 
range of human cancers (Hollstein et al., 1991). p53 mutation is normally a 
late event in carcinogenesis. More than half of all human cancers are found 
to have lesions in the p53 gene which include cancers of the breast, cervix, 
colon, lung, liver, prostate, bladder, and the skin (Greenblatt et al, 1994; 
IARC p53 mutation database). The mutations are typically somatic missense 
mutations that result in aberrant p53 proteins with lost suppressor function 
and that promote cancer (Figure 1.1). Inactivated or mutated p53 protein 
results in the failure to cause suppression of aberrant cell growth, and results 
in the accumulation of cells with aberrant DNA, in turn results in tumour 
growth. This leads to genetic instability. It is now acknowledged that genome 
instability and mutation is an enabling characteristic of cancer cells (Hanahan 
and Weinberg, 2011). There is extensive debate as to whether such events 
are the cause or consequence of tumoriogenesis (as reviewed by Sieber et 
al., 2003). 
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Figure 1.1. A diagram showing the distribution of mutations in the p53 
gene. The majority are missense mutations (70%) which are clustered in the 
DNA binding domain (80%) with mutation hotspots including R175, G245, 
R248, R249, R273 and R282. TA, transactivation domain; PR, proline rich 
domain; DBD, DNA binding domain; Tet, tetramerisation domain; Reg, C-
terminal regulatory domain; R, Arginine; G, Glycine (adapted from Brown et 
al., 2009). 
 
1.2  p53 Structure-Function 
The p53 has been conserved in vertebrate species during evolution 
(reviewed by Soussi et al., 1987, 1990). The human p53 protein contains five 
major functional domains which are typical structural domains of a 
transcription factor. These are the N-terminal transcription activation domains 
TAD1 (amino acids 1-40) and TAD2 (amino acids 41-83), a proline rich 
region (amino acids 63-97) containing five repeats of the SH3 binding motif 
PXXP, the central sequence-specific DNA binding domain (amino acids 102-
292) and the C-terminal region which includes both the oligomerisation or 
tetramerisation domain (amino acids 323-356) and the regulatory domain 
(amino acids 360-393). Figure 1.2 illustrates the structure of p53 protein with 
five main domains shown. 
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1.2.1  N-terminal region 
The N-terminal region of p53 protein is a highly acidic region. It contains two 
Transactivation domains TAD1 (Met1-Met40) and TAD2 (Asp41-Pro83), both 
have a role in p53 activation and function independently (Candau et al., 1997; 
Anderson and Apella, 2010).). TAD1 has highly conserved residues Met1-
Met40 and is mostly important for transactivation function. TAD1 binds with 
transcription factors TFIID, TFIIH, several TAFs, the coactivator histone 
acetyltransferase KAT3A/KAT3B, PCAF and MDM2 ubiquitin ligase (Anderson 
and Apella, 2010). Residues Glu17-Asn29 form an amphipathic helix which 
binds to a hydrophobic cleft in the MDM2 N-terminal domain (Kussie et al., 
1996). Residues Glu11-Leu26 acts as a nuclear export signal (Zhang and 
Xiong, 2001; Anderson and Apella, 2010). TAD1 allows p53 to recruit the basal 
transcriptional machinery in positively regulating gene expression, including 
TATA box binding protein (TBP) and TBP-associated factors (TAF) 
components of TFIID (Lu and Levine, 1995; Thut et al., 1995). TAD2 was found 
overlap with a proline-rich domain (PRD) (Asp61-Leu94). TAD2 is required for 
p53 stability, transactivation and transcription-independent apoptosis (Walker 
and Levine, 1996; Anderson and Apella, 2010). 
 
TAD1 mutation termed p5325,26 (L25Q; W26S mutations) show impaired 
transactivation of most known p53 target genes such as p21, Puma and Noxa. 
However, it retained the ability to induce certain p53 target genes such as Bax 
(Johnson et al., 2005; Brady et al., 2011; Bieging and Attardi, 2012). p5325,26 
could not induce G1 cell-cycle arrest or apoptosis in response to acute DNA 
damage signals. However, p5325,26 can promote apoptosis in non-genotoxic-
induced MEFs indicating that full p53 transactivation is not required for 
apoptosis in response to non-genotoxic stresses (Lozano and Zambetti, 2005). 
TAD2 mutation (p5353, 54) (F53Q; F54S mutations) alone do not affect p53 
transactivation activity but mutation of both TADs (p5325, 26, 53, 54) shows a gene 
expression profile similar to that of p53-null cells. The mutant p53 is ineffective 
in tumour suppression both in vitro and in vivo (Brady et al., 2011; Bieging and 
Attardi, 2012). 
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The N-terminal domain also contains a hydrophobic Proline-rich region 
(amino acids 63-97), which links the transcriptional activation domain with the 
central core. It consists of five copies of the sequence "PxxP" that is important 
in the apoptotic function of p53 (Sakamuro et al., 1997; Venot et al., 1998; 
Baptiste et al., 2002). Pro-apoptotic activity of p53 was lost when this Proline-
rich region was deleted (Ozaki and Nakagawara, 2011). 
 
1.2.2  Central core DNA binding domain  
The central core region of the p53 protein (amino acids 102-292) is highly 
hydrophobic and contains highly conserved regions II-V. This domain contains 
the DNA binding domain that interacts with the target sequences in the genes 
undergoing transcriptional transactivation. An X-ray crystallography study by 
Cho and colleagues (Cho et al., 1994) of the complex containing the p53 core 
domain and DNA target sequence shows that the core domain structure 
contains a large  sandwich, made up of two anti-parallel  sheets containing 
four and five -strands, respectively, which acts as a scaffold for three loop-
based elements (L1, L2, L3) that interact directly with the DNA. The first loop 
L1 (LSH-loop sheet helix) binds to DNA within the major groove, the second 
loop L2 binds within the minor groove of DNA and the third loop L3 acts to 
stabilise L1. The L1 and L3 loops are connected by a zinc atom, which 
stabilises the overall structure.  
 
This region is flexible and has low thermal and chemical stability and 
point mutations make it prone to aggregation, and tumour associated mutations 
destabilise the protein at body temperature (reviewed by Saha et al., 2015). 
The tetramerisation domain also has a role in maintaining stabilisation for the 
core domain (McCoy et al., 1997; Mateu and Fersht, 1998). 
 
In normal cells, WT p53 acts as a latent sequence specific DNA 
transcription factor but upon exposure to cellular stress it becomes active as a 
transcription factor which transactivates target genes through the binding of the 
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core DNA binding domain to the p53 Response Elements (R.E.) of the genes. 
el-Deiry et al (1992) have identified that a consensus binding sequence or R.E. 
of human genomic fragments that can bind to the DNA binding domain of WT 
p53 protein in vitro contains two copies of a 10 base pair (bp) motif 5’- 
Pu.Pu.Pu.C.A/T.A/T.G.Py.Py.Py – 3’ separated between 0 and 13 bp. One 
copy of the 10 bp motif is insufficient for binding and affinity for p53 protein will 
be lost if the motif alters (el-Deiry et al., 1992; Ozaki and Nakagawara, 2011).  
 
1.2.3  C-terminal region 
The carboxy-terminal region (residues 300-393) of the p53 protein is 
hydrophilic and rich in base residues. This domain consists of a flexible linker 
(amino acids 300-318) that connects the central core domain with the C-
terminal region, a region responsible for oligomerisation (amino acids 323-356) 
and a regulatory domain (amino acids 363-393). The native p53 protein is a 
tetramer in solution and amino acid residues 323-356 are essential for 
oligomerisation of the protein (Kraiss et al., 1988). Tetramerisation is required 
for efficient transactivation in vivo and for p53-mediated tumour suppression 
(Pietenpol et al., 1994). The three dimensional structure of this region has been 
mapped from nuclear magnetic resonance (NMR) (Clore et al., 1994) and X-ray 
crystallography (Jeffrey et al., 1995). It forms a highly symmetrical tetramer 
where each monomer is composed of a turn, a -strand, a second turn and an 
-helix. Two monomer peptides form a dimer in which the -helices and -
strands lie antiparallel and two dimers in turn interact through their -helices to 
form four-helix tetramers. Since p53 interacts with DNA as a tetrameric protein, 
therefore mutant p53 proteins fail to bind a p53 consensus sequence. As a 
transcription factor, p53 must be localised to the nucleus, thus the C-terminal 
region also contains three nuclear localisation signals (NLS) for efficient 
nuclear access of p53. These NLSs are recognised by importin α/β complex 
(Fabbro and Henderson, 2003; Ozaki and Nakagawara, 2011) that regulate the 
subcellular localisation of the p53 protein. Mutations in NLS1 (amino acids 316-
325) cause p53 protein to become located primarily in the cytoplasm, while 
alterations of NLS2 (amino acids 369-375) and NLS3 (amino acids 379-384) 
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result in both cytoplasmic and nuclear localisation (Dang and Lee, 1989; 
Shaulsky et al., 1990). p53 also contains Leu-rich nuclear export signal NES 
(amino acids 339-352) which is recognised by nuclear export machinery CRM1 
(chromosomal region maintenance 1) (Fabbro and Henderson, 2003). NES is 
masked by tetramer formation of p53 which inhibits p53 nuclear export 
(Stommel et al., 1999). In contrast, monoubiquitination of C-terminal lysine 
residues of p53 by MDM2 disrupted p53 tetramer formation, thus exposed NES 
to CRM1 binding (Brooks et al. 2007; Ozaki and Nakagawara, 2011). 
 
The extreme C-terminal domain (amino acids 363-393) acts as a 
negative regulator of p53 sequence specific DNA binding that may keep the 
tetramer poised in a state inactive for sequence-specific DNA binding (Hupp 
and Lane, 1994). This idea is further supported by a study showing that binding 
of p53 to the anti-p53 monoclonal antibody PAb421 (which recognises a C-
terminal epitope) can activate specific DNA binding (Hupp et al., 1992; Hupp 
and Lane, 1995; Abarzua et al., 1996). It has also been shown that PAb421 is 
able to restore binding ability to some mutant p53 proteins in vitro (Hupp et al., 
1993) and in vivo (Abarzua et al., 1995). Phosphorylation of this region by 
protein kinase C or Casein kinase II, association with DnaK protein (E. coli 
homologue of human Hsp70), or 14-3-3 protein induces the p53 tetramer to 
bind DNA sequence specifically with high affinity. It has been demonstrated 
that deletion of the C terminus results in constitutive sequence-specific DNA 
binding by p53 (Hupp et al., 1992), as does interaction of the C terminus 
nonspecifically with single-stranded DNA (Jayaraman and Prives, 1995; Kim 
and Deppert, 2006) or peptides derived from the C terminus (Hupp et al., 
1995). The p53 C-terminus is able to form complexes with non-specific DNA 
targets such as mismatched DNA, double-strand breaks, (DSBs), single-
stranded DNA (ssDNA) and Holliday junction structures (Okorokov and Orlova, 
2009). The C-terminal domain was initially thought to negatively regulate the 
core DNA binding domain activity (Hupp and Lane, 1994; Anderson and Apella, 
2010) but it was later shown to modulate the promoter activation efficiency 
through facilitating diffusion of p53 protein along DNA for searching for 
response elements (Liu et al., 2004; McKinney et al., 2004; Tafvizi et al., 2008; 
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Anderson and Apella, 2010). This region has been reported to bind with more 
than 50 proteins such as components of transcription apparatus and other 
transcription factors. 
 
1.3  Tumour suppressor function of p53 
p53 protein is said to act as tumour suppressor due to its ability to inhibit cell 
growth by inducing cell cycle arrest or apoptosis. Cell cycle arrest and 
apoptosis are two major tumour suppressive activities contributed by the ability 
of p53 to function as a transcription factor (reviewed by Bates and Vousden, 
1996; Riley et al., 2008; Kruse and Gu, 2009; Meek, 2009). Many cellular 
genes which are transcriptional targets of p53 are divided into those 
contributing to activation of a cell cycle arrest and those mediating the apoptotic 
response (reviewed by Ko and Prives, 1996; Riley et al., 2008; Kruse and Gu, 
2009). All tumour-derived p53 mutants producing proteins with reduced affinity 
for DNA strongly suggests that sequence-specific DNA binding activity of p53 
protein is important as its function as a tumour suppressor (Pietenpol et al., 
1994). A study by Chen et al. (1990) showed that the wild type p53 protein acts 
as tumour suppressor where the transfection of the wild-type p53 gene into 
human osteosarcoma cells lacking endogenous p53 abrogates the cells 
neoplasticity by reducing cell growth and division. p53 knock-out or p53-null 
mice show a high incidence of spontaneous tumours and enhanced 
susceptibility to carcinogen- and radiation-induced tumourigenesis but are 
viable and develop normally (Donehower et al., 1992). This indicates that p53 
is not essential for cell growth and normal development, but is important in 
tumour suppression. In 1990, Malkin and colleagues demonstrated that some 
individuals with Li-Fraumeni syndrome that inherited germline mutations of p53, 
are at increased risk of developing a variety of cancers including soft tissue 
sarcoma and cancers of the bone, breast, brain and genito-urinary tract at an 
earlier age than usual. Some affected individuals carry a heterozygous p53 
mutation in the germline, and tumours arise due to loss of the remaining wild-
type allele in the tumour cells (Malkin et al., 1990). This phenomenon illustrates 
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the role of p53 in cancer susceptibility and tumour development and mirrors the 
phenotype of heterozygote +/- mice (except the cancer spectrum is different) 
(Lozano and Jackson, 2013; Muller and Vousden, 2013; Garcia and Attardi, 
2014). Other than mediating cell cycle arrest and apoptosis upon responding to 
genotoxic and non-genotoxic stresses, p53 also involves in aging, senescence, 
metabolism, autophagy, cellular differentiation, anti-oxidant defence, 
angiogenesis, fertility, pigmentation and in regulating microRNA processing 
(Vousden and Lu, 2002). Figure 1.3 represents a schematic view of some 
upstream and downstream regulators of p53. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3. Schematic view of some upstream and downstream regulators 
of p53 (adapted from Levine & Oren, 2009). 
 
1.4  p53 and the cellular response to DNA damage 
The p53 protein has been implicated in the cellular response to DNA damage 
and in the maintenance of genomic integrity. p53 protein is activated in 
response to a wide range of cellular stresses including DNA damage, most 
probably in the form of double strand breaks induced by genotoxic agents 
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(Kastan et al., 1991; Lu and Lane, 1993; Riley et al., 2008; Meek, 2009) 
through strongly binding of the p53 C-terminal domain to strand breaks (Nelson 
and Kastan, 1994).  Several forms of DNA damage that activate p53 protein 
include those generated by ionising radiation (IR), radiomemetic drugs, 
ultraviolet light (UV) and chemicals such as methane sulfonate. Under normal 
conditions, p53 protein levels are very low due to its extremely short half life 
(Kubbutat and Vousden, 1998). It also exists in an inactive state that is 
relatively inefficient at binding to DNA and activating transcription. Following 
DNA damage, ensuing p53 activation results in a rapid elevation in p53 protein 
levels due to its increased half-life and its ability to bind to DNA and 
transcriptional activation also increases (Maltzman and Czyzyk, 1984; Price 
and Calderwood, 1993; Riley et al., 2008; Kruse and Gu, 2009; Meek, 2009). 
p53 can either activate or repress its target genes depending on factors such 
as cofactors, spacer lengths, quarter site orientation, nucleosomes and post-
translationally modified p53 protein (Riley et al., 2008). There are pathways 
leading to the activation of p53 by signals emanating from damaged DNA, with 
p53 integrating these signals and triggering a cascade of responses leading to 
either growth arrest and/or apoptosis. Other studies suggest that p53 protein 
may be involved in the repair machinery (Smith et al, 1994; Wang et al, 1995). 
For instance, Wang and colleagues (1994, 1995) have shown that p53 protein 
binds to and modulate the repair activity of the nucleotide excision repair (NER) 
factors XPB and XPD. Activated p53 induces genes responsible for promoting 
growth arrest, DNA repair or apoptosis, and represses genes stimulating 
growth or blocking apoptosis. It has been shown that DNA damage triggers a 
series of phosphorylation, dephosphorylation and acetylation events on the p53 
polypeptide (reviewed by Giaccia and Kastan, 1998) which is to be discussed 
in further details under p53 post-translational modifications section. Figures 1.4 
and 1.5 show a list of genes activated or repressed by active p53 and p53 
tumour suppressive functions, respectively. 
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Figure 1.4. Numerous target genes involved in a variety of responses 
transcriptionally activated or repressed by active p53 protein in response 
to both genotoxic and non-genotoxic stresses (adapted from Brady and 
Attardi, 2010). 
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Figure 1.5. p53 activation and its tumour suppressive functions by upregulating 
genes involved in cell-cycle arrest, DNA repair or apoptosis depending on the 
contextual conditions of the cells. Step 1: Cells are subject to many types of 
stresses most of the time. Step 2: Signal mediator proteins upregulate p53 by 
phosphorylation or suppressing ubiquitylation by MDM2. Step 3: Both processes 
increase the half-life of p53 which quickly leads to higher levels of p53. Step 4: 
Moreover p53 can be modified by acetyltransferases (CBP, p300, PCAF) and 
methyltransferases (SET9) that accumulate p53 protein and increase its DNA binding. 
Step 5: The deacetylase HDAC2 can inhibit p53 binding to DNA by deacetylation. Step 
6: The p53 tetramer binds to a p53 response element (RE) to promote transcription of 
its gene. Step 7: P53 also needs cofactors such as histone acetyltransferases (HATs) 
and TATA-binding protein-associated factors (TAFs). Step 8: In this example, p53 
mediates transactivation of its target genes. Step 9: P53 protein mediates various 
genes which produce proteins involved in various functions. Step 10: The previously 
activated proteins can perform DNA repair, cell-cycle arrest, senescence and 
apoptosis. ATM, ataxia telangiectasia mutated; BAX, BCL2-associated X protein; 
BBC3, BCL2-binding component-3; BIRC5, survivin; CDKN1A, cyclin-dependent 
kinase inhibitor-1A; CHK2, checkpoint kinase-2; DDB2, damage-specific DNA-binding 
protein-2; DDIT4, DNA-damage-inducible transcript-4; FAS, TNF receptor subfamily, 
member 6; GADD45 , growth arrest and DNA-damage inducible; p14ARF; SFN, 
stratifin; TP53I3, tumour protein p53-inducible protein-3; TRIM22, tripartite motif 
containing-22 (adapted from Riley et al., 2008). 
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1.5  p53 and cell cycle arrest 
Involvement of p53 in cell cycle arrest is important for maintaining the integrity 
of the genome and as a safeguard for the prevention and initiation of cancer 
formation by arresting cells with damaged DNA time to repair the abberant 
DNA before re-entering of the repaired cells to the proliferating pool of cells 
after the repair is complete. This is in order to make sure cells with damaged 
DNA do not propagate aberrant DNA to daughter cells. This normally involves 
not severe and repairable DNA damage. 
 
Activation of p53 in many cell types leads to an arrest at G1 and G2-M 
phases of the cell cycle. Ionising irradiation produces p53-dependent transient 
arrest in G1 phase of the cell cycle in proliferating fibroblasts (Kastan et al., 
1991). It is well established that wild-type p53 is required for the initiation of G1 
arrest in response to ionising radiation (IR) because cell lines engineered to 
lack p53 activity show an attenuated response (Kuerbitz et al., 1992, Kessis et 
al., 1993). Furthermore, embryonic fibroblasts from p53-null mice lose the 
ability to G1 growth arrest in response to IR (Kastan et al., 1992). 
 
Several genes have been shown to be involved in p53-dependent cell 
cycle arrest. Perhaps the most important gene that is critical in p53-mediated 
G1 growth arrest is p21WAF1 (El-Deiry et al., 1993; Bartek and Lukas, 2003; 
Giono and Manfredi, 2006; Riley et al., 2008). It contains a p53-binding motif 
(p53 response element or in short R.E.) in its promoter and encodes a 21 kDa 
protein (p21). p21WAF1 serves as a potent inhibitor of several cyclin dependent 
kinases (CDKs) complexes including cyclin E-CDK2 and cyclin A-CDK2 that 
are necessary for the G1-S transition. Two separate studies have shown that 
embryonic fibroblasts from p21-/- (null) mice are only partially defective in 
mediating G1 arrest following exposure to IR (Brugarolas et al., 1995; Deng et 
al., 1995), indicating another gene product transactivated by p53 responsible 
for a complete response.  
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p21 protein inhibits the activity of CDKs involved in the phosphorylation 
of the retinoblastoma (RB) protein. RB protein is  hypophosphorylated during 
G1 where it binds and sequesters transcription factor E2F which is required for 
entry into S phase (Giaccia and Kastan, 1998; Sherr, 1998). Upon 
hyperphosophorylation of RB protein by G1 cyclin-dependent kinases, active 
E2F is released, which leads to the transcriptional activation of genes required 
for S phase progression (Giaccia and Kastan, 1998; Sherr, 1998). However, 
the inhibition of cyclin D-CDK4/6 complexes by p21 prevents the release of 
E2F which then causes the accumulation of unphosphorylated RB and 
subsequently results in G1 cell cycle arrest (Giaccia and Kastan, 1998; Sherr, 
1998). Transient arrest of the cell cycle during G1 is to allow time for repair of 
damaged DNA, which might otherwise interfere with accurate DNA replication 
and for repair of lesions that might be perpetuated as mutations in cells 
entering S phase. p53 protein also binds to proliferating cell nuclear antigen 
(PCNA), a co-factor of DNA polymerase  and a protein involved in both DNA 
replication and repair, and inhibits PCNA-dependent DNA replication but not 
DNA repair (Li et al., 1994; Waga et al., 1994). 
 
The first p53-regulated gene identified to be involved in G1 cell cycle 
arrest was gadd45 which is expressed in response to a variety of DNA-
damaging agents including ionising radiation (Kastan et al., 1992; Zhan et al., 
1994). Gadd45 belongs to the gadd (growth arrest and DNA damage inducible) 
family of genes and has a response element in its third intron (Kastan et al., 
1992). In gene transfer experiments, expression of GADD45 protein results in 
growth inhibition as measured by reduced ability of recipient cells to form 
colonies in culture. The GADD45 protein exerts its effect through binding to 
PCNA. The association results in inhibition of DNA replication while at the 
same time enhancing DNA repair (Smith et al., 1994).  
 
p53 also mediates the G2/M transition by directly inhibiting Cdc2 
function via repression of cyclin B1 from binding to Cdc2 (Taylor and Stark, 
2001; Zilfou and Lowe, 2009). The 14-3-3  gene has been implicated in 
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mediating G2 arrest. This was shown by a study by Hermeking and colleagues 
(1997) where exposure of colorectal cancer cells to ionising radiation resulted 
in induction of 14-3-3  gene, which then stimulated G2 arrest. 14-3-3σ is a 
negative cell cycle regulator and induces G2/M arrest in response to DNA 
damage in a p53-dependent manner (Hermeking, 1997; review in Ozaki and 
Nakagawara, 2011). Studies by Yang showed that 14-3-3σ abrogated MDM2-
mediated degradation of p53 protein and p53 nuclear export (Yang, 2003). 
Other p53-target genes discovered to be involved in G2/M arrest in response to 
DNA damage are Reprimo (Ohki et al., 2000) and p53R2 (Tanaka et al., 2000) 
(review in Ozaki and Nakagawara, 2011). Figure 1.6 depicts a shematic 
diagram for p53-mediated cell cycle arrest. 
 
Figure 1.6. p53-mediated cell-cycle arrest upon response to DNA damage 
(adapted from Alberts et al., 2002). 
 
18 
 
1.6  p53-mediated apoptosis 
Apoptosis is the ordered and rapid destruction of the cell without the 
involvement of inflammatory response (Schmitt et al., 2002; Taylor et al., 2008; 
reviewed in Meek, 2009). Apoptosis is characterised by morphological changes 
that include cell shrinkage, plasma membrane blebbing, nuclear condensation, 
DNA fragmentation and apoptotic vesicles (cell remnants). To exert its function 
as a tumour suppressor protein, p53 plays a role in apoptosis and inhibition of 
pro-survival signals as represented in Figure 1.7 below. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7. Regulation of apoptosis and inhibition of pro-survival signals. 
Once activated, p53 induces the expression of Bax which then induces the 
release of cytochrome c from the mitochondria resulting in the activation of a 
caspase cascade leading to apoptosis. In inhibiting pro-survival, p53 acts by 
inducing the expression of IGFBP-3 which binds to IGF-1/2, thus inhibits IGF-
1/2 from binding to IGF-1R to inhibit the activation of survival proteins PI3k 
kinase and Akt/PKB (Weinberg Biology of Cancer, 2014). 
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p53-mediated apoptosis occurs when the DNA damage is too severe 
and irrepairable and it is induced to get rid of damaged cells from the replicative 
pools in order to eliminate malignant transformation. p53-mediated apoptosis 
most often involves mitochondrial dysfunction (review in Ozaki and 
Nakagawara, 2011). p53 protein was first identified as having a role in 
apoptosis by a study using a clone of the mouse myeloid cell line M1 lacking 
endogenous expression of p53. These cells were stably transfected with a 
temperature-sensitive p53 mutant (32oC). Upon downshift to the permissive 
temperature, it was observed that transfectants underwent massive apoptotic 
cell death (Yonich-Rouach et al., 1991). Subsequent studies have shown that 
normal murine thymocytes and quiescent lymphocytes exposed to ionising 
radiation in culture underwent apoptosis whereas thymocytes of p53 null 
(knock-out) mice were severely deficient in their ability to undergo apoptosis in 
response to irradiation (Clarke et al., 1993; Lowe et al., 1993), a treatment that 
normally results in a marked increase in p53 protein levels (Maltzman and 
Czyzyk, 1984;  Kastan et al., 1991). 
 
 p53 protein has been shown to mediate apoptosis in cells exposed to 
agents that either directly or indirectly cause DNA strand breakage. Its loss of 
function can contribute to tumourigenesis by allowing inappropriate cell 
survival. In response to DNA damage, p53 induces the expression of a variety 
of different genes involved in mediating an apoptotic response. The genes 
involved include BAX, the product of which antagonises the anti-apoptotic 
activity of Bcl-2 protein, insulin growth factor binding protein 3 (IGF-BP3) which 
inhibits the mitogenic activity of IGF receptor signalling and a series of p53-
induced genes (PIG genes) that are assumed to encode proteins that could 
generate or response to oxidative stress. Other genes induced include 
Killer/DR5, CD95 (Fas or Apo-1), p53AIP1(p53-regulated apoptosis-inducing 
protein 1),  Perp and BH3-only proteins Noxa and PUMA (Riley et al., 2008; 
Brady and Attardi, 2010) which are mostly members of pro-apoptotic Bcl-2 
family (Green and Kroemer, 2009; review in  Zilfou and Lowe, 2009). In 
contrast to all these genes, p53 protein down-regulates the bcl-2 gene whose 
product acts as an anti-apoptotic agent (White, 1996). BAX was the first 
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identified pro-apoptotic protein from the Bcl-2 family member (Selvakumaran et 
al., 1994). It has a dominant negative effect against pro-survival Bcl-2. BAX 
protein promotes apoptosis by dysregulating the mitochondrial outer membrane 
permeability (MOMP) and  inducing  the release of cytochrome c to the cytosol 
from the mitochondrial intermembrane space, which in turn activates caspases 
culminating in the activation of a caspase cascade important in apoptosis 
(Green, 2006; review in Ozaki and Nakagawara, 2011). The bax gene itself has 
been shown to contain a p53 response element (R.E.) within its promoter 
region and to be upregulated in response to DNA damage and p53 (Miyashita 
and Reed, 1995). On top of this, p53 protein was also shown to repress the 
promoter of Bcl-xl, which has an anti-apoptotic activity, and survivin, which is 
important for cell growth and survival (Sugars et al., 2001; Hoffman et al., 
2002). P53AIP1 was transcriptionally upregulated upon response to apoptotic 
stimuli by phosphorylated p53 Ser46. P53AIP1 promotes MOMP by directly 
interacting with Bcl-2 which then induces the release of cytochrome c from 
mitochondria (Matsuda et al., 2002; review in Ozaki and Nakagawara, 2011). 
 
In response to stress stimuli, p53 mediates apoptosis through induction 
of Bcl-2 family members such as Bax (Miyashita et al., 1994), Bid (Sax et al., 
2002), Puma (Nakano and Vousden, 2001) and Noxa (Oda et al., 2000). PUMA 
has been shown to mediate p53-dependent and –independent apoptosis in 
vivo. PUMA is located at mitochondria and like p53AIP1, it induces apoptosis 
by interacting with Bcl2 causing the release of cytochrome c leading to 
activation of a caspase cascade (Nakano and Vousden, 2001; review in Ozaki 
and Nakagawara, 2011). PUMA knockout mice showed complete deficiency in 
DNA damage-induced apoptosis, reminiscent as those observed in p53 
knockout mice (Jeffers et al., 2003; Villunger et al., 2003; Yu and Zhang, 2003). 
BAX has been shown to be required for PUMA-mediated apoptosis, 
demonstrating that BAX action is downstream of PUMA (Yu, 2001; Jeffers et 
al., 2003; review in Ozaki and Nakagawara, 2011). PUMA is a key mediator of 
p53-dependent and –independent apoptosis in vivo (Yu and Zhang, 2003).  
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Separate studies by Haupt and colleagues (1995) and Chen and co-
workers (1996) have demonstrated that mutant p53 which fail to activate 
transcription can still induce apoptosis. Furthermore, p53-dependent apoptosis 
can occur in the presence of inhibitors of transcription and translation (Caelles 
et al., 1994). The direct interaction of the extreme C-terminal region of p53 with 
the XPB and XPD DNA helicases has been shown to play a role in p53-
dependent apoptosis (Wang et al., 1996). p53 protein is able to traffic the death 
receptor protein, Fas, to the cell surface, thereby sensitising cells to Fas-
mediated apoptosis (Bennett et al., 1998). p53 has been linked to oncogene-
induced apoptosis by oncogenes such as c-myc and Adenovirus EIA, 
particularly after serum depletion and this apoptosis is said to be p53-
dependent. Loss of p53-mediated apoptosis resulted in the survival of 
oncogene expressing cells undergoing inappropriate cell growth carrying 
mutations and carcinogenic lesions (Lowe et al., 1994).  
 
p53 also activates apoptotic protein activating factor-1 (APAF-1) which 
then associates with cytochrome c and pro-caspase 9 and thus forms 
apoptosome resulting in the initiation of a caspase cascade by promoting the 
cleavage of pro-caspase 9, the initiator caspase. The active caspase 9 then 
activates executioner pro-caspases 3 and 7 resulting in active caspases 3 and 
7 which then mediate DNA fragmentation through cleaving the inhibitor of 
Caspase Activated DNase (ICAD) leading to activation of Caspase Activated 
DNase (CAD) which then cleaves the DNA into internucleosomal fragments of 
about 180 base pairs, the event of which is an important hallmark of apoptosis 
(review in Helton and Chen, 2007). 
 
p53 protein is also able to induce apoptosis in a transcription-
independent mechanism. Considerable evidence has accumulated to support 
this notion. In transcription-independent pathways of p53-mediated apoptosis, 
p53 localises to mitochondria and forms a complex with the anti-apoptotic 
proteins Bcl-2 and Bcl-XL to liberate BAX and BAK resulting in the release of 
cytochrome c which activates the caspase cascades (Sakahira et al., 1998; 
Mihara et al., 2003). In addition, it has been shown that a common p53 
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polymorphic variant R72 greatly promotes nuclear export to mitochondria and 
apoptosis (Dumont et al., 2003). A study by Chipuk et al. shows that p53 
directly bound with BAX which enabled BAX to associate with mitochondria 
resulting in the release of cytochrome c from the mitochondria and subsequent 
induction of apoptosis (Chipuk et al., 2004). p53 interaction with BAK forming 
the p53-BAK complex inhibits BAK from interacting with the anti-apoptotic Bcl-2 
family member Mcl1 (Leu et al., 2004).  
 
Loss of p53-dependent apoptosis causes aggressive mouse brain 
tumourigenesis (Symonds et al., 1994; Bai and Zhu, 2006). Also found that 
mice harbouring the p53 R172P mutant develop a variety of tumours probably 
due to defect in p53-mediated apoptosis (Liu et al., 2004; Bai and Zhu, 2006). 
This indicates that p53-mediated apoptosis plays an important role in tumour 
suppression function of p53. p53 also mediates TRAIL-induced apoptosis upon 
responding to cellular stress via the extrinsic pathway or death receptor 
pathway through its upregulation of DR4/5 and caspase-8 (Zhao et al., 2012). 
Figure 1.8 below is a representative diagram showing p53-dependent TRAIL-
induced apoptosis pathway. 
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Figure 1.8. TRAIL-mediated signaling and p53-dependent TRAIL-induced 
apoptosis either the extrinsic pathway (through activation of caspase-8 
and caspase-10) or the intrinsic/mitochondrial pathway (through 
activation of caspase-9). In response to cellular stress, p53 upregulate some 
pro-apoptotic genes and downregulate some anti-apoptotic genes to enhance 
the intrinsic pathway (adapted from Zhao et al., 2012). 
 
 
1.7 p53 roles in senescence and aging 
Senescence is a permanent growth arrest where the cells cannot re-enter the 
cell cycle (Rufini et al., 2013). Senescent cells are enlarged and flat, reduced 
replicative capacity and increased upregulation of p53, p21, p16, p27 and p15 
(Kuilman et al., 2010; Romagosa et al., 2011). Both initiation and maintenance 
of senescence depend on p53. Senescence is important in both tumour 
suppression and organismal aging (Rufini et al., 2013). Senescence cells are 
unable to replicate DNA, thus resulting in permanent cell-cycle arrest (Zilfou 
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and Lowe, 2009). p53-induced senescence can eliminate tumour cells through 
the mediation of p21. “Eat me” or opsonisation signal of senescent cells 
triggers an innate immune response leading to phagocytosis and killing by 
macrophages to eliminate the tumour cells from the host (Suzuki and 
Matsubara, 2011). p53 family members p63 and p73 also involve in the 
regulation of senescence and aging (Rufini et al., 2013). 
 
The decision to induce either growth arrest, senescence or apoptosis 
after p53 activation is determined by several large, highly complex and inter-
dependent factors including the cell type, the types of cellular stress stimuli, the 
amount and severity of the stress, the presence or absence of survival factors 
in the extracellular environment, the p53-MDM2 autoregulatory feedback loop 
and the levels of p53 protein, promoter selectivity and response levels and 
duration. The absolute p53 protein levels and the presence of p53-binding 
proteins influence promoter selectivity (Khoo et al., 2014). Generally, cells with 
low levels of p53 protein will arrest in G1 and those with high levels will 
undergo apoptosis after a certain threshold is achieved (Chen et al., 1996; Wu 
and El-Diery, 1996; Kracikova et al., 2013; Khoo et al., 2014). 
 
Other than functioning mainly in cell cycle arrest and apoptotic cell 
death, there is emerging evidence that p53 protein is also involved in cellular 
metabolism and autophagy, lysosome-mediated degradation of cellular 
components such as degradation of cytoplasms and organelles (Feng et al., 
2005; Bensaad et al., 2006; Crighton et al., 2006; review in Helton and Chen, 
2007; Ide et al., 2009; Meek, 2009), both atypical tumour suppressive 
mechanisms of p53 protein. While apoptosis is dependent on ATP-mediated 
caspase activation, autophagy induction may be an alternative to apoptosis in 
times when cellular energy levels are low following DNA damage (review in 
Helton and Chen, 2007). Autophagy is promoted during nutritional starvation to 
replace metabolic reserves and promote cell survival (Kroemer et al., 2010; 
Maddocks and Vousden, 2011). p53 has a dual role in autophagy, to either 
induce or inhibit autophagy (Crighton et al., 2006; Tasdemir et al., 2008; Yee et 
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al., 2009; Maddocks and Vousden, 2011). Figure 1.9 below shows senescence 
regulation by p53.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.9. Regulation of senescence by p53. Several posttranslational 
modifications modulate p53 activity. Active p53 induces senescence and 
represses mitosis. p53 also controls other pathways such as ROS generation 
and mTOR. ROS, Reactive Oxygen Species (adapted from Rufini et al., 2013). 
 
1.8 p53 roles in cellular metabolism 
There is an emerging, novel role of p53 in regulation of cellular metabolism in 
physiology and diseases. p53 involves in a wide range of human physiology 
and pathologies including diabetes, dysfunctions of central nervous system and 
obesity. Metabolic alterations are a hallmark of tumour cells for continued 
growth, survival and proliferation (Maddocks and Vousden, 2011; Liang et al., 
2013). Tumour cells uptake and utilise glucose at a much higher rate than 
normal cells thus produce excessive lactate while normal cells gain energy 
from mitochondrial oxidative phosphorylation. Most tumour cells primarily 
obtain their energy from aerobic glycolysis known as the Warburg effect 
(Warburg, 1956). p53 regulates mitochondrial oxidative phosphorylation 
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(OXPHOS), glycolysis, glutamine metabolism, lipid metabolism, antioxidant 
defense. Through this regulation p53 maintains the cellular metabolism 
homeostasis and redox balance thus contributing to tumour suppressor role of 
p53 (Maddocks and Vousden, 2011; Liang et al., 2013). 
 
1.8.1 Mitochondrial oxidative phosphorylation (OXPHOS) and glucose 
metabolism (glycolysis) 
p53 involves in maintaining mitochondrial integrity and promoting mitochondrial 
oxidative phosphorylation and glycolysis. Down-regulation or loss of p53 lead to 
reduction in mitochondrial oxidative phosphorylation and increased glycolysis in 
both in vitro cultured cells and in vivo mouse models (Matoba et al., 2006; 
Liang et al., 2013). On the contrary, p53 represses aerobic glycolysis by the 
regulation of glucose transportes and glycolytic enzymes. Reduction of glucose 
uptake by p53 is through downregulation of the expression of transporters 1 
and 4 (GLUT1 and GLUT4) (Schwartzenberg-Bar-Yoseph et al., 2004) and 
indirect downregulation of glucose transporter 3 (GLUT3) through the negative 
regulation of NF-κB signalling (Vousden and Lane, 2007; Kawauchi et al., 
2008). In summary, p53 induces mitochondrial oxidative phosphorylation and 
inhibits aerobic glycolysis, resulting in the deregulation of the Warburg effect 
through the differential expression of p53 target genes and various signaling 
pathways involved. 
 
1.8.2 Glutamine metabolism (Glutaminolysis)  
Rapidly growing tumour cells use glutamine for proteins and nucleotide 
synthesis and ATP generation. p53 plays an important role in glutaminolysis, a 
process by which glutamine is converted to glutamate by glutaminase. A further 
conversion of glutamate to α-ketoglutarate is used as  an  important substrate 
for the tricarboxyclic acid (TCA) to generate ATP in cells (Dang, 2010; Wang et 
al., 2010; Liang et al., 2013). 
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1.8.3 Lipid metabolism (lipid oxidation) 
Under glucose starvation, p53 promotes fatty acid oxidation used to drive the 
TCA cycle to provide energy (ATP) to meet the cellular energy demands 
(Jensen, 2003). Promotion of fatty acid oxidation (FAO) by p53 is an alternative 
energy source as evidenced by starvation of mouse models expressing 
wildtype p53 showed increased FAO compared to p53-null mice. FAO occurs 
partly through the activation of guanidine acetate methyl transferase (GAMT) 
which in turn facilitates apoptosis instead of cell survival (Ide et al., 2009; Liang 
et al., 2013). 
 
1.8.4 Antioxidant defense 
In tumour cells, oxidative stress and accumulated reactive oxygen species 
(ROS) are important in tumourigenesis. Several studies have shown that 
reduction of the ROS levels and elicited anti-oxidant defense is part of 
mechanism by which p53 exerts its role in tumour suppression. Increased 
endogenous ROS levels in cells are the result of mitochondrial oxidative 
phosphorylation. A group of antioxidant genes transcriptionally induced by p53 
include sestrins 1 and 2, TIGAR, GPX1, ALDH4, GLS2 and Parkin in order to 
lower ROS levels and prevention of DNA damage (Budanov et al., 2004; Yoon 
et al., 2004; Bensaad et al., 2006; Hu et al., 2010; Zhang et al., 2011; Liang et 
al., 2013). On the contrary, p53 deficiency causes the elevated levels of 
intracellular ROS, which greatly enhances DNA oxidation and mutagenic rate in 
cells. Paradoxically to p53 role in antioxidant defense, in severe oxidative 
stress, the elevated ROS levels activate p53 to prooxidant function by 
transcriptionally up-regulating a group of antioxidant genes such as PIG3, 
PIG6, FDXR, Bax and Puma which can further increase intracellular ROS 
levels thus promote apoptosis and senescence in order to eliminate damaged 
cells in order to maintain genomic stability (Bensaad et al., 2006; Liang et al., 
2013). 
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1.9 p53 mutation 
The p53 gene is mutated in over 50% of human cancers where most frequently 
missense mutation in one allele is accompanied by loss of the second allele 
with alterations in every region of the protein (Hollstein et al., 1991; Leroy et al, 
2013). This ultimately leads to a complete loss of wild-type expression. Most 
p53 mutations in human tumours are missense mutations and most are single 
amino acid mutations/substitution clusters in the central DNA-binding domain 
with mutation hotspots at R175, G245, R248, R249, R273 and R282 
(Greenblatt, 1994; Brosh and Rotter, 2009; Muller and Vousden, 2012), 
indicating that DNA-binding activity is mostly altered resulting in the changes in 
the transcription of p53 target genes. It is within this central part that more than 
90% of the missense mutations in p53 are found. p53 mutations can be divided 
into two categories: i) structural mutants which cause unfolding of the p53 
protein, ii) DNA-contact mutants which change amino acids important for DNA 
binding. p53 structural mutants dramatically affect the folding of the p53 protein 
in comparison to p53 DNA contact mutants. Both mutations interfere the 
binding of p53 to its response elements and result in the loss of the tumour 
suppressor functions of p53 (Cho et al., 1994; Sigal and Rotter, 2000; Muller 
and Vousden, 2012). 
 
1.9.1 p53 mutation gain-of-function (GOF) 
Different p53 hotspot mutants elicit different gain-of-function (GOF) phenotypes 
(contact mutant versus conformation mutant). p53 mutant displays GOF 
activities by exerting carcinogenesis (Liu et al., 2010; Muller and Vousden, 
2012; Garcia and Attardi, 2014). The changes in p53 structural stability may be 
crucial for the acquired gain of function phenotypes. Mutant p53 exerts a 
dominant-negative regulation/effects towards wildtype p53. Mutant p53 also 
acquires  novel oncogenic properties/functions such that it promotes genomic 
instability, survival, proliferation, invasion and metastasis. Mutant p53 gains 
tumour-promoting functions where it shows oncogenic properties in the 
absence of wtp53 (Muller and Vousden, 2012; Jackson and Lozano, 2013; 
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Garcia and Attardi, 2014). Figure 1.10 depicts the oncogenic phenotypes 
associated with p53 mutant gain-of function activities. 
  
Mutant p53 binds and inhibits the tumour suppressor activities of p53 
family members p63 and p73. p53 structural mutants have high binding affinity 
to p63 and p73 compared to p53 contact mutants. Both mutants inhibit p63 
and/or p73 by promoting invasion and metastasis or apoptosis inhibition. Mice 
heterozygous for p63 and p73 (p63+/- and p73+/-) develop spontaneous 
metastatic tumours reminiscent in mice with mutant p53 suggesting that mutant 
p53 inhibits p63/p73 (Muller and Vousden, 2012; Garcia and Attardi, 2014). 
Mutp53 deregulates the tumour suppressing functions of TAp63/TAp73 and 
promotes the oncogenic activities of ΔNp63/ΔNp73. ΔNp63 and ΔNp73 are 
both pro-survival and anti-apoptotic. While TA forms of both p63 and p73 have 
tumour suppressive activities, their ΔN variants are likely to be oncogenic (Lee 
et al., 2006; Ravni et al., 2010; Wilhelm et al., 2010). Mutant p53 invasive 
capabilities is mainly mediated by inhibition of p63 and/or p73 (Adorno et al., 
2009; Muller et al., 2009). Mutant p53 sequesters both p63 and p73 from their 
target genes thus represents a potential molecular mechanism underlying 
inactivation of p63 and p73 in cells harbouring mutant p53 (Flores et al., 2002; 
Strano et al., 2003; Strano et al., 2007). Inhibition of mutant p53-p73 interaction 
by small peptides sensitise mutant p53-expressing cells to genotoxic drugs 
whereas such peptides show no effects on cells expressing wtp53 or null-p53 
(Di Agostino et al., 2008; Oren and Rotter, 2009). p73 knockdown causes 
cancer cells to become chemoresistant and elimination of mutant p53 
sensitises cancer cells to chemotherapeutic agents (Strano et al., 2003; Strano 
et al., 2007). This suggests that mutant p53-p73 complex causes 
chemoresistant of tumours with mutant p53 compared to wt-p53 bearing 
tumours. 
 
Mutant p53s cannot recognise wt-p53 consensus sequence but still 
serve as oncogenic transcription factors. Genome-wide expression profile study 
shows that mutant p53 regulates a set of genes mediating oncogenic activities 
(O’Farrell et al., 2004; Scian et al., 2004; Strano et al., 2007). Mutant p53 can 
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either directly bind to undefined DNA consensus or physically interact with 
other proteins to function as a bona fide transcription factor. While wt p53 
transcribes genes to induce apoptosis and inhibit tumourigenesis, mutant p53 
suppresses CD95 (Fas/APO-1) gene expression implicated in apoptotic 
responses. Mutant p53 proteins are phosphorylated and acetylated at sites that 
stabilise wt p53, thus facilitates the accumulation of dysfunctional mutant p53 in 
the nucleus of tumour cells (Bai and Zhu, 2006). Mutant p53 can transcribe 
genes involved in growth and survival. Some mutant p53 selectively bind to 
promoters of p53 target genes such as p21 and MDM2 but not promoters of 
proapoptotic genes such as bax and PIG3 (Pan and Haines, 2000; Bai and 
Zhu, 2006). This results in mutant p53 to induce cel cycle arrest just like wt p53 
but defective in mediating apoptosis (Friedlander et al., 1996; Ludwig et al., 
1996; Bai and Zhu, 2006). 
 
Studies on mutant p53 isoforms transfected into p53-null cell lines 
indicate that cells with mutant p53 GOF feature became resistant to the killing 
effects of various anticancer agents while the knockdown of endogenous 
mutant p53 sensitised the cells to killing by such agents (Oren and Rotter, 
2009). siRNA-mediated knockdown of endogenous mutant p53 in cancer cells 
rendered cells more susceptible to apoptosis by anticancer agents 
(Vikhanskaya et al., 2007), also in vivo setting (Bossi et al., 2006). 
Overexpressed mutant p53 increased cell proliferation, increased tumour 
aggressiveness and enhanced metastasis which are among the hallmarks of 
mutant p53 GOF in mouse models. Mutant p53 can increase cell migration and 
invasion in in vitro assay (Adorno et al., 2009; Oren and Rotter, 2009; Wang et 
al., 2009). Mutant p53 knockdown in mouse models shows that tumours were 
less vascularised implicating p53 regulation of angiogenesis (Bossi et al., 
2008). Mutant p53 knockin mice developed aggressive, metastatic tumours 
compared to p53-null counterparts (p53 knockout mice) (Lang et al., 2004; 
Olive et al., 2004; Oren and Rotter, 2009). Microarray analysis showed 
overexpression of mutant p53 isoforms can exert gene expression involved in 
pro-proliferative or antiapoptotic proteins including multidrug resistant gene 1 
(MDR1), PCNA, EGFR, c-myc and IGF2. On the other hand, the mutant p53 
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isoforms also repress the transcription of other genes such as 
CD95/Fas/AApo1, caspase-3, p21, GADD45 and PTEN (Vikhanskaya et al., 
2007). Mutant p53 interacts with transcription factors, modulate both positive 
and negative transcriptional output (Oren and Rotter, 2009). Mutant p53 also 
regulates microRNAs thus altering the stability of various microRNA target 
transcripts such as miR-130b, miR-155 and miR-205, each of which involves in 
invasive and metastatic pathways (Dong et al., 2012; Neilsen et al., 2012; Tucci 
et al., 2012). 
 
Mutant p53s gain new functions to drive tumour cell migration, invasion 
and metastasis. The Slug/Snail and Twist family of transcription factors are 
master regulators of the epithelial-mesenchymal transition (EMT) (Shiota et al., 
2008; Muller et al., 2011) by opposing p53 function, indicating p53 prevents a 
transcriptional program of EMT. p53 expression promotes MDM2-mediated 
degradation of Slug, thus enhances E-cadherin expression (Wang et al., 2006). 
Loss of E-cadherin commonly occurs in cancer which is able to drive 
metastasis in animal models (Derksen et al., 2006). Athough p53 mutation 
mostly in the DNA binding domain, mutant p53 still promotes promoter activity 
via the N-terminal transactivation domain. It has been shown that mutant p53 
inhibition of apoptosis is abrogated by abolition of its N-terminal trasactivation 
domain (Muller et al., 2011). p63 knockdown enhances the expression of genes 
involved in motility, invasion and metastasis (Barbieri et al., 2006; Gu et al., 
2008). Mutant p53 regulates Sharp-1 and Cyclin G2. Suppression of Sharp-1 or 
Cyclin G2 mimicked mutant p53 to induce cell migration and reduced Sharp-1 
and Cyclin G2 expression resulted in poor prognosis and recurrence in breast 
cancer. TAp63 modulates Dicer to prevent metastasis (Sue et al., 2010). 
miRNA processing is down-regulated in many cancers (Lu et al., 2005; Kumar 
et al., 2009). Reduced levels of Dicer can promote tumourigenesis and invasion 
and are associated with a poor prognosis (Kumar et al., 2009; Sue et al., 2010). 
Decreased Dicer levels increased PKB/Akt activation suggesting that it acts on 
the same pathway as mutant p53 and p63 to induce invasion (Han et al., 2010; 
Muller et al., 2011). 
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Dong et al. found that over-expressed mutant p53-R175H enhanced cell 
migration and invasion of human endometrial cancer cells and activated 
epidermal growth factor receptor (EGFR/phosphatidylinositol 3-kinase 
(PI3K)/Akt pathway. However, upon knockdown of mutant p53-R175H the 
reverse occurred (Dong et al., 2009). Mutant p53 promotes cell growth via 
inhibition of AMP-activated protein kinase (AMPK) activation. Mutant p53 
downregulation increases AMPK activation under energy stress. AMPK acts a 
an energy sensor and tumour suppressor. Inhibition of AMPK activation is 
revealed as an important mechanism of mutant p53 gain of function properties 
(Zhou et al., 2014). 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.10. The inner light blue circle represents the oncogenic 
phenotypes associated with the mutant p53 proteins activities. The outer 
circle represents the key mechanistic properties that mutant p53 adopts to 
contribute to the phenotypes listed in the inner circle. Most of the phenotypic 
effects can be attributed to almost each of the mechanistic properties; therefore 
the inner blue circle can be rotated freely. Image adapted from Brosh and 
Rotter (2009).  
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1.10  Post-translational modifications of p53 protein 
p53 is activated in response to both genotoxic and non-genotoxic stresses, 
however, the patterns of p53 post-translational modifications (PTMs) and the 
activation or repression of p53 target genes are quite distinct, thus their cellular 
outcomes are different. This also potentially affects numerous protein 
interactions with p53 protein (Anderson and Apella, 2010). Post-translational 
modifications of p53 protein are crucial for stabilisation (by escape from 
constitutive, proteosome-dependent degradation) and transcriptional activation 
(by conversion from ‘latent’ into ‘active’ form) of the protein where over 60 sites 
of 363 residues of the human p53 protein have been reported to be post-
translationally modified (reviewed in Apella and Anderson, 2000 and 2001; 
Anderson and Apella, 2010; Nguyen et al., 2014) (see Figure 1.11). Figure 1.12 
shows a diagram summarising posttranslational modifications to p53 in 
response to genotoxic and non-genotoxic stress. 
 
 
 
 
 
 
 
 
 
 
Figure 1.11. A schematic diagram showing p53 main domains, posttranslational 
modification sites and proteins that interact with human p53. Posttranslational 
modification sites (P, phosphorylation; Ac, acetylation; G, glycosylation; Me, 
methylation, N8, neddylation; Ub, ubiquination) are indicated together with enzymes 
that can accomplish the modifications in vitro. (adapted from Anderson and Apella, 
2010). 
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Figure 1.12. Posttranslational modifications to p53 in response to 
genotoxic and non-genotoxic stress. The bar at the bottom represents the 
human 393 amino acid p53 polypeptide; functional regions are indicated. 
Selected posttranslational modification sites (Figure 1.12) are indicated above 
the bar; S, serine; T, threonine; K, lysine. Filled circles (phosphorylation) or 
squares (acetylation) indicate modification in response to the indicated stress 
(left); open symbols (or light gray) indicate no change in modification in 
response to stress. No symbol indicates the site has not been examined. An “*” 
denotes ATM dependent phosphorylations; a “?” indicates conflicting literature 
reports; a down arrow indicates treatment induced a decrease in site 
modification (adapted from Anderson and Apella, 2010). 
 
It is now clear that full cell-specific transcription responses in response 
to cellular stresses require a rich cascade of post-translational modifications of 
p53 protein (as reviewed in Anderson and Appella, 2010), which ultimately 
determine the cell fate. Exposure of cells to a wide range of genotoxic and non-
genotoxic stresses such as ionising radiation (IR), ultraviolet irradiation (UV), 
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oncogene activation, nucleotide depletion or hypoxia results in transient 
stabilisation of the p53 protein, causes its accumulation in the nucleus, and 
activates it as a transcription factor (reviewed in Prives and Hall, 1999; Apella 
and Anderson, 2000; Anderson and Apella, 2010). It has been proposed that 
different stress signals lead to different types of p53 protein modifications and 
consequently the transcriptional programme of p53 (Riley et al., 2008), for 
details see Figure 1.12. Activation of p53 mainly leads to either growth arrest at 
the G1/S or G2/M transitions of the cell cycle or apoptosis. p53 stabilisation, 
nuclear accumulation and activation or in short, the regulation of p53 activity, 
involve a variety of post-translational modifications, mostly by phosphorylation 
and acetylation. Other types of post-translational modifications of p53 protein 
include sumoylation, ubiquitination and to a lesser extent glycosylation and 
ribosylation (Meek and Anderson, 2009). Another post-translational 
modification on p53 protein is neddylation (Xirodimas et al., 2004), see Figure 
1.11 and Table 1.1 for details. Overall, these modifications serve to regulate 
p53 protein by affecting its DNA binding, degradation, localisation, 
oligomerisation and association with cellular factors such as co-activators or 
negative regulators (reviewed in Liu and Kulesz-Martin, 2001; Meek and 
Anderson, 2009). However, this thesis will only focus on the two most common 
types of p53 post-translational modifications phosphorylation and acetylation, 
briefly mention on other p53 PTMs and mainly to study p53 nitration. To date, 
nitration sites of p53 protein in the form of nitrotyrosine have not been mapped 
and nitration can either activate or inactivate p53 protein. 
 
1.10.1 Phosphorylation of p53 protein 
p53 protein has been identified as a substrate for many different kinases that 
phosphorylate it at several sites mainly within the N-terminal and C-terminal 
regulatory domain in vitro. The kinase signalling to p53 protein includes casein 
kinase 1 and 2, CHK1 and 2, ATM (ataxia telangiectasia mutated), ATR 
(ATM/Rad3 related kinase), JNK (c-jun N-terminal kinase) and DNA-PK (DNA-
dependent protein kinase) (Jayaraman and Prives, 1999). Phosphorylation on 
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p53 protein has been studied intensively and these studies have been greatly 
facilitated by the availability of phosphoserine and phosphothreonine antibodies 
on phosphorylated-modified p53 protein (reviewed in Apella and Anderson, 
2001; Anderson and Apella, 2010). Seven serines (Ser6, 9, 15, 20, 33, 37, 46) 
and two threonines (Thr18 and 81) in the N-terminal transactivation domain of 
human p53 are phosphorylated and dephosphorylated in response to DNA 
damage stimuli such as ionizing radiation or UV light. In unstressed cells, Thr55 
is constitutively phosphorylated but dephosphorylated after DNA damage 
(Anderson and Apella, 2010). 
 
MDM2 protein is a key negative regulator of p53 protein stability and 
activities in normal cells. Disruption of the interaction of p53 protein with MDM2 
protein prevents ubiquitin-mediated degradation of p53 protein. Increased p53 
stability occurs through multi-site phosphorylation of both p53 and MDM2 
proteins (review in Appella and Anderson, 2001; Meek, 2004; Anderson and 
Apella, 2010). Studies by Shieh and colleagues have shown that 
phosphorylation of serines 15 and 37 of p53 protein in vitro by DNA-PK disrupts 
the interaction of p53 protein with MDM2 protein, leads to p53 protein stability 
and accumulation in the nucleus and also disrupts MDM2-mediated inhibition of 
p53-dependent transcription (Shieh et al., 1997; Shmueli and Oren, 2007; 
Meek and Anderson, 2009; Nguyen et al., 2014). To further support this notion, 
it was shown that substitution of serine-15 with glutamic acid gives rise to 
increased p53 stability (Ashcroft et al., 1999). Serine-15 phosphorylation has 
also been shown to enhance the interaction of p53 protein with transcriptional 
co-activators CBP and PCAF (Lambert et al., 1998; Sakaguchi et al., 1998; Liu 
et al., 1999). Ser15 phosphorylation acts as a nucleation event to stimulate 
modifications of other sites by phosphorylation and acetylation (Meek and 
Anderson, 2009). Furthermore, serine-20 has been shown to be 
phosphorylated in response to DNA damage and interestingly, it resides in the 
region of p53 that binds to MDM2 (Picksley et al., 1994). Phosphorylation of 
serine-20 by checkpoint kinase 1 (Chk1) and Chk2 in response to IR can lead 
to abrogation of the p53-MDM2 interaction (Hirao et al., 2000).  
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p300 and CBP have dual role in p53 regulation. Both act as 
transcriptional activator proteins and also ubiquitinate p53 for MDM2 
degradation (Grossman et al., 1998 & 2003). Several studies showed that 
phosphorylation of p53 amino terminal sites including Ser15, Thr18 and Ser20 
augments p53 association with p300/CBP and stimulate p53 transcriptional 
activities (Lambert et al., 1998; Dumaz and Meek, 1999; Dornan et al., 2003; 
Finlan and Hupp, 2004; Meek and Anderson, 2009). Furthermore, 
phosphorylation of these residues blocked MDM2 binding to p53 and 
decreased p53 turnover (Shieh et al., 1997; Bottger et al., 1999; Craig et al., 
1999; Dumaz et al., 1999; Schon et al., 2002). Thr18 phosphorylation 
enhances the inhibition of p53 binding to MDM2 compared to other residues 
(Ser15, -20, -33, -37, -46, -55). However phosphorylation of all seven amino-
terminal residues inhibits MDM2 binding by four fold higher than Thr18 
phosphorylation alone (Teufel et al., 2009). 
 
Phosphorylation of serine-46 has been implicated in the activation of 
p53-mediated apoptotic response (D’Orazi et al., 2002; Saito et al., 2002; 
Nguyen et al., 2014). Phosphorylation of Threonine-81 by c-Jun N-terminal 
kinase (JNK) has been shown to result in p53 stabilisation (Buschmann et al., 
2001(b)). It has been reported that serine-315 and serine-392 phosphorylation 
may be responsible for the regulation of the oligomerisation of p53 protein and 
thus its sequence-specific DNA binding (Wang and Prives, 1995; Sakaguchi et 
al., 1997). DNA damaged-induce phosphorylation of p53 protein has been 
reported to cause propyl isomerase Pin1 to bind to p53 protein and enhance 
p53 DNA binding and transcriptional activity (Zacchi et al., 2002; Zheng et al., 
2002; Nguyen et al., 2013).  
 
Phosphorylation of the p53 C-terminal regulatory domain by CKII, PKC 
or Cdks has been shown to activate sequence-specific DNA binding of p53 in 
vitro (Hupp et al., 1992; Hupp and Lane, 1994; Wang and Prives, 1995). Upon 
exposure to UV light, phosphorylation at S392 activates specific DNA binding 
activity through the p53 tetramer stabilisation (Matsumoto et al., 2006). S389A 
(human S392A) mutation in knock-in mice showed unaffected p53 stability but 
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were predisposed to UV-induced skin cancer (Johnson et al., 2006), also 
altered induction of p53 target genes in comparison to wild-type mice (Bruins et 
al., 2007 & 2008). It is reported that S392 hyper-phosphorylation correlates with 
poor prognosis, advanced tumour stage and tumour grade (Matsumoto et al., 
2004(a) & (b), Bar et al., 2009). All of the studies mentioned above have led to 
the conclusion that each phosphorylation of p53 protein is a key mechanism 
responsible for activation and regulation of its tumour suppressor function in 
response to cellular stress in a tissue- and promoter-specific manner (reviewed 
in Dai and Gu, 2010). However, p53 phosphorylation is dispensable on its 
induction by the ARF pathway or in response to small molecules inducers such 
as Nutins (Meek and Anderson, 2009). 
 
Several studies on Tp53 knock-in mouse models on individual or 
combination sites of p53 phosphorylation had been conducted by several 
groups have provided valuable information about modulation of p53 functions 
(Menendez et al., 2009; Nguyen et al., 2014). These include single mutation, a 
change of serine to alanine, at the N-terminal domain Trp53S18A/S18A, 
TrpS23A/S23A, double homozygous mutation Trp53S18A/S18A;S23A/S23A and at the C-
terminal domain such as p53 knockin mutant S312A and S389A. Humanise 
p53 mouse model was also created (hupki) with human p53 Ser46 
modification. Overall, mice with some p53 PTM site mutations showed low 
survival rates and increased spontaneous tumour formation. However, none of 
these mutations had such a severe impact as compared to the Trp53-/- 
mutation (Nguyen et al., 2014). 
 
p53 protein activity may also be regulated by being dephosphorylated in 
response to DNA damage. Waterman et al (1998) have shown that p53 is 
ATM-dependent dephosphorylated on serine-376 in response to IR (Waterman 
et al., 1998). This dephosphorylation event induces the interaction of p53 with 
14-3-3 proteins resulting in activation of its sequence-specific DNA binding 
potential. Thr55 and Ser376 were shown to be dephosphorylated upon DNA 
damage induced by ionising radiation, indicating that dephosphorylation also 
activates p53 (Bai and Zhu, 2006). 
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1.10.2 Acetylation of p53 protein 
The histone acetyltransferase (HATs), CREB-binding protein (CBP) and p300 
can co-activate numerous transcription factors, including p53 protein (Gu and 
Roeder, 1997). p53 protein is covalently modified by acetylation at multiple 
lysine residues namely lysine-370, 371, 372, 381, 382 and 386 of the carboxy-
terminal regulatory domain by CBP/p300 and, to a lesser extent, lysine-320, 
which is located within the main nuclear localisation signal of p53, by p300/CBP 
associated factor (PCAF) (Sakaguchi et al., 1998). Both CBP/p300 and PCAF 
possess intrinsic HATs activity and therefore can acetylate human p53 protein 
by adding one or more acetyl groups to the stated lysine sites. Acetylation of 
these residues has been found to enhance sequence-specific DNA binding of 
wild-type p53 protein, possibly by inhibiting p53’s non-sequence-specific DNA-
binding activity, (Anderson et al., 1997) and therefore transcriptional activity, 
possibly as a result of an acetylation-induced conformational change of the C-
terminus, thus increasing p53 DNA binding capacity (Gu and Roeder, 1997; 
Sakaguchi et al., 1998). The acetylation of lysine residues in the carboxy-
terminal of p53 protein, which also targets for ubiquitination, results in the 
inhibition of p53 degradation. Notably, prior phosphorylation of p53 on serine-
33 and/or serine-37 (Sakaguchi et al., 1998) has been implicated in recruiting 
CBP/p300 to p53 and thereby controlling p53 acetylation in vitro. This therefore 
leads to the possibility that a combination of phosphorylation and acetylation 
events on p53 protein is collectively responsible for its activation in response to 
genotoxic stresses. Modifications of p53 protein are therefore highly complex 
and inter-dependent. 
 
  Lysine residues K120 (Sykes et al., 2006; Tang et al., 2006) and K164 
(Tang et al., 2008) in the DNA binding domain of p53 protein are two recently 
discovered acetylation sites. K120 acetylation is indispensable for induction of 
genes involved in apoptosis but not in cell cycle arrest. (Sykes et al., 2006; 
Tang et al., 2006). K120 acetylation has been shown for p53 to dissociate BAK 
from MCL-1 at mitochondria (Sykes et al., 2009). It is likely that K120 
acetylation might be involved in transcription-dependent and transcription-
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independent mechanisms of p53-mediated apoptosis (review in Dai and Gu, 
2010). While K120 acetylation involved in the activation of pro-apoptotic genes, 
K164 acetylation is important for the activation of most p53 target genes (Tang 
et al., 2008). Mutations of K (lysine) to R (arginine) in K120, K164 and the six 
C-terminal lysine residues completely abolishes p53-induced cell cycle arrest 
and apoptosis (Tang et al., 2008), indicating that acetylation is indispensable 
for the activation of p53 protein as a tumour suppressor (review in Dai and Gu, 
2010).  
   
  K320 in the tetramerisation domain in p53 protein is acetylated by PCAF 
(Kruse and Gu, 2008) which then mediates the activation of p21 (Knights et al., 
2006). K317R (human K320R) mutation in p53 gene in mice enhanced p53-
mediated apoptosis upon irradiation (Chao et al., 2006), suggesting the 
inhibition of p53 apoptotic activities by K320 acetylation upon exposure to DNA 
damage (review in Dai and Gu, 2010).  
 
The C-terminal lysine acetylation sites of p53 protein are essential for 
ubiquitination and subsequent degradation of p53 by MDM2. MDM2 might 
suppress p53 acetylation by p300 by forming a complex with p300 and p53 
protein (Kobet et al., 2000). Acetylation of these residues is therefore thought to 
contribute to p53 stabilisation by impairing ubiquitination. 
 
Tumour suppressor promyelocytic leukaemia (PML) protein has also 
been shown to induce p53 acetylation at lysine-382 through the formation of a 
trimeric p53-PML-CBP complex (Pearson et al., 2000). Overexpression of PML 
relocalises p53 protein into nuclear bodies and induces phosphorylation and 
acetylation of p53 protein, thereby enhancing its transcriptional activity (Fogal 
et al., 2000; Guo et al., 2000; Pearson et al., 2000). 
 
Histone deacetylase complexes (HDACs) are often associated with co-
repressor complexes and can exert their repressive effects on both histone and 
non-histone proteins by removing an acetyl group resulting in deacetylation of 
the proteins (Smith, 2002). Even though the influence of HDAC activity on p53 
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function and the general role of p53 deacetylation is not clear, deacetylation 
probably provides a quick acting mechanism to stop p53 function once 
transcription activation of target genes is no longer needed. This therefore 
leads to the restoration of the steady-state level of p53 target genes which is 
crucial for cellular homeostasis. De-acetylation of p53 protein could also play 
an important step in the MDM2-mediated degradation of p53 protein by 
promoting its ubiquitination and subsequently degradation (Ito et al., 2002; 
reviewed in Brooks and Gu, 2003; Kruse and Gu, 2009) but this inhibitory effect 
can be abrogated by the tumour suppressor p19ARF, suggesting that acetylation 
also plays an important role in the p53-MDM2-p19ARF feed back loop (Ito et al., 
2001; Bai and Zhu, 2006). 
 
1.10.3 Other post-translational modifications of p53 protein 
Sumoylation of p53 protein is another type of p53 post-translational 
modification where p53 protein is modified in response to DNA damage by a 
small ubiquitin-like modifier protein 1 (SUMO-1) which conjugates p53 protein 
at lysine-386 (Gostissa et al., 1999). Although SUMO modification does not 
regulate p53 stability, this modification enhances p53’s transcriptional activity 
(Gostissa et al., 1999, Rodriguez et al., 1999, Muller et al., 2000). It is still 
under intense debate as to whether sumoylation activates or inactivates p53 
protein activity (Chen & Chen, 2003; reviewed in Liu and Shuai, 2008). Several 
other modifications of p53 protein namely methylation (Chuikov et al., 2004), 
glycosylation (Shaw et al., 1996) and ribosylation by poly (ADP-ribose) 
polymerase (PARP) might affect both protein stability and protein function 
(Vaziri et al., 1997; Kumari et al., 1998, Wang et al., 1998; Simbulan-Rosenthal 
et al., 1999). 
 
A finding by Xirodimas and colleagues has shown that p53 
transactivation might be repressed by neddylation promoted by MDM2 
(Xirodimas et al., 2004). In this process, the C-terminal glycine residue of the 
ubiquitin-like protein NEDD8 can be covalently linked to lysine-370, lysine-372 
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and/or lysine-373 of p53 protein (Xirodimas et al., 2004). These lysine residues 
are also targeted by ubiquitination. A question is still raised whether p53-
specific de-neddylation pathways exist, or whether neddylation competes with 
acetylation or enhances ubiquitination (reviewed in Bode and Dong, 2004). 
Moreover, NEDD8 ulimate buster 1 (NUB1), a non-covalent interactor of the 
ubiquitin-like molecule Ubl NEDD8, has been shown to cooperate with the 
NEDD8 and ubiquitin pathways in controlling p53 localisation and function, 
notably resulting in the cytoplasmic localisation and loss of p53 transcriptional 
activity (Liu and Xirodimas, 2010). NUB1 exerts its effects on p53 largely 
dependent on NEDDylation and MDM2, also through the co-operation of 
NEDD8 with ubiquitin by decreasing p53 NEDDylation and promoting p53 
ubiquitination. 
 
Lysine and arginine residues in p53 protein are potential targets for 
methylation. Arginine methylation is targeted only by Protein Arginine N-methyl 
Transferase 5 (PRMT5) at R333, R335 and R337 (Jansson et al., 2008; 
Scoumanne and Chen, 2008). On the other hand, lysine methylation is better 
understood of which three Lysine Methyl Transferase (KMTs) are responsible 
for mono-methylating p53 protein and at least two KMTs for demethylating it. 
p53 lysine methylation can result in either activating or repressing the p53 
activity depending on the site of modification and the number of attached 
methyl groups (review in Dai and Gu, 2010). K372 is mono-methylated by 
SET7/9 (also known as KMT7) and this activates the transactivation activity of 
p53 target genes (Chuikov et al., 2004). K382-mono-methylation by SET 
(KMT5A) and SMYD2 (KMT3C)-mediated K370 mono-methylation inhibit p53 
transcriptional activities (Huang et al., 2006; Shi et al., 2007) while G9A 
(KMT1C) and G9A-like protein (KMT1D) di-methylate p53 at K373 which 
suppresses p53-mediated apoptosis (Huang et al., 2010). Overall, these 
findings clearly show that p53 function is regulated at least in part by the 
interplay between methylation and demethylation of the protein together with 
the crosstalk with other well characterised p53 modifications principally by 
phosphorylation and acetylation and to a lesser extent by ubiquitination, 
sumoylation and neddylation.  
43 
 
In summary, protein posttranslational modifications are usually 
reversible due to the available enzymes which can convert phosphorylation (by 
kinases) to dephosphorylation (by phosphatases), acetylation (by acetyl-
transferases) to deacetylation (by de-acetylase), ubiquitination (ubiquitin 
ligases) to deubiquitination (by de-ubiquitinases) and methylation (by 
methyltransferases) to de-methylation (by de-methylases). The involvement of 
the actions of these opposite enzymes thus results in setting thresholds and re-
setting activation for p53 to exert its main function as a tumour suppressive 
protein and to restore p53 normal levels after cellular stresses dissipate 
(Anderson and Appella, 2010). Table 1.1 below summarises the post-
translational modification events of human p53 protein. 
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Table 1.1: Covalent modifications of human p53 protein 
Amino acid Modification Putative 
enzymes 
involved 
References 
Serine-6, 
Serine-9 
Phosphorylation CKI Milne et al., 1992; 
Knippschild et al., 
1997; Higashimoto 
et al., 2000 
Serine-15 Phosphorylation DNA-PK, ATM, 
ATR, Chk1, 
AMPK 
Shieh et al., 1997;  
Canman et al., 1998; 
Khanna et al., 1998; 
Tibbetts et al., 1999; 
Goudelock et al., 
2003; 
Jones et al., 2005 
Threonine-
18 
Phosphorylation CKI Sakaguchi et al., 
2000 
Serine-20 Phosphorylation Chk2, Plk3 Chehab et al., 2000;  
Xie et al., 2001; 
Craig et al., 2003 
Serine-33 Phosphorylation CAK Ko et al., 1997 
Serine-37 Phosphorylation DNA-PK, ATR, 
JNK 
Shieh et al., 1997; 
Canman et al., 1998 
Serine-46 Phosphorylation p38 MAPK, 
HIPK2, 
PKCdelta, 
DYRK-2 
Bulavin et al., 1999; 
D’Orazi et al., 2002; 
Perfettini et al., 
2005;  
Yoshida et al., 2006; 
Taira et al., 2007 
Threonine-
55 
Constitutive 
Phosphorylation 
TAF1 Gatti et al., 2000;  
Li et al., 2004 
Threonine-
81 
Phosphorylation JNK Ronai, the 10th p53 
Workshop. 2000, 
California, USA. 
Serine-149 
Threonine-
150, 
Threonine-
155 
Phosphorylation COP9 
signalosome 
(CSN)-
associated 
kinase 
Bech-Otschir et al., 
2001 
Serine-313 Phosphorylation Chk1, Chk2 Anderson and 
Apella, 2010 
Serine-314 Phosphorylation Chk1, Chk2 Anderson and 
Apella, 2010 
Serine-315 Phosphorylation cdk Wang and Prives, 
1995 
Serine-366 Phosphorylation Chk2 Anderson and 
Apella, 2010 
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Serine-371 
Serine-376 
Serine-378 
Constitutive 
Phosphorylation 
PKC, TFIIH Milne et al., 1994; 
Delphin et al., 1997 
Serine-392 Phosphorylation CKII, p38 
MAPK 
Herrmann et al., 
1991; Keller et al., 
2001 
Serine-15 
Serine-376, 
Threonine-
55 
Dephosphorylation PP1, PP2A Lu et al., 2007 
Lysine-120 Acetylation TIP60/hMOF Sykes et al., 2006 
Lysine-164 Acetylation CBP/p300 Tang et al., 2006 
Lysine-320  Acetylation PCAF Liu et al., 1999 
Lysine-370, 
Lysine-372, 
Lysine-373,  
Lysine-381, 
Lysine-382,  
Lysine-386 
Acetylation p300/CBP, 
KAT3B 
Gu and Roeder, 
1997; 
Sakaguchi et al., 
1998; Liu et al., 
1999; 
Ivanov et al., 2007 
Lysine-373 
Lysine-382 
Deacetylation SIRT1 Luo et al., 2000; 
Michishita et al., 
2005, 
Lysine-370, 
Lysine-372, 
Lysine-382 
Methylation KMT3, KMT5, 
KMT5A 
Ivanov et al., 2007; 
Shi et al., 2007; 
Kurash et al., 2008 
Lysine-386 Sumoylation PIASy, Topors Bischof et al., 2006; 
Stehmeier et al., 
2009 
Lysine-320, 
Lysine-321 
Neddylation FBXO11 Abida et al., 2007 
Lysine-370, 
Lysine-372, 
Lysine-373 
Neddylation MDM2 Xirodimas et al., 
2004 
C-terminal 
lysine 
residues 
Ubiquitination MDM2, Pirh2, 
COP1, ARF-
BP1 
Rodriguez et al., 
2000; 
Leng et al., 2003; 
Harris and Levine, 
2005 
C-terminal 
lysine 
residues 
Deubiquitination HAUSP 
(USP7), USP10 
Li et al., 2004; 
Brooks et al., 2007; 
Yuan et al., 2010 
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1.11 The p53 gene family 
Two p53 family members, p63 and p73, were discovered in 1997 (Kaghad et 
al., 1997; Yang et al., 1998; review in Bourdon, 2007(a) & (b)). The p53 gene 
family members p53, p63 and p73 are involved in development, differentiation 
and cellular response to stress (review in Bourdon, 2007(a) & (b)). These p53 
family members are not functionally redundant as individual knockout mice 
showed they have different phenotypes, thus, they have their own unique 
functions. p53 gene encodes 9 protein isoforms, 6 protein isoforms by p63 
gene and at least 29 protein isoforms by p73 gene. These protein isoforms 
arise due to multiple splicing sites, alternative internal promoter usage and 
alternative translation initiation (review in Murray-Zmijewski et al., 2006). The 
high level of sequence homology in the DNA binding domain among p53 
protein family members allows p63 and p73 to bind to p53 responsive elements 
and transactivate genes responsible for cell cycle arrest and apoptosis. The 
p53 family members p53, p63  and p73 functions are regulated by subcellular 
localisation, post-translational modifications and regulatory proteins, however, 
little is known about p63 and p73 post-translational modifications (Melino et al., 
2003). 
 
1.11.1 p53 isoforms 
Some evidence shows that p53 isoforms exist in human normal and cancerous 
cells. Since 1985, there is accumulating evidence showing that p53 exists in 
shorter forms which are derived due to various mechanisms, such as 
alternative internal promoter, alternative mRNA splicing, proteolytic cleavage, 
autodegradation, and internal translation initiation. 9 different p53 isoforms 
have been discovered which are abnormally expressed in tumour tissues in 
comparison to normal cells (Bourdon et al., 2005). The p53 isoforms are p53, 
p53β, p53γ, Δ133p53, Δ133p53β, Δ133p53γ, Δ40p53, Δ40p53β and Δ40p53γ. 
p53 gene is transcribed from two distinct sites upstream of exon 1 and from an 
internal promoter in intron 4. These alternative promoter expression results in 
N-terminally truncated p53 protein at codon 133 (Δ133 p53). Alternatively, 
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spliced intron 9 produces 3 isoforms, p53, p53β and p53γ, of which the p53β 
and p53γ isoforms are without the oligomerisation domain. The 9 isoforms that 
the human p53 gene encodes are due to the intron 9 alternative splicing and 
the alternative promoter usage in intron 4 (p53, p53β, p53γ, Δ133p53, 
Δ133p53β and Δ133p53γ) and also due to the intron 9 alternative splicing and 
alternative translation initiation or intron 2 alternative splicing (Figure 1.13) 
(Bourdon et al., 2005; review in Bourdon, 2007(a) & (b)). 
   
These p53 isoforms likely coordinate with full length wild-type p53 
function as a tumour suppressor. Studies on the potential roles of the various 
isoforms are still lacking and current knowledge is controversial. However, 
these variants were reported to either enhance the tumour suppressor activity 
of wild-type p53 or in contrast, inhibit the transactivation and suppressive 
functions via dominant-negative effect, and in short these isoforms can function 
as an activator or a repressor. The abnormal p53 isoform expression could 
deregulate the p53 response to stress stimuli making further genetic damage to 
cells thereby leading to tumour initiation and progression (Murray- Zmijewski et 
al., 2006). p53 isoforms have distinct biochemical activities such that co-
transfection of p53 and p53β slightly enhanced p53-mediated apoptosis while 
co-transfection of p53 and Δ133p53 strongly blocked p53-mediated apoptosis 
in a dose-dependent manner (Bourdon et al., 2005; Murray-Zmijewski et al., 
2006; Khoury and Bourdon, 2010). On the other hand, Δ40p53 isoform acts in 
a dominant negative manner towards wtp53 by inhibiting both p53 
transcriptional transactivation and p53-mediated apoptosis (Ghosh et al., 2004; 
Murray-Zmijewski et al., 2006). It is suggested that p53 isoforms can modulate 
p53 transcriptional transactivation activities. Each p53 isoform possibly has 
distinct biological and biochemical activities independent of full length p53, 
suggesting the involvement of p53 in a wide range of biological functions such 
as cell cycle arrest, apoptosis, differentiaton, replication, and DNA repair 
(Murray-Zmijewski et al., 2006). p53 isoforms similar in structure and functions 
to those of p63 and p73. They have a conserved DNA-binding domain and vary 
in their N- and C-terminal regions (Courtois et al., 2004). The abnormal and 
differential expression of p53 isoforms in different types of cancer suggest that 
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they disrupt the normal p53 response and contribute to tumourigenesis. Thus, 
this might explain why it is difficult in many clinical studies to link p53 status to 
prognosis and cancer treatment (review in Khoury and Bourdon, 2010).  
 
1.11.2 p53 family members (p63 & p73) & their isoforms 
p63 and p73 are two members of the p53 family which were discovered in late 
1990s (Kaghad et al., 1997; Yang et al., 1998). p63 and p73 genes are rarely 
mutated in human cancers, however, p73 is lost in neuroblastomas and T-cell 
lymphoma. This indicates that both p63 and p73 are not classical tumour 
suppressor genes as p53 is. They share significant homology with p53, though, 
they are structurally similar to each other than to p53. p63 and p73 show 
similarity with the TAD, the DBD and the TD of p53 (Schmale and Bamberger, 
1997; Scoumanne et al., 2005). The basic  domain (BD) is only present in p53 
but not in p63 and p73 and certain p63 and p73 isoforms, but not p53, have the 
sterile-α motif (SAM) domain. Thus, they also induce p53 target genes involved 
in cell cycle arrest and apoptosis (Scoumanne et al., 2005). p63-/- (Mills et al., 
1999; Yang et al., 1999) and p73-/- (Yang et al., 2000) knockout mice were not 
cancer prone but showed epidermal and neuronal defects in development 
(review in Melino et al., 2003) as compared to p53-/- null mice which developed 
normally but were tumour prone  (Donehower et al., 1992 & 1995; Scoumanne 
et al., 2005) but it was recently demonstrated that p63 and p73 have a role in 
tumour suppression since mice heterozygous for p63 and p73 were susceptible 
to tumour formation (Flores et al., 2005). Thus, the p53 family members show 
both common as well as distinct functions. Like p53, p63 and p73 give rise to 
multiple isoforms with distinct functions due to alternative promoter utilisation 
and alternative mRNA splicing (Marin & Kaelin, 2000).   
 
Both p63 and p73, like p53, can form homo-oligomers, bind to DNA to 
transcribe p53-target genes and mediate apoptosis (Jost et al., 1997, Osada et 
al., 1998, Yang et al., 1998). p53, p63 and p73 activate the expression of many 
common genes, such as p21 and Bax. Like p53, p63 and p73 are mostly 
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located in the nucleus and contain NLS and NES sequences. Similar to p53, 
p73 might undergo ubiquitination in the nucleus and be exported to the 
cytoplasm for degradation by the 26S proteasome pathway. N-terminally 
truncated (ΔN) forms of p63 and p73 that lack the TA domain act as dominant 
negative inhibitors of the TA isoforms and p53 where TA is pro-apoptotic while 
ΔN is anti-apoptotic.  
 
1.11.2.1 p63 and its isoforms 
p63 has 6 different isoforms (TAp63α, TAp63β, TAp63γ, ΔNp63α, ΔNp63β and 
ΔNp63γ). ΔNp63 isoforms lack transactivation domain found in TAp63 
isoforms. At least 3 alternatively spliced C-terminal isoforms (α, β and γ) are 
expressed by human and mouse p63 genes which can also be transcribed by 
promoter in the intron 3. While TA isoforms are formed in the upstream 
promoter in exon-1, the N-terminal truncated p63 isoforms (ΔNp63) are 
alternatively spliced by promoter in intron 3 (Figure 1.14). 
 
p63 isoforms bind DNA through p53RE and p63RE leading to 
upregulation of target genes involved in differentiation, cell-cycle arrest or 
apoptosis (Murray-Zmijewski et al., 2006; Bourdon 2007(a) & (b); Stiewe 2007). 
p63 is important for epidermal morphogenesis and limb development. p63-null 
mice are fatal after birth and show malformations in the limb and failure in the 
skin and other epidermal tissues development (Mills et al., 1999; review in 
Bourdon, 2007(a) & (b)). However, p63 role in cancer is still elusive. 
Paradoxically, Flores et al. (2005) have shown that p63+/- mice were shown to 
be cancer-prone while Keyes at al. (2005) demonstrated that p63+/- mice show 
premature aging without any sign of cancer growth.  
 
1.11.2.2 p73 and its isoforms 
p73 gene expresses at least 35 mRNA variants which theorytically give rise to 
29 different p73 protein isoforms, however, only 14 isoforms have so far been 
described (review in Khoury and Bourdon, 2010). The p73 gene can be 
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alternatively transcribed by promoter in the intron 3, where at least 7 isoforms 
arise from alternative C-terminal splicing (such as α, β, γ, δ, ε, ζ, η) and at least 
4 from alternative N-terminal splicing, each with different transactivation domain 
(TA, Ex2, Ex2/3 and ΔN). (Figure 1.15). p73 isoforms specifically bind DNA 
through p53RE and p73RE leading to trancription of target genes which either 
induce cell cycle arrest or apoptosis (Murray-Zmijewski et al., 2006; review in 
Bourdon, 2007(a) & (b); Stiewe, 2007). Mice null for all the p73 isoforms 
exhibited defects in development but did not susceptible to cancer (Yang et al., 
2000; review in Bourdon 2007(a) & (b)).  
 
p73 isoforms are differentially expressed in a wide range of tumours 
compared to normal tissues (review in Murray-Zmijewski et al., 2006). ΔNp73 
isoforms overexpression has been linked to be a poor prognostic marker in 
patients with neuroblastoma and is important for tumour survival by inactivating 
the apoptotic activities of p53 and TAp73 (Casciano et al., 2002; Murray-
Zmijewski et al., 2006). ΔNp73 isoforms have been shown to activate specific 
target genes not induced by TAp73 isoforms (Liu et al., 2004). 
 
1.11.3 The interplay between the p53 family members 
The interplay between the p53 family members p53, p63 and p73 and their 
isoforms might play a role in carcinogenesis (Deyoung and Ellisen, 2007; 
Mochado-Silva et al., 2010). p53 response to stress is dependent on the 
dynamics of the p53/p63/p73 isoforms and the ratio between these isoforms 
determine cell fate (Strano et al., 2000; Lang et al., 2004; Olive et al., 2004; 
Murray-Zmijewski et al., 2006). The interplay of the p53/p63/p73 family 
members and their isoforms involves direct and indirect protein-protein 
interactions, the regulation of the same target gene promoter as well as each 
other’s promoters (review in Murray-Zmijewski et al., 2006). TAp63 and TAp73 
recognise p53RE thus activate genes involved in cell cycle arrest and 
apoptosis. TAp63/TAp73 isoforms are tumour suppressive and these two 
isoforms are inactivated by ΔNp63/ΔNp73 isoforms which are dominant-
negative inhibitors of the p53 family members by either competition of DNA 
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binding sites or by direct protein-protein interactions. p53 mutants are capable 
of binding and inactivating p73 isoforms thus abrogate the TAp73 apoptotic 
function (Strano et al., 2000; Lang et al., 2004; Olive et al., 2004; Murray-
Zmijewski, 2006). It is assumed that the presence/absence as well as the ratio 
of p53 isoforms determine cell fate. The interplay between p53/p63/p73 
isoforms is important to our understanding of the transformation of normal cells 
to tumour formation (Machado-Silva et al., 2010). 
 
 
(a) Human p53 gene structure 
 
 
(b) p53 protein isoforms 
 
 
 
 
Figure 1.13. (a) Human p53 gene: Alternative splicing (α, β, γ) and 
alternative promoters (P1, P1’ and P2) and (b) its isoforms (9 isoforms 
altogether; p53, p53β, p53γ, Δ133p53, Δ133p53β, Δ133p53γ, Δ40p53, 
Δ40p53β and Δ40p53γ) (adapted from Machado-Silva et al., 2010). 
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(a) Human p63 gene structure 
 
 
 
 
 
 
 
(b) p63 protein isoforms 
 
 
 
 
Figure 1.14. (a) Human p63 gene: Alternative splicing (α, β, γ) and 
alternative promoters (P1 and P2)  and (b) its isoforms (6 isoforms 
altogether; TAp63α, TAp63β, TAp63γ, ΔNp63α, ΔNp63β and ΔNp63γ) 
(adapted from Machado-Silva et al., 2010). 
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(a) Human p73 gene structure 
 
 
 
(b) p73 protein isoforms 
 
 
 
Figure 1.15. (a) Human p73 gene: Alternative splicing (α, β, γ, ζ, Δ, ε, η) 
and alternative promoters (P1 and P2) and (b) its isoforms (29 isoforms 
altogether) (adapted from Machado-Silva et al., 2010). 
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1.12 MDM2 
1.12.1 The MDM2 oncogene and oncoprotein 
The mdm2 oncogene was first discovered as an amplified gene on a murine 
double- minute chromosome in a spontaneously transformed Balb/c 3T3DM 
mouse cell line (Cahilly-Snyder et al., 1987). The murine mdm2 gene is located 
at chromosome 10, region C1-C3, while its human homologue known as hdm2 
gene is located at chromosome locus 12q13-15, a region that is frequently 
amplified in over 30% of human sarcomas (Oliner et al., 1992). In this context 
both mouse and human gene and protein are referred to as mdm2 and MDM2, 
respectively. The mdm2 gene encodes at least five MDM2-related polypeptides 
(p90-95, p85, p76, p74, p57-58) within cultured mouse cells (Olson et al., 
1993), presumably due to alternative splice variants of mdm2 and/or post-
translationally modified forms. As shown in Figure 1.16, MDM2 protein consists 
of a p53 binding domain at the N-terminus (aa 1-220), a nuclear localisation 
signal (NLS) (aa 181-185), a nuclear export signal (NES) (aa 197-211), a 
central acidic domain (aa 223-274) and C-terminal zinc finger (aa 305-322) and 
RING (really interesting new gene) finger domains (aa 438-478).  
 
 
 
 
 
 
 
 
 
 
Figure 1.16. Structure of human MDM2 protein. NLS, Nuclear localisation 
signal; NES, Nuclear export signal (adapted from Picksley et al., 2001). 
 
 
 
p53 and E2F1 
binding 
domain aa 1-220 
NLS aa  
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NES aa 
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domain aa 438-
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The N-terminal p53 binding of MDM2 protein has been demonstrated to be 
involved in protein-protein interactions. The central acidic domain has been 
shown to interact with the ribosomal L5 protein where the ribosomal L5 protein 
can form complexes with MDM2 and MDM2-p53 protein complex. Both MDM2-
L5 and MDM2-L5-p53 protein complexes can bind 5SRNA (Marechal et al., 
1994). The MDM2 protein also contains a nuclear localisation signal and a 
nuclear export signal. The nuclear export signal is believed to be involved in the 
nucleocytoplasmic shuttling of MDM2 protein from the nucleus to the 
cytoplasm, required for efficient cytoplasmic MDM2-targeted p53 degradation 
(Roth et al., 1998). Nuclear export was proposed to be mediated through a 
short lysine-rich sequence present in MDM2, similar to the NES of the Rev 
protein from the human immunodeficiency virus (Roth et al., 1998). The Ring 
finger domain may mediate both protein-protein and protein-nucleic acid 
interactions (Elenbaas et al., 1996) and is critical for MDM2 E3 ligase activity 
(Fang et al., 2000). MDM2 is typically a very short-lived protein, whose rapid 
degradation is due to autoubiquitin-dependent proteolysis. Thus, the E3 ligase 
activity of MDM2 is not only important for the regulation of cellular p53 protein 
levels but also for the regulation of MDM2 levels. 
 
The MDM2 oncogene is amplified or overexpressed in a number of human 
tumours and it has been suggested that MDM2 levels are associated with poor 
prognosis in these tumours (review in Momand, 1998). In combination of a p53 
mutation, the prognosis is far worse than either event alone (Cordon-Cardo et 
al., 1994; Wurl et al., 1998). In general, human cancer cell lines or tumour 
tissues with MDM2 gene amplifications often have wt p53 protein, suggesting 
an inactivation of p53 by MDM2 (review in Momand, 1998; Wade et al., 2013). 
 
1.12.2 The p53-MDM2 autoregulatory interaction 
MDM2 is the main E3 ubiquitin ligase that ubiquitinates p53 (Yang and Li, 
2004). Other ubiquitin ligases that target p53 for ubiquitination and degradation 
include COP1, Pirh2, Topors, Synoviolin and ARF-BP1 (Brook and Gu, 2006; 
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Anderson and Apella, 2010). MDM2 protein is a negative regulator of p53 
protein activity. This is strongly shown by the evidence that the mdm2 null 
genotype results in embryonic lethality but is rescued in mice null for p53 gene 
(Jones et al., 1995; de Oca Luna et al., 1996) suggesting that the principle 
function of MDM2 protein is to regulate p53 protein function. Lack of MDM2 
causes cell death, mainly by p53-mediated apoptosis. 
 
 Crystallographic analysis showed that the N-terminus of p53 protein 
formed an amphipathic helix with Phe19, Trp23 and Leu26  buried deep into a 
deep hydrophobic cleft formed by the N-terminus of MDM2 protein (Figure 
1.17) (Kussie et al., 1996). Interaction between the MDM2 and p53 proteins 
has been shown to inhibit p53 protein from recruiting the transcriptional 
machinery, thereby inactivating the ability of p53 protein to act as a 
transcription factor (Momand et al., 1992; Oliner et al., 1993).  
 
Figure 1.17. p53-MDM2 protein-protein interactions. p53 protein is shown in 
yellow while MDM2 protein in blue. Amino acid residues F19, W23 and L26 of 
the p53 protein are buried deep into a hydrophobic cleft of the MDM2 N-
terminus. F, Phenylalanine; W, Tryptophan; L, Leucine  (adapted from Kussie 
et al., 1996).  
 
 
MDM2 binds to p53 protein preferentially when p53 protein is present as 
a tetramer (Marston et al., 1995). This is to ensure that, under normal 
conditions and without DNA damage insults, MDM2 will not cause a complete 
elimination of cellular p53, and p53 (and MDM2) will remain at basal level 
(reviewed in Zhang and Wang, 2000). MDM2 acts on p53 in two ways. Firstly, 
by binding to p53 transactivation domain TAD1, thus masking p53 from its 
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transcriptional machinery leading to inhibition of p53 to transcribe its target 
genes. Secondly, MDM2 acts as an E3 ubiquitin ligase to ubiquitinate p53 and 
translocate p53 from the nucleus to the cytoplasm in a RING domain-
dependent manner, thus subjecting p53 for proteosomal degradation (Shadfan 
et al., 2012). The C-terminal part of p53 as well as the oligomerisation domain 
was shown to be important for MDM2-targeted degradation (Kubbutat et al., 
1998). This might be due to the presence of multiple lysine residues, which 
serve as sites for MDM2-directed ubiquitination (Kubbutat et al., 1998). Change 
of cysteine to alanine (C462A) in the knockin mutation of the MDM2 RING 
finger shows that the physical interaction between MDM2 and p53 is not 
sufficient to regulate p53 but is co-modulated by MDMX, the MDM2 family 
member (Anderson and Apella, 2010). p53 activation involves uncoupling it 
from its main negative regulators, MDM2 and MDM2 homologue MDMX 
(Marine et al., 2007). Inhibition and/or degradation of MDM2 and MDMX is 
needed for a rapid accumulation of p53 protein and its activation as 
transcription factor (review in Toledo and Wahl, 2006; Meek, 2009). In addition, 
a small reduction in MDM2 can significantly increase p53 activity (Brown et al., 
2009; Khoury et al., 2011). 
 
p53 protein degradation is mediated by the ubiquitin-proteosome 
pathway which involves a system of enzymes that conjugate multiple ubiquitin 
chains to lysines in the targeted protein. Polyubiquitinated proteins are then 
degraded by the 26S proteosome. More importantly, MDM2 protein functions 
as the E3 ligase that ubiquitinates p53 protein for proteosome degradation 
(Honda et al., 1997; Michael and Oren, 2003). p53 ubiquitination may serve not 
only as a degradation tag, but also as a subcellular relocalisation tag. After p53 
mono-ubiquitination by MDM2, p300 can catalyse poly-ubiquitination of mono-
ubiquitinated p53 and promote p53-protein degradation (Grossman et al., 
2003). Li and colleagues reported that the different levels of MDM2 protein 
mediate either mono-ubiquitination of p53 protein resulting from low levels of 
MDM2 protein or poly-ubiquitination of p53 protein due to higher levels of 
MDM2 protein (Li et al., 2003), possibly indicating that MDM2 protein levels 
determines a ubiquitination switch (review in Wahl et al., 2005). Indeed, p53 
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mono-ubiquitination leads to subcellular localisation but not degradation 
through nuclear export of p53 protein, while p53 poly-ubiquitination leads to 
p53 proteosomal degradation having a chain of at least four ubiquitins attached 
(Li et al., 2003; Wahl et al., 2005). The ubiquitination of p53 on C-terminal 
lysines may alter the conformation of that region, in a manner that exposes the 
C-terminally located NES and thus, allows its efficient recognition by the 
nuclear export machinery (reviewed in Michael and Oren, 2003). It is believed 
that optimal p53 protein ubiquitination relates to p53 oligomerisation. The 
oligomerisation domain of p53 protein was found to be important for MDM2 
binding and degradation (Kubbutat et al., 1998). The Ring finger domain, the N-
terminal p53-binding domain as well as the central acidic domain of MDM2 are 
required for efficient p53 degradation (reviewed in Kubbutat et al, 1999; 
Argentini et al., 2001). Several p53 C-terminal lysine residues involved in 
acetylation are also subjected to MDM2-mediated ubiquitination (Lee and Gu, 
2010; Pei et al., 2012). When these residues become acetylated in responding 
to cellular stress, p53 becomes stable and active because acetylation of p53 
prevents it from being ubiquitinated and degraded by MDM2 (Pei et al., 2012). 
 
The SUMO-1 protein inhibits MDM2 self-ubiquitination and increases the 
ubiquitin-ligase activity of MDM2 protein. DNA damage inhibits the activity of 
the SUMO-1 protein, thus indirectly stabilising p53 protein (Buschmann et al., 
2000). The ubiquitin ligase activity of MDM2 can be inhibited by the binding of 
another tumour suppressor protein, p14ARF (p19ARF in mice), to the Ring finger 
domain of MDM2 which contains the E3 ligase activity and importantly is 
distinct from the p53 binding site (Honda and Yasuda, 1999). p14ARF is a direct 
inhibitor of the E3 ligase activity of MDM2 protein. p14ARF also sequesters 
MDM2 into the nucleolus, thus preventing nuclear export of p53 protein and in 
turn its degradation (Tao and Levine, 1999; Weber et al., 1999; Hu et al., 
2012). Sequestration requires the combined nucleolar localisation signals 
(NoLS) of both ARF and MDM2 (Honda and Yasuda, 1999; Lohrum et al., 
2000). The major consequence of MDM2-ARF interaction lies in the 
stabilisation and increased levels of transcriptionally active p53 protein in the 
nucleoplasm (Honda and Yasuda, 1999). A  p14ARF –p53-MDM2 regulatory 
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loop exists since p14ARF stabilises p53 protein and elevated p53 protein in turn 
down-regulates p14ARF protein expression (Gu and Kruse, 2009). 
  
Inhibition of cell growth and marked cell death are often observed in the 
absence of p53 regulation by MDM2, further emphasising the importance of the 
p53-MDM2 auto-regulatory loop in the control of cell growth and death (review 
in Alarcon-Vargas and Ronai, 2002). Figure 1.18 below summarises the control 
of cellular p53 protein levels by the p53-MDM2 negative autoregulatory 
feedback loop. 
 
Figure 1.18. p53-MDM2 negative autoregulatory feedback loop controlling 
the p53 cellular protein levels. Ub, ubiquitin; DUBs, deubiquitinations 
(adapted from Brown et al., 2009). 
 
1.12.3 Post-translational modifications of MDM2 
Post-translational modifications can prevent the interaction between MDM2 and 
p53 proteins. It was shown that phosphorylation of serine 15 and/or serine 20 
of p53 protein in response to DNA damage can disrupt its interaction with 
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MDM2 (Unger et al., 1999) and as a consequence p53 protein levels increase 
by preventing MDM2 from targeting p53 protein for cytoplasmic degradation.  
 
MDM2 is also a phosphoprotein, hence its interaction with p53 may be 
regulated through phosphorylation not only of p53 as mentioned above but also 
of MDM2 protein itself (Barak and Oren, 1992; Momand et al., 1992). MDM2 
protein has many putative phosphorylation sites for various protein kinases, 
with most of the modification sites clustered within the p53-binding domain and 
the central acidic  domain (Hay and Meek, 2000). To date, the kinases 
implicated in MDM2 phosphorylation are DNA-dependent protein kinase (DNA-
PK), ataxia telangiectasia-mutated kinase (ATM), mitogen-activated kinase 
(MAPK), AKT, p38 and cyclin-dependent kinases 1 and 2 (CDK1 and CDK2) 
(Mayo et al., 1997; Maya et al., 2001; Zhang et al., 2001;  Zhu et al., 2002). 
Importantly, in vitro phosphorylation of MDM2 by DNA-PK abrogates its 
interaction with p53 protein (Mayo et al., 1997). MDM2 entry into the nucleus is 
dependent on its phosphorylation by the phosphatidylinositol 3-kinase 
(PI3K)/AKT kinases (Mayo and Donner, 2001; Gottlieb et al., 2002). AKT 
phosphorylation of MDM2 at Ser166 and Ser186 results in the translocation of 
MDM2 from the cytoplasm to the nucleus where it ubiquitinates p53 protein and 
mediates its degradation (Mayo et al., 2002; review in Meek 2004) while 
abrogation of the PI3K/Akt pathway by overexpression of PTEN and PI3K 
inhibitor LY294002 and withdrawal of survival signalling inhibits 
phosphorylation of these residues and blocks MDM2 entry into the nucleus. 
PTEN tumour suppressor gene product inactivates AKT but mutated PTEN can 
constitutively increase MDM2 activity in tumour cells (Mayo et al., 2002; review 
in Meek 2004). Ser166/186 phosphorylation of MDM2 also abrogates the 
interaction between MDM2 and its negative regulator ARF. The induction of 
MDM2 by the PI3K/Akt pathway results in increased p53 turnover, inhibition of 
p53 transcriptional activities and inhibition of p53-mediated apoptosis (Mayo 
and Donner, 2001; Zhou et al., 2001; Mayo et al., 2002; Ogawara et al., 2002). 
Thr216 phosphorylation of MDM2 reduces the MDM2-p53 interaction and 
augments the MDM2-ARF association. Ser17 phosphorylation of MDM2 
disrupts MDM2-p53 protein-protein interactions. However, S17A mutant of 
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MDM2 effectively inhibited p53-mediated transactivation. Thr216 
phosphorylation thus synergises with Ser17 phosphorylation to maximise p53 
induction (review in Meek and Knippschild, 2003). 
 
 Phosphorylated MDM2 inhibits p53 degradation (review in Meek and 
Knippschild, 2003; Meek, 2004). MDM2 phosphorylated at serine 395 by ATM 
inhibits MDM2-mediated degradation of p53 protein. MDM2 serine 395 
phosphorylation blocks nuclear export of p53 protein by MDM2 protein and 
increases p53 stability. Dephosphorylation of this residue does not interfere 
with MDM2-mediated ubiquitination of p53 protein but abolishes p53 
degradation. Phosphorylated MDM2 at serines 386, 395, 425 and 428 and at 
threonine 419 cooperatively stabilise p53 protein by preventing its poly-
ubiquitination. Likewise, MDM2 phosphorylation at serine 407 by ATR inhibits 
p53 nuclear export. In response to DNA damage, ATM activates downstream c-
Abl kinase by direct phosphorylation, which then phosphorylates MDM2 at 
tyrosines 276 and 394 (Goldberg et al., 2002; Dias et al., 2006). 
Phosphorylation of MDM2 at tyrosine 276 increases MDM2 binding to its 
negative regulator ARF which protects p53 protein by re-localisation of MDM2 
to the nucleolus (Dias et al., 2006; Waning et al., 2010). Ser267 of murine 
MDM2 (Ser269 in human MDM2) was mainly phosphorylated by CK2 while 
Ser258 was a minor CK2 target  (Hjerrild et al., 2001). Phosphorylated Ser267 
by CK2 occurs physiologically which regulates p53 turnover by MDM2.  
 
Upon DNA damage, ATM is activated and phosphorylates MDM2 at 
Ser394 (human Ser395) resulting in inactivation of MDM2 ubiquitin ligase 
activity, thus increases p53 levels and tumour suppressive activities by 
inducing apoptosis, thereby inhibiting tumour formation in mouse models 
(Gannon et al., 2012; Li and Wahl; 2012). It is evident that phosphorylated 
MDM2 Ser394 regulates the amplitude and duration of the response to DNA 
damage at least in mice. Mouse knockin model of substitution of S394A (serine 
to alanine) which cannot be phosphorylated by ATM in response to DNA 
damage stimuli by ionising radiation/ irradiation (IR) causes MDM2 to 
ubiquitinate p53 leading its export to the cytoplasm and degradation in 
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proteasome and also inactivation of p53 tumour suppressive functions (cell 
cycle arrest, apoptosis). However, knockin mutant S394D (serine to aspartic 
acid) mice, mimicking constitutively phosphorylated serine, proved to be viable 
and showed inhibition of p53 nuclear export and degradation. These two mice 
models demonstrate that phosphorylation status of MDM2 Ser394 impact p53 
protein levels and its tumour suppressive functions in response to DNA 
damage in vivo (Gannon et al., 2012; Li and Wahl; 2012). 
 
Dephosphorylation of some or all of these residues (Ser240, 242, 260, 
262) reduces MDM2-mediated degradation of p53 protein and consequently 
promotes p53 accumulation (review in Meek and Knippschild, 2003). Wip1, a 
phosphatase, dephosphorylates MDM2 at Ser395 and MDMX at Ser403, 
increasing their stability thus inactivating p53 tumour suppressive activities (Lu 
et al., 2008; Zhang et al., 2009; Pei et al., 2012). 
 
 MDM2 was sumoylated at Lys136, 146, 182 and 185 in vivo by Sumo E3 
ligases Ubc9, PIAS1 and PIASxβ and by these enzymes and RanBP2 in vitro. 
ARF has been shown to stimulate MDM2 sumoylation (Xirodimas et al., 2002) 
as ARF blocks the ubiquitination of p53 by MDM2. Mutant Ubc9 protein results 
in inhibition of MDM2 sumoylation in a dominant negative manner, leading to 
increased MDM2 ubiquitination and decreased p53 ubiquitination thus favours 
p53 accumulation. UV radiation has been shown to inhibit MDM2 interaction 
with Ubc9 and subsequent loss of MDM2 sumoylation (Buschmann et al., 
2001(a); review in Meek and Knippschild, 2003). HAUSP (USP7), a 
deubiquitinase, deubiquitinates p53 as well as MDM2 and MDMX, resulting in 
their stability (Kruse and Gu, 2009; Brady and Attardi, 2010; Wang and Jiang, 
2012). The protein DAXX regulates HAUSP-mediated MDM2 deubiquitination 
(Tang et al., 2006; Kruse and Gu, 2009). Figure 1.19 depicts important post-
translational events of Mdm2 protein. Thus, in a nutshell, posttranslational 
modifications to both p53 protein and MDM2 protein can influence the 
stabilisation and activation of the p53 pathway. 
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Figure 1.19. Posttranslational modification events of MDM2 protein. NLS, 
Nuclear localisation signal; NES, Nuclear export signal (adapted from Meek 
and Knippschild, 2003). 
 
1.12.4 p53-MDM2 inhibitors 
Nutlin is the first non-peptidic molecule that interrupts the p53-MDM2 binding. 
Nutlin induces apoptosis via p53 transcription-dependent and transcription-
independent mechanisms (Vassilev et al., 2004; Khoo et al., 2014). Other 
drugs such as MI-219 (Shangary et al., 2008), RG7388 (Ding et al., 2013) and 
MI-888 (Zhao et al., 2013) result in tumour regression in xenograft model of 
human cancer cells with wildtype p53. These drugs induced p53 accumulation 
and apoptosis (Khoo et al., 2014). RG7112, the second-generation nutlin, 
potently killed cancer cells. It also promoted cell cycle arrest and apoptosis in 
human tumour xenograft (Tovar et al., 2013). 
 
1.13 MDMX (MDM4), an MDM2 homologue 
A structural analogue of MDM2 called MDMX, also known as MDM4, was first 
discovered by Shvarts and colleagues in 1996 (Shvarts et al., 1996), however, 
it is much less characterised in comparison to MDM2. p53 is postulated to be 
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constitutively active, meaning it inherently binds to DNA but is repressed by its 
major negative regulators MDM2 and MDMX complex (Kruse and Gu, 2009; 
Zilfou and Lowe, 2009). MDMX, like MDM2, binds to p53 protein via its N 
terminus thus inhibits p53-mediated transcription activation in vitro (Shvarts et 
al., 1996; Finch et al., 2002). However, MDMX itself is not an E3 ligase, nor 
does it have nuclear localisation and export signals, thus it does not mediate 
degradation of p53 protein and it depends on MDM2 for nucleocytoplasmic 
shuttling (Shvarts et al., 1996; Finch et al., 2002; Pei et al., 2012; Shadfan et 
al., 2012). In contrast to MDM2, MDMX is not a p53 target gene but it is an 
essential negative regulator of p53 like MDM2 (Marine et al., 2007). MDMX 
mainly functions to regulate p53 transcriptional activity instead of p53 protein 
levels since it is not an ubiquitin ligase itself, therefore it cannot ubiquitinate p53 
and target p53 for proteosomal degradation (Toledo et al., 2006). Sharp et al. 
(1999) have shown that MDMX interferes with MDM2-mediated degradation of 
p53 protein resulting in increased levels of p53 protein (Jackson and Berberich, 
2000). MDMX also prevents MDM2 degradation and translocation of p53 
protein to the cytoplasm by MDM2 (Stad et al., 2000 & 2001). In the absence of 
MDMX, MDM2 is relatively ineffective in down-regulating p53 protein due to its 
extremely short half-life (Gu et al., 2002). However, at appropriate ratio 
between MDMX and MDM2, MDMX renders MDM2 protein sufficiently stable to 
function at its optimal potential for p53 degradation by interacting through their 
RING finger domains (Tanimura et al., 1999; Gu et al., 2002; Wang and Jiang, 
2012). Heterodimerisation between MDM2 and MDMX through their Ring finger 
domains stimulate the ubiquitin ligase activity of MDM2 (Kawai et al., 2007). 
These findings show the mutual interplay between MDM2 and MDMX to 
achieve maximal inhibition of p53 protein and are consistent with the studies on 
deletion of either gene eliciting embryonic lethality, although occurring later in 
embryogenesis in Mdmx-/- mice than in Mdm2-/- mice, thus showing their 
distinct activities (Review in Wahl et al., 2005; Brady and Attardi, 2010). p53QS 
knockin mutant mice were unable to interact with both MDM2 and MDMX and 
this might be the reason for the embryonic lethality reminiscent to MDM2 null 
mice resulting from uncontrolled p53-mediated apoptosis (Johnson et al., 2005; 
Kruse and Gu, 2009). The relative level of MDM2 and MDMX determines p53 
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stability and activity (Pei et al., 2012). Figure 1.20 below shows a comparison 
between MDM2 and MDMX protein structures. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.20. A schematic diagram showing MDMX protein structure in 
comparison with MDM2 protein (adapted from Lenos and Jochemsen, 2011). 
 
 
MDMX is either amplified or overexpressed in numerous tumours and 
tumour-derived cell lines, where it coexists with elevated levels of wt p53 
(Ramos et al., 2001; Pei et al., 2012). It has also been shown that MDMX 
overexpression stabilises and increases both p53 and MDM2 proteins levels 
(Sharp et al., 1999; Stad et al., 2000). Importantly, mdmx knock-out in mice 
leads to p53-dependent embryonic lethality (Parant et al., 2001). However, the 
mdmx null phenotype is completely rescued by deletion of the p53 gene, 
thereby resembling some of the major characteristics of MDM2 (Parant et al., 
2001). Similar to p53, MDMX is ubiquitinated and degraded by MDM2 in stress 
conditions (Tang et al., 2006). Like MDM2, MDMX is also phosphorylated at 
multiple sites in DNA damage response but their impact on MDMX regulation 
remains to be determined (Meek & Hupp, 2010; Waning et al., 2010). Figure 
1.21 below shows important phosphorylation events of MDM2 and MDMX 
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proteins. To summarise, MDM2 and MDMX protein levels and their interactions 
with p53 are in part important determinant for p53 activity (Toledo and Wahl, 
2006; Fu et al., 2012).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.21. Phosphorylation events of MDM2 and MDMX proteins 
(adapted from Wade et al., 2010). 
 
1.14  Protein nitration 
Having discussed the well characterised modifications of p53 protein 
(phosphorylation and acetylation), this section will now discuss a modification 
type poorly characterised for p53 protein i.e. protein nitration. Protein nitration 
is a covalent post-translational protein modification resulting from the reaction 
of proteins with nitrating agents. The nitrating agents attack phenol groups on 
protein to produce nitrophenol. Nitrotyrosine has been the most well 
characterised amino acid due to the availability of nitrotyrosine antibodies 
which are not species-specific and also due to a historical role of 
phosphotyrosine in signal transduction. Tryptophan and phenylalanine are also 
nitrated but are poorly characterised. Figure 1.22 shows the location of tyrosine 
(Y), tryptophan (W) and phenylalanine (F) in a p53 amino acid sequence while 
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Figure 1.23 shows the positions of tyrosine (Y), tryptophan (W) and 
phenylalanine (F) in the p53 main domains. Following are examples of a 
precursor of nitrating agent nitric oxide and one commonly known and most 
important nitrating agent peroxynitrite. 
 
 1.14.1 Precursor of nitrating agents 
Nitric Oxide (NO•)  
Nitric oxide (NO•) is one of several free radicals ubiquitous  in our body which 
are generated by normal physiological process, including aerobic metabolism 
and inflammatory responses, to kill tumour cells and to eliminate invading 
bacteria or parasites (reviewed by Hussain et al, 2003). Free radicals have 
been shown to cause DNA damage, and protein structural and functional 
modifications (reviewed by Wiseman and Halliwell, 1996). NO• is a small 
hydrophobic molecule and freely permeable to cell membranes without through 
channels or receptors where there is no barrier between NO• and membranes 
(Muntane and De la Mata, 2010). 
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     NO• 
NOS  
L-Citrulline 
Enzyme cofactors 
e.g. NADPH (e
-      
       donor) 
       FAD 
       FMN 
       Calmodulin    
       (iNOS) 
       BH4 
L-Arginine + O2 
NO• is a physiological intracellular and intercellular messenger that is 
produced by several kinds of cells, including endothelial cells, nerve cells, and 
macrophages (Bredt and Snyder, 1994). NO• serves as a key signalling 
molecule virtually in every physiological process in the human body (review in 
Choudhari, 2013). In 1987, NO• was identified as the endothelium-derived 
relaxing factor (EDRF) that increases blood flow and decreases blood pressure 
through vasodilatation of blood vessels as well as being important in platelet 
inhibition (Ignarro et al., 1987; Palmer et al., 1987; Muntane and De la Mata, 
2010). NO• also acts as a neurotransmitter in certain types of nerves.  NO• is 
also an important component of host-defense and innate immunity against 
invading microorganisms. NO• is enzymatically generated in vivo from the 
amino acid L-arginine by a family of enzymes called NO• synthases (NOS) 
which metabolise arginine into citrulline with the formation of NO•. Oxygen and 
NADPH are necessary cofactors in this process (Muntane and De la Mata, 
2010). NO• is widely and actively synthesised, thereby virtually every type of 
mammalian cell is under the influence of NO• (reviewed in Schmidt and Walter, 
1994). Figure 1.24 shows a schematic diagram which simplifies the in vivo 
generation of NO•.  
     
Figure 1.24. In vivo Generation of Nitric Oxide (NO•). 
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Two functional classes of the NOS are constitutive and inducible forms. In 
human and mouse, 3 different genes, namely nNOS (NOS1), eNOS (NOS3) 
and iNOS (NOS2),  named according to their activity or the tissue type in which 
they were first described, encode for NO• synthases isolated from neurons, 
endothelial cells and inducible NOS isoforms, respectively (Leon et al., 2008; 
Muntane and De la Mata, 2010). nNOS and eNOS isoforms are constitutively 
expressed and dependent on elevated concentrations of calcium and 
calmodulin for activity (Nathan and Xie, 1994; Muntane and De la Mata, 2010). 
The inducible NOS (iNOS) isoforms are generally independent of increases in 
calcium concentrations and can produce consistent, high concentrations of NO• 
upon exposure with cytokines and lipopolysaccharide (Nathan and Xie, 1994; 
Hussain and Harris, 2007; Muntane and De la Mata, 2010). iNOS produces 
prolonged and at much higher concentrations of NO• in the cell compared to the 
other two isoforms. 
 
 NO• takes part in diverse biological signalling such as cell-mediated 
immune responses, cytotoxicity, regulation of cell death (apoptosis), cell 
motility, vasodilation and neurotransmission (Moncada et al., 1991; Leon et al., 
2008). NO• is a highly reactive free radical species as it has an unpaired 
electron and participates in many chemical reactions. It is lipophilic and 
neutrally charged in vertebrates that allows it to diffuse freely in and out of cell 
membranes thousands of times a second and is able to diffuse of more than 
several hundred microns (Lancaster, 1994). NO• has a very short biological  
half-life of a few seconds (1-10 s in biological fluids) and can interact with many 
molecules resulting in it is rapidly utilised close to where it is synthesised. NO• 
reactions with a number of targets such as haem groups, cysteine residues and 
iron and zinc clusters help to explain the wide range of roles it plays. NO• can 
activate p53, which acts as anti-carcinogenic agent, or it can be mutagenic and 
increase cancer risk, implicating it in carcinogenesis (Goodman et al., 2004). 
NO•, as a mediator of inflammation, was also shown by Hussain et al (2004) to 
suppress tumourigenesis where lymphomas developed more rapidly in p53-/-
NOS2-/- or p53-/-NOS2+/- mice than in p53-/-NOS2+/+ mice. In addition, 
sarcomas and lymphomas developed faster in p53+/-NOS2-/- or p53+/-
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NOS2+/- than in p53+/-NOS2+/+ mice. Thus, NO• has a double-edged role 
where it plays both beneficial and detrimental roles (Schmidt et al, 1992) 
depending on its concentration, its chemical fate, the microenvironment and the 
rate and location of its production (Mayer and Hemmens, 1997). It has been 
demonstrated that lower concentrations of NO• stimulates growth and is anti-
apoptotic while higher levels induce cell cycle arrest, senescence and/or 
apoptosis (reviewed in Thomas et al., 2008). 
 
1.14.2 Cytotoxic effects of NO• 
NO• oxidation products rather than NO• itself most likely mediate its cytotoxic 
effects. Thus, NO• does not directly attack DNA instead it is due to its oxidation 
derivatives such nitrogen oxide and dinitrogen trioxide (Wink et al., 2005). 
Activated macrophages which produce both NO• and superoxide inactivate 
mitochondria in tumour cells through the action of peroxynitrite formed from the 
reaction of these two free radicals (Radi et al., 1994). The rate constant 
between reaction of NO• and superoxide to produce peroxynitrite is 6.7 x 109 M-
1. s-1 The rate of superoxide reacting with antioxidant superoxide dismutase 
(SOD) is ~2 x 109 M-1. s-1. (Huie and Padmaja, 1993). This shows that NO• 
reacts with superoxide faster than SOD reacts with superoxide indicating that 
NO• outcompetes endogenous SOD for superoxide.   
 
The detrimental effects of NO• in diseases are mostly mediated by 
peroxynitrite (review in Pacher et al., 2007), produced through diffusion-limited 
reaction between NO• and superoxide radicals. 5-10 nM NO• will activate 
guanylate cyclase to produce cGMP which then activates cGMP-dependent 
kinases in the target tissue which controls intracellular calcium levels to 
modulate various processes in the target tissues (review in Pacher et al., 
2007). Excessive and upregulated NO• synthesis can cause pathophysiological 
conditions such as cancer (review in Choudhari et al., 2013) but 
downregulation also can cause Cardiovascular disease (CVD). 
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NO• is cytostatic and/or cytotoxic to tumour cells. NO• produced from 
macrophages, Kupffer cells, natural killer cells and endothelial cells acts to kill 
tumour cells i.e. showing tumouricidal activity (Li et al., 1991; Lechner et al., 
2005). NO• can either inhibit (cytostatic/cytotoxic or tumouricidal effects) or 
stimulate (tumour promoting effects by promoting tumour growth and 
proliferation) carcinogenesis. When cancer has occurred, NO• seems to be pro-
tumoural rather than anti-tumoural  because cancer cells cannot achieve NO• 
concentrations sufficient to cause tumour cell cytotoxicity (review in Korde-
Choudhari et al., 2012; review in Choudhari et al., 2013). 
 
1.14.3 Nitric oxide (NO•) role in apoptosis 
NO•-mediated apoptosis depends on the dose of NO• and the type of cells 
used. NO• has been shown to be able to both induce apoptosis for instance by 
activating p53 and to protect from apoptosis in different cell types. NO• was 
reported to be a potent activator of p53 protein. p53 accumulation and 
activation by NO• is reported through NO•-induced down-regulation of MDM2 
protein which is accompanied by a corresponding reduction in the rate of p53 
ubiquitination which precedes the rise in p53 protein (Wang et al., 2002). Wang 
et al (2003) have shown that NO• promotes p53 nuclear retention and inhibits 
MDM2-mediated p53 nuclear export. NO• induces phosphorylation of p53 on 
serine 15 resulting in increased p53 stability and its nuclear accumulation due 
to attenuated nuclear-cytoplasmic shuttling and failure of ubiquitin-mediated 
degradation of phosphorylated p53 protein (Schneiderhan et al., 2003; Lee et 
al., 2006). It was found that NO• markedly enhances the ability of ionising 
radiation to elicit apoptotic killing of neuroblastoma cells expressing 
cytoplasmic wild-type p53 (Wang et al., 2003). These findings imply that NO• 
can sensitise tumour cells to p53-dependent apoptosis. Thus, NO• donors may 
potentially increase the effectiveness of chemotherapy or radiotherapy for 
treatment of all types of cancer in general. The followings are some 
descriptions of the involvement of NO• and peroxynitrite in apoptosis in other 
pathological conditions in the human body. 
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In Parkinsons disease, NO• donor SNP in SN4741 dopaminergic neuron 
cells nitrated and activated protein kinase C (PKC)-δ which then 
phosphorylated p53 at Ser-15 resulting in the increased p53 protein stability 
leading to NO•-induced apoptosis (Lee et al., 2006). In RAW 264.7 
macrophages, NO• induced apoptosis through upregulation of mitochondrial 
manganese superoxide dismutase (MnSOD; SOD2) and down-regulation of 
cytosolic copper zinc superoxide dismutase (CuZnSOD; SOD1) at both mRNA 
and protein levels. Down-regulation of CuZnSOD resulted in NO• cytotoxicity 
and CuZnSOD over-expression inhibited macrophage from apoptosis mediated 
by NO• cytotoxicity (Brockhaus and Brune, 1999). 
 
In Type 1 diabetes mellitus (T1DM), proinflammatory cytokines such as 
tumour necrosis factor alpha (TNF-α) and interferon gamma (IFN-γ), produced 
by activated lymphocytes and macrophages, activate iNOS expression in β 
cells resulting in increased NO• levels and induction of apoptosis (Eizirik et al., 
1996; review in Quitana-Lopez et al., 2013). Mechanisms of NO•-mediated β-
cell apoptosis involve DNA damage by NO• oxidative derivatives leading to 
DNA strand breaks which then activate p53 resulting in the induction of pro-
apoptotic effector genes such as the Bcl-2 family of proteins BAX, NOXA, 
PUMA and FAS, caspases and cytochrome (review in Quitana-Lopez et al., 
2013). It has been demonstrated that NO• shows an anti-apoptotic effect at low 
concentration in several systems, including β cells (Sata et al., 2000; Ozaki et 
al., 2002; Dash et al., 2003). 
 
Both exogenously supplied (NO• donors) and endogenously produced 
NO• (iNOS induction) induce apoptosis in megakaryocytes. Treatment with 
peroxynitrite also promotes apoptosis in these cells (Battinelli and Loscalzo, 
2000). Stably transfected human Bcl-2 inhibits apoptosis after exposing RAW 
264.7 macrophages with NO• donors such as S-nitrosoglutathione (GSNO) and 
spermine-NO whereas these NO• donors induce internucleosomal DNA 
cleavage in a dose-dependent manner in parental RAW 264.7 and neomycin 
control-transfected cells. iNOS expression via response to lipopolysaccharide 
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and interferon-γ also induce apoptosis in parental RAW 264.7 and neo controls 
within 24 hr incubation (Mebmer et al., 1996). 
 
Cytokine IL-1β-induced iNOS expression stimulates NO•-dependent 
apoptosis in cardiac fibroblasts resulting from DNA damage and through p53-
dependent apoptotic pathway. IL-1β induces iNOS expression and NO• 
generation is associated with increased expression of p53 and Bax, enhanced 
caspase-3 activity and induction of apoptotic cell death (Tian et al., 2002). 
 
1.14.4 The nitrating agent Peroxynitrite 
Peroxynitrite (ONOO‾ ) is a strong cytotoxic oxidant and nitrating species which 
is formed by the extremely rapid, diffusion-limited reaction between two parent 
free radicals, NO• and superoxide anion (O2
•- ) (Pacher et al., 2007; Szabo et 
al., 2007; Jones, 2012). While the sources of NO• are mainly from the various 
isoforms of NOS, O2
•- is mainly formed from the mitochondrial electron transport 
chain, NADPH oxidase and xanthine oxidase (review in Liaudet et al., 2009). 
The intermediate product peroxynitrous acid (peroxynitrite conjugate acid) then 
easily decomposes at physiological pH to the highly reactive and toxic hydroxyl 
radical (HO•) and nitrogen dioxide (NO2
•) (Beckman et al, 1990) as shown in 
the following equations: 
 
NO• + O2
•-          ONOO‾ (peroxynitrite) 
ONOO‾ + H+             ONOOH (peroxynitrous acid)  
ONOOH          HO• + NO2
• 
  
Peroxynitrite has a relatively short half-life of around 10 ms but despite 
this it can easily crosses biological membranes and interact with target 
molecules within one or two cell diameters (Pacher et al., 2007; Szabo et al., 
2007: review in Liaudet et al., 2009). Peroxynitrite has been associated with 
both deleterious and beneficial effects (Moro et al, 1994; Vinten-Johansen, 
2000). Peroxynitrite plays important roles in virtually all diseases affecting 
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humans (review in Pacher et al., 2007). The physiological effects of 
peroxynitrite are dependent on the environment in which the anion is present 
and also on its concentrations (Mallozzi et al., 1997; Ronson et al., 1999; Ma et 
al., 2000). In comparison to NO•, peroxynitrite is toxic to cells, killing E. coli at 
micromolar concentrations (Zhu et  al, 1992). Peroxynitrite can cause oxidative 
damage to protein, lipid and DNA, mainly resulting in structural and functional 
inactivation of these molecules leading to dysfunction of multiple cellular 
processes (Pacher et al., 2007; Szabo et al., 2007: review in Liaudet et al., 
2009). Peroxynitrite can react with DNA by attacking both deoxyribose and by 
direct oxidation of purines and pyrimidines which consequently result in DNA 
damage (Salgo et al, 1995). Peroxynitrite can damage DNA through 
modifications in nucleobases by modifying guanine to 8-nitroguanine, 
modification in sugar-phosphate backbone resulting in DNA strand breaks and 
inactivation of DNA repair enzyme (Burney et al., 1999; Niles et al., 2006). 
 
Peroxynitrite levels are low in normal physiological conditions controlled 
by endogenous antioxidant defences (Radi et al., 2002(a) & 2002(b)). A 
moderate flux of prolonged peroxynitrite production will result in oxidative 
damage to host cellular constituents which in turn can result in the dysfunction 
of critical cellular processes, dysregulation of cell signalling pathways and 
mediation of cell death via both apoptosis and necrosis (Schroeder et al., 
2001). Thus, peroxynitrite plays a role in the development of many pathological 
processes in vivo. Peroxynitrite generated under inflammatory conditions can 
inactivate NOS by oxidatively modifying its haem group (Huhmer et al., 1997) 
which contributes to a negative feedback regulation between these two 
molecules. Ischiropoulos et al (1992) have found that peroxynitrite nitrates the 
ortho positions of tyrosine residues on proteins to form nitrotyrosine. 
Nitrotyrosine has been found in human pathologies (Kaur and Halliwell, 1994) 
and is a useful marker for peroxynitrite formation in vivo. Peroxynitrite may 
change protein structure and function by tyrosine nitration of the protein. 
Inactivation of proteins will lead to impaired cell signal transduction and loss of 
normal physiological functions which are two main aspects of peroxynitrite-
mediated cytotoxicity. Proteomic analyses have shown that nitration is a highly 
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selective process and specific to certain tyrosine residues in a small number of 
proteins. It has been shown that tyrosine nitration is found in at least 50 human 
diseases and more than 80 in animal models of diseases (Greenarce and 
Ischiropoulos, 2001). Tyrosine nitration is associated with significant loss of 
function. For instance, mitochondrial Mn-SOD lost its enzyme activity upon 
nitration, the first protein found to be nitrated in vivo. Nitration of a single 
tyrosine residue (Tyr-34) causes complete enzyme inactivation (MacMillan-
Crow and Thompson, 1999). 
 
1.14.5 Peroxynitrite and apoptosis 
Peroxynitrite activates apoptotic program through permeabilisation of 
mitochondria outer membrane (MOMP), which depends on the cell type and 
experimental conditions. This apoptotic program is initiated by the efflux of a 
variety of proapoptotic signalling molecules which promote apoptosis via both 
caspase-dependent and caspase-independent mechanisms (review in Pacher 
et al., 2007). MOMP is triggered by pore formation within the outer membrane 
by pro-apoptotic proteins (e.g. Bax, Bak and Bid) which are inhibited by anti-
apoptotic Bcl-2 and Bcl-XL proteins or by mitochondrial permeability transition 
(MPT) (review in Armstrong, 2006). Other than directly targeting mitochondria, 
peroxynitrite modulates various cell signalling processes such as MAPKs 
(mitogen-activated protein kinases) and Akt (protein kinase B). It has been 
shown in vitro that peroxynitrite activates MAPKs resulting in apoptosis but on 
the other hand it significantly inhibits Akt, a serine-threonine protein kinase 
which functions to promote survival or limit apoptosis in various stress 
conditions including oxidative stress (Martindale and Holbrook, 2002). 
Peroxynitrite inactivates Akt through nitration and inactivation of PI3K 
(phosphatidylinositol 3-kinase) which is upstream of Akt (Hellberg et al., 1998; 
El-Remessy et al., 2005; review in Parcher et al., 2007). However, an 
increased level of active Akt masks the pro-apoptotic effects of peroxynitrite 
(El-Remessy et al., 2005; Shacka et al., 2006). Thus, there is a link between 
Akt inhibition and apoptosis in such experimental conditions. 
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1.14.6 Peroxynitrite in phosphotyrosine and nitrotyrosine signalling 
Protein nitration by peroxynitrite results in inhibition of cell signalling processes 
dependent on tyrosine phosphorylation (Shi et al., 2007; Leon et al., 2008; 
Singh and Gupta, 2011), however, in other instances, peroxynitrite also 
promotes phosphotyrosine signaling. Peroxynitrite nitration of tyrosine residue 
can impair cell signalling relying on tyrosine phosphorylation and tyrosine 
nitration is capable of blocking downstream signalling in vitro. The 
dysregulation of tyrosine phosphorylation by peroxynitrite may affect various 
crucial cellular functions. Paradox to inhibition of phosphotyrosine-dependent 
signalling, peroxynitrite has been shown to activate phosphotyrosine-
dependent signalling in various cell types. For instance, peroxynitrite strongly 
activates MAPK family members, consequences from the upstream activation 
of various protein-tyrosine kinases, which further supports a positive tyrosine 
phosphorylation by peroxynitrite. (Pacher et al, 2007). The up-regulation of 
phosphotyrosine signalling by peroxynitrite at a relatively low concentration is 
transient and reversible, which is typical in any signalling processes. A higher 
concentration of peroxynitrite leads to irreversible nitrotyrosine formation and 
downregulation of phosphotyrosine signalling indicating that nitration and 
phosphorylation processes compete at high concentrations of peroxynitrite. Up-
regulated phosphotyrosine signalling can be either due to inhibited 
phosphotyrosine phosphatases (PTPs) or activated phosphotyrosine kinases 
(PTKs). Peroxynitrite has been shown to regulate these two events (review in 
Pacher et al., 2007). 
 
1.15  Relationships between nitric oxide/peroxynitrite, inflammatory 
processes and carcinogenesis  
An imbalance between production in reactive oxygen species (ROS) and their 
elimination by anti-oxidant mechanisms leads to oxidative stress. Sustained 
oxidative stress significantly damages important biomolecules, cell structure 
and functions and may induce mutation and neoplastic initiation (Fang et al., 
2009; Khandrika et al., 2009; Reuter et al., 2010). Oxidative stress has been 
79 
 
linked to carcinogenesis by increasing DNA mutation and DNA damage, 
inactivation of DNA repair enzymes, genomic instability and cell proliferation 
(Figure 1.25). Persistent oxidative or nitrosative stresses can result in chronic 
inflammation which ultimately lead to most chronic diseases such as cancer, 
diabetes, cardiovascular, pulmonary and neurological diseases (Visconti & 
Grieco, 2009; Reuter et al., 2010).  
 
Chronic infection and inflammation have long been known as risk factors 
for human cancers at various sites (reviewed by Ohshima and Bartsch, 1994), 
for instance, Hepatitis B virus infection and hepatocellular carcinoma; and 
chronic inflammatory bowel disease and colon carcinoma. The cytotoxic effect 
of NO• has been attributed to its reactive nitrogen species such as peroxynitrite. 
Reactive nitrogen and oxygen species generated in inflamed tissues can cause 
injury to target cells and also damage DNA. NO• and its derivatives can react 
directly with various enzymes and proteins to either activate or inhibit their 
function by reacting with their thiol groups (Li et al., 1997; Mohr et al., 1999), 
oxidizing SH groups, complexing with metal ions, or by reacting with tyrosine 
residues (reviewed by Henry et al., 1993). Overproduction of NO• and its 
derivatives over a long period of time in inflamed tissues play a role in the 
multistage process of carcinogenesis (reviewed by Tamir and Tannenbaum, 
1996; Muntane and De la Mata, 2010). eNOS is expressed in various cancers 
such as cervical, breast and central nervous system and the resulting NO• is 
implicated in different cancer-related events including cell cycle, apoptosis, 
angiogenesis, invasion and metastasis (Ying and Hofseth, 2007; review in 
Choudhari et al., 2013). NO• can act dichotomously either as tumour promoting 
or tumoricidal dependent on its timing, location, concentrations, the cell type, 
the redox state and the duration of exposure (review in Choudhari et al., 2013). 
 
In the pathophysiology of inflammation, proinflammatory cytokines 
produced will induce iNOS expression resulting in an increased NO• 
production. This NO• is toxic to the cells by, i) oxidatively modifying 
nucleobases, mostly guanine resulting in 8-oxoguanine, ii) nitrating guanine to 
form 8-nitroguanine, iii) inactivating DNA repair enzymes e.g. OGG1, and iv) 
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inhibiting p53 through tyrosine nitration. As NO• levels are increased in 
mitochondria during inflammation, superoxide levels are also increased within 
the mitochondrial matrix resulting in an increased in peroxynitrite levels. 
Peroxynitrite then nitrates and inhibits Mn-SOD, thus inhibits the breakdown of 
superoxide produced in mitochondria which in turn results in increased 
peroxynitrite formation (MacMillan-Crow and Thompson, 1999; review in 
Pacher et al., 2007). Peroxynitrite inhibits most electron transport chain 
components through mechanisms such as oxidation of cysteine residue, 
nitration of tyrosine and damage of iron sulphur centres (Radi et al., 2002(a) & 
(b)). Peroxynitrite also has genotoxic potential, where prolonged peroxynitrite-
oxidative and -nitrative stress in cell cultures and purified DNA mimicking 
inflammatory conditions/chronic infections, can increase the risk of cancer, 
consequently leading to cancer development. Similar to NO•, peroxynitrite can 
cause oxidative DNA damage and formation of DNA strand breaks. 
 
1.16  Nitration of p53 protein and the cellular response to genotoxic 
stress 
Nitration of tyrosine residues in various proteins and enzymes has been 
associated with inactivation of their functions. Several studies have shown that 
tyrosine nitration is a selective process as not all proteins and not all tyrosine 
residues of a protein are nitrated in vivo (Gow et al., 1996; Leon et al., 2008). 
Protein 3-nitrotyrosine has been found in a number of human and animal 
models of diseases (reviewed by Ischiropoulos, 1998). Nitrotyrosine (NTYR) is 
present in a variety of human tissues with significantly high levels in diverse 
human diseases such as Alzhemier’s disease (Good et al., 1996) and 
inflammatory bowel disease (Singer et al., 1996) as well as in animal models of 
diseases such as liver and skin carcinogenesis (Robertson et al., 1996; Ahn et 
al., 1999).  
 
p53 protein nitration is not extensively studied and to date there are only 
a few relevant studies concerning p53 nitration (25 articles on current PubMed 
search). Here are some of the landmark findings of the studies carried out by 
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independent groups of investigators. Forrester et al (1996) and Chazotte-
Aubert et al (2000) have suggested that p53 functions may be regulated post-
translationally by tyrosine nitration, thus indicating the existence of a close 
interaction between NO• and p53. It has been shown that p53 accumulates in 
cells incubated with NO•-releasing compounds (Forrester et al., 1996; Calmels 
et al., 1997; Hofseth et al., 2003) which cause DNA damage. p53 protein is 
also post-translationally modified upon exposure to NO• resulting in the 
inhibition of cellular growth (Hofseth et al., 2003; reviewed in Hussain et al., 
2003). In human gliomas, p53 is nitrated at Tyr327 within the tetramerisation 
domain, promoting p53 oligomerisation, nuclear accumulation and 
transcriptional activation without p53 Ser15 phosphorylation (Cobbs et al., 
2001; Yakovlev et al., 2010). p53 is also transcriptionally inactivated in human 
glioblastoma cells upon exposure to nitric oxide donor 3-
morpholinosyndonimine-1 (SIN-1) (Cobbs et al., 2003; Kim et al., 2011). On the 
other hand, overexpression of WT p53 transcriptionally transrepresses iNOS 
mRNA expression through inhibition of the iNOS promoter. These data are 
consistent with the hypothesis of a negative feedback loop in which NO•-
induced DNA damage induces wild-type (WT) p53 accumulation and 
subsequent down-regulation of NO• synthesis through p53-mediated 
transrepression of NOS2 gene expression through inhibition of NOS2 promoter. 
(Forrester et al., 1996; Ambs et al., 1997) (Figure 1.25). 
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Figure 1.25. Negative feedback loop between p53 and NO• (adapted from 
Ambs et al., 1997). 
 
 
NO• has also been shown to induce the accumulation and activation of 
p53 protein through downregulation of MDM2 protein resulting in reduced p53 
ubiquitination by MDM2 protein. However, prolonged exposure to NO• resulted 
in the increased levels of MDM2 protein owing to the upregulation the mdm2 
gene by active p53 protein resulting in the reduced level of p53 protein due to 
MDM2-mediated degradation of the p53 protein (Wang et al., 2002; Muntane 
and De la Mata, 2010). In addition, S-nitrosylation of cysteine 77 residue of 
MDM2 by NO inhibits MDM2 binding to p53 protein and this reaction is 
reversible (Schonhoff et al., 2002; Kim et al., 2011). This clearly shows that 
MDM2 plays a central role in the p53 and NO• signalling pathways (Figure 
1.26). 
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Figure 1.26. Nuclear accumulation of p53 protein in NO-stressed cells in 
comparison to its low levels in unstressed cells (adapted from Brune, 
2003). 
 
 
Calmels et al (1997) have shown that high levels of NO• cause profound 
structural changes of p53 from a wild type to a mutant conformation with loss of  
DNA binding activity and subsequently impairing its tumour suppressor 
functions. These could be due to a direct reaction of NO• with the zinc atom in 
p53 protein or from oxidation of cysteine residues (Calmels et al., 1997). 
Chazotte-Aubert et al. (2000) have demonstrated that incubation of MCF-7 
cells, expressing WT p53 protein, with an NO• donor results in nitration of 
tyrosine residues in p53 protein, which has been suggested to be a possible 
mechanism that could contribute to p53 functional impairment by NO•. 
However, p53 protein isolated from control cells has been shown only to 
contain low levels of nitrotyrosine. Thus, there is a possibility that p53 functions 
are partly regulated by nitration of its tyrosine residues by NO• and its 
derivatives (Chazotte-Aubert et al., 2000) but the evidence is weak. The 
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possibility that these effects are due to nitration of tryptophan and 
phenylalanine residues have not yet been explored. In another study by 
Hofseth et al. (2003), they found that p53 protein was post-translationally 
modified by NO• from donor drugs, leading to an increase in p53 transcriptional 
targets such an MDM2, p21(WAF1) and an increased expression of pro-
apoptotic proteins such as Bax together with a down-regulation of Bcl-2 and a 
G(2)M cell cycle checkpoint. They also found that inducible NO• synthase 
protein levels were positively correlated with p53 serine 15 phosphorylation 
levels. This proves a pivotal role of NO• in the induction of cellular stress and in 
the activation of a p53 response pathway by genotoxic stress.  
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AIMS AND OBJECTIVES OF THE STUDY 
 
This project is initiated a few aims and objectives as stated below: 
 
1)  In this thesis, we ask whether nitration of p53, a less common form of 
post-translational modification, will result in stabilisation of the p53 protein just 
like in phosphorylation and acetylation? 
 
2)  Before starting to embark on the nitration of p53 protein, the optimal 
conditions for nitration has to be determined using BSA since it is highly pure 
and easily nitrated as it contains 19 tyrosine residues. So a preliminary study is 
to make a lot of p53 protein both soluble and insoluble from the pT7.7Hup53 
construct expressed in E. coli expression system BL21(DE3) strain. Both forms 
of p53 protein will be purified by a series of purification systems. The purified 
p53 protein will then be nitrated with different doses of nitrating agent 
peroxynitrite and the levels of nitrated p53 and total p53 proteins will be 
determined by Western blotting.  
 
3) GST-MDM2 fusion protein (a.a 1 to 188) from the pGEX-2T-MDM2 
construct along with its control protein GST from the pGEX-2T construct are to 
be expressed in E. coli expression system BL21 strain followed by a single-step 
purification. The purified GST-MDM2 protein is to be nitrated with peroxynitrite 
at different doses to see nitration effects on its stability and on the protein-
protein interactions of GST-MDM2 protein with p53 protein. 
 
4)  In vitro nitration of the MCF-7 cell line harbouring wild-type p53 gene 
with NO donor GSNO will be examined to see whether nitration induces stability 
of wild-type p53 protein. 
 
86 
 
5)  In vitro nitration of mutant p53 protein in the PANC-1 cell lysates will be 
carried out. This cell line facilitates the analysis of nitrated p53 protein since it is 
abundant in mutant p53 protein. 
 
6)  Cell lysates from various cell lines with different p53 status, such as 
HCT116 p53+/+ (wt-p53), HCT116 p53-/- (null-53), PANC-1 (mut-p53) and 
SW620 (mut-p53), will either be directly nitrated with peroxynitrite before being 
immunoprecipitated for p53 protein by anti-p53 antibody or first be 
immunoprecipitated for p53 protein before being nitrated with peroxynitrite in 
order to determine nitration effects on nitro-p53 protein levels and also on total 
p53 protein levels. 
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CHAPTER 2 
 
MATERIALS AND METHODS 
 
2.1  General reagents 
 
All reagents for microbiological media (e.g. agar, yeast extract and tryptone) 
were obtained from Oxoid, Ltd, Basingstoke U.K. General laboratory 
chemicals were obtained from Sigma, Fissons plc and BDH, unless stated to 
the contrary. 
 
2.2  Microbiological media 
The following descriptions were for preparing a litre of the stated media. 
 
i.  Luria-Bertani (LB) Media  
LB media contained 10 g of bacto-tryptone, 5 g of bacto-yeast extract, 10 g 
of  NaCl and was adjusted to pH 7.0 using 5 M NaOH and then sterilised by 
autoclaving. Solid LB agar contained the same ingredients supplemented 
with 20 g of agar. Where required LB media was supplemented with filter 
sterilised ampicillin to a final concentration of 50 μg/ml. 
 
2.3  Buffers 
i. Phosphate Buffered Saline (PBS) 
1 litre PBS was prepared by dissolving 8.0 g of NaCl, 0.2 g of KCl, 1.44 g of 
Na2HPO4 and 0.24 g of KH2PO4 in distilled water and the pH was adjusted to 
7.4 with 0.1 M HCl and then sterilised by autoclaving. 
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2.4  Bacterial strains 
The bacterial strains used in this work are shown in Table 2.1, and with the 
exception of strain BL21 and derivatives thereof, are all derived from 
Escherichia coli K12.  The E. coli strain BL21 was derived from Escherichia  
coli strain B. Where E. coli strains have been used to over-express human 
proteins, prior approval was obtained from the local Genetically Manipulation 
Safety Committee at the University of Bradford, and the regulatory body 
notified. 
 
Table 2.1: E. coli bacterial strains used in this work 
Strain Genotype Source 
BL21 F
- ompT hsdSB (rB
-mB
-) gal  
dcm 
Studier & Moffat, 
1986. 
BL21(DE3) hsdS gal (cIts857 ind1 Sam7 
nin5 lacUV5-T7 gene 1 
Studier & Moffat, 
1986. 
BL21(DE3) Star F‾ompT hsdSB (rB
- mB
-) gal dcm 
rne131 (DE3) 
Invitrogen. 
DH5 supE44 hsdR17 recA1 endA1 
gyrA96 thi-1 relA1 
Meselson and Yuan 
1968; Hanahan 1983 
DH5α supE44 lac U169 (ø80lacZ 
M150 hsdR17 recA1 endA1 
gyrA96 thi-1 relA1 
Hanahan 1983; 
Bethesda Research 
Laboratories. 
 
 
Two host E. coli strains namely BL21(DE3) and BL21(DE3)Star were used in 
the over-expression of p53 protein. These two genetic backgrounds are 
deficient in both lon and ompT proteases, thus proteins are not degraded by 
these proteases. BL21(DE3)Star has additional feature where it is also 
RNAse E deficient, designed to increase protein expression by preventing 
RNA from being degraded. The two host E. coli strains are λDE3 
bacteriophage lysogens of the BL21 strain that carry the gene for the T7 
RNA polymerase, under the control of the isopropyl β-D-
thiogalactopyranoside (IPTG)-inducible promoter Ptac. 
 
 
89 
 
2.5  Plasmid vectors and derivatives 
Below is a list of plasmids used in this work. 
 
Table 2.2: Plasmids used in this work 
Plasmid Characteristic Source 
pT7.7 AmpR, a MCS under the 
regulation of a T7 
promoter. 
Tabor and Richardson, 
1985; Studier et al., 
Methods of Enzymology 
(1990). 
pT7.7Hup53 AmpR, with the human 
p53 gene under the 
regulation of a T7 
promoter. 
Midgley et al., J. Cell 
Science (1992). 
 
 
pGEX-2T AmpR, a MCS under the 
regulation of a Ptac 
promoter. 
Pharmacia 
pGEX-2T-MDM2 AmpR, with the human N-
terminal MDM2 (a.a. 1-
188) gene under the 
regulation of a Ptac 
promoter. 
Bottger et al., Oncogene 
(1996); Bottger et al., J. 
Mol. Biol. (1997). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1.  Map showing the pT7.7 plasmid with an inserted full length 
human p53 gene (Midgley et al., 1992). 
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2.6  Purification of plasmid DNA 
Plasmid DNA was purified using the alkaline lysis method of Birnboim and 
Doly (1979) and Ish-Horowicz and Burke (1981) in the form of Qiagen mini-
kits to prepare plasmid DNA from 10 ml overnight cultures.  1.5 ml of culture 
was transferred into 2 separate sterile microcentrifuge tubes and the cells 
were pelleted by centrifugation at 13,000 rpm for 2 minutes in a benchtop 
MSE micro-centrifuge at room temperature, and the supernatants were then 
discarded. The cell pellets were resuspended with 250 μl Buffer P1 (100 
µg/ml RNase, 50 mM Tris-HCl, 10 mM EDTA, pH 8.0) and following 
resuspension 250 μl of Buffer P2 (200 mM NaOH, 1% w/v SDS) was added 
and the tube inverted 4-6 times to gently mix the two solutions until the 
solution became viscous and slightly clear. 350 μl of Buffer N3 (5.6 M KAc, 
pH 4.8) was the added and the tubes were again inverted several times to 
mix. At this point, a cloudy precipitate was noticed which was followed by 
centrifugation for 10 minutes at 13,000 rpm at room temperature in a 
benchtop micro-centrifuge. A compact white pellet was formed. The 
supernatants were then applied to 2 separate QIAprep spin columns and 
centrifuged at 13,000 rpm for 30-60 seconds at room temperature in a 
benchtop micro-centrifuge. The flow-through was discarded. The columns 
were then washed by adding 0.75 ml Buffer PE (1.0 M NaCl, 50 mM MOPS, 
15% v/v ethanol, pH 7.0) and centrifuged as before for 30-60 seconds. The 
flow-through was discarded again and the columns were centrifuged for an 
additional 1 minute to remove residual wash buffer. The QIAprep columns 
were then placed in 2 autoclaved 1.5 ml micro-centrifuge tubes. To elute 
DNA, 5 μl Buffer EB (10 mM Tris-HCl, pH 8.5) was added to the centre of 
each QIAprep spin column, let stand for 1 minute and finally centrifuged for 1 
minute at 13,000 rpm at room temperature in a benchtop micro-centrifuge.  
 
2.7  DNA transformation using Calcium chloride (CaCl2) 
2.7.1  Preparation of competent cells 
A single colony was inoculated into 5 ml of sterile LB medium in two 15 ml 
Falcon tubes. One Falcon tube with 5 ml of un-inoculated LB medium was 
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used as negative control. The cultures were grown overnight at 37oC with 
moderate shaking at 180 rpm in an orbital shaker. 100 μl of each overnight 
culture was inoculated into 10 ml of fresh LB medium in 2 separate sterile 50 
ml Falcon tubes. They were grown at 37oC with moderate shaking at 180 
rpm in an orbital shaker until an OD600nm of 0.3 to 0.4 (mid-log phase). The 
cells were then centrifuged for 5 min at 5000 rpm at 4oC. The supernatants 
were decanted and each pellet was re-suspended in 5 ml ice cold 0.1 M 
CaCl2 solution. The mixtures were held on ice for 20 min and then 
centrifuged again as before. The supernatants were discarded and each 
pellet was re-suspended in 2.5 ml ice cold 0.1 M CaCl2. The re-suspended 
pellets were kept on ice for 10 min and followed by centrifugation at 5000 
rpm for 5 min at 4oC. Finally, the pellets were re-suspended in 1 ml ice-cold 
0.1 M CaCl2 solution. 
 
2.7.2  Transformation of competent cells 
200 μl competent cells were transferred into 2 separate 1.5 ml sterile 
Eppendorf tubes followed by addition of 5 μl plasmid DNA. The tubes were 
inverted gently to mix, and then placed on ice for 30 min. To facilitate the 
uptake of plasmid DNA, the cultures were heat shocked at 42oC for 45 sec, 
followed by incubation on ice water for 5 min. 1 ml of LB medium was added 
to each tube and then incubated 45 min at 37oC with shaking at 180 rpm in 
an orbital shaker to allow expression of β-lactamase. 200 μl of cells were 
plated on selective LB agar plates supplemented with 50 µg/ml of ampicillin. 
Another aliquot of cells were also plated on LB plates without ampicillin to 
demonstrate cell viability. The cells were then spread evenly on the agar 
plates using sterile spreaders. The plates were left to dry for a few minutes, 
inverted and then incubated overnight at 37oC. 
 
2.8  Small scale expression of p53 protein  
Overnight cultures of pT7.7Hup53 transformed strains were prepared by 
inoculating 5 ml of LB broth supplemented with 50 μg/ml of ampicillin, in 
separate sterile 15 ml Falcon tubes with a colony of each strain from their 
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respective selection agar plates. The cultures for each transformed strain 
were prepared in duplicates. One 15 ml Falcon tube containing 5 ml of un-
inoculated LB broth supplemented with 50 μg/ml ampicillin served as a 
negative control. The next day, 20 ml of ampicillin selective LB broth was 
then inoculated with 200 μl of each overnight culture in separate sterile 50 ml 
Falcon tubes. The cultures were grown to early mid-log phase (OD600nm 0.15-
0.20) at 37oC at 180 rpm in a shaking incubator and growth was monitored 
every 30 min. Once the OD600nm of the culture was within 0.15-0.20, 
isopropyl β-D-thiogalactopyranoside (IPTG) was added to the final 
concentration of 1 mM to one of each pair of the cultures. The other tubes 
where no IPTG was added served as negative controls. The growth was 
continued to 4 hours with growth monitored at 30 min time points. At each 
time point 1 ml of culture was removed and OD600nm reading was taken. The 
cells were pelleted by centrifugation at 13,000 rpm for 2 min at room 
temperature in a micro-centrifuge. The supernatants were discarded and the 
pellets were then re-suspended in 100 μl of 2x SDS gel-loading buffer (50 
mM Tris-HCl, pH 6.8, 2% w/v SDS, 0.1% w/v bromophenol blue, 10% v/v 
glycerol) and 100 mM dithiothreitol (DTT) which was added fresh. Cells were 
then stored at -20 oC for future use. 
 
2.9  Analysis of p53 expression   
p53 protein expression was analysed by two methods namely SDS-PAGE 
and Western Blot as described below. 
 
2.9.1  SDS-PAGE of protein samples 
The electrophoresis analysis of protein was carried out in a one-dimensional 
SDS-Polyacrylamide gel Bio-Rad Mini Protean II vertical slab apparatus 
which was assembled according to the manufacturer’s instructions. Table 2.3 
shows the concentration of acrylamide to be used according to the size of 
the desired protein. Since p53 protein falls within 16-68 kDa, therefore we 
used 10% acrylamide to prepare resolving gels throughout this work. 
93 
 
Table 2.3: Concentrations of acrylamide and its corresponding linear 
range of separation on SDS-polyacrylamide gels (adapted from Molecular 
Cloning by Sambrook, 1989) 
 
Acrylamidea concentration (%) Linear range of separation (kDa) 
15 12-43 
10 16-68 
7.5 36-94 
5.0 57-212 
aMolar ratio of bisacrylamide:acrylamide is 1:29 
 
Tables 2.4 and 2.5 below are recipes for preparing 10% resolving and 5% 
stacking gels, respectively: 
 
Table 2.4: Solutions for preparing 10% resolving gels for Tris-glycine 
SDS-polyacrylamide gel electrophoresis (adapted from Molecular Cloning 
by Sambrook, 1989) 
 
Solution components Component volumes (ml) per gel mold 
volume of: 
5 ml 10 ml 15 ml 20 ml 
H2O 2.6 5.3 7.9 10.6 
30% (v/v) acrylamide mix 1.0 2.0 3.0 4.0 
1.5 M Tris (pH 8.8) 1.3 2.5 3.8 5.0 
10% (w/v) SDS 0.05 0.1 0.15 0.2 
10% (w/v) ammonium 
persulfate (APS) 
0.05 0.1 0.15 0.2 
TEMED (density 0.775 g/ml) 0.004 0.008 0.012 0.016 
 
 
Table 2.5: Solutions for preparing 5% stacking gels for Tris-glycine 
SDS-polyacrylamide gel electrophoresis (adapted from Molecular Cloning 
by Sambrook, 1989) 
 
Solution components Component volumes (ml) per gel mold 
volume of: 
1 ml 2 ml 3 ml 4 ml 
H2O 0.68 1.4 2.1 2.7 
30% (v/v) acrylamide mix 0.17 0.33 0.5 0.67 
1.0 M Tris (pH 6.8) 0.13 0.25 0.38 0.5 
10% (w/v) SDS 0.01 0.02 0.03 0.04 
10% (w/v) ammonium 
persulfate (APS) 
0.01 0.02 0.03 0.04 
TEMED (density 0.775 g/ml) 0.001 0.002 0.003 0.004 
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Upon preparation of the samples they were loaded directly onto an SDS-
PAGE gel or stored at -20oC. Stored samples were thawed to room 
temperature and later sonicated three times for approximately 10 seconds 
each on ice at maximum amplitude (using a MSE 150 Watt Ultrasonic 
Disintegrator - MK2) to degrade chromosomal DNA. Samples were then 
boiled for 5 min. 20 μl of each sample and 10 μl of a pre-stained protein 
molecular weight marker (MBI Fermentas, Sunderland, UK) were loaded 
onto a polyacrylamide gel consisting of a 10% w/v resolving gel and a 5% 
w/v stacking gel. The gel was run at 90 V for about 2 hours in Tris-Glycine 
running buffer (25 mM Tris, 250 mM glycine, 0.1% w/v SDS) at pH 8.3.  
 
For protein bands visualisation, the gel was first incubated in Destain I (50% 
v/v methanol, 10% v/v acetic acid in distilled water) for approximately 10 
minutes and the protein bands were stained with Coomassie Blue (50% v/v 
methanol, 10% v/v acetic acid and 0.2% w/v Coomassie Brilliant Blue R-250, 
Sigma, in distilled water) for about 10 minutes. Following this the gel was 
destained overnight with Destain II (7.5% v/v methanol, 10% v/v acetic acid 
in distilled water). 
 
2.9.2  Western Blotting 
Samples were run on a 10% w/v resolving gel and a 5% w/v stacking gel as 
2.9.1 above. The gel was removed and briefly soaked in transfer buffer (39 
mM glycine, 48 mM Tris base, 0.037% w/v SDS and 20% v/v methanol) 
before being placed onto a nitrocellulose membrane, which were then 
sandwiched with a Whatmann 3MM filter paper and absorbent sponges on 
either side. The proteins were transferred using an electro-transfer apparatus 
(BioRad), at 90 V in transfer buffer for about 3 hours. 
 
After several trials, the following optimal conditions were obtained for 
immuno-detection of the p53 proteins. Following protein transfer, the 
membrane was removed from the transfer apparatus and incubated in 
blocking buffer solution (5% w/v non-fat dry milk powder in PBS/0.2% v/v 
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Tween 20) for 1 hour at room temperature with gentle agitation to block non-
specific binding to the membrane. The membrane was then washed 3 times, 
5 minutes each in PBS/0.2% v/v Tween 20. It was then incubated with the 
stated primary mouse monoclonal antibody at 1:1000 dilution in 1% w/v 
bovine serum albumin (BSA, Sigma) dissolved in PBS/0.2% v/v Tween 20 
overnight at 4oC. The unbound primary antibody was removed by washing 3 
times, 5 min each with PBST solution with constant shaking. A secondary 
horseradish peroxidase (HRP) conjugated rabbit anti-mouse IgG antibody 
(1:1000 dilution) (DAKO, Ely, UK) prepared in 1% w/v BSA in PBS buffer 
was added and left for at least 1 hour at room temperature. Three further 
washes of 5 minutes each were carried out using PBST with continuous 
shaking. The membrane was then immersed in 1:1 mix of ECL solutions I (1 
ml of 250 mM luminol in DMSO, 0.44 ml of 90 mM p-coumaric acid in DMSO, 
10 ml of 1M Tris-HCl pH 8.5 in 100 ml total volume) and ECL solution II (64 
µl of 30 % v/v H2O2, 10 ml of Tris-HCl pH 8.5 in 100 ml total volume) 
sufficient to cover the membrane surface for 1 minute, and then blotted to 
remove excess solution before being wrapped in cling film. The membrane 
was then exposed to Kodak X-ray film for a defined period of time in the 
dark, and then developed before a final wash by immersion in water.  
 
2.10 Large scale expression and solubilisation of human p53 
A 10 ml of overnight culture was used to inoculate 1 litre of LB broth 
supplemented with 50 µg/ml of ampicillin. The culture was incubated at 37oC 
with shaking at 180 rpm until its OD600nm reached 0.15 - 1.2 (early mid-log 
phase). IPTG was added to a final concentration of 1 mM and growth was 
continued with aeration for a further 4 hours. Cells were harvested by 
centrifugation at 8000 rpm for 10 minutes at 4oC in a Beckmann Avanti J25 
centrifuge in JLA 10,500 rotor. The pellet of induced cells was re-suspended 
twice in 20 ml ice-cold 50 mM Tris-HCl pH 8.0 and was finally resuspended 
in 0.66 ml/g of cells of lysis buffer (10% w/v sucrose, 50 mM Tris-HCl pH 8.0) 
and stored at -80oC until further use.  
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After thawing at 25oC, 15 µl of 10 mg/ml lysozyme and 20 µl of 5 M NaCl per 
ml of cells was added to the cells, mixed gently and kept on ice for 45 
minutes. The cells were warmed at 37oC for 1 minute, the tube rolled gently 
and then returned to ice-water. The cells were sonicated 3 times at maximum 
amplitude on ice for approximately 30 seconds each until the cells became 
less viscous. The insoluble proteins including p53 were pelleted by 
centrifugation at 10,000 rpm at 4oC for 10 minutes. At this stage, the 
supernatant which was assumed to contain 2% soluble p53 protein could be 
kept for further analysis. The pellet was then re-suspended in 5 ml of lysis 
buffer (50 mM Tris HCl pH 8.0, 2 mM EDTA, 10 mM NaCl, 1 mM PMSF, 
0.5% v/v Triton-X100) and repelleted. The wash was repeated two times in 
order to obtain a firm pellet. The protein was solubilised in 5 ml of: 5 M 
guanidine hydrochloride, 50 mM Tris-HCl pH 8.0, 0.005% v/v Tween 80 by 
mixing gently by a rotating wheel at 4oC (in a cold room) for 5 hours. The 
remaining insoluble material was pelleted as before. The supernatant was 
rapidly diluted to a final concentration of 1 M guanidine hydrochloride (20 mls 
of a mixture of 50 mM Tris-HCl pH 8.0, 0.005% v/v Tween 80, 2 mM reduced 
glutathione and 0.02 mM oxidised glutathione) and was mixed for a further 
12-18 hours. Protein was then dialysed at 4oC against 800 ml of the following 
buffers for at least 5 hours each: 
 
i) 50 mM Tris-HCl pH 8.0, 300 mM NaCl, 0.005% v/v Tween 80 
ii) 50 mM Tris-HCl pH 8.0, 250 mM NaCl, 0.005% v/v Tween 80 
iii) 50 mM Tris-HCl pH 8.0, 200 mM NaCl, 0.005% v/v Tween 80 
iv) 50 mM Tris-HCl pH 8.0, 150 mM NaCl, 0.005% v/v Tween 80 
 
Any insoluble or precipitated protein was pelleted at 10,000 rpm for 20 
minutes at 4 oC. 100 µl of the supernatant (dialysed protein) was taken and 
the same volume of 2x gel loading dye was added supplemented with 1/10 
volume of DTT which was freshly added and kept at -20 oC before checking 
the protein purity on a SDS-PAGE gel. 10% v/v glycerol was added to the 
remaining dialysed protein and kept at -80oC for future purification. 
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2.11  Purification of p53 protein dialysate 
Several purification techniques were carried out in order get optimal 
conditions for purification in order to produce about 5 mg of purified p53 
protein.  
 
2.11.1  Purification of human p53 protein by ion-exchange 
chromatography by stepwise gradient 
5 ml of dialysed human p53 protein from 2.10 above which was stored at -
80oC, was thawed and purified by ion-exchange chromatography (DEAE). 5 
ml of DEAE-Sepharose was poured into a 25 ml empty column (manual 
purification process through gravity) and was equilibrated with Buffer A (50 
mM Tris-HCl pH 8.0, 10% v/v glycerol, 0.1 mM EDTA, 1 mM DTT, 1 mM 
benzamidine, 0.1% v/v Triton-X100, 0.5 mM PMSF). The p53 protein was 
first diluted with 2 volumes of buffer A so that the final concentration of NaCl 
was 50mM. The diluted p53 lysate was then loaded onto the column in buffer 
A containing 50mM NaCl. 10 mls fractions of flow through (pre-washed) were 
collected. The washing step was followed where buffer A was loaded onto 
the column to remove unbound proteins and 10 ml fractions were again 
collected. After washing the column with buffer A, bound proteins were 
eluted from the column by a salt gradient ranging from 50 mM to 500 mM 
NaCl (in a step-wise manner). 1.5 ml fractions were collected and then 
analysed by a 10% (w/v) SDS-PAGE gel. 
 
i. p53 concentration by TCA precipitation 
To 900 µl of sample, 10 µl of 100% TCA to a final concentration of 10% v/v 
was added and left 30 minutes on ice. The mixture was pelleted by 
centrifugation at 13,000 rpm for 10 minutes and the supernatant was 
removed. The pellet was re-centrifuged, the supernatant discarded, and all 
traces of TCA were removed, followed by washing with absolute alcohol. A 
centrifugation was repeated as before and the pellet was drained and the 
alcohol was allowed to evaporate. 50 µl 1x SDS gel loading buffer was 
added. In case a yellow colour was obtained, the sample was neutralised 
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with 1 M Tris-HCl, pH 8.0 unadjusted until the dye turned blue. The proteins 
were then assayed by a 10% w/v SDS-PAGE gel.  
 
2.11.2  Purification of human p53 protein by affinity chromatography 
5 ml dialysed protein from pooled pellet from 6 litre cultures was subjected to 
heparin purification. The sample was first dialysed against 800 ml of  Buffer 
B (10% v/v glycerol, 25 mM HEPES pH 8.0, 0.1 mM EDTA, 0.1 mM EGTA, 
0.1% v/v Triton X-100, 5 mM DTT, 1 mM benzamidine, 0.5 mM PMSF) 
overnight at 4oC in a cold room. A 1 ml Hi-Trap-Heparin Sepharose 
(Pharmacia Biotech Inc.) column was equilibrated with 20 ml buffer B. The 
dialysed lysate containing p53 was first diluted with Buffer B containing 50 
mM NaCl and loaded onto the column by a pump connecting the sample and 
the column via a tubing. 1 ml fractions of flow-through  was collected. The 
column was washed with 20 ml buffer B to remove unbound proteins and 1 
ml fractions were collected. Bound proteins including p53 protein were then 
eluted from the column by a stepwise elution with buffer B containing NaCl 
ranging from 0.05 M to 1.00 M. To be precise, six different concentrations of 
NaCl were used as follows: 50 mM, 100 mM, 200 mM, 300 mM, 500 mM and 
finally 1 M. The flow rate was 0.5 ml/min, and 1 ml eluted fractions were 
collected. The fractions were then analysed by a 10% w/v SDS-PAGE gel. 
 
2.11.3  Purification of human p53 protein by phosphocellulose, P-11 
(Whatman) 
Selected fractions containing enriched p53 proteins in 2.11.2 above were 
pooled together and applied to a phosphocellulose, P-11 (Whatman), 
column. The phosphocellulose (resin) (5 ml) was first activated by incubating 
it with 10 column volumes (50 ml) 0.5 M NaOH which was stirred for a while 
and then let to stand for 10 minutes, then with 10 column volumes 0.5 M HCl 
and followed by washes in 0.1 M HEPES, pH 8.0. The column was washed 
with buffer B containing 1 M NaCl and then equilibrated in Buffer B 
containing 50 mM NaCl. The pooled fractions were applied to the 
equilibrated phosphocellulose column. The column was washed with Buffer 
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B to remove unbound proteins. The bound proteins were eluted from the 
column by a salt gradient (step elution) ranging from 0.05 M to 1.0 M NaCl at 
a flow rate of 0.5 ml/min and 1.5 ml fractions were collected. To be precise, 
six different concentrations of NaCl were used as follows: 50 mM, 100 mM, 
300 mM, 500 mM, 800 mM and finally 1 M. The proteins were then assayed 
by a 10% (w/v) SDS-PAGE gel. 
  
 
2.11.4 Purification and concentration of p53 protein by 
ultracentrifugation 
 
All the sample was loaded into 2 ml Centricon-30 (microcentrifuge filter, 
NMWL: 30 kDa, Millipore). The sample in the centricon was first centrifuged 
at 2,000 rpm for 10 minutes at 4oC. Centrifugation was repeated and 
concentrated by TCA precipitation as described previously. 1 ml of buffer B 
was added to the sample and repeatedly centrifuged as before until the 
volume reached the indicated level. Concentrated p53 protein (retentate) 
was then collected by transferring it into a 15 ml falcon tube. The two 
collected fractions, i.e. flow-through and retentate, were assayed by a 10% 
w/v SDS-PAGE gel. The retentate was stored at -20oC until required. 
 
2.12 In vitro Generation of Peroxynitrite 
Sodium nitrite (1.2 M NaNO2) was placed in one 30 ml syringe and nitric acid 
(1 M HNO3)/ 0.26% H2O2 in the other. Both the syringes were connected via 
a T-junction tubing. The syringes were pressed simultaneously with even 
pressure and the mixture was passed into a beaker containing 10 ml of 1.5 M 
NaOH. Below are the chemical equations for in vitro generation of 
peroxynitrite: 
 
H2O2 + HNO2                 ONOOH + H2O     (1) 
ONOOH + OH-              ONOO- + H2O       (2) 
(Pryor and Sequadrito, 1995; Saha et al., 1998) 
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The reaction was quenched by NaOH (reaction 2) where peroxynitrite is 
more stable in alkaline solution. Excess H2O2 was removed by passing the 
mixture down onto a manganese oxide placed in a funnel lined with filter 
paper until effervescence had ceased. The peroxynitrite solution was then 
scanned from 200-400 nm using a multi-wavelength scanning 
spectrophotometer. Absorbance readings of the peroxynitrite solution at 302 
nm were taken in triplicate and the peroxynitrite concentration was measured 
using the formula below:  
 
[Peroxynitrite] = (Optical Density302nm / 1.67 X 10
3  X  Dilution Factor) M 
 
The peroxynitrite solution was either used directly or aliquoted and kept at -
80°C for approximately 6 months. The aliquoted peroxynitrite solution was 
only thawed once and the optical density was measured each time the 
thawed peroxynitrite was used for nitration work. 
 
2.13 Nitration methods for proteins  
2.13.1 Two nitration methods 
2 nitration methods were employed namely an aggregometer set at 37°C at 
maximum speed (1200 rpm), and vortexing and a rocking water bath set at 
37°C at 200 rpm to determine the best method for nitration by nitrating 2 
mg/ml free fatty-acid bovine serum albumin (BSA) (a common nitration 
standard protein) dissolved in PBS, pH 7.4 with increasing concentrations of 
peroxynitrite ranging from 10 µM to 1 mM. 
 
2.13.1.1 Aggregometer set at 37°C at 1200 rpm 
100 µl of 2 mg/ml fatty acid-free BSA was first incubated for 10 min in an 
aggregometer set at 37°C at 1200 rpm. Peroxynitrite was then added slowly 
and the mixture was allowed to incubate for a further 15 minutes. 
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2.13.1.2 Vortexing and rocking water bath set at 37°C at 200 rpm 
100 µl of 2 mg/ml fatty acid-free BSA was first incubated for 10 min in a 
rocking water bath set at 37°C at 200 rpm. With constant and vigorous 
vortexing of the BSA, peroxynitrite was added directly and slowly to the BSA. 
The mixture was then incubated for a further 15 min in a rocking water bath 
set at 37°C at 200 rpm. 
 
2.13.2 Nitration of human p53, GST and GST-MDM2 proteins 
The proteins were nitrated with increasing concentrations of peroxynitrite (0, 
10 µM, 50 µM, 100 µM, 300 µM  and 500 µM) using a vortex and rocking 
water bath method as described above in Section  2.13.1.2 for BSA. 
 
2.14 Western blot for nitration of proteins 
2 different anti-nitrotyrosine antibodies were used to determine the one which 
gave a better signal (Table 2.6). Blots with untreated and 100 µM 
peroxynitrite treated BSA were also incubated with a variety of secondary 
anti-mouse antibodies. 
 
Table 2.6: Antibodies used in western blot optimisation for nitration 
Primary anti-nitrotyrosine used Secondary antibody used 
Anti-nitrotyrosine mouse monoclonal 
IgG, Clone 16A (Upstate 
Biotechnology) 
Rabbit anti-mouse monoclonal 
antibody IgG HRP conjugated 
(DAKO Cytomation) 
 
Anti-rabbit IgG HRP conjugated 
(Cell Signalling) 
 
Goat anti-rabbit IgG HRP 
conjugated 
(Amersham Biosciences) 
 
Rabbit polyclonal anti-nitrotyrosine 
IgG (Sigma) 
Sheep anti-rabbit IgG HRP 
conjugated (Serotec) 
 
Swine anti-rabbit IgG HRP 
conjugated (DAKO Cytomation) 
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Titration study of rabbit polyclonal anti-nitrotyrosine IgG (Sigma) was also 
carried out at 1:1000, 1:1500, 1:2000, 1:3000 and 1:5000 dilution. Protein 
transfer was carried out using 2 different membranes namely PVDF transfer 
membrane (Amersham Biosciences, 0.45 µm) and nitrocellulose (BDH 
Laboratory Supplies, 0.2 µm). The evaluations of different blocking 
conditions were also carried out. This was carried out by making one large 
well loaded with 100 µl of 1 mg/ml BSA dissolved in PBS in a 10% w/v SDS-
PAGE gel. After electrophoretic transfer, 2 blots with the same amount of 
BSA loaded were cut into 5 strips each and then incubated the blocking 
buffer below. One set of 5 strips were incubated with an anti-mouse 
monoclonal IgG HRP-conjugated alone in each blocking buffer used and the 
other set was incubated with an anti-rabbit polyclonal IgG HRP-conjugated 
alone in each blocking buffer used. Tables 2.7 and 2.8 below show the 
optimisation of blocking conditions and optimised Western blot conditions for 
nitration studies, respectively.  
 
 
Table 2.7: Blocking conditions used for optimisation of western blot for 
nitration (adapted from Antibody Manual by Harlow & Lane with slight 
modifications) 
 
Blocking Buffer Composition 
Blotto 5% (w/v) non-fat dry milk (Marvel) in PBS 
Blotto/Tween 5% (w/v) non-fat dry milk (Marvel) & 0.4% (v/v) 
Tween 20 in PBS 
Tween 0.4% (v/v) Tween 20 in PBS 
BSA 3% (w/v) BSA in PBS 
Horse Serum 10% (v/v) horse serum in PBS 
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Table 2.8: Optimised Western blot conditions for nitration studies 
(adapted from Dr Picksley’s lab protocol with slight modifications) 
 
Steps Details 
1. Blocking 5% non-fat dry milk (Marvel), 0.4% Tween 20 in 
PBS for 1 hr. 
2. Washes 3 changes of PBS, 10 min each 
3. Primary antibody 1:1000 dilution in 2% Marvel/0.2% Tween 20 in 
PBS for 1 hr. 
4. Washes 3 changes in PBS/0.2% Tween 20, 10 min each. 
5. Secondary antibody 1:1000 dilution in 2% Marvel/0.2% Tween 20 in 
PBS for 1 hr. 
6. Washes 5 changes ( ~ 5 mins each) with 2% skimmed 
milk Marvel, 0.2% Tween 20 in PBS and lastly 
transfer in PBS with 2 changes for ~ 2 mins each 
to rinse out the skimmed milk Marvel. 
 
2.15 Purification of soluble p53 protein using an FPLC system 
The supernatant obtained from large scale expression of p53 protein as 
mentioned in 2.10 was diluted 4-fold by the addition of buffer C [10% (v/v) 
glycerol, 25 mM HEPES (pH 7.6), 0.1 mM EDTA, and 2 mM dithiothreitol 
(DTT)] followed by the addition of MgCl2 to 5 mM. This lysate was loaded 1 
column volume per hour onto a 5 ml prepacked heparin Sepharose column 
that had been equilibrated in buffer C containing 50 mM KCl. After washing 
the column with 2 column volumes of buffer C containing 50 mM KCl, a 20 
column volume linear gradient was performed at 1-2 column volumes/hour in 
buffer C from 0.05 to 1.0 M KCl. Fractions were assayed for p53 protein by 
immuno-blot analysis using the DO-1 antibody. p53 protein derived from this 
step was concentrated using Centricon-30 and applied to Pharmacia 
Superose 12 column equilibrated in 10% (v/v) glycerol, 25 mM HEPES 
(pH7.6), 0.5 M KCl, 0.1 mM EDTA, 0.1% Triton X-100, and 5 mM DTT. The 
column was pre-calibrated with prestained gel filtration molecular weight 
markers consisting of Cytochrome c (12.4 kDa), Carbonic Anhydrase (29 
kDa), Bovine Serum Albumin (66 kDa), Alcohol Dehydrogenase (150 kDa) 
(Sigma) to determine the void volume of Blue Dextran (2000 kDa) and the 
elution volumes of other protein markers. The mobility (Ve/Vo) of each protein 
band was determined as the ratio of distance moved by each protein band to 
distance moves by tracking dye Blue Dextran. The gel filtration standard 
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curve was then generated by plotting the logarithm of the molecular weight 
against the mobility. 
 
Selected fractions obtained were then subjected to SDS gel electrophoresis 
and Western blot probed with DO-1 to detect possible active soluble p53 
protein. Attempted nitration of soluble p53 protein was carried out with 
increasing concentrations of peroxynitrite (0, 10 µM, 50 µM, 100 µM, 300 µM  
and 500 µM) using a vortex and rocking water bath method as previously 
described in Section  2.13. 
 
2.16 Determination of protein concentration - Bradford Assay 
Protein concentration was determined by Bradford Assay which involves the 
addition of an acidic dye to a protein solution. Several dilutions of standard 
protein (BSA) (1 mg/ml stock) ranging from 0 to 20 µg were prepared. 0.8 ml 
of standards and protein sample in distilled water were pipetted in a plastic 
cuvette. 0.2 ml of Dye Reagent Concentrate (Bio-Rad) was then added and 
mixed several times by gentle inversion. The samples were incubated at 
room temperature for at least 5 minutes. After incubation period the 
absorbance at OD595nm was measured versus reagent blank. Using the 
standard curve the test protein concentration was calculated. Table 2.9 
below shows the protein quantitation setup for Bradford Assay. 
 
 
Table 2.9: Preparation of Bradford Assay using standard protein BSA. 
BSA amounts ranging from 0 to 20 µg was added to distilled water and 
Bradford Assay dye was added to the mixtures. After incubation, the 
mixtures were measured at 595 nm and a BSA standard curve was plotted. 
 
Tube 
number 
1 mg/ml 
Standard BSA 
(µl) 
BSA 
(µg) 
Distilled water 
(µl) 
Bradford 
reagent dye (µl) 
1 0 0 800 200 
2 5 5 795 200 
3 10 10 790 200 
4 15 15 785 200 
5 20 20 780 200 
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1 mg/ml stock of standard protein BSA was prepared by dissolving 1 mg of 
BSA in 1 ml of distilled water. 
  
The components in the table above were mixed in 1.5 ml microcentrifuge 
tubes and briefly vortexed and incubated for at least 5 min at room 
temperature. The mixtures were then transferred into plastic cuvettes and 
then readings at 595 nm were taken using a spectrophotometer. 
 
2.17 Cell culture and cell extract preparation 
A panel of cancer cell lines were used in the nitration study. These include: 
the MCF7 breast cancer cell line (wt p53), the PANC-1 pancreatic cancer cell 
line (mutant p53), SW620 colorectal cancer cell line (mutant p53) and the 
HCT116 colorectal cancer cell line (null or wt p53). SW620 and HCT116 cells 
were used by Dart et al. (2004) to study the role of p53 in chemotherapeutic 
responses to selected anti-cancer drugs. Dart et al. found that the status of 
p53 protein in SW620 is mutant, non-functional, shows positive nuclear 
staining and p53 band present on Western blot. HCT116 shows negative p53 
staining, no band present on Western blot, p53 is wild type and functional. In 
the meanwhile, HCT116 p53-/- shows negative staining, no band present on 
Western blot, null p53 status and function.  These cells were grown in T25 or 
T75 flasks in DMEM medium (Biosera) supplemented with 100 U/ml penicillin 
and 100 µg/ml streptomycin, 2 mM L-glutamine and 10% (v/v) foetal bovine 
serum (FBS) until 80% confluent. MCF7 cells were priorly treated with 500 
ng/ml Actinomycin D for 24 hrs to induce the expression of wt p53 protein (as 
employed by Cobbs et al., 2001) as and when needed before the cell lysates 
were treated with peroxynitrite. The cell lysates were used in order to directly 
nitrate p53 protein. For NO donor S-Nitrosoglutathione (GSNO) (Sigma) 
treatment, MCF7 cells which were used as a model cell, were grown to ~80% 
confluent and incubated with 0.5 mM or 1.0 mM GSNO for a duration of 4 hrs 
before being harvested. Below is a molecular structure of GSNO: 
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Figure 2.2. GSNO Molecular Structure (taken from Sigma Aldrich) 
 
In order to harvest the cells, they were first washed with PBS before adding 
trypsin-EDTA and after the cells fully detached from the flask, complete 
growth medium was added which inactivated the trypsin due to the presence 
of serum. The cells were then pelleted by a low speed centrifugation at 1000 
rpm for 5 min. Some of the cells were left in the flask and grown in a 5% (v/v) 
CO2 incubator at 37°C for further growth. The cell pellets were lysed by 
incubating in NET buffer [150 mM NaCl, 5 mM EDTA pH 8.0, 50 mM Tris-
HCl pH 8.0, 1% (v/v) Igepal supplemented with protease inhibitors cocktail 
(Roche)] for 30 minutes on ice, with occasional gentle mixing. Cell extracts 
were collected by centrifugation at 13000 rpm for 30 minutes at 4oC. The 
supernatant was immediately transferred to a fresh micro-centrifuge tube and 
used directly while the pellet was discarded. The supernatant was pre-
cleared of non-specifically reacting material by incubating it with protein G 
Sepharose bead slurry for 30 min on ice with occasional mixing. Protein G 
Sepharose was prepared by washing the beads twice with PBS and restored 
to 50% (v/v) slurry with PBS. The sample was then centrifuged for 30 sec in 
a microcentrifuge at 13,000 rpm to remove non-specifically reacting material 
and the supernatant was transferred to a fresh tube for use in 
immunoprecipitation assay. The protein concentration of the cell lysate was 
determined by performing Bradford assay. The cell lysates were nitrated with 
increasing concentrations of peroxynitrite (0, 10 µM, 50 µM, 100 µM, 300 µM  
and 500 µM) using a vortex and rocking water bath method as previously 
described in Section 2.13.1.2. 
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2.18 Immunoprecipitation 
The pre-cleared cell extract (100 µg) was incubated with 1 µl of either anti-
nitrotyrosine monoclonal antibody or anti-p53 polyclonal (CM-1) antibody on 
ice for 60 min. 20 µl of protein G Sepharose bead slurry was then added and 
mixed in a rotating wheel for 15 minutes. The immune complexes bound to 
the beads were pelleted by centrifugation for 30 sec in a micro-centrifuge 
tube at 13000 rpm and then the supernatant was removed. The beads were 
then washed four times with 200 µl of NET buffer [150 mM NaCl, 5 mM 
EDTA pH 8.0, 50 mM Tris-HCl pH 8.0, 1% (v/v) Igepal supplemented with 
protease inhibitors cocktail (Roche)] containing 0.5 M NaCl. The washing 
step involved pelleting by centrifugation, the removal of supernatant and the 
addition of fresh buffer. The pellet was then resuspended in 50 µl of 2X SDS 
loading dye with freshly added DTT to a final concentration of 100 nM, boiled 
for 5 min to dissociate the immuno-complexes from the beads. The proteins 
were fractionated on an SDS-polyacrylamide gel and then followed by 
western blotting. 
 
2.19 GST and GST-MDM2 proteins 
2.19.1 Expression of GST and GST-MDM2 proteins 
Overnight cultures of pGEX-2T or pGEX-2T-MDM2 transformed strains were 
prepared by inoculating 5 ml LB broth supplemented with 50 μg/ml ampicillin 
in 15 ml Falcon tubes with a colony of each strain from their respective 
selection agar plates. A 10 ml of overnight culture was used to inoculate 1 
litre of LB broth (1:100 dilution) supplemented with 50 µg/ml of ampicillin. 
The culture was incubated at 37oC with shaking at 180 rpm until its OD600nm 
reached ~0.8 (late log phase). IPTG was added to a final concentration of 1 
mM and growth was continued with aeration for a further 4 hours. Cells were 
harvested by centrifugation at 8000 rpm for 10 minutes at 4oC in a 
Beckmann Avanti J25 centrifuge in JLA 10,500 rotor. The supernatant was 
discarded and the pellet drained and placed on ice. The pellet was then 
completely suspended in 50 µl of ice-cold 1 X PBS per ml of culture. The 
suspended cells were disrupted using a sonicator (MSE 150 Watt Ultrasonic 
Disintegrator MK2) on ice in short bursts at maximum amplitude. An aliquot 
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of the sonicate was saved for analysis by SDS-PAGE gel electrophoresis. 
20% (v/v) Triton X-100 was added to a final concentration of 1% (v/v). A 
protease inhibitor dissolved in distilled water was also added to the 
suspension. The mixture was gently mixed for 30 min to aid in solubilisation 
of the fusion protein. The suspension was centrifuged at 10,000 rpm for 10 
min at 4oC. The supernatant was then transferred to a fresh container. 
Aliquots of the supernatant and the cell debris pellet were saved for analysis 
by SDS-PAGE.  
 
2.19.2  Purification of GST and GST-MDM2 proteins 
2.19.2.1  Preparation of a 50% Glutathione Sepharose 4B slurry 
Glutathione Sepharose 4B (Amersham Biosciences) was used for batch 
purification of glutathione S-transferase (GST) or recombinant fusion GST-
MDM2 using the pGEX expression vector. A 50% (w/v) slurry was produced 
from approximately a 75% (w/v) slurry as supplied by the manufacturers. 
1.33 ml of the original Glutathione Sepharose 4B slurry per ml of bed volume 
was dispensed. One ml of drained gel was capable of binding at least 8 mg 
of recombinant GST. The gel was sedimented by centrifugation at 500 rpm 
for 5 min and the supernatant was carefully decanted. The Glutathione 
Sepharose 4B was then washed with 10 ml of cold 1 X PBS per 1.33 ml of 
the original slurry of Glutathione Sepharose 4B dispensed and inverted to 
mix. The gel was sedimented by centrifugation at 500 rpm for 5 min and the 
supernatant decanted. 1 ml of 1 X PBS was added to each 1.33 ml of the 
original slurry which produced a 50% (w/v) slurry. 
 
2.19.3 Batch purification of GST and GST-MDM2 proteins 
2.19.3.1 Binding 
2 ml of a 50% v/v slurry of Glutathione Sepharose 4B equilibrated with 1 X 
PBS was added to each 100 ml bacterial sonicate as described earlier. The 
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mixture was incubated with gentle agitation at room temperature for 30 min. 
The suspension was then centrifuged at 500 rpm for 5 min to sediment the 
gel and the supernatant was removed. The Glutathione Sepharose 4B pellet 
was washed with 10 bed volumes of 1 X PBS. The suspension was 
centrifuged in a 4 X 750 ml MSE Windshield rotor at 500 rpm for 5 min to 
sediment the gel and the wash discarded. The wash was repeated twice for 
a total of three washes.  
 
2.19.3.2 Elution 
1.0 ml of glutathione elution buffer (0.154 g of reduced glutathione dissolved 
in 50 ml of 50 mM Tris-HCl, pH 8.0) was added per ml of bed volume of 
Glutathione Sepharose 4B. The suspension was mixed gently to resuspend 
the gel and incubated at room temperature for 10 min to liberate the fusion 
protein from the gel. The mixture was centrifuged at 500 rpm for 5 min to 
sediment the gel. The supernatant was then removed and transferred to a 
fresh centrifuge tube. Elution and centrifugation steps were repeated twice 
more. Finally the three eluates were pooled, after confirming they all 
contained the GST or GST fusion protein. 
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RESULTS CHAPTER 3 
 
The aim of this work was to investigate the effects of nitration on p53 
function, therefore, to start off, a significant amount of pure p53 protein was 
needed for this study. In order to do this human p53 protein was first 
overexpressed in small scale in two E. coli strains BL21(DE3) and 
BL21(DE3) Star transformed with pT7-7Hup53, a plasmid encoding a full 
length human p53 gene which was originally constructed by Midgley et al 
(1992). The optimum conditions for the human p53 protein expression were 
then to be determined and the human p53 protein expression levels between 
the two E. coli strains were compared before a large scale expression of p53 
protein was carried out.  
 
3.1  Small scale expression of p53 protein 
The two competent strains as prepared in Materials and Methods (Section 
2.7.1) were transformed either with pT7.7 Hup53 or a pT7.7 plasmid alone 
(Section 2.7.2). Each  culture was split into two, one was grown until OD600nm 
of 0.15 to 0.20 (early mid-log phase) prior to the addition of isopropyl β-D-
thiogalactopyranoside (IPTG) to a final concentration of 1 mM to induce the 
expression of p53 protein and the other one was left uninduced to act as a 
control for induction. Transformed BL21(DE3) and BL21(DE3) Star strains 
with pT7.7 plasmids alone were only induced with IPTG and served as 
negative controls to monitor specific expression of p53 protein from the 
pT7.7Hup53 expression construct. Figure 3.1 shows IPTG-induced E. coli 
strain BL21(DE3)  containing a pT7.7 plasmid alone. In Figure 3.1, no bands 
corresponding to p53 protein can be seen as expected as no p53 gene was 
present in the plasmid vector, thus, no p53 protein was produced. Figure 3.2 
shows IPTG induction of human p53 protein from BL21(DE3) with a 
pT7.7Hup53 construct where bands corresponding to p53 protein can be 
seen with modest increased band intensity over time. A gel photograph of 
non-induced BL21(DE3) strain containing a pT7.7Hup53 construct (Figure 
3.3) shows that bands corresponding to p53 protein can be seen with 
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increased band intensity over time. This indicates that p53 protein was 
expressed in the non-induced BL21(DE3)/pT7.7Hup53 culture. The possible 
reason for this event is due to a leaky Ptac promoter where even without 
IPTG being added the promoter was initiated to transcribe T7 polymerase 
gene with concomitant p53 protein expression (Dubendoff and Studier, 
1991). Induced BL21(DE3) containing a pT7.7 plasmid alone is a more 
appropriate control as no bands corresponding to p53 protein were observed 
as expected. The same observation can be seen in the other E. coli strain 
i.e. BL21(DE3) Star (data not shown), as in BL21(DE3) above. These 
observations confirm that the two non-induced E. coli strains transformed 
with a pT7.7Hup53 construct constitutively produced T7 RNA polymerase 
which therefore resulted in a basal expression of p53 protein and made the 
induction of p53 protein expression less pronounced. This issue will be 
addressed in greater detail in the Discussion section. 
 
The optical density at λ=600nm of the induced and non-inducedcultures of 
each sample was measured during the induction process and are shown in 
Figure 3.4. The optical density of the induced culture of both E. coli strains 
was less than that for the non-induced culture. This is more likely due to the 
domination of cellular transcription of T7 RNA polymerase was more of the 
problem which resulted in the retardation of the growth of the host cells 
(Studier et al., 1990). To confirm that p53 protein was expressed in both non-
induced BL21(DE3) and BL21(DE3) Star transformed with pT7-7Hup53 
constructs, the transformation process for the two strains was repeated and 
small scale cultures of the strains were grown as before (i.e. OD600nm of 0.15-
0.2, 37oC at 180 rpm). Each culture was then split into two, one was induced 
with IPTG at OD600nm of 0.15-0.2 and the other one was left non-induced. 
Both Figures 3.5 and  3.6 show that p53 protein was expressed in both non-
induced transformed strains where p53 protein was expressed as early as at 
120 min time point in BL21(DE3) cells (Figure 3.5, Lane 3) whereas p53 
protein was only expressed at 240 min time point in BL21(DE3) Star cells 
(Figure 3.6, Lane 6). Since only two time points were taken, i.e. 120 min and 
240 min, these show that there is a difference in the start of the expression in 
the two non-induced strains. These figures show that in the two induced 
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strains, stronger p53 bands were seen at 240 min time point compared to 
120 min time point. Thus, the optimal time for the growth of the strains after 
IPTG induction is at least for 240 min (i.e. 4 hours), giving enough time for 
accumulation of target protein (Studier et al, 1990) which is evident by the 
earlier induction profile (Figure 3.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1.  A 10% SDS-PAGE gel showing IPTG induced E.coli strain 
BL21(DE3) containing a pT7.7 plasmid alone to act as a negative control for 
expression of p53 protein.                                    
 
Lane 1   – prestained protein molecular weight markers (Fermentas) 
Lane 2   – induced cells at 0 min 
Lane 3   – induced cells at 30 min 
Lane 4   – induced cells at 60 min 
Lane 5   – induced cells at 90 min 
Lane 6   – induced cells at 120 min 
Lane 7   – induced cells at 150 min 
Lane 8   – induced cells at 180 min  
Lane 9   – induced cells at 210 min 
Lane 10 – induced cells at 240 min 
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Figure 3.2. A 10% SDS-PAGE gel showing IPTG induction of the expression 
of human p53 protein from E. coli strain BL21(DE3) containing a pT7.7Hup53 
plasmid. The position of p53 protein is indicated. 
 
Lane 1   -  prestained protein molecular weight markers (Fermentas) 
Lane 2   -  non-induced cells at 240 min (negative control) 
Lane 3   -  induced cells at 30 min 
Lane 4   -  induced cells at 60 min 
Lane 5   -  induced cells at 90 min 
Lane 6   -  induced cells at 120 min 
Lane 7   -  induced cells at 150 min 
Lane 8   -  induced cells at 180 min 
Lane 9   -  induced cells at 210 min 
Lane 10 -  induced cells at 240 min 
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Figure 3.3.  A 10% SDS-PAGE gel showing non-induced E. coli strain 
BL21(DE3) containing pT7.7Hup53 plasmid. 
 
Lane 1   – prestained protein molecular weight markers (Fermentas) 
Lane 2   – non-induced cells at 30 min 
Lane 3   – non-induced cells at 60 min 
Lane 4   – non-induced cells at 90 min 
Lane 5   – non-induced cells at 120 min 
Lane 6   – non-induced cells at 150 min 
Lane 7   – non-induced cells at 180 min 
Lane 8   – non-induced cells at 210 min 
Lane 9   – non-induced cells at 240 min 
Lane 10 – induced cells at 240 min (positive control) 
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Figure 3.4.  Growth curves of IPTG induced and non-induced E. coli strains 
BL21(DE3) and BL21(DE3) Star. The bacterial cultures were taken every 30 
min and measured at OD600nm. 
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Figure 3.5.  A 10% SDS PAGE gel showing induced and non-induced E. coli  
strain BL21(DE3) containing a pT7.7Hup53 construct. 
 
Lane 1 – prestained protein molecular weight markers (Fermentas) 
Lane 2 – sample at 0 min 
Lane 3 – non-induced cells at 120 min 
Lane 4 – non-induced cells at 240 min 
Lane 5 – induced cells at 120 min 
Lane 6 – induced cells at 240 min 
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Figure 3.6.  A 10% SDS PAGE gel showing induced and non-induced E. coli 
strain BL21(DE3) Star containing a pT7.7Hup53 construct. 
 
Lane 1 – prestained protein molecular weight markers (Fermentas) 
Lane 2 – sample at 0 min 
Lane 3 – induced cells at 120 min 
Lane 4 – induced cells at 240 min 
Lane 5 – non-induced cells at 120 min 
Lane 6 – non-induced cells at 240 min   
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3.2  Western Blotting 
Western blotting was then carried out to confirm the band observed was the 
presence of p53 protein. After several trials, finally optimum conditions for 
western blotting were determined as described in the Materials and Methods 
Section. The data in Figure 3.7 further confirms that the two induced strains 
with the plasmid vector pT7.7 alone show no expression of p53 protein which 
is expected since no human p53 gene was inserted in the plasmid and 
therefore no p53 protein was expected to be produced (Figure 3.7, Lanes 2 
and 3). Thus, these are good to be used as negative controls for expression 
of p53 protein. However, the two strains transformed with pT7-7Hup53 
constructs expressed p53 protein even though they were not at all induced 
by IPTG (Figure 3.7, Lanes 4 and 7). From Figure 3.7 also we can notice that 
p53 protein was greatly expressed in both the induced strains at 240 min 
(Lanes 6 and 9). p53 degradation products can also be seen in Figure 3.7 
with greater intensities especially in both the transformed strains induced at 
240 min since DO-1 can detect not just full length p53 protein but also other 
forms of p53 protein. 
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Figure 3.7. A Western blot analysis of non-induced and induced E. coli 
strains BL21(DE3) and BL21(DE3) Star containing pT7.7Hup53 constructs 
compared to induced strains transformed only with plasmid alone to act as 
negative controls. The primary antibody was anti-p53 mouse monoclonal 
antibody DO-1 and the secondary antibody used for detection was rabbit 
anti-mouse antibody conjugated with HRP. 
 
Lane 1   – prestained protein molecular weight markers (Fermentas) 
Lane 2   – BL21(DE3) pT7.7 induced at 240 min 
Lane 3   – BL21(DE3) Star pT7.7 induced at 240 min 
Lane 4   – BL21(DE3) pT7.7Hup53 non-induced at 240 min 
Lane 5   – BL21(DE3) pT7.7Hup53 induced at 0 min 
Lane 6   – BL21(DE3) pT7.7Hup53 induced at 240 min 
Lane 7   – BL21(DE3) Star pT7.7Hup53 non-induced at 240 min 
Lane 8   – BL21(DE3) Star pT7.7Hup53 induced at 0 min 
Lane 9   – BL21(DE3) Star pT7.7Hup53 induced at 240 min 
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3.3  Large scale expression of human p53 protein 
Given the conditions for the induction of p53 protein (final IPTG 
concentration of 1 mM, incubation time of 240 min after induction, incubation 
temperature of 37oC with vigorous shaking at 180 rpm), our next step was to 
proceed with a large scale expression of p53 protein as described in 
‘Materials and Methods’(Section 2.10). In brief, the cell pellet was lysed and 
the inclusion bodies where 98% of human p53 protein present (Hupp et al., 
1992) were solubilised in denaturant, 5 mM guanidine-hydrochloride, and 
subsequently dialysed in buffers with decreasing NaCl concentration where 
renaturation of p53 protein took place and finally native form of the protein 
was obtained. A flow chart showing purification steps of p53 protein is shown 
below. 
 
Figure 3.8. Flow chart of steps involved in purification of p53 protein 
 
 
 
 
 
 
Inclusion bodies 
Renaturation of p53 protein and generation of disulphide bonds by the 
gradual removal of excess denaturant and reducing agent by dialysis in 
four buffers differing by NaCl concentration ranging from 300 mM to 
150 mM. 
Proceed with purification by a series of purification systems such as 
ion-exchange chromatography, affinity chromatography and 
phosphocellulose, P-11 (Whatman). 
Solubilisation of p53 protein by denaturant (5 M guanidine 
hydrochloride) and reduction of disulphide bonds by 2 mM 
reduced glutathione and 0.02 mM oxidised glutathione. 
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Figure 3.9 shows dialysed p53 protein loaded at different volumes, the higher 
the volume loaded the more stronger the p53 protein band seen which was 
the major component of protein expressed by E. coli. However, no further 
checks were carried out to determine if p53 was successfully isolated 
following dialysis.  
 
3.4  Purification of p53 protein 
Purification of p53 protein was first carried out with a 1 ml Hi-Trap-Heparin 
Sepharose column where a stepwise gradient elution was employed with 
buffer B with NaCl concentration ranging from 50 mM to 1 M. In this 
procedure, 1.5 ml fractions were collected which include flowthrough (pre-
washed), wash and eluted fractions as shown in Figures 3.10(a) and (b). In 
Figure 3.10(a) we can see proteins in the flowthroughs (Lanes 4 and 5) 
indicating that some proteins including p53 protein were not bound to the 
column. The reason might be due to the p53 protein was not properly bound 
to the column due to improper folding of the protein. Since most 
contaminating proteins passed through the column as shown in Lane 5, 
Figure 3.10(a), therefore not many contaminating proteins present in the 
wash and the eluted fractions since little left which were previously weakly 
bound to the column. In Figure 3.10(b), Lanes 8 and 9, enriched p53 protein 
but with several minor low molecular weight contaminating proteins or p53 
degradation products can be seen.  
 
The next purification step was then carried out by pooling together eluted 
fractions (Els) 30 to 37 as shown in Lanes 8 and 9 in Figure 3.10(b) and then 
subjected the pooled fractions to further purification by phosphocellulose P-
11 which is described in details in ‘Materials and Methods’ (Section 2.11.3). 
1.5 ml fractions were also collected which included flowthroughs, wash and 
eluted fractions. Figure 3.11(b), Lane 8, shows a quite faint p53 protein band 
still with few low molecular weight contaminating proteins or p53 degradation 
products. The eluted fractions from Lane 8 (Figure 3.11(b)), i.e. eluted 
fractions 34 to 36, were concentrated by centricon and also TCA 
precipitation. Faint protein bands were obtained with two low molecular 
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weight contaminating proteins or p53 degradation products still present 
which can be clearly seen in TCA precipitation sample (data not shown). 
Protein quantitation was carried out but the levels were below level of 
detection of the Bradford Assay used which was not ideal to do the nitration 
work. While relatively pure p53 protein had been obtained, it was worth 
revisiting the induction conditions. 
 
 
 
 
 
 
 
       
 
 
 
 
 
 
 
Figure 3.9.  A 10% SDS-PAGE gel showing different volume loaded of 
dialysed p53.  
 
Lane 1 –  prestained molecular weight markers (Fermentas) 
Lane 2 –  5 μl sample 
Lane 3 – 10 μl sample 
Lane 4 – 15 μl sample 
Lane 5 – 20 μl sample  
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Figure 3.10(a). A 10% SDS PAGE gel showing fractions purified from a 
stepwise gradient elution on Hi-Trap Heparin Sepharose column.  
 
Lane 1   – prestained protein molecular weight markers (Fermentas) 
Lane 2   – non-purified p53 
Lane 3   – Flowthrough 1-2 
Lane 4   – Flowthrough 3-4 
Lane 5   – Flowthrough 5 
Lane 6   – Wash 1 
Lane 7   – Wash 2 
Lane 8   – Eluted #1-3 
Lane 9   – Eluted #4-6 
Lane 10 – Eluted #7-9 
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Figure 3.10(b).  A 10% SDS PAGE gel showing fractions purified from a 
stepwise gradient elution on Hi-Trap Heparin Sepharose column. 
 
Lane 1   – prestained protein molecular weight markers (Fermentas) 
Lane 2   – non-purified p53 
Lane 3   – Eluted # 10-13 
Lane 4   – Eluted #14-17 
Lane 5   – Eluted #18-21 
Lane 6   – Eluted #22-25 
Lane 7   – Eluted #26-29 
Lane 8   – Eluted #30-33 
Lane 9   – Eluted #34-37 
Lane 10 – Eluted #38-41 
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Figure 3.11(a).  A 10% SDS PAGE gel showing fractions purified from a 
stepwise gradient elution on a Phosphocellulose P-11 column.  
 
Lane 1   – prestained protein molecular weight markers (Fermentas) 
Lane 2   – non-purified p53 
Lane 3   – Flowthrough 1-4 
Lane 4   – Flowthrough 5-8 
Lane 5   – Wash 1 
Lane 6   – Wash 2 
Lane 7   – Eluted #1-4 
Lane 8   – Eluted #5-8  
Lane 9   – Eluted #9-12 
Lane 10 – Eluted #13-16 
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Figure 3.11(b).  A 10% SDS PAGE gel showing fractions purified from a 
stepwise gradient elution on a Phosphocellulose P-11 column. 
 
Lane 1   – prestained protein molecular weight markers (Fermentas) 
Lane 2   – non-purified p53 
Lane 3   – Eluted #17-20 
Lane 4   – Eluted #21-24 
Lane 5   – Eluted #25-27 
Lane 6   – Eluted # 28-30 
Lane 7   – Eluted #31-33 
Lane 8   – Eluted #34-36 
Lane 9   – Eluted #37-39 
Lane 10  - Eluted #40-41 
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3.5  Optimisation of the p53 expression conditions 
Small scale expression of p53 protein was repeated initially using freshly 
transformed E. coli strains BL21(DE3) pT7.7Hup53 in order to re-optimise 
the p53 expression conditions so that substantial amount of p53 protein 
would be obtained. Four OD600nm values for induction start points were 
chosen this time around namely ~0.2, ~0.8, ~0.9 and ~1.0 at which 1 mM 
IPTG was added and the cultures were grown for 4 hr and then left to grow 
overnight. 1.5 ml of cells were harvested at 4 hr, centrifuged at 13,000 rpm 
for 2 min, the pellet was resuspended in 100 µl 2x SDS gel loading dye, 
sonicated 1x for 10 sec on ice at maximum amplitude, boiled for 5 min and 
10 µl sample volume loaded onto a 10% SDS-PAGE gel. Finally 1.5 ml of 
cells were again harvested after overnight growth and then treated as before. 
From Figures 3.12(a) and (b) no obvious difference can be seen in the 
expression levels of p53 protein at OD600nm of ~0.8, ~0.9 and ~1.0 that were 
grown for 4 hr. The growth between 4 hr and overnight at these ODs also 
show no obvious difference in the p53 protein expression levels. Thus, the 
growth duration for at least 4 hr after IPTG induction is sufficient to get 
substantial amount of p53 protein as determined earlier. Therefore, in the 
next step of p53 protein re-optimisation conditions, the growth duration for 4 
hr after induction was followed. 
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Figure 3.12(a).  A 10% SDS PAGE gel showing optimisation of p53 protein 
expression in E. coli strain BL21(DE3) containing a pT7.7Hup53 construct. 
 
Lane 1   – prestained protein molecular weight markers (Fermentas) 
Lane 2   – induced cells at OD600nm ~ 0.2 (0 min) 
Lane 3   – induced cells at OD600nm ~ 0.2 (4 hr) 
Lane 4   – induced cells at OD600nm ~ 0.2 (O/N) 
Lane 5   – induced cells at OD600nm ~ 0.8 (0 min) 
Lane 6   – induced cells at OD600nm ~ 0.8 (4 hr) 
Lane 7   – induced cells at OD600nm ~ 0.8 (O/N) 
Lane 8   – induced cells at OD600nm ~ 0.9 (0 min) 
Lane 9   – induced cells at OD600nm ~ 0.9 (4 hr) 
Lane 10 – induced cells at OD600nm ~ 0.9 (O/N) 
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Figure 3.12(b).  A 10% SDS PAGE gel showing optimisation of p53 
expression in E. coli strain BL21(DE3) containing a pT7.7Hup53 construct. 
 
Lane 1   – prestained protein molecular weight markers (Fermentas) 
Lane 2   – induced cells at OD600nm ~ 1.0 (0 min) 
Lane 3   – induced cells at OD600nm ~ 1.0 (4 hr) 
Lane 4   – induced cells at OD600nm ~ 1.0 (O/N) 
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E. coli strains BL21(DE3) and BL21(DE3) Star transformed with pT7.7Hup53 
were cultured and grown to OD600nm of ~0.2, ~0.4, ~0.6 and ~0.8 (OD600nm 
ranging from early mid-log to late log phases) before 1 mM IPTG was added 
and left to grow for a further 4 hr. From Figure 3.13(b), we can see that p53 
protein from transformed BL21(DE3) was best expressed after induction at 
OD600nm of ~0.8 (Lane 7) and the best expression level of p53 protein in 
transformed BL21(DE3) Star was also after induction at OD600nm of ~0.8 
(Lane 9). However, there was no significant difference between the level of 
expression of p53 protein between BL21(DE3) Star and BL21(DE3). It has 
been reported that the presence of mutation of the gene encoding RNAse E 
(rne131) in BL21(DE3)Star increases the expression of heterologous protein 
due to increased mRNA stability (Invitrogen). Since no major differences in 
the expression levels of p53 protein between the two transformed strains, 
thus, mRNA stability is not an issue here, but rather codon usage bias which 
is discussed in details in the Discussion Section. 
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Figure 3.13(a).  A 10% SDS PAGE gel showing optimisation of p53 
expression in E. coli strains BL21(DE3) and BL21(DE3) Star both carrying 
pT7.7Hup53 constructs. 
 
Lane 1   – prestained protein molecular weight markers (Fermentas) 
Lane 2   – induced BL21(DE3) cells at OD600nm ~ 0.2 (0 min) 
Lane 3   – induced BL21(DE3) cells at OD600nm ~ 0.2 (4 hr) 
Lane 4   – induced BL21(DE3) Star cells at OD600nm ~ 0.2 (0 min) 
Lane 5   – induced BL21(DE3) Star cells at OD600nm ~ 0.2 (4 hr) 
Lane 6   – induced BL21(DE3) cells at OD600nm ~ 0.4 (0 min) 
Lane 7   – induced BL21(DE3) cells at OD600nm ~ 0.4 (4 hr) 
Lane 8   – induced BL21(DE3) Star cells at OD600nm ~ 0.4 (0 min) 
Lane 9   – induced BL21(DE3) Star cells at OD600nm ~ 0.4 (4 hr) 
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Figure 3.13(b). A 10% SDS PAGE gel showing optimisation of p53 
expression in E. coli strains BL21(DE3) and BL21(DE3) Star both carrying 
pT7.7Hup53 constructs. 
 
Lane 1   – prestained protein molecular weight markers (Fermentas) 
Lane 2   – induced BL21(DE3) cells at OD600nm ~ 0.6 (0 min) 
Lane 3   – induced BL21(DE3) cells at OD600nm ~ 0.6 (4 hr) 
Lane 4   – induced BL21(DE3) Star cells at OD600nm ~ 0.6 (0 min) 
Lane 5   – induced BL21(DE3) Star cells at OD600nm ~ 0.6 (4 hr) 
Lane 6   – induced BL21(DE3) cells at OD600nm ~ 0.8 (0 min) 
Lane 7   – induced BL21(DE3) cells at OD600nm ~ 0.8 (4 hr) 
Lane 8   – induced BL21(DE3) Star cells at OD600nm ~ 0.8 (0 min) 
Lane 9   – induced BL21(DE3) Star cells at OD600nm ~ 0.8 (4 hr) 
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Finally, the optimum conditions for the expression of p53 protein were 
determined as follows: pT7.7Hup53 transformed cells were grown at 37oC 
with vigorous shaking (180 rpm) to OD600nm=0.8-1.0 (late log phase) where 
bacteria grow at exponential phase giving rise to high yield of bacteria 
(Scope, 1982) which in turn express more p53 protein upon induction by 
IPTG, then 1 mM IPTG added to induce p53 protein expression and left to 
grow for at least 4 hr. Table 3.1 below is a summary of optimal conditions for 
expression of recombinant p53 protein in BL21(DE3): 
 
Table 3.1: Optimised expression conditions for recombinant p53 
protein in E.coli BL21(DE3) 
Growth 
temperature 
IPTG 
concentration 
Induction OD600nm Duration of 
growth after 
addition of 
IPTG 
37˚C at vigorous 
shaking at 180 
rpm in an orbital 
shaker 
1 mM 0.8-1.0 (late log 
phase) 
At least 4 hrs or 
let to grow 
overnight 
 
 
Figures 3.14 and 3.15 show induction profiles of large scale expression of 
p53 protein in BL21(DE3) pT7.7Hup53 and BL21(DE3) Star pT7.7Hup53, 
respectively where cells were harvested every 30 min and assayed by a 10% 
SDS-PAGE gel. From Figures 3.14 and 3.15, p53 protein expression levels 
in both BL21(DE3) and BL21(DE3) Star show no major difference. These two 
induction profiles confirm the previous results (Figures 3.13). Also seen are 
clear induction of p53 protein though not formally compared with uninduced. 
More importantly, much more p53 protein was produced at these optimum 
conditions and subsequently we expected to get more purified p53 protein for 
the nitration study. 
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Figure 3.14. A 10% SDS PAGE gel showing a large scale expression of p53 
protein induced at OD600nm =0.8-1.0 in E. coli strain BL21(DE3) containing a 
pT7.7Hup53 construct. 
 
Lane 1   – prestained protein molecular weight markers (Fermentas) 
Lane 2   – induced cells at 0 min  
Lane 3   – induced cells at 30 min 
Lane 4   – induced cells at 60 min 
Lane 5   – induced cells at 90 min 
Lane 6   – induced cells at 120 min 
Lane 7   – induced cells at 150 min  
Lane 8   – induced cells at 180 min 
Lane 9   – induced cells at 210 min 
Lane 10 – induced cells at 240 min 
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Figure 3.15. A 10% SDS PAGE gel showing a large scale expression of p53 
protein induced at OD600nm =0.8-1.0 in E. coli strain BL21(DE3) Star 
containing a pT7.7Hup53 construct. 
 
Lane 1   – prestained protein molecular weight markers (Fermentas) 
Lane 2   – induced cells at 0 min  
Lane 3   – induced cells at 30 min 
Lane 4   – induced cells at 60 min 
Lane 5   – induced cells at 90 min 
Lane 6   – induced cells at 120 min 
Lane 7   – induced cells at 150 min  
Lane 8   – induced cells at 180 min 
Lane 9   – induced cells at 210 min 
Lane 10 – induced cells at 240 min 
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Large scale p53 protein production using BL21(DE3) transformed with pT7-
7Hup53 was then carried out. 12 litres of cultures of BL21(DE3) pT7.7Hup53 
were grown until OD600n of 0.8-1.0 prior to the addition of 1 mM IPTG and the 
cell pellets were re-suspended in 10% sucrose in 50 mM Tris HCl (pH 8.0) 
and frozen down at -80oC until the cells were lysed, subjected to dialysis and 
subsequent purification. 
 
 
3.6 Discussion 
 A small scale optimisation of the expression of proteins from expression 
plasmid containing the gene of interest in bacterial expression strains need 
to be determined before cultivating the bacterial cells in a large scale. The 
optimisation involved includes determination of which bacterial strain 
expresses the protein better, the concentration of inducer used such as IPTG 
and the optimal duration of the induction, the optical density at the start of 
induction and the optimal temperature for the growth of bacteria as 
temperature will affect the solubility of the protein. When the optimal 
conditions of protein expression is determined, a large scale production of 
the protein can be carried out.  
 
p53 protein is expressed as inclusion bodies at about 98% of the total 
p53 protein whereas soluble p53 is expressed in the remaining 2% of the 
total p53 protein. This section mainly purified resolubilised p53 protein from 
inclusion bodies using a series of column purifications. The inclusion bodies 
were first resolubilised followed by dialysis for refolding before subjected to 
purification. The main problem with refolding of p53 protein from resolubilsed 
p53 protein is that some fractions of the protein were not properly folded 
causing the partially folded p53 proteins passed through the column as a 
flowthrough due to their inefficiency in binding to the column. This results in 
the loss of p53 protein and a low yield of pure p53 protein. Indeed, the 
conformation of purified p53 protein fractions can be determined by 
conformation-specific p53 antibodies such as PAb1620 which specifically 
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recognises the wild-type or native conformation and PAb240 which is specific 
for the mutant or denatured conformation (Santa Cruz). 
 
In order to get the most expression levels of p53 protein, it is worth 
trying to express and compare the p53 protein in different bacterial 
expression strains with improved properties such as BL21(DE3)pLysS, which 
carry both DE3 lysogen and the plasmid pLysS. pLyS expresses T7 
lysozyme to induce the basal expression of target gene through inhibition of 
T7 RNA polymerase (Novagen). Another strain worth trying is Lemo21(DE3), 
which is a derivative of BL21(DE3) with tunable T7 expression especially for 
proteins prone to insoluble expression (New England Biolab, 2013-2014 
Catalogue and Technical Reference).   
 
. 
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RESULTS CHAPTER 4 
 
Both the soluble and insoluble forms of p53 protein were isolated and then 
separately subjected to a series of purification steps as described by Midgley 
et al. (1992) and Hupp et al. (1992). The resolubilised material was to look at 
nitration sites that might intrinsically be nitrated in the p53 protein, but might 
not be exposed in the native and active protein. Soluble p53 protein which 
was considered properly folded and active was to be used to study the effect 
of nitration on the functional activities of p53 protein such as in DNA-binding 
assay (EMSA) and in the study of protein-protein interactions between p53 
and MDM2 proteins. We also isolated the N-terminus of MDM2 protein as a 
GST-MDM2 expression construct (a.a. 1-188)  (Bottger et al., 1996) and a 
control GST protein  from a pGEX-2T construct (Pharmacia) which were 
subsequently purified to obtain pure proteins to be used in nitration work. 
  
4.1 Preparation of p53 protein 
As detailed in the Materials & Methods (Sections 2.10-2.11 & 2.15), the 
human p53 protein was expressed as soluble (~2%) (in the supernatant of 
the cell lysate) and insoluble (~98%) (in the pellet of the cell lysate) of the 
total p53 protein (Hupp et al., 1992). The two forms of human p53 protein 
were purified separately as detailed in the Methods section.  
 
4.1.1 Purification of resolubilised p53 protein 
In order to do preliminary nitration work, we needed a large amount of p53 
protein to work with which could be easily obtained from resolubilised p53 
protein comprising of ~98% from the total p53 protein produced (Hupp et al., 
1992). Preliminary work included whether p53 protein was easily nitrated at 
tyrosine residues at varying concentrations of nitrating agent peroxynitrite 
and to determine the effects of nitration on the stability and levels of p53 
protein. 
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Resolubilised p53 protein expressed in E. coli BL21(DE3) strain was purified, 
according to Hupp et al. (1992), from a gradient elution (50 mM to 1 M NaCl 
in Buffer B) on a 5 ml Hi-Trap Heparin Sepharose column (1.6 cm X 2.5 cm) 
(Amersham Biosciences) that had been priorly equilibrated with buffer B 
containing 50 mM NaCl using an FPLC system at a flowrate of 0.5 ml/min 
where 5 ml fractions were collected in a total of 14 fractions. As can be seen 
in Fig. 4.1, the resolubilised p53 extract contained high levels of p53 protein 
(Lane 2, Fig. 4.1(a) and (b)) together with contaminating bacterial proteins. 
14 fractions were collected altogether where fractions 1 and 2 were 
flowthroughs, fractions 3 and 4 were washes with 50 mM NaCl in Buffer B 
and fractions 5 to 14 were eluted fractions. The absence of the strong p53 
band in the fractions 1-4 suggested that renatured p53 protein has bound 
and in flowthrough fraction 2 (Lane 4, Fig. 4.1(a)), many unbound proteins 
passed through the column where the protein profile looks similar to wash 
fraction 3 (Lane 5, Fig. 4.1(a)), leaving behind a few other unbound proteins 
in wash fraction 4 when passed through the column (Lane 6). In eluted 
fractions 5 to 14, all other bacterial contaminating proteins were eluted in 
eluted fractions 5 to 9 and the p53 protein only appeared in eluted fractions 
10 to 12 with several other host contaminating proteins, both bigger and 
smaller sizes than p53 protein. The last two eluted fractions 13 and 14 
(Lanes 7-8, Fig. 4.1(b)) did not seem to contain any p53 proteins but had a 
few low molecular weight proteins which could be p53 degradation products 
and/or bacterial contaminating proteins. These results were further confirmed 
by Western blot analyses (Fig. 4.2). As can be seen in Fig. 4.2(a), there were 
very little p53 proteins with its degradation products throughout flowthrough 
fractions to eluted fractions 8 (Lanes 3-10, Fig. 4.2(a)). Looking at SDS-
PAGE protein profile in Fig. 4.1(b) and  its corresponding western blot in Fig. 
4.2(b), most of p53 proteins were eluted in fractions 9-14 where all these 
fractions contained p53 degradation products (sizes lower than p53 protein) 
as well as p53 non-reducible high molecular weight aggregates (Fig. 4.2(b), 
Lanes 3-6). If looked closely at, there were high mwt aggregates above 118 
kDa marker in Fig. 4.2(b), Lane 2, as well as in Lanes 3-6, which was very 
much expected as not all the p53 protein had been completely solubilised. 
Eluted fractions 9-14 purified from Hi-Trap Heparin Sepharose which were 
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enriched with p53 proteins (Fig. 4.2(b), Lanes 3-8) were pooled together and 
then were further purified on a Phospocellulose P11 column (Whatman) as 
done (see Materials & Methods, Section 2.11.3) and described previously by 
Hupp et al. (1992). However, we could not detect any purified resolubilised  
 
 
 
 
 
 
 
 
 
 
Figure 4.1(a). A 10% SDS PAGE gel showing purification profile of 
resolubilised p53 protein expressed in E. coli BL21(DE3) purified from a 
gradient elution (50 mM to 1 M NaCl in Buffer B) on a 5 ml Hi-Trap Heparin 
Sepharose column (1.65 cm X 2.5 cm)(Amersham Biosciences) using an 
FPLC system. 5 ml fractions were collected. The gel was stained with 
Coomassie Blue staining. 
 
Lane 1   - prestained protein molecular weight markers (Fermentas) 
Lane 2   - resolubilised p53 extract 
Lane 3   - fraction 1 
Lane 4   - fraction 2 
Lane 5   - fraction 3 
Lane 6   - fraction 4 
Lane 7   - fraction 5 
Lane 8   - fraction 6 
Lane 9   - fraction 7 
Lane 10 - fraction 8 
Washes with 50 mM 
NaCl in Buffer B 
118.0 
46.0 
33.0 
26.0 
 MW             1       2       3      4      5       6      7       8       9     10 
(kDa) 
 
85.0 
Flowthrough 
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Figure 4.1(b). A 10% SDS PAGE gel showing purification profile of 
resolubilised p53 protein expressed in E. coli BL21(DE3) purified from a 
gradient elution (50 mM to 1 M NaCl in Buffer B) on a 5 ml Hi-Trap Heparin 
Sepharose column (1.65 cm X 2.5 cm) (Amersham Biosciences) using an 
FPLC system. 5 ml fractions were collected. The gel was stained with 
Coomassie Blue staining. 
 
Lane 1  - prestained protein molecular weight markers (Fermentas) 
Lane 2  - resolubilised p53 extract 
Lane 3  - fraction 9 
Lane 4  - fraction 10 
Lane 5  - fraction 11 
Lane 6  - fraction 12 
Lane 7  - fraction 13 
Lane 8  - fraction 14 
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Figure 4.2(a). Western blot analysis showing purification profile of 
resolubilised p53 protein expressed in E. coli BL21(DE3) purified from a 
gradient elution (50 mM to 1 M NaCl in Buffer B) on a 5 ml Hi-Trap Heparin 
Sepharose column (1.65 cm X 2.5 cm) (Amersham Biosciences) using an 
FPLC system. 5 ml fractions were collected. The primary antibody used was 
mouse monoclonal anti-p53 (DO-1) and the secondary antibody was rabbit 
anti-mouse HRP conjugated polyclonal antibody (DAKO Cytomation).  
 
Lane 1   - prestained protein molecular weight markers (Fermentas) 
Lane 2   - resolubilised p53 extract 
Lane 3   - fraction 1 
Lane 4   - fraction 2 
Lane 5   - fraction 3 
Lane 6   - fraction 4 
Lane 7   - fraction 5 
Lane 8   - fraction 6 
Lane 9   - fraction 7 
Lane 10 - fraction 8 
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Figure 4.2(b). Western blot analysis showing purification profile of 
resolubilised p53 protein expressed in E. coli BL21(DE3) purified from a 
gradient elution (50 mM to 1 M NaCl in Buffer B) on a 5 ml Hi-Trap Heparin 
Sepharose column (1.65 cm X 2.5 cm) (Amersham Biosciences) using an 
FPLC system. 5 ml fractions were collected. The primary antibody used was 
mouse monoclonal anti-p53 (DO-1) and the secondary antibody was rabbit 
anti-mouse HRP conjugated polyclonal antibody (DAKO Cytomation). 
 
Lane 1  – prestained protein molecular weight markers (Fermentas) 
Lane 2  – resolubilised p53 extract 
Lane 3  – fraction 9 
Lane 4  - fraction 10 
Lane 5  - fraction 11 
Lane 6  - fraction 12 
Lane 7  - fraction 13 
Lane 8  - fraction 14 
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p53 protein on SDS-PAGE gels as it was likely due to the low levels of 
resolubilised p53 protein in the pooled fractions starting material (data not 
shown). As this problem persisted, it was decided not to proceed further 
purification with Phosphocellulose P-11 column but instead to purify and 
concentrate resolubilised p53 protein with a Centricon-30 with 30 kDa cut-off 
point in order to get purified resolubilised p53 protein. 
 
4.1.2 Purification of soluble p53 protein 
Since soluble p53 protein  only constitutes ~ 2% of the total p53 protein 
expressed in E. coli, therefore it was quite a challenge to isolate it and 
subsequently purify it. This would require a substantial amount of soluble cell 
lysate, from at least several litres of IPTG-induced E. coli BL21(DE3) 
bacterial strain transformed with pT7.7Hup53 followed by purification. The 
preparation and purification of the soluble p53 protein was described in the 
Materials & Methods, Sections 2.10 & 2.15. The SDS-PAGE purification 
profile of soluble p53 protein is shown in Fig. 4.3. As can be seen in Fig. 
4.3(a) and (b), Lane 2, there was a lot of soluble p53 protein in the initial 
lysate which was confirmed in Western blot analyses in Fig. 4.4(a) and (b), 
Lane 2. However, a lot of soluble p53 protein together with a lot of bacterial 
contaminating proteins passed through the column in flowthrough fraction 2 
and wash fraction 3 (Lanes 4 and 5, respectively). This means that a big 
fraction of soluble p53 protein did not bind to the resin and therefore passed 
through the column. In the SDS-PAGE gel soluble p53 protein purification 
profiles, Figs. 4.3(a) and (b), we can only see that most purified soluble p53 
proteins were eluted at fractions 9 and 10. This might be due to the soluble 
p53 was not in the correct conformation to bind to the resin and/or the 
charges on the soluble p53 protein was not balanced or not in the correct  
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Figure 4.3(a). A 10% SDS PAGE gel showing purification profile of soluble 
p53 protein expressed in E. coli BL21(DE3) purified from a gradient elution 
(50 mM to 1 M KCl in Buffer C) on a 5 ml Hi-Trap Heparin Sepharose column 
(1.65 cm X 2.5 cm) (Amersham Biosciences) using an FPLC system. 5 ml 
fractions were collected. The gel was stained with Coomassie Blue staining. 
 
Lane 1   - prestained protein molecular weight markers (Fermentas) 
Lane 2   - non-purified soluble p53 
Lane 3   - Fraction 1 
Lane 4   - Fraction 2 
Lane 5   - Fraction 3 
Lane 6   - Fraction 4 
Lane 7   - Fraction 5 
Lane 8   - Fraction 6 
Lane 9   - Fraction 7 
Lane 10 - Fraction 8 
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Figure 4.3(b). A 10% SDS PAGE gel showing purification profile of soluble 
p53 protein expressed in E. coli BL21(DE3) purified from a gradient elution 
(50 mM to 1 M KCl in Buffer C) on a 5 ml Hi-Trap Heparin Sepharose column 
(1.65 cm X 2.5 cm) (Amersham Biosciences) using an FPLC system. 5 ml 
fractions were collected. The gel was stained with Coomassie Blue staining. 
 
Lane 1  - prestained protein molecular weight markers (Fermentas) 
Lane 2  - non-purified soluble p53 
Lane 3  - Fraction 9 
Lane 4  - Fraction 10 
Lane 5  - Fraction 11 
Lane 6  - Fraction 12 
Lane 7  - Fraction 13 
Lane 8  - Fraction 14 
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Figure 4.4(a). Western blot analysis showing purification profile of soluble 
p53 protein expressed in E. coli BL21(DE3) purified from a linear gradient 
elution (50 mM to 1 M KCl in Buffer C) on a 5 ml Hi-Trap Heparin Sepharose 
column (1.65 cm X 2.5 cm) (Amersham Biosciences) using an FPLC system. 
The primary antibody used was mouse monoclonal anti-p53 (DO-1) and the 
secondary antibody was rabbit anti-mouse HRP conjugated polyclonal 
antibody. 
 
Lane 1   - prestained protein molecular weight markers (Fermentas) 
Lane 2   - non-purified soluble p53 
Lane 3   - Fraction 1 
Lane 4   - Fraction 2 
Lane 5   - Fraction 3 
Lane 6   - Fraction 4 
Lane 7   - Fraction 5 
Lane 8   - Fraction 6 
Lane 9   - Fraction 7 
Lane 10 - Fraction 8 
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Figure 4.4(b). Western blot analysis showing purification profile of soluble 
p53 protein expressed in E. coli BL21(DE3) purified from a linear gradient 
elution (50 mM to 1 M KCl in Buffer C) on a 5 ml Hi-Trap Heparin Sepharose 
column (1.65 cm X 2.5 cm) (Amersham Biosciences) using an FPLC system. 
The primary antibody used was mouse monoclonal anti-p53 (DO-1) and the 
secondary antibody was rabbit anti-mouse HRP conjugated polyclonal 
antibody (DAKO Cytomation). 
 
Lane 1  - prestained protein molecular weight markers (Fermentas) 
Lane 2  - non-purified soluble p53 
Lane 3  - Fraction 9 
Lane 4  - Fraction 10 
Lane 5  - Fraction 11 
Lane 6  - Fraction 12 
Lane 7  - Fraction 13 
Lane 8  - Fraction 14 
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ratio with the charges on the resin thus their binding was weak resulting in a 
large fraction of soluble p53 protein passed through the column. However, 
Western blot analyses (Figs. 4.4(a) and (b)) show that purified full length 
soluble p53 proteins were mostly obtained in eluted fractions 9-13 (Figs. 
4.4(b), Lanes 3-7). Eluted fractions 7 and 8 were predominantly p53 
degradation products. Therefore we selected and pooled together eluted 
fractions 9-13 for further purification on a Superose 12 gel filtration column. 
 
Before proceeding with gel filtration purification on a Superose 12 gel 
filtration column (10 mm X 310 mm) (Amersham Biosciences), the column 
had to be calibrated with gel filtration molecular weight markers (following 
protocol from Sigma gel filtration molecular weight markers) on a 30 ml gel 
filtration column using an FPLC system at a flowrate of 0.2 ml/min. Blue 
Dextran (2000 kDa) was used to determine the void volume (Vo). The other 
protein markers were eluted from the column according to their molecular 
weights, the heavier the earlier. Fig. 4.5 shows the elution profile of gel 
filtration molecular weight markers as they passed through the gel filtration 
column. The elution volume (Ve) of each protein marker was determined from 
the distance of their peaks to the starting point. The Ve / Vo ratio for each 
protein marker was then determined and the gel filtration markers standard 
curve was generated by plotting log molecular weights versus the Ve / Vo 
ratio (Fig. 4.6). 
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Figure 4.5. A chart showing distinct peaks produced when gel filtration 
molecular weight markers (Sigma) were passed through a 30 ml gel filtration 
column Superose 12 (10 mm X 310 mm) (Amersham Biosciences) at  a 
flowrate of 0.2 ml/min using an FPLC system. These proteins eluted from the 
column according to their molecular weights, the heavier the earlier. 
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Peak C  - Bovine Serum Albumin, 66 kDa (Ve =16.9) 
Peak D  - Carbonic Anhydrase, 29 kDa (Ve = 18.2) 
Peak E  - Cytochrome c, 12.4 kDa (Ve =19.3) 
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Figure 4.6. Standard curve for gel filtration markers 
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Table 4.1 below shows the values for Ve and Ve / Vo ratio of gel filtration 
molecular weight markers (from Sigma). 
 
Table 4.1: Showing Ve and Ve / Vo ratio of gel filtration molecular weight 
markers with their molecular weights indicated 
Components MW (kDa) Ve Ve / Vo 
Blue Dextran 2000 11.1 1.00 
Alcohol Dehydrogenase 150 15.3 1.38 
Bovine Serum Albumin 
(BSA) 
66 16.9 1.52 
Carbonic Anhydrase 29 18.2 1.64 
Cytochrome c 12.4 19.3 1.74 
* Void volume (Vo) for Blue Dextran was 11.1  
 
The next step was to further purify p53 protein isolated from the Hi-Trap 
Heparin sepharose purification procedure.  Fractions 9-13 which were 
enriched in p53 protein were pooled together and further purified and 
concentrated by ultrafiltration using a Centricon-30 with 30 kDa cut-off point 
before being loaded onto Superose 12 gel filtration column for further 
purification. Several batches of p53 gel filtration purifications of soluble p53 
protein on Superose 12 column were carried out at a flowrate of 0.2 ml/min 
where 1 ml fractions were collected in a total of 30 fractions. All the 30 
fractions from the first purification batch were then run on SDS-PAGE gels 
and then subjected to Western blot analysis in order to screen for which 
fractions contained the purified soluble p53 proteins. From Western blots of 
the 30 fractions from the first batch purification we found that most of purified 
soluble p53 protein was in eluted fractions 9 to 16. Therefore, in subsequent 
gel filtration purifications of soluble p53 proteins only eluted fractions 9 to 16 
were run on an SDS-PAGE gel and then electroblotted for Western blot 
analysis. However, there were variations in the degree of p53 protein being 
eluted in these fractions between batch to batch but a representative blot Fig. 
4.7 shows high amounts of soluble p53 proteins were detected in eluted 
fractions 10 to 12 (Lanes 4-6). Weak p53 signals in fractions 9, 13 and 14 
(Lanes 3, 7 and 8, respectively) (refer Table 4.2 for the calculated masses of 
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these fractions). No signals were detected in eluted fractions 15 and 16 
(Lanes 9 and 10, respectively). From the calculation of p53 elution volume in 
corresponse to its molecular weight, it is expected that p53 protein as a 
tetramer is eluted between fractions 14 and 15 when taking into account the 
masses of p53 monomer, 43-53 kDa obtained (43 kDa is obtained by 
multiplying 393 a.a. of p53 protein sequence with the average amino acid 
mass of 110 Da and 53 kDa is observed as an apparent mass of p53 protein 
migrating in denaturing SDS-polyacrylamide gel) multiplied by 4, so the 
masses of p53 tetramers will be between 172-212 kDa which contradict with 
our findings shown by western blot analysis Fig. 4.7 as described above 
where most p53 protein was eluted from fractions as early as fraction 9 
throughout fraction 14 and none p53 protein was eluted in fractions 15 and 
beyond. As mass/molecular weight is indirectly proportional to elution volume 
(see gel filtration standard curve Fig. 4.6), thus bigger mass has low elution 
volume so elutes earlier than smaller mass with high elution volume. The 
bigger p53 protein masses obtained in this experiment (especially fractions 
earlier than fraction 14) show that p53 protein masses eluted were between 
350-1700 kDa which were 2-10 fold higher than the masses of the expected 
p53 protein tetramers (Table 4.2). This might be due to the p53 protein 
tetramers clumped to each other to form multiple of tetramers/oligomers 
under the buffer condition parameters used (pH, ionic strength and 
temperature). This is not surprising as p53 forms tetramers in solution, which 
is the form p53 protein predominantly assembled both in vitro and in vivo 
(Friedman et al., 1993; Wang et al., 1994; review in Okorokov and Orlova, 
2009) but the evidence for multiples of tetramers i.e. 2-10x tetramers, is 
weak. However, we still pooled fractions 9-14 since western blot analysis 
showed the p53 protein was enriched in these fractions and thus could then 
be used for later nitration work. 
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Figure 4.7. Western blot analysis showing purification of soluble p53 protein 
expressed in E. coli BL21(DE3) purified from Superose 12 gel filtration 
column (10 mm X 310 mm)(Amersham Biosciences) using an FPLC system. 
26 fractions were collected altogether, 1 ml each. Eluted fractions 9-16, 
where expected soluble p53 protein were eluted, were selected and run onto 
an SDS-PAGE gel and then electroblotted. The volumes of the samples 
loaded were 20 µl. The primary antibody used was mouse monoclonal anti-
p53 (DO-1) and the secondary antibody was rabbit anti-mouse HRP 
conjugated polyclonal antibody (DAKO Cytomation).  
 
Lane 1   - prestained protein molecular weight markers (Fermentas) 
Lane 2   - soluble p53 extract 
Lane 3   - eluted fraction 9 
Lane 4   - eluted fraction 10 
Lane 5   - eluted fraction 11 
Lane 6   - eluted fraction 12 
Lane 7   - eluted fraction 13 
Lane 8   - eluted fraction 14 
Lane 9   - eluted fraction 15 
Lane 10 - eluted fraction 16 
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Table 4.2: Showing the masses of p53 protein at fractions 9-14 
determined from the gel filtration standard curve (Fig. 4.6) by the 
correlation of  the Ve / Vo ratio of each fraction to their masses 
 
Fractions Ve Ve / Vo Masses (kDa) 
9 9 0.81 1700 
10 10 0.90 1290 
11 11 0.99 1100 
12 12 1.08 1030 
13 13 1.17 650 
14 14 1.26 350 
* Void volume (Vo) for Blue Dextran was 11.1  
 
4.2 Expression and purification of GST and GST-MDM2 proteins 
MDM2 protein is known to be a negative regulator of p53 protein by 
inactivating p53 transcriptional activity by masking the N-terminal region 
[mapped at residues 18-23 (TFSDLW)] (Picksley et al., 1994;  Bottger et al., 
1996) of p53 protein from binding to its transcriptional machinery proteins 
and it also ubiquitinates p53 protein, shuttles p53 protein from the nucleus to 
the cytoplasm and finally targets p53 protein for 26S proteosomal 
degradation in the cytoplasm (Momand et al., 1992; Chen et al., 1993 & 
1995; Oliner et al., 1993; Kussie et al., 1996; Moll & Petrenko, 2003). This 
thus raises the question what will happen to the interactions between p53 
and MDM2 proteins when p53 protein is nitrated especially at the N-terminal 
region where it binds MDM2 protein especially at Trp 23 to form nitro-
tryptophan (however no nitro-tryptophan antibody available in the market yet) 
as Phe19, Trp23 and Leu26 are the most critical contact points (Chen et al., 
1993; Picksley et al., 1994). Will it inhibit their interactions and thus will it 
lead to p53 protein stabilisation and activity? As MDM2 protein binds p53 
protein also through its N-terminal region (residues 1-188 a.a), we also would 
like to look at the other angle by also attempting to nitrate MDM2 protein and 
hopefully to gain insights of the effects of nitrated MDM2 protein on its 
interaction with p53 protein. This is because 2 tyrosine residues, located at 
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amino acids 54 and 61 at the N-terminal region of MDM2 protein, are  
potential targets for nitration to form nitro-tyrosines. 
 
In this work, we also heterologously overexpressed GST-MDM2 fusion 
protein  from the expression construct of Bottger et al. (1996) by which a 
PCR product of human MDM2 cDNA (encompassing a.a. 1-188) was ligated 
into the pGEX-2T plasmid (Pharmacia). GST protein, as a control protein, 
was obtained form the expression plasmid pGEX-2T (Pharmacia). The 
plasmids were then introduced to  E. coli BL21 strains (Bottger et al., 1996;  
Bottger et al., 1997) and the protein expression was induced by 1 mM IPTG 
for 4 hrs at 37°C before being harvested. This was then followed by a batch 
purification of the proteins using Glutathione Sepharose 4B (Amersham 
Biosciences). The purpose of this work was to prepare purified GST-MDM2 
protein and its control  protein GST, either being nitrated or not, for future 
experiments to see their effects on the interactions with both nitrated and 
non-nitrated p53 protein. But first we needed to do a small scale expression 
of GST and GST-MDM2 proteins in order to determine the optimal conditions 
for the expression of both proteins.  
 
4.2.1  Small scale expression of GST and GST-MDM2 in E. coli BL21 
strain 
In order to determine the optimal expression conditions for GST and GST-
MDM2 proteins, E. coli BL21 strains transformed either with pGEX-2T or 
pGEX-2T-MDM2 carrying the GST-MDM2 fusion protein were grown at a 
small scale until late log phase, the OD600 nm of ~ 0.8 – 1.0 before they were 
induced by the addition of IPTG to 1 mM. Uninduced BL21 strain 
transformed with pGEX-2T-MDM2 and induced BL21 alone were also grown 
in parallel. Growth curves for the 4 cultures were plotted as shown in Fig. 4.8 
(BL21 + IPTG and pGEX-2T + IPTG served as controls. The IPTG-induced 
BL21 cultures either untransformed or transformed with pGEX-2T-MDM2 or 
transformed with pGEX-2T vector showed  similar growth curves where their 
OD600 nm values increased gradually when compared to the uninduced 
pGEX-2T-MDM2 transformed BL21 with markedly increased in OD600 nm 
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values. This showed that IPTG induction retarded the growth of the BL21 
strain. Another way to explain this observation is by a direct comparison of 
the BL21 cultures transformed with pGEX-2T-MDM2 either induced with 
IPTG or not indicated that the expression relied on a strong promoter that 
dominated cellular transcription making the GST-MDM2 protein in the IPTG-
induced transformed BL21, consequently their own growth was halted. Thus, 
we can see that in the uninduced transformed BL21 the cells kept growing 
since they did not produce foreign proteins. 
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Figure 4.8. Growth curve of BL21 either untransformed or transformed with 
pGEX-2T or pGEX-2T-MDM2 and either non-induced or induced with 1 mM 
IPTG for a period of 4 hrs. 
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4.2.2 Uninduced and IPTG induction profiles of GST-MDM2 protein 
1 ml of each culture was also removed and then pelleted at 13,000 rpm for 2 
min and the pellets were resuspended in SDS loading dye with freshly added 
1 mM reducing agent DTT. The cultures were removed at 0 time and every 
hour until 4 hrs period after IPTG addition. Fig. 4.9 shows the uninduced 
GST-MDM2 protein profile together with untransformed BL21 and BL21 
transformed with pGEX-2T vector, both uninduced, as experimental controls 
(Lanes 2 and 3, respectively). A 4 hrs-IPTG-induced pGEX-2T-MDM2 
transformed BL21 was used as a positive control for GST-MDM2 protein 
expression (Lane 9). In this profile, we can see that the levels of GST-MDM2 
protein slightly increased from 1 to 4 hrs period even though they were not 
induced (Lanes 5-8). Hardly any GST-MDM2 protein was seen at 0 time 
(Lane 4). In order to explain this observation, it was likely due to a leaky 
promoter where the protein was induced to express even without the inducer 
IPTG. This explanation is further confirmed by the presence of high levels of 
GST protein in uninduced pGEX-2T transformed BL21 grown in parallel for 4 
hrs (Lane 3). The leaky promoter, however, can be reduced by growing the 
bacterial BL21 strain in Minimal Media (M63, M9 etc.) which contain 
minimum nutrients typically glucose as a carbon source for bacterial growth 
(Studier et al., 1990). However, we did not do this because we were not 
going to do further work with the uninduced bacterial cells and only the IPTG-
induced cells were to be lysed to purify the GST and GST-MDM2 proteins.  
 
Fig. 4.10 shows an IPTG-induced GST-MDM2 protein profile together with 
untransformed BL21 and BL21 transformed with pGEX-2T vector, both 
induced for 4 hrs, as experimental controls (Lanes 2 and 3, respectively). A 4 
hrs non-induced pGEX-2T-MDM2 transformed BL21 was used as a negative 
control eventhough there were some GST-MDM2 proteins present probably 
due to a leaky promoter as mentioned earlier (Lane 4). As can be seen in 
Fig. 4.10, there was an increased in the expression levels of GST-MDM2 
proteins when induced with IPTG from 0 to 4 hrs. Hardly any GST-MDM2 
protein was observed at 0 time induction and the highest levels of GST-
MDM2 protein at 4 hrs after induction. This indicates that the optimal 
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conditions for the expression of GST-MDM2 protein is to IPTG induce the 
cells at 1 mM at late log phase (~ 0.8-1.0) and then harvesting at least 4 hrs 
after IPTG addition. 
 
The above results were further verified by Western blot analysis using anti-
GST mouse monoclonal antibody HRP-conjugated by selecting only a few 
samples. In Fig. 4.11, untransformed BL21 IPTG-induced at 0 min and after 
4 hrs show no bands as expected as the bacteria did not have any GST or 
GST-MDM2 genes, and thus no expression of the proteins (Lanes 2 and 3, 
respectively). These two samples acted as negative controls for the 
experiment. It can be seen that GST protein was expressed even at 0 min 
after induction and the levels increased at 4 hrs after the IPTG-induction 
together with a few smaller sizes degradation products (Lanes 4 and 5). We 
can also see GST-MDM2 protein being expressed at 0 min after IPTG-
induction (Lane 6). GST-MDM2 protein was also expressed in the pGEX-2T-
MDM2 transformed BL21 uninduced for 4 hrs (Lane 7). This band confirms 
the SDS-PAGE result we have in Fig. 4.9, Lane 8. A high level of GST-
MDM2 proteins with a lot of smaller sizes degradation products were 
observed in pGEX-2T-MDM2 transformed BL21 induced with IPTG for 4 hrs. 
This band confirms the previous SDS-PAGE gel (Fig. 4.10, Lane 9). These 
degradation products might be due to the proteolysis of the proteins by 
proteases other than lon and ompT proteases in BL21 and/or due to the 
handling of the proteins. Therefore, in order to minimise protein degradation, 
the protein preparation must be done very fast and the samples should be 
kept cold on ice all the time. 
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Figure 4.9. A 10% SDS-PAGE gel showing uninduced GST-MDM2 protein. 
4 hr- IPTG-induced GST-MDM2 protein was loaded in parallel as a positive 
control. 
 
Lane 1   - prestained protein molecular weight markers (Fermentas) 
Lane 2   - BL21 (4 hr) 
Lane 3   - pGEX-2T (4 hr) 
Lane 4   - non-induced GST-MDM2 (0 hr) 
Lane 5   - non-induced GST-MDM2 (1 hr) 
Lane 6   - non-induced GST-MDM2 (2 hr) 
Lane 7   - non-induced GST-MDM2 (3 hr) 
Lane 8   - non-induced GST-MDM2 (4 hr) 
Lane 9   - IPTG-induced GST-MDM2 (4 hr) 
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Figure 4.10. A 10% SDS-PAGE gel showing 1 mM IPTG-induced GST-
MDM2 protein. 4 hr-uninduced GST-MDM2 was run in parallel as a negative 
control. 
 
Lane 1   - prestained protein molecular weight markers (Fermentas) 
Lane 2   - IPTG-induced BL21 (4 hr) 
Lane 3   - IPTG-induced pGEX-2T (4 hr) 
Lane 4   - non-induced GST-MDM2 (4 hr) 
Lane 5   - IPTG-induced GST-MDM2 (0 hr) 
Lane 6   - IPTG-induced GST-MDM2 (1 hr) 
Lane 7   - IPTG-induced GST-MDM2 (2 hr) 
Lane 8   - IPTG-induced GST-MDM2 (3 hr) 
Lane 9   - IPTG-induced GST-MDM2 (4 hr) 
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Figure 4.11. A Western blot analysis of pGEX-2T and GST-MDM2 non-
induced or induced with 1 mM PTG. The blot was probed with anti-GST 
mouse monoclonal antibody conjugated with HRP (DAKO Cytomation). 
 
Lane 1   - prestained protein molecular weight markers (Fermentas) 
Lane 2   - BL21 (0 min) 
Lane 3   - BL21 induced with IPTG (4 hr) 
Lane 4   - pGEX-2T (0 min) 
Lane 5   - pGEX-2T induced with IPTG (4 hr) 
Lane 6   - GST-MDM2 (0 min) 
Lane 7   - GST-MDM2 non-induced (4 hr) 
Lane 8   - GST-MDM2 induced with IPTG (4 hr) 
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4.2.3 Large scale expression of GST and GST-MDM2 proteins and their 
purification using Glutathione Sepharose 4B.                                                                             
After determining the optimal conditions for the expression of GST and GST-
MDM2 proteins i.e. to IPTG induce the cells at 1 mM at late log phase (~ 0.8-
1.0) and then harvesting at least 4 hrs after IPTG addition, we then 
proceeded with a large scale expression of both the proteins followed by a 
batch purification of the proteins using Glutathione Sepharose 4B 
(Amersham Biosciences) as described in the Materials and Methods, Section 
2.19.2. This was in order to get a large amount of purified GST and GST-
MDM2 proteins for nitration work. 
 
4.2.3.1 GST protein gel purification profile 
As can be seen in Fig. 4.12, a lot of GST protein among other contaminating 
host proteins in the sonicated GST lysate (Lane 2). However, hardly any 
GST protein can be seen in the initial GST lysate (Lane 9). Decreased 
amounts of GST protein when compared to its amount in the sonicated 
lysate (Lane 2) were observed in the supernatant after solubilisation and in 
the supernatant after beads binding (Lanes 3 and 4, respectively). Very pure 
GST proteins were found in all the three elutions 1, 2 and 3 (Lane 5, 6 and 7, 
respectively). A lot of GST proteins were found in the GST final beads (Lane 
8) which might be due to inefficient or incomplete elution of the protein from 
the beads. The purified GST proteins in elutions 1, 2 and 3 was verified by 
western blot analysis using anti-GST mouse monoclonal antibody HRP-
conjugated (Fig. 4.13). These results were quite satisfactory as we managed 
to obtain relatively pure GST proteins with only minor contaminations. 
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Figure 4.12. A 10% SDS PAGE gel showing a batch purification profile of 
GST protein using Glutathione Sepharose 4B (Amersham Biosciences). The 
gel was stained with Coomassie Blue stain for 15 min and then destained 
overnight. 
 
Lane 1   - prestained protein molecular weight markers (Fermentas) 
Lane 2   - sonicated GST lysate 
Lane 3   - supernatant after solubilisation 
Lane 4   - supernatant after beads binding 
Lane 5   - elution 1 
Lane 6   - elution 2 
Lane 7   - elution 3 
Lane 8   - GST final beads 
Lane 9   - initial GST lysate 
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Figure 4.13. A Western blot analysis of a batch purification profile of GST 
protein by Glutathione Sepharose 4B (Amersham Biosciences). The blot was 
probed with anti-GST mouse monoclonal antibody conjugated with HRP 
(DAKO Cytomation). 
 
Lane 1   - initial GST lysate 
Lane 2   - prestained protein molecular weight markers (Fermentas) 
Lane 3   - right after sonication 
Lane 4   - supernatant after solubilisation 
Lane 5   - pellet after solubilisation 
Lane 6   - supernatant after beads binding 
Lane 7   - elution 1 
Lane 8   - elution 2 
Lane 9   - elution 3 
Lane 10 - beads after elution 
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 4.2.3.2 GST-MDM2 protein gel purification profile 
 
Upon induction of GST-MDM2 fusion protein expression with 1 mM IPTG for 
4 hr, the BL21 cells were harvested and the pellet resuspended with ice-cold 
PBS was sonicated. Then the sonicated pellet was solubilized with Triton X-
100 to 1% followed by centrifugation at 12,000 x g for 10 min at 4°C. The 
supernatant was transferred into a fresh container. The supernatant and the 
pellet after solubilisation were run in parallel as shown in Fig. 4.14, Lanes 4 
and 5, respectively. In Fig. 4.14, we can see a lot of GST-MDM2 protein 
among other contaminating host proteins in the supernatant after 
solubilisation (Lane 4) of the GST-MDM2 fusion proteins (See Protocol 
2.19.1) but hardly any GST-MDM2 protein was found in the sonicated GST-
MDM2 lysate (Lane 3). A higher amount of GST-MDM2 in the supernatant 
after solubilisation when compared to it in the sonicated GST-MDM2 lysate 
might be due to solubilisation had enriched the GST-MDM2 protein levels. 
However, the levels of GST-MDM2 protein decreased in the pellet after 
solubilisation and in the supernatant after beads binding (Lanes 5 and 6) 
when compared to its levels in the supernatant after solubilisation (Lane 4). 
However, we are not interested in the pellet after solubilisation as we 
obtained higher levels of GST-MDM2 in the supernatant. This was just to 
show that fewer GST-MDM2 proteins remained in the pellet but most were in 
the supernatant (Lanes 4 and 5, respectively). Lower levels of GST-MDM2 
proteins in the supernatant after beads binding (Lane 6) when compared to it 
in the supernatant after solubilisation (Lane 4) was as expected as most of 
GST-MDM2 proteins formed complexes with the beads and thus very little 
left in the supernatant. 
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Figure 4.14. A 10% SDS PAGE gel showing a  batch purification profile of 
GST-MDM2 protein using Glutathione Sepharose 4B (Amersham 
Biosciences). The gel was stained with Coomassie Blue stain for 15 min and 
then destained overnight. 
 
Lane 1   - initial GST-MDM2 lysate 
Lane 2   - prestained protein molecular weight markers (Fermentas) 
Lane 3   - sonicated GST-MDM2 lysate 
Lane 4   - supernatant after solubilisation 
Lane 5   - pellet after solubilisation 
Lane 6   - supernatant after beads binding 
Lane 7   - elution 1 
Lane 8   - elution 2 
Lane 9   - elution 3 
Lane 10 - GST-MDM2 final beads 
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Figure 4.15. A Western blot analysis of a batch purification profile of GST-
MDM2 protein by Glutathione Sepharose 4B (Amersham Biosciences). The 
blot was probed with anti-GST mouse monoclonal antibody conjugated with 
HRP (DAKO Cytomation). 
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Lane 2   - prestained protein molecular weight markers (Fermentas) 
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Lane 4   - supernatant after solubilisation 
Lane 5   - supernatant after beads binding 
Lane 6   - elution 1 
Lane 7   - elution 2 
Lane 8   - elution 3 
Lane 9   - beads after elution 
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Quite a lot of highly enriched GST-MDM2 proteins were eluted in all the three 
beads elutions 1, 2 and 3 with a few smaller sizes host contaminating 
proteins and/or its degradation products (Lanes 7, 8 and 9). As can be seen 
in Lane 10, a lot of GST-MDM2 proteins were remained in GST-MDM2 final 
beads which might due to inefficient or incomplete elution of GST-MDM2 
proteins. The GST-MDM2 protein gel purification profile finding was further 
verified by a Western blot analysis as shown in Fig. 4.15. As we are 
interested to see the elution part, a lot of GST-MDM2 proteins were found in 
all the three elutions 1, 2 and 3 with a few smaller sizes GST-MDM2 
degradation products (Lanes 6, 7 and 8). We confirmed that the smaller 
sizes proteins lower than the GST-MDM2 protein were its degradation 
products since they were picked up by anti-GST mouse monoclonal antibody 
HRP-conjugated. The three elutions 1, 2 and 3 were then pooled together to 
be used for nitration work. 
 
Now that we have obtained purified soluble native p53 protein, though at 
very low concentrations, and purified resolubilised p53 protein, supposedly at 
sufficient amounts, from a few litres of pT7.7Hup53 transformed E.coli 
bacterial culture and purified GST-MDM2 fusion proteins to be used for 
nitration work in order to see the effects of nitration on the stability and the 
levels of the proteins and on the interactions between the two proteins. In 
order to get substantial amounts of purified soluble native p53 protein, it is 
apparently clear to grow more pT7.7Hup53 transformed E.coli BL21(DE3) 
bacterial culture and then combine the purified batches and concentrate by 
ultracentrifugation by using centricon-30. Failing this, it is worth trying to 
transform  pT7.7Hup53 construct into Lemo21(DE3) (New England Biolabs, 
2013-2014 Catalog & Technical Reference), a derivative of BL21(DE23), 
which features tunable T7 expression for potential elimination of inclusion 
body formation so more soluble p53 protein will be obtained in supernatant of 
the cell lysates. 
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4.3 Discussion 
The difficulties encountered when p53 protein was expressed in BL21(DE) in 
inclusion bodies include the incomplete resolubilisation resulting in reduced 
amount of soluble crude extracts. Also, several steps to follow from 
resolubilisation to dialysis and then through a series of purification steps 
resulted in the loss of p53 protein and ultimately a low yield of purified p53 
protein. The purification of soluble p53 protein using gel filtration column on 
the FPLC system is easy and fast. The other advantage is only a small 
volume of starting crude extracts were applied to the column, thus 
eliminating the preparation of a large volume of samples. However, 
purification of soluble p53 protein is very challenging as the total yield was 
quite little.   
 
The expression of MDM2 protein fused with GST using pGEX vector 
with in-built GST gene is very convenient, fast and only employed a single 
step purification on Glutathione Sepharose affinity chromatography. The 
GST-MDM2 protein expressed was soluble. Purification of the protein gave a 
high yield although low molecular weight contaminating proteins or 
degradation products were present. This can be improved by selecting the 
most efficient protease inhibitors at the correct concentrations. Thus, in the 
future should consider to fuse p53 gene with pGEX vector in order to get 
soluble p53 protein, thus eliminating the difficulty and lengthy processes of 
resolubilisation and refolding of inclusion bodies, which ultimately influence 
the biological activity of the protein (Young et al., 2012). The purification uses 
very mild elution conditions thus retaining the antigenicity and functional 
activity of the protein (GE Healthcare). Furthermore, the yield of pure protein 
is quite high.  
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RESULTS CHAPTER 5 
 
In vitro generation of peroxynitrite and optimisation of nitration 
methods and conditions using BSA as a model protein for nitration   
 
5.1 In vitro generation of peroxynitrite 
 
In order to conduct in vitro nitration of proteins, we had to generate 
peroxynitrite, a potent nitrating agent used to nitrate protein, in the lab since 
due to its labile nature. Peroxynitrite was prepared by simultaneously 
flushing together 1.2 M NaNO2 and 1 M HNO3/H2O2 in plungers connected to 
a T-junction tube where the mixture was collected in a beaker containing 1.5 
M NaOH. Excess H2O2 was then removed from the mixture by passing 
through manganese oxide (MnO2) on a filter paper support (Naseem et al., 
2004). The concentration of the resulting peroxynitrite could then be 
determined by spectroscopy. Scanning spectroscopy could also be used to 
determine the quality of the peroxynitrite produced. 
 
 
5.2 Multiwavelength scanning of generated peroxynitrite 
 
Individual components that made up peroxynitrite such as 1.5 M NaOH, 1 M 
HNO3 alone, 1M HNO3/H2O2  and 1.2 M NaNO2 were scanned after 
calibrating the spectrophotometer with 1.5 M NaOH over a wavelength range 
200-400 nm. As was expected no distinct UV absorbance spectrum for 
NaOH was observed as shown in Fig. 5.1(a) as it was blanked against itself. 
The UV absorbance spectra for HNO3 alone and a combination of 
HNO3/H2O2 showed no significant differences which were a single broad 
peak spanning from 200 nm to 350 nm as shown in Figs. 5.1(b) and 5.1(c), 
respectively. No distinct spectrum for NaNO2 was seen as shown in 
Fig.5.1(d) where there was another single broad peak from 200 nm and to 
over 400 nm. Combination of all these components resulted in a peroxynitrite 
solution, the absorbance spectrum of which as shown in Fig. 5.2. The 
spectrum for the peroxynitrite solution gave two peaks, A and B, where peak 
B had a maximum absorbance approximately at 302 nm as expected 
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(approximately 70% peroxynitrite) (Robinson and Beckman, 2005). Peak A 
might be due to unreacted HNO3 or a by-product of peroxynitrite formation 
(nitrate) or possibly due to other contaminants (remaining 30%) (Robinson 
and Beckman, 2005). 
 
 
5.3 Determination of appropriate nitration method 
 
Before nitration experiments could proceed, we needed to evaluate two 
nitration procedures. Because peroxynitrite is very labile, we needed to 
optimise the exposure of the target protein to peroxynitrite. The two methods 
recommended by Prof. Naseem (University of Bradford) were using an 
aggregometer set at 37°C at maximum speed and using vortex and a rocking 
water bath set at 37°C at vigorous speed. Free fatty acid bovine serum 
albumin (BSA) (Sigma) dissolved in 10 mM PBS was used as a model 
protein for preliminary nitration experiments since it is available commercially 
and 99.8% pure, and furthermore it is easily nitrated mainly because of its 
high content of  tyrosine residues (19 tyrosine residues). BSA was subjected 
to nitrating agent peroxynitrite at various concentrations ranging from 10 µM 
to 500 µM using both mentioned nitration methods. Stronger signals of 
nitrated BSA were observed when it was nitrated using vortex and a rocking 
water bath set at 37°C (Fig. 5.3(b)) when compared to using an 
aggregometer (Fig. 5.3(a)). Thus, nitration with vortex and a rocking water 
bath was the preferred method for all the following nitration work.  
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Figure 5.1. A multiwavelength scan of each component to prepare 
peroxynitrite solution indicated above which was first calibrated with NaOH 
using a Beckman DU-64 spectrophotometer at wavelengths ranging from 
200 nm to 400 nm and absorbance limits from 0.0000 to 1.0000. 
 
Wavelength (nm) Wavelength (nm) 
Wavelength (nm) 
(a) 1.5 M NaOH (b) 1.0 M HNO3 spectrum 
(c) 1.0 M HNO3/H2O2 (d) 1.2 M NaNO2 spectrum 
Wavelength (nm) 
 
A
b
s
o
r
b
a
n
c
e 
A
b
s
o
r
b
a
n
c
e 
A
b
s
o
r
b
a
n
c
e 
A
b
s
o
r
b
a
n
c
e 
175 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2. A multiwavelength scan of a peroxynitrite solution showing the 
quality of peroxynitrite formation using a Beckman DU-64 spectrophotometer 
at wavelengths ranging from 200 nm to 400 nm and absorbance limits from 
0.0000 to 1.0000.  
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Figure 5.3. A comparison of two methods used to nitrate 2 mg/ml BSA 
dissolved in PBS : a) Method used was aggregometer set at 37°C and b) 
Method used was vortex and rocking water bath set at 37°C. The samples 
were incubated for 15 min with peroxynitrite. The same amounts of non-
nitrated and nitrated BSA (2 µg) were loaded onto SDS-PAGE gels. The 
primary antibody used for both blots was anti-nitrotyrosine mouse 
monoclonal IgG, Clone 1A6 (Upstate Biotechnology) and the secondary 
antibody polyclonal rabbit anti-mouse IgG/HRP conjugated from DAKO 
Cytomation. 
 
Lane 1   - prestained protein molecular weight markers (Fermentas) 
Lane 2   - non-nitrated BSA as a negative control 
Lane 3   - 10 µM peroxynitrite nitrated BSA 
Lane 4   - 50 µM peroxynitrite nitrated BSA 
Lane 5   - 100 µM peroxynitrite nitrated BSA 
Lane 6   - 200 µM peroxynitrite nitrated BSA 
Lane 7   - 300 µM peroxynitrite nitrated BSA 
Lane 8   - 400 µM peroxynitrite nitrated BSA 
Lane 9   - 500 µM peroxynitrite nitrated BSA 
Lane 10 - 100 µM peroxynitrite previously nitrated BSA as a positive control 
19.0 
26.0 
34.0 
47.0 
86.0 
118.0 
   1   2   3   4   5    6    7   8   9  10  
   
 MW      1    2    3    4    5   6    7   8    9  10  
(kDa)  
   
a) Method used: 
Aggregometer set at 37°C 
b) Method used: Vortex and 
rocking water bath set at 37°C 
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 5.4 Optimisation of nitration conditions 
In our preliminary nitration study, we nitrated a model protein BSA and 
dialysed p53 lysate with 3 mM peroxynitrite using the preferred method 
vortexing and a rocking water bath set at 37˚C as determined above in 
Section 5.3. The samples were then run on a 10% SDS-PAGE gel along with 
their non-nitrated counterparts (Fig. 5.4). As can be seen in Fig. 5.4, the 
levels of BSA protein and dialysed p53 protein nitrated with 3 mM were lower 
than their non-nitrated total proteins. This might be due to the degrading 
properties of peroxynitrite which resulted in the degradation of the proteins 
especially at its high concentration (3 mM) as shown by Ischiropoulos and Al-
Mehdi on fatty acid-free BSA fragmentation when treated with peroxynitrite 
(Ischiropoulos and Al-Mehdi, 1995). To check for nitro-BSA and nitro-p53 
protein, Western blot analyses were carried out on the same samples in Fig. 
5.4. Two blots of the same samples were either probed with anti-nitrotyrosine 
mouse monoclonal IgG, Clone 1A6 (Upstate Biotechnology) and then with 
the secondary antibody sheep anti-mouse HRP conjugated (a kind gift of Dr 
Patel, University of Bradford) (Fig. 5.5(a)) or with the same secondary 
antibody alone (Fig. 5.5(b)). In Fig. 5.5(a), we can see that there was a weak 
nitrotyrosine signal in non-nitrated BSA and a relatively strong nitrotyrosine 
signal was detected in 3 mM peroxynitrite nitrated BSA (Fig.5.5(a), Lanes 2 
and 3, respectively). The weak nitrotyrosine signal in non-nitrated BSA might 
be due to BSA was endogenously nitrated in cow as it is  
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Figure 5.4. A 10% SDS-PAGE gel preliminary nitration of bovine serum 
albumin (BSA) and dialysed p53 lysate in PBS in comparison with Western 
blot analysis of the same samples as shown on Figure 5.5. The samples 
were subjected to 3 mM peroxynitrite and incubated for 15 min in a rocking 
water bath at 37°C. 
 
Lane 1 – prestained protein molecular weight markers (Fermentas) 
Lane 2 – non-nitrated BSA (15 μg) 
Lane 3 – nitrated BSA (15 μg) 
Lane 4 – non-nitrated dialysed p53 lysate (13.7 μg) 
Lane 5 – nitrated dialysed p53 lysate (13.7 μg) 
  
26.0 
34.0 
47.0 
86.0 
118.0 
 MW              1             2              3             4             5 
(kDa) 
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Figure 5.5. Western Blot analysis showing preliminary nitration of bovine 
serum albumin (BSA) and dialysed p53 lysate in PBS. Nitrated samples were 
subjected to 3 mM nitrating agent peroxynitrite and incubated for 15 min in a 
rocking water bath at 37°C: a) The primary antibody used was anti-
nitrotyrosine mouse monoclonal IgG, Clone 1A6 (Upstate Biotechnology) and 
the secondary antibody sheep anti-mouse HRP conjugated (Amersham 
Biosciences, a kind gift of Mr Patel, University of Bradford. b) The secondary 
antibody sheep anti-mouse HRP conjugated alone (Amersham Biosciences) 
was used to probe the blot to act as a negative control.  
 
Lane 1 – prestained protein molecular weight markers (Fermentas) 
Lane 2 – non-nitrated BSA (15 μg) 
Lane 3 – nitrated BSA (15 μg) 
Lane 4 – non-nitrated dialysed p53 lysate (13.7 μg) 
Lane 5 – nitrated dialysed p53 lysate (13.7 μg) 
19.0 
26.0 
34.0 
47.0 
86.0 
118.0 
 MW    a)   1        2        3         4        5 
(kDa) 
b)  1       2        3        4        5 
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believed that tyrosine nitration is part of normal physiological processes in 
humans (Moncada et al., 1991; Beckman and Koppenol., 1996) and 
presumably also in other mammals and organisms. Dialysed p53 lysate gave 
about similar nitrotyrosine signals of the host contaminating proteins in both 
the non-nitrated and the nitrated (Fig. 5.5(a), Lanes 4 and 5, respectively), 
showing a very weak nitro-p53 protein signal in non-nitrated lysate but no 
additional one in response to nitration. A possible explanation to this 
phenomenon is that the bacterial proteins were endogenously nitrated. 
However, in Fig. 5.5(b), as the secondary antibody used picked up bacterial 
proteins in both non-nitrated and nitrated dialysed p53 lysate (Fig. 5.5(b), 
Lanes 4 and 5, respectively), it is clear that the non-specific binding of the 
secondary antibody resulted in false-positive nitrotyrosine signals for both the 
samples when probed with the primary antibody anti-nitrotyrosine mouse 
monoclonal IgG, Clone 1A6. Nevertheless, both non-nitrated and nitrated 
BSA were not obviously picked up by the secondary antibody alone as no 
signals were observed (Fig. 5.5(b), Lanes 2 and 3, respectively). This shows 
that the primary antibody anti-nitrotyrosine might work. The nitrotyrosine 
signals depicted in Fig 5.5(a) might be due to the overlapping actions 
between the primary antibody anti-nitrotyrosine and the secondary antibody 
sheep anti-mouse HRP conjugated or the secondary antibody used was not 
good enough, therefore, it is unlikely to comment on the primary antibody (Dr 
Picksley, personal communication). 
 
Similar experiments were repeated but this time using a variety of samples 
such as bacterial lysate, BSA, bovine platelet, dialysed p53 lysate and 
purified resolubilised p53 protein. The samples except bacterial lysate were 
nitrated with 3 mM peroxynitrite and their non-nitrated counterparts were run 
in parallel. The primary antibody used was the same as before i.e. Clone 1A6 
antibody with a change in secondary antibody rabbit anti-mouse IgG HRP 
conjugated polyclonal antibody (DAKO Cytomation). As can be seen in Fig. 
5.6, the bacterial lysate, non-nitrated and nitrated BSA, non-nitrated and 
nitrated bovine platelet and non-nitrated dialysed p53 lysate but not nitrated 
dialysed p53 lysate gave nitrotyrosine signals (Fig. 5.6, Lanes 2-7). No 
nitrotyrosine signals were detected in nitrated dialysed p53 lysate and in both 
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non-nitrated and nitrated purified resolubilised p53 protein (Fig. 5.6, Lanes 8, 
9 and 10, respectively). A possible explanation for no nitrotyrosine signal in 
nitrated dialysed p53 lysate is that high peroxynitrite concentration (3 mM) 
used to nitrate the proteins resulted in their degradation or loss. Since the 
starting amount of purified resolubilised p53 protein was quite low, thus, no 
detectable nitrotyrosine signal was observed in nitrated purified resolubilised 
p53 protein (Fig. 5.6, Lane 10). The nitrotysrosine signals observed in both 
the non-nitrated and the nitrated (Fig. 5.6, Lanes 2-7) are probably due to the 
presence of endogenous nitrated proteins or due to the secondary antibody 
problem where it non-specifically bound to the proteins in the samples. 
 
In order to find out further the causes of this problem, nitration experiments 
were done using BSA nitrated at various concentrations of peroxynitrite 
ranging from 10 µM to 3 mM using this time around a different primary 
antibody rabbit anti-nitrotyrosine polyclonal antibody (from SIGMA) and 
therefore a different secondary antibody  swine anti-rabbit polyclonal 
antibody (from DAKO Cytomation).  Two negative control blots were used by 
preabsorbing the primary antibody with 10 mM 3-nitro-tyrosine right before its 
incubation to the blot and incubation of a blot with the secondary antibody 
alone Fig. 5.7(a) and (b), respectively). Both these blots gave false positive 
nitrotyrosine signals where blot in Fig 5.7(b) gave weaker nitrotyrosine 
signals when compared to blot in Fig. 5.7(a). Blot in Fig. 5.7(c) where the blot 
was incubated with the primary rabbit anti-nitrotyrosine polyclonal antibody 
and the secondary swine anti-rabbit polyclonal antibody showed about 
similar nitrotyrosine signals intensity as blot in Fig. 5.7(a). Secondary 
antibody was still a problem here where it non-specifically bound to BSA both 
non-nitrated and nitrated, indicating that it was not fit for the purpose. 
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Figure 5.6. Western Blot analysis showing various samples nitrated with 3 
mM peroxynitrite and incubated for 15 min in a rocking water bath at 37°C. 
The primary antibody used was anti-nitrotyrosine monoclonal antibody 
(Clone 1A6) (Upstate Biotechnology) and the secondary antibody was rabbit 
anti-mouse IgG HRP conjugated polyclonal antibody (Dako Cytomation). 
 
Lane 1   - prestained protein molecular weight markers (Fermentas) 
Lane 2   - BL21(DE3) bacterial lysate grown for 4 hours 
Lane 3   - non-nitrated BSA (5 μg) 
Lane 4   - nitrated BSA (5 μg) 
Lane 5   - non-nitrated bovine platelet (20 μg) 
Lane 6   - nitrated bovine platelet (20 μg) 
Lane 7   - non- nitrated dialysed p53 lysate (20.6 μg) 
Lane 8   - nitrated dialysed p53 lysate (20.6 μg) 
Lane 9   - non-nitrated purified resolubilised p53 (2.6 μg) 
Lane 10 - nitrated purified resolubilised p53 (2.6 μg) 
 
 
 
 
 
 
19.0 
34.0 
47.0 
118.0 
 MW           1      2       3       4       5       6       7       8       9      10 
(kDa) 
86.0 
26.0 
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Figure 5.7(a). Western Blot showing non-nitrated and nitrated BSA at 
various peroxynitrite concentrations and incubated for 15 min in a rocking 
water bath at 37°C. Rabbit anti-nitrotyrosine polyclonal antibody (Sigma) was 
used as the primary antibody which was first preabsorbed with 10 mM 3-
nitro-tyrosine (Sigma) and swine anti-rabbit polyclonal antibody (DAKO 
Cytomation) as the secondary antibody. The amount of all the samples 
loaded was 10 μg. This blot acts as a negative control blot. 
 
Lane 1 – prestained protein molecular weight markers (Fermentas) 
Lane 2 – non-nitrated BSA 
Lane 3 – 10 μM peroxynitrite nitrated BSA 
Lane 4 – 100 μM peroxynitrite nitrated BSA 
Lane 5 – 250 μM peroxynitrite nitrated BSA 
Lane 6 – 500 μM peroxynitrite nitrated BSA 
Lane 7 – 1 mM peroxynitrite nitrated BSA 
Lane 8 – 2 mM peroxynitrite nitrated BSA 
Lane 9 – 3 mM peroxynitrite nitrated BSA 
  
86.0 
19.0 
26.0 
34.0 
47.0 
118.0 
 MW           1       2        3        4        5        6        7       8        9 
(kDa) 
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Figure 5.7(b). Western Blot showing non- nitrated and nitrated BSA at 
various peroxynitrite concentrations and incubated for 15 min in a rocking 
water bath at 37°C. The secondary antibody used was swine anti-rabbit 
polyclonal antibody (DAKO Cytomation) alone. The amount of all the 
samples loaded was 10 μg. 
 
Lane 1 – prestained protein molecular weight markers (Fermentas) 
Lane 2 – non-nitrated BSA 
Lane 3 – 10 μM peroxynitrite nitrated BSA 
Lane 4 – 100 μM peroxynitrite nitrated BSA 
Lane 5 – 250 μM peroxynitrite nitrated BSA 
Lane 6 – 500 μM peroxynitrite nitrated BSA 
Lane 7 – 1 mM peroxynitrite nitrated BSA 
Lane 8 – 2 mM peroxynitrite nitrated BSA 
Lane 9 – 3 mM peroxynitrite nitrated BSA 
  
26.0 
34.0 
47.0 
 MW             1        2        3       4        5        6        7       8       9 
(kDa) 
118.0 
86.0 
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Figure 5.7(c). Western Blot showing non- nitrated and nitrated BSA at 
various concentrations of peroxynitrite and incubated for 15 min in a rocking 
water bath at 37°C. Rabbit anti-nitrotyrosine polyclonal antibody (Sigma) was 
used as  the primary antibody and swine anti-rabbit polyclonal antibody 
(DAKO Cytomation) as the secondary antibody. The amount of all samples 
loaded was 10 μg. 
 
Lane 1 – prestained protein molecular weight markers (Fermentas) 
Lane 2 – non-nitrated BSA 
Lane 3 – 10 μM peroxynitrite nitrated BSA 
Lane 4 – 100 μM peroxynitrite nitrated BSA 
Lane 5 – 250 μM peroxynitrite nitrated BSA 
Lane 6 – 500 μM peroxynitrite nitrated BSA 
Lane 7 – 1 mM peroxynitrite nitrated BSA 
Lane 8 – 2 mM peroxynitrite nitrated BSA 
Lane 9 – 3 mM peroxynitrite nitrated BSA 
  
19.0 
26.0 
34.0 
47.0 
118.0 
 MW             1       2        3        4        5        6        7        8        9 
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Figure 5.8.  Western Blot analysis showing non-nitrated and nitrated BSA 
with 250 μM peroxynitrite and incubated for 15 min in a rocking water bath at 
37°C.  The samples were blotted with different anti-rabbit secondary antibody 
alone: a) swine anti-rabbit IgG/HRP conjugated (DAKO Cytomation), b) anti-
rabbit HRP conjugated (Cell Signalling), c) goat anti-rabbit IgG/HRP 
conjugated (Amersham Biosciences), d) sheep anti-rabbit IgG/HRP 
conjugated. The amount of BSA loaded was 2 μg. 
 
Lane 1 – prestained protein molecular weight markers (Fermentas) 
Lane 2  - non-nitrated BSA 
Lane 3  - 250 μM peroxynitrite nitrated BSA 
  
47.0 
118.0 
47.0 
118.0 
 MW      a)      1           2           3 
(kDa) 
  b)   1          2           3 
 
 MW      c)     1            2             3 
(kDa) 
  d)    1              2            3 
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This therefore led us to use a variety of secondary antibodies alone including 
the ones we used in the previous experiments namely swine anti-rabbit IgG 
HRP conjugated (DAKO Cytomation), anti-rabbit HRP conjugated (Cell 
Signalling), goat anti-rabbit IgG HRP conjugated (Amershan Biosciences) 
and sheep anti-rabbit IgG HRP conjugated (a kind gift of Dr Patel, University 
of Bradford) to incubate strips of small cut blots containing non-nitrated and 
250 µM peroxynitrite nitrated BSA (Fig. 5.8(a), (b), (c) and (d), respectively). 
These data show that all the four secondary antibodies used gave signals 
indicating that these antibodies picked up both non-nitrated and nitrated 
BSA. From these data, we then came to identify that secondary antibodies 
were the cause of the problems for false positive signals.  
 
In order to solve the secondary antibody problems, we then explored 
different blocking conditions with secondary antibody alone using non-
nitrated BSA as a sample. Two representative secondary antibodies were 
used namely rabbit anti-mouse polyclonal antibody HRP conjugated and 
swine anti-rabbit polyclonal antibody HRP conjugated (both from DAKO 
Cytomation). Four blocking conditions were used as summarised in Materials 
& Methods, Section 2.14, Table 2.7. Briefly, the blocking conditions used 
were (i) 5% non-fat dry milk in PBS, (ii) 5% non-fat dry milk/0.2% Tween 20 
in PBS, (iii) 0.2% Tween 20 in PBS, (iv) 3% BSA in PBS. As can be seen in 
Fig. 5.9, Very clear background was found in blocking conditions (i) and (ii) 
whereas non-specific binding of both secondary antibodies to non-nitrated 
BSA were found when using blocking conditions (iii) and (iv). From this 
experiment, we finally determined the best blocking conditions to be used 
namely either with 5% non-fat milk in PBS or with 5% non-fat dry milk/0.2% 
Tween 20 in PBS.  
 
Having solved the problems, we now proceeded with nitration of purified 
resolubilised p53 protein with various concentrations of peroxynitrite ranging 
from 10 µM to 3 mM but this time we probed the membrane with the primary 
rabbit anti-nitrotyrosine polyclonal antibody (Sigma). A dirty background was 
observed when we incubated a blot containing nitrated purified resolubilised 
p53 samples with this primary antibody [Fig. 5.10(a)]. However, we could 
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only see a moderate nitrotyrosine signal in purified resolubilised p53 protein 
nitrated with 250 µM peroxynitrite (Fig. 5.10(a), Lane 5). In addition, the non-
nitrated purified resolublised p53 protein as expected and the rest of the 
nitrated samples gave no nitrotyrosine signals. A negative control blot where 
the primary antibody rabbit polyclonal anti-nitrotyrosine was first preabsorbed 
with 10 mM 3-nitrotyrosine showed a clear background or reduced signal 
(Fig. 5.10(b)), consistent with the antigen binding sites were blocked as 
expected. In Fig. 5.10(c), a lot of p53 protein degradation products were 
observed in non-nitrated samples and nitrated samples with peroxynitrite 
from 10 µM to 1 mM (Fig. 5.10(c), Lanes 2-7). The levels of nitrated purified 
resolubilised p53 protein nitrated with 2 and 3 mM peroxynitrite seem to be 
reduced (Fig. 5.10(c), Lanes 8 and 9, respectively). The experiments had 
been repeated with 2 repeats (n=2). 
 
As the primary rabbit anti-nitrotyrosine polyclonal antibody (Sigma) [see Fig. 
5.10(a)] resulted in a dirty background, we then decided to switch back to 
use anti-nitrotyrosine mouse monoclonal IgG, Clone 1A6 (Upstate 
Biotechnology) for the following nitration work as so far it did not give a dirty 
background.  
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Figure 5.9. Western Blot analysis showing different blocking conditions used and all 
the blots were probed only with secondary antibody alone either with rabbit anti-
mouse monoclonal antibody HRP conjugated or with swine anti-rabbit polyclonal 
antibody HRP conjugated, both of which from DAKO Cytomation. 9 out of 10 wells 
were combined together with a cellotape to form one big well. 100 µl of 1mg/ml BSA 
was loaded onto the well, thus making the amount of BSA in each small blot about 
20 µg when one big blot was cut into 4 small strips. Since MW marker was not 
visible, therefore a Strategene marker was placed on top of cling film used to wrap 
the blots after poured with ECL and then exposed to X-ray film before being 
developed and fixed. However, the cut blots were first marked with a red pen on its 
upper part and with a black pen on its lower part in order to aid marking of the 
marker.  
Lane 1  - prestained protein molecular weight markers (Fermentas) 
Lane 2  - bovine serum albumin (BSA) (non-nitrated) 
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Figure 5.10(a). Western Blot analysis showing purified resolubilised p53 
protein nitrated with various concentrations of peroxynitrite ranging from 10 
μM to 3 mM and incubated for 15 min in a rocking water bath at 37°C. Non-
nitrated purified resolubilised p53 protein was used as a negative control. 
The amount of all samples loaded was 2.04 μg. The primary antibody used 
was rabbit polyclonal anti-nitrotyrosine (Sigma) and the secondary antibody 
was swine anti-rabbit IgG/HRP conjugated (DAKO Cytomation) (n=2 
repeats). 
 
Lane 1   - prestained protein molecular weight markers (Fermentas) 
Lane 2   - non-nitrated purified p53  
Lane 3   - 10 μM peroxynitrite nitrated purified resolubilised p53 
Lane 4   - 100 μM peroxynitrite nitrated purified resolubilised p53 
Lane 5   - 250 μM peroxynitrite nitrated purified resolubilised p53 
Lane 6   - 500 μM peroxynitrite nitrated purified resolubilised p53 
Lane 7   - 1 mM peroxynitrite nitrated purified resolubilised p53 
Lane 8   - 2 mM peroxynitrite nitrated purified resolubilised p53 
Lane 9   - 3 mMperoxynitrite nitrated purified resolubilised p53 
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Figure 5.10(b). Western Blot analysis showing purified resolubilised p53 
protein nitrated with various concentrations of peroxynitrite ranging from 10 
μM to 3 mM and incubated for 15 min in a rocking water bath at 37°C. Non-
nitrated purified p53 protein was used as a negative control. The amount of 
all samples loaded was 2.04 μg. The primary antibody used was rabbit 
polyclonal anti-nitrotyrosine (Sigma) which was first pre-absorbed with 10 
mM 3-nitro-L-tyrosine (Sigma) and the secondary antibody was swine anti-
rabbit IgG/HRP conjugated (DAKO Cytomation). This blot acted as a 
negative control blot. 
 
Lane 1   - prestained protein molecular weight markers (Fermentas) 
Lane 2   - non-nitrated purified p53  
Lane 3   - 10 μM peroxynitrite nitrated purified resolubilised p53 
Lane 4   - 100 μM peroxynitrite nitrated purified resolubilised p53 
Lane 5   - 250 μM peroxynitrite nitrated purified resolubilised p53 
Lane 6   - 500 μM peroxynitrite nitrated purified resolubilised p53 
Lane 7   - 1 mM peroxynitrite nitrated purified resolubilised p53 
Lane 8   - 2 mM peroxynitrite nitrated purified resolubilised p53 
Lane 9   - 3 mM peroxynitrite nitrated purified resolubilised p53 
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Figure 5.10(c). Western Blot analysis showing purified resolubilised p53 
protein nitrated with various concentrations of peroxynitrite ranging from 10 
μM to 3 mM and incubated for 15 min in a rocking water bath at 37°C. Non-
nitrated purified p53 protein was used as a negative control. The amount of 
all samples loaded was 2.04 μg. The primary antibody used was anti-p53 
monoclonal antibody (DO-1), a kind gift of Dr Borivoj Vojtesek from the 
Czech Republic and the secondary antibody was polyclonal rabbit anti-
mouse IgG from DAKO Cytomation.  
 
Lane 1   - prestained protein molecular weight markers (Fermentas) 
Lane 2   - non-nitrated purified resolubilised p53  
Lane 3   - 10 μM peroxynitrite nitrated purified  resolubilised p53 
Lane 4   - 100 μM peroxynitrite nitrated purified  resolubilised p53 
Lane 5   - 250 μM peroxynitrite nitrated purified  resolubilised p53 
Lane 6   - 500 μM peroxynitrite nitrated purified  resolubilised p53 
Lane 7   - 1 mM peroxynitrite nitrated purified  resolubilised p53 
Lane 8   - 2 mM peroxynitrite nitrated purified  resolubilised p53 
Lane 9   - 3 mMperoxynitrite nitrated purified  resolubilised p53 
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We now proceeded with nitration of BSA but this time we narrowed down the 
concentrations of peroxynitrite used from 10 µM to 1 mM in order to see a 
dose response. In Fig. 5.11(a), increasing the concentrations of peroxynitrite 
increased the nitrotyrosine signals up to 200 µM peroxynitrite. However, the 
nitrotyrosine signals started to level off beyond 200 µM peroxynitrite namely 
at 300 µM,  400 µM, 500 µM and 1 mM. A blot with the same BSA samples 
as in a blot in Fig. 5.11(a) where the primary anti-nitrotyrosine Clone 1A6 
was first preabsorbed with 10 mM 3-nitro-L-tyrosine before being incubated 
to the blot acted as a negative control blot (Fig. 5.11(b)). We expected to get 
no signals at all, however, there were nitrotyrosine signals and a weaker 
signal in BSA samples nitrated with 50 µM and 100 µM peroxynitrite, 
respectively (Fig. 5.11(b), Lanes 4 and 5, respectively). A possible reason for 
this is that BSA nitrated with 50 µM peroxynitrite had the strongest 
nitrotyrosine levels and then followed by BSA nitrated with 100 µM 
peroxynitrite where even after the primary antibody Clone 1A6 had been pre-
absorbed with 10 mM 3-nitro-L-tyrosine, a little amount of unabsorbed 
antibody would still react with the abundant nitro-BSA protein. The fact is 100 
µM peroxynitrite can be seen as a pathological relevant concentration of the 
nitrating agent in vivo. 
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Figure 5.11(a). Western Blot analysis showing non-nitrated BSA and nitrated 
BSA with various concentrations of peroxynitrite and incubated for 15 min in 
a rocking water bath at 37°C. The primary antibody used was anti-
nitrotyrosine mouse monoclonal IgG, Clone 1A6 (Upstate Biotechnology) and 
the secondary antibody was polyclonal rabbit anti-mouse IgG/HRP 
conjugated (Dako Cytomation). The amount of BSA loaded was 2 μg. 
 
Lane 1   - prestained protein molecular weight markers (Fermentas) 
Lane 2   - non-nitrated BSA 
Lane 3   - 10 μM peroxynitrite nitrated BSA 
Lane 4   - 50 μM peroxynitrite nitrated BSA 
Lane 5   - 100 μM peroxynitrite nitrated BSA 
Lane 6   - 200 μM peroxynitrite nitrated BSA 
Lane 7   - 300 μM peroxynitrite nitrated BSA 
Lane 8   - 400 μM peroxynitrite nitrated BSA 
Lane 9   - 500 μM peroxynitrite nitrated BSA  
Lane 10 - 1 mM peroxynitrite nitrated BSA  
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Figure 5.11(b). Western Blot analysis showing non-nitrated BSA and nitrated 
BSA with various concentrations of peroxynitrite and incubated for 15 min in 
a rocking water bath at 37°C. The primary antibody used was anti-
nitrotyrosine mouse monoclonal IgG, Clone 1A6 (Upstate Biotechnology) 
which was first pre-absorbed with 10 mM 3-nitrotyrosine (Sigma) and the 
secondary antibody was polyclonal rabbit anti-mouse IgG/HRP conjugated 
(Dako Cytomation). The amount of BSA loaded was 2 μg. This blot acts as a 
negative control blot. 
 
Lane 1   - prestained protein molecular weight markers (Fermentas) 
Lane 2   - non-nitrated BSA 
Lane 3   - 10 μM peroxynitrite nitrated BSA 
Lane 4   - 50 μM peroxynitrite nitrated BSA 
Lane 5   - 100 μM peroxynitrite nitrated BSA 
Lane 6   - 200 μM peroxynitrite nitrated BSA 
Lane 7   - 300 μM peroxynitrite nitrated BSA 
Lane 8   - 400 μM peroxynitrite nitrated BSA 
Lane 9   - 500 μM peroxynitrite nitrated BSA  
Lane 10 - 1 mM peroxynitrite nitrated BSA  
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We then repeated the dose response of increasing concentrations of 
peroxynitrite on purified resolubilised p53 protein. The dose response effects 
of nitrated purified resolubilised p53 protein was a bit different from the dose 
response effects of nitrated BSA. In Fig. 5.12(a), we can see that the 
nitrotyrosine signals increased from 50 µM to 400 µM peroxynitrite (Fig. 
5.12(a), Lanes 5 to 9). Weaker signals were observed in purified 
resolubilised p53 protein samples nitrated with 50 µM and 100 µM 
peroxynitrite (Fig. 5.12(a), Lanes 5 and 6, respectively). No nitrotyrosine 
signal was obtained in non-nitrated purified resolubilised p53 protein as 
expected where it acted as a negative control for nitration (Fig. 5.12(a), Lane 
3). No signal was also found in 10 µM peroxynitrite nitrated purified 
resolubilised p53 protein samples (Fig. 5.12(a), Lane 4). We can see very 
strong nitro-p53 protein signals in purified resolubilised p53 protein samples 
nitrated with 200, 300 and 400 µM peroxynitrite with unreduced high 
molecular weight aggregates (Fig. 5.12(a), Lanes 7-9) which were also seen 
by Calmels et al. (1997) and Cobbs et al. (2001) in  MCF7 and D54MG cells 
at 0.5-1 mM and 10-100 µM, peroxynitrite, respectively. This is believed to be 
due to the formation of carbonyl or dityrosine (i.e. tyrosine oxidation by 
peroxynitrite) or loss of zinc from p53 active site (Cobbs et al., 2001), which 
has been shown when p53 protein was treated with zinc chelators or with 
oxidizing agents (Hainut and Milner, 1993; Hainut et al., 1995). This 
modification on the p53 protein might affects p53 structure and functions.  
However, at 500 µM peroxynitrite, no nitro-p53 protein signal was observed 
at 53 kDa but we can see that there were still some unreduced high 
molecular weight aggregates present (Fig. 5.12(a), Lane 10). A possible 
explanation for the loss of nitrotyrosine signal at high concentration of 
peroxynitrite used (500 µM)  is that due to the degrading properties of 
peroxynitrite on proteins as evident by a study by Ischiropoulos and Al-Mehdi 
which showed that fatty acid-free BSA was fragmented after exposure to 
peroxynitrite (Ischiropoulos and Al-Mehdi, 1995). 50 µM peroxynitrite nitrated 
BSA was run in parallel to act as a positive control for nitration (Fig. 5.12(a), 
Lane 2).  A negative blot by pre-absorbing the primary antibody Clone 1A6 
with 10 mM 3-nitro-L-tyrosine prior to incubating the blot was acceptable as 
no nitrotyrosine signals for all the samples on the blot except that we can see 
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a weak nitrotyrosine signal of 50 µM peroxynitrite nitrated BSA (Fig. 5.12(b)). 
The possible reason for this is that due to a high amount of nitrotyrosine 
shown in Fig. 5.12(a), thus the incomplete pre-absorbed anti-nitrotyrosine 
antibody could easily pick up the excess nitrated BSA. In Fig. 5.12(c), the 
blot with the same samples as the blots in Figs. 5.12(a) and (b), was probed 
with anti-p53 monoclonal antibody (DO-1) in order to check p53 protein 
levels after nitration with different concentrations of peroxynitrite and also to 
compare with non-nitrated purified resolubilised p53 protein sample. As can 
be seen in Fig. 5.12(c), a lot of p53 degradation products were observed 
from non-nitrated to 500 µM peroxynitrite nitrated purified resolubilised p53 
protein samples. We cannot see an obvious increasing trend of p53 protein 
degradation products with increasing concentrations of peroxynitrite in this 
figure as reported by Cobbs and co-workers (2001 and 2003) where they 
found that tyrosine nitration of purified baculovirus-derived recombinant wt 
p53 protein and of p53 protein in D54MG cells system treated with 0-100 µM 
peroxynitrite caused increased p53 protein degradation. Non-reduced high 
molecular weight aggregates are also seen in samples in Lanes 3-9 (Fig. 
5.12(c)) with higher intensities in samples 7-9. 
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Figure 5.12(a). Western Blot analysis showing nitrated purified resolubilised 
p53 protein with various concentrations of peroxynitrite ranging from 10 μM 
to 500 μM and incubated for 15 min in a rocking water bath at 37°C. 50 μM 
peroxynitrite nitrated BSA was used as a positive control and non-nitrated 
purified resolubilised p53 protein as a negative control. The amount of 
nitrated BSA loaded was 2 μg and non-nitrated and nitrated purified 
resolubilised p53 protein was 2.04 μg. The primary antibody used was anti-
nitrotyrosine mouse monoclonal IgG, Clone 1A6 (Upstate Biotechnology) and 
the secondary antibody was polyclonal rabbit anti-mouse IgG/HRP 
conjugated (Dako Cytomation). 
 
Lane 1   - prestained protein molecular weight markers (Fermentas) 
Lane 2   - 50 μM peroxynitrite nitrated BSA 
Lane 3   - non-nitrated purified resolubilised p53 
Lane 4   - 10 μM peroxynitrite nitrated purified resolubilised p53 
Lane 5   - 50 μM peroxynitrite nitrated purified resolubilised p53 
Lane 6   - 100 μM peroxynitrite nitrated purified resolubilised p53 
Lane 7   - 200 μM peroxynitrite nitrated purified resolubilised p53 
Lane 8   - 300 μM peroxynitrite nitrated purified resolubilised p53 
Lane 9   - 400 μM peroxynitrite nitrated purified resolubilised p53 
Lane 10 - 500 μM peroxynitrite nitrated purified resolubilised p53 
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Figure 5.12(b). Western Blot analysis showing nitrated purified resolubilised 
p53 protein with various concentrations of peroxynitrite ranging from 10 μM 
to 500 μM and incubated for 15 min in a rocking water bath at 37°C. 50 μM 
peroxynitrite nitrated BSA was used as a positive control and non-nitrated 
purified p53 protein as a negative control. The amount of nitrated BSA 
loaded was 2 μg and non-nitrated and nitrated purified p53 protein was 2.04 
μg. The primary antibody used was anti-nitrotyrosine mouse monoclonal IgG, 
Clone 1A6 (Upstate Biotechnology) which was first pre-absorbed with 3-nitro-
L-tyrosine (Sigma) and the secondary antibody was polyclonal rabbit anti-
mouse IgG/HRP conjugated (Dako Cytomation). This blot acts as a negative 
control blot. 
 
Lane 1   - prestained protein molecular weight markers (Fermentas) 
Lane 2   - 50 μM peroxynitrite nitrated BSA 
Lane 3   - non-nitrated purified resolubilised p53 
Lane 4   - 10 μM peroxynitrite nitrated purified resolubilised p53 
Lane 5   - 50 μM peroxynitrite nitrated purified resolubilised p53 
Lane 6   - 100 μM peroxynitrite nitrated purified resolubilised p53 
Lane 7   - 200 μM peroxynitrite nitrated purified resolubilised p53 
Lane 8   - 300 μM peroxynitrite nitrated purified resolubilised p53 
Lane 9   - 400 μM peroxynitrite nitrated purified resolubilised p53 
Lane 10 - 500 μM peroxynitrite nitrated purified resolubilised p53 
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Figure 5.12(c). Western Blot analysis showing nitrated purified resolubilised  
p53 protein with various concentrations of peroxynitrite ranging from 10 μM 
to 500 μM and incubated for 15 min in a rocking water bath at 37°C. 50 μM 
peroxynitrite nitrated BSA was used as a positive control and non-nitrated 
purified resolubilised p53 protein as a negative control. The amount of 
nitrated BSA loaded was 2 μg and non-nitrated and nitrated purified 
resolubilised  p53 protein was 2.04 μg. The primary antibody used was anti-
p53 monoclonal antibody (DO-1), a kind gift of Dr Borivoj Vojtesek from the 
Czech Republic and the secondary antibody was rabbit polyclonal anti-
mouse IgG HRP conjugated (DAKO Cytomation). 
 
Lane 1   - prestained protein molecular weight markers (Fermentas) 
Lane 2   - 50 μM peroxynitrite nitrated BSA 
Lane 3   - non-nitrated purified resolubilised p53 
Lane 4   - 10 μM peroxynitrite nitrated purified resolubilised p53 
Lane 5   - 50 μM peroxynitrite nitrated purified resolubilised p53 
Lane 6   - 100 μM peroxynitrite nitrated purified resolubilised p53 
Lane 7   - 200 μM peroxynitrite nitrated purified resolubilised p53 
Lane 8   - 300 μM peroxynitrite nitrated purified resolubilised p53 
Lane 9   - 400 μM peroxynitrite nitrated purified resolubilised p53 
Lane 10 - 500 μM peroxynitrite nitrated purified resolubilised p53 
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 5.5 Nitration of a model protein BSA at different amounts 
In order to get the most suitable conditions for nitration, as usual we used 
BSA as a model protein for nitration. BSA was nitrated at different amounts 
i.e. 100, 200, 300 and 500 µg with 100 µM peroxynitrite. From the results in 
Fig. 5.13, we found that there was no obvious different signals or 
nitrotyrosine levels in nitrated BSA in all the four amounts. But in a large 
scale nitration (20 mg), we can see that weak nitrotyrosine signals in 50 µM, 
200 µM and 1 mM peroxynitrite when compared to 3 mM peroxynitrite which 
shows the strongest signal among the four concentrations of peroxynitrite 
used (Fig. 5.14) and interestingly the signal was about similar to signal in 
Lane 3 (500 µg BSA previously nitrated with 100 uM peroxynitrite)  as also 
evident in Fig. 5.13, Lane 4, 100 µM peroxynitrite in 500 µg BSA. In non-
nitrated BSA (Lane 2, Fig. 5.14) we can see a very weak signal of 
nitrotyrosine which was probably due to BSA being endogenously nitrated in 
cow as it is believed that nitration may occur as part of a normal 
physiological process with a potential role in signal transduction 
mechanisms, possibly by influencing tyrosine phosphorylation or 
dephosphorylation (Bruckdorfer, 2001). 
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Figure 5.13. Western blot analysis showing 100 µM peroxynitrite nitration of 
BSA at different amounts in order to determine the effects of amounts on 
nitrotyrosine signals. The samples were incubated with peroxynitrite for 15 
min in a rocking water bath at 37°C. The primary antibody used was anti-
nitrotyrosine mouse monoclonal IgG, Clone 1A6 (Upstate Biotechnology) and 
the secondary antibody was rabbit anti-mouse IgG/HRP conjugated (DAKO 
Cytomation). The amount of BSA loaded was 2 µg.  
 
Lane 1  - prestained protein molecular weight markers (Fermentas) 
Lane 2  - non-nitrated BSA 
Lane 3  - 100 µM peroxynitrite previously nitration of 500 µg BSA as a                             
positive control 
Lane 4  - 100 µM peroxynitrite nitration of 500 µg BSA 
Lane 5  - 100 µM peroxynitrite nitration of 300 µg BSA 
Lane 6  - 100 µM peroxynitrite nitration of 200 µg BSA 
Lane 7  - 100 µM peroxynitrite nitration of 100 µg BSA 
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Figure 5.14. Western blot analysis showing a large scale nitration (20 mg) of 
BSA at various concentrations of peroxynitrite and incubated for 15 min in a 
rocking water bath at 37°C. 100 µM peroxynitrite previously nitration of 500 
µg BSA was used as a positive control. The primary antibody used was anti-
nitrotyrosine mouse monoclonal IgG, Clone 1A6 (Upstate Biotechnology and 
the secondary antibody was rabbit anti-mouse IgG/HRP conjugated (DAKO 
Cytomation). The amount of BSA loaded was 2 µg. 
 
Lane 1 - prestained protein molecular weight markers (Fermentas) 
Lane 2 - non-nitrated BSA 
Lane 3 - 100 µM peroxynitrite previously nitration of 500 µg BSA  
Lane 4 - 50 µM peroxynitrite nitration of 20 mg BSA 
Lane 5 - 200 µM peroxynitrite nitration of 20 mg BSA 
Lane 6 - 1 mM peroxynitrite nitration of 20 mg BSA 
Lane 7 - 3 mM peroxynitrite nitration of 20 mg BSA 
47.0 
86.0 
118.0 
 MW          1       2        3         4        5         6         7 
(kDa) 
204 
 
5.6 Increased in the amounts of nitrated BSA resulted in increased in 
nitrotyrosine signals 
We also attempted to determine whether nitrotyrosine signals increased with 
increasing amount of nitrated BSA loaded (from 0.5 to 6.0 µg) onto an SDS 
polyacrylamide gel. BSA was nitrated with 3 mM peroxynitrite, loaded onto a 
SDS polyacryamide gel and then immunoblotted onto a nitrocellulose 
membrane and was subsequently detected with anti-nitrotyrosine 
monoclonal antibody (Upstate Biotechnology). From Fig. 5.15, we can see 
that the nitrotyrosine signals increased from 0.5 to 3.0 µg nitrated BSA 
loaded (Lanes 4-8) and then the signals seemed to plateau from 3.0 to 6.0 
µg nitrated BSA loaded (Lanes 8-15).  
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Figure 5.15. Western blot analysis showing 3 mM peroxynitrite nitrated BSA 
was incubated for 15 min in a rocking water bath at 37°C. The samples were 
loaded on an SDS-PAGE gel with increasing in amount from 0.5 µg to 6.0 µg 
to detect whether an increase in nitrotyrosine signal with increasing amounts 
of nitrated BSA. The primary antibody used was anti-nitrotyrosine mouse 
monoclonal IgG, Clone 1A6 (Upstate Biotechnology) and the secondary 
antibody was rabbit anti-mouse IgG/HRP conjugated (DAKO Cytomation). 
 
Lane 1  - prestained protein molecular weight markers (Fermentas) 
Lane 2  - non-nitrated BSA (2 µg) 
Lane 3  -100 µM peroxynitrite previously nitrated BSA (2 µg) 
Lane 4  - 3 mM peroxynitrite nitrated BSA (0.5 µg) 
Lane 5  - 3 mM peroxynitrite nitrated BSA (1.0 µg) 
Lane 6  - 3 mM peroxynitrite nitrated BSA (1.5 µg) 
Lane 7  - 3 mM peroxynitrite nitrated BSA (2.0 µg) 
Lane 8  - 3 mM peroxynitrite nitrated BSA (2.5 µg) 
Lane 9  - 3 mM peroxynitrite nitrated BSA (3.0 µg) 
Lane 10 - 3 mM peroxynitrite nitrated BSA (3.5 µg) 
Lane 11 - 3 mM peroxynitrite nitrated BSA (4.0 µg) 
Lane 12 - 3 mM peroxynitrite nitrated BSA (4.5 µg) 
Lane 13 - 3 mM peroxynitrite nitrated BSA (5.0 µg) 
Lane 14 - 3 mM peroxynitrite nitrated BSA (5.5 µg) 
Lane 15 - 3 mM peroxynitrite nitrated BSA (6.0 µg) 
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5.7  Use of platelets in the pilot nitration study 
 
Peroxynitrite affects platelet functions in a concentration-dependent manner. 
At higher concentrations (> 150 µM), peroxynitrite acts as a platelet agonist 
by stimulating platelet aggregation (Moro et al., 1994). However, at lower 
concentrations (3-10 µM) , peroxynitrite acts as a platelet inhibitor with an 
I.C.50 of 3 µM, but less effective than NO (Moro et al., 1994; Naseem, 1995). 
It has been shown that the addition of peroxynitrite leads to the nitration of 
specific platelet proteins and the regulation of platelet functions (Mandoro et 
al., 1997). Among the most prominently nitrated proteins had molecular 
weights of 187, 164, 113, 89, and 61 kDa. Platelet proteins nitrated to a 
lesser extent were of molecular weights of 208, 182, 122, 91, 70, and 50 kDa 
(Mondoro et al., 1997).  Therefore, in order to reproduce this finding using 
our nitration system, we then tried to nitrate bovine platelets as 
recommended by Prof. Naseem (Biomedical Sciences Department).  The 
platelets were either lysed or left intact (kindly prepared by Dr Andrew 
Milward, Biomedical Sciences Department) and then were nitrated with 
peroxynitrite concentrations ranging from 5 to 100 µM and BSA was nitrated 
in parallel with 100 µM peroxynitrite to act as a positive control for nitration. 
As can be seen  on  an SDS polyacrylamide gel stained with Commassie 
blue in Fig. 5.16(a), the platelet proteins profiles for both unlysed and lysed 
platelets were very similar either they were nitrated or not.  The platelet 
proteins were hardly nitrated as evident in Fig. 5.16(b) where very weak 
signals of nitrotyrosine detected in both nitrated unlysed and lysed platelets 
with the exception that at 50 µM and 100 µM peroxynitrite-treated unlysed 
bovine platelets where quite strong signals were detected when compared to 
the rest. Interestingly, the size of the nitrated platelet protein is about the 
same size as the nitrated BSA (66 kDa). This might be residual BSA 
remained in the unlysed washed platelet as BSA is very readily nitrated due 
to its high content of tyrosine residues and these results show a clear evident 
for the readily nitrated BSA at 50 µM and 100 µM peroxynitrite. 
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Figure 5.16(a). A 10% SDS-PAGE gel showing nitration of unlysed and 
lysed bovine platelets with peroxynitrite concentrations ranging from 5 to 100 
µM and incubated for 15 min in a rocking water bath at 37°C. BSA was 
nitrated at the same time with 100 µM peroxynitrite to act as a positive 
control for nitration. The amount of BSA loaded was 2 µg. The gel was 
stained with Coomassie Blue for 15 minutes and then destained overnight. 
 
Lane 1   - prestained protein molecular weight markers (Fermentas) 
Lane 2   - non-nitrated BSA dissolved in PBS 
Lane 3   - 100 µM peroxynitrite nitrated BSA dissolved in PBS 
Lane 4   - non-nitrated unlysed bovine platelets 
Lane 5   - 5 µM peroxynitrite nitrated unlysed  bovine platelets 
Lane 6   - 10 µM peroxynitrite nitrated unlysed bovine platelets 
Lane 7   - 25 µM peroxynitrite nitrated unlysed bovine platelets 
Lane 8   - 50 µM peroxynitrite nitrated unlysed bovine platelets 
Lane 9   - 100 µM peroxynitrite nitrated unlysed bovine platelets 
Lane 10 - non-nitrated lysed bovine platelets 
Lane 11 - 5 µM peroxynitrite nitrated lysed  bovine platelets 
Lane 12 - 10 µM peroxynitrite nitrated lysed bovine platelets 
Lane 13 - 25 µM peroxynitrite nitrated lysed bovine platelets 
Lane 14 - 50 µM peroxynitrite nitrated lysed bovine platelets 
Lane 15 - 100 µM peroxynitrite nitrated lysed bovine platelets 
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Figure 5.16(b). A western blot analysis showing nitration of unlysed and 
lysed bovine platelets with peroxynitrite concentrations ranging from 5 to 100 
µM and incubated for 15 min in a rocking water bath at 37°C. BSA was 
nitrated at the same time with 100 µM peroxynitrite to act as a positive 
control for nitration. The primary antibody used was mouse monoclonal anti-
nitrotyrosine (Upstate Biotechnology) and the secondary antibody was rabbit 
anti-mouse HRP conjugated polyclonal antibody (DAKO Cytomation). The 
amount of BSA loaded was 2 µg. 
 
Lane 1   - prestained protein molecular weight markers (Fermentas) 
Lane 2   - non-nitrated BSA dissolved in PBS 
Lane 3   - 100 µM peroxynitrite nitrated BSA dissolved in PBS 
Lane 4   - non-nitrated unlysed bovine platelets 
Lane 5   - 5 µM peroxynitrite nitrated unlysed  bovine platelets 
Lane 6   - 10 µM peroxynitrite nitrated unlysed bovine platelets 
Lane 7   - 25 µM peroxynitrite nitrated unlysed bovine platelets 
Lane 8   - 50 µM peroxynitrite nitrated unlysed bovine platelets 
Lane 9   - 100 µM peroxynitrite nitrated unlysed bovine platelets 
Lane 10 - non-nitrated lysed bovine platelets 
Lane 11 - 5 µM peroxynitrite nitrated lysed  bovine platelets 
Lane 12 - 10 µM peroxynitrite nitrated lysed bovine platelets 
Lane 13 - 25 µM peroxynitrite nitrated lysed bovine platelets 
Lane 14 - 50 µM peroxynitrite nitrated lysed bovine platelets 
Lane 15 - 100 µM peroxynitrite nitrated lysed bovine platelets 
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5.8 pH measurements of peroxynitrite, NaOH, Potassium Phosphate 
Buffer (KPi), PBS and distilled water and OD302 nm of diluted 
peroxynitrite 
The objective of this work was to determine whether the differences in the pH 
values of diluents used to dilute peroxynitrite (PN) would affect its stability 
and its effectiveness as a nitrating agent. First, we measured the pH of each 
solution employed and then the pH of peroxynitrite diluted in each diluent 
and their corresponding optical densities (ODs) at 302 nm were read using a 
spectrophotometer. The pH of stock of freshly prepared peroxynitrite, 1.5 M 
NaOH, 50 mM KPi, PBS and distilled water (both sterile and non-sterile) 
were measured by using pH indicator sticks. We found that the pH of 
peroxynitrite (30 mM) was around 13.0. 1.5 M NaOH was the most alkaline 
with a pH of 14.0. KPi with a pH of 8.0 was more alkaline than PBS (pH 7.5). 
These results are summarised in Table 5.1 below. 
 
Table 5.1: pH checking of 30 mM stock peroxynitrite (PN), 1.5 M NaOH, 
50 mM Potassium Phosphate Buffer (KPi), PBS and distilled water (both 
sterile and non-sterile) using pH indicator sticks.  
Reagents pH 
Peroxynitrite (30 mM) 13.0 
1.5 M NaOH 14.0 
50 mM KPi 8.0 
PBS 7.5 
Sterile distilled water 5.0 
Non-sterile distilled water 4.7 
 
 
Stock peroxynitrite was diluted 1:2, 1:10 and 1:20 in 1.5 M NaOH, 50 mM 
KPi, PBS or sterile distilled water to see the effects of these solutions on the 
pH of peroxynitrite. As shown in Table 5.2 below, the pH of stock 
peroxynitrite diluted in 1.5 M NaOH increased to 14.0 in all the 3 dilutions. 
The pH of stock peroxynitrite remained at 13.0 when diluted 1:2 in 50 mM 
KPi, PBS or sterile distilled water. The pH dropped to 12.0 and then further 
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dropped to 11.0 when diluted 1:10 and 1:20, respectively in 50 mM KPi, PBS 
or sterile distilled water.  
 
Table 5.2: pH checking of peroxynitrite (PN) after 1:2, 1:10 and 1:20 
dilution either in 1.5 M NaOH, 50 mM KPi, PBS or sterile distilled water 
using pH indicator sticks 
Diluent /  
Dilution 
pH 
1:2 1:10 1:20 
1.5 M NaOH 14.0 14.0 14.0 
50 mM KPi 13.0 12.0 11.0 
PBS 13.0 12.0 11.0 
Sterile distilled 
water 
13.0 12.0 11.0 
 
 
The stock peroxynitrite diluted 1:2, 1:10 or 1:20 in 1.5 M NaOH, 50 mM KPi, 
PBS or sterile distilled water was measured at OD302 nm. OD302 nm of 
peroxynitrite diluted in 1.5 M NaOH  at all the 3 dilutions were slightly higher 
than that of in 50 mM KPi, PBS or distilled water, however, were still lower 
than the expected OD302 nm. As we increased dilution from 1:2 to 1:10 to 
1:20, by right the ODs would decrease 2 fold to 5 fold to 10 fold as calculated 
in the expected OD302 nm. The decrease in ODs corresponds to the decrease 
in the peroxynitrite concentration. As what can be seen in Table 5.3 below, 
peroxynitrite was quite stable in 1.5 M NaOH when compared to in 50 mM 
KPi, PBS or sterile distilled water. The data are also presented graphically in 
Fig. 5.17. The half-life of peroxynitrite in solution at physiological pH 7.4 is 
approximately 1 s (Koppenol et al., 1992). Once prepared, peroxynitrite 
needs to be stored in 1.5 M NaOH to increase its stability. 
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Table 5.3: Summary of OD 302 nm of peroxynitrite (PN) diluted either in 
1.5 M NaOH, 50 mM KPi, PBS or sterile distilled water. Expected ODs 
were also included 
 OD 302 nm 
PN 
dilution 
Expected 
OD302 nm 
1.5 M NaOH 50 mM 
KPi 
PBS Sterile 
distilled 
water 
1:2 0.349 0.313 0.283 0.252 0.271 
1:10 0.070 0.024 0.012 0.016 0.024 
1:20 0.035 0.011 -0.008 0.003 0.004 
 
 
Peroxynitrite solution diluted 1:2, 1:10 and 1:30 either in distilled water, PBS 
or 1.5 M NaOH were scanned with a multiwavelength spectrophotometer 
(Beckman DU-64) (Fig. 5.18). The absorbance peak at 302 nm of 
peroxynitrite diluted 1:2 in distilled water was slightly lower than that of 
diluted in PBS and 1.5 M NaOH (Fig. 5.18(a)). In 1:10 dilution, we expected 
to get a 5-fold lower of OD 302 nm where this can only be seen in 1.5 M 
NaOH diluent but the other two diluent gave much lower ODs. Reduction in 
OD 302 nm of peroxynitrite diluted 1:30 in 1.5 M NaOH was as expected (15-
fold reduction) however in 1:30 dilution in PBS, no peak at OD 302 nm was 
detected and a very low peak in distilled water when compared to in 1.5 M 
NaOH. We can conclude here that peroxynitrite diluted in 1.5 M NaOH was 
more stable since NaOH is very alkaline (pH 14.0) and is therefore more 
efficient in nitrating proteins.   
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5.9  Effects of buffers used in dissolving BSA on nitration 
 
We then carried out experiments to determine whether buffer used to dissolve 
BSA would affect its nitration.  Two different buffers were used namely PBS (pH 
7.4) or 50 mM Potassium Phosphate Buffer (KPi, pH 8.2, as used in the 
literature).  As can be seen in Fig. 5.19(a), the levels of nitrated BSA were lower 
when it was dissolved in PBS (Lanes 4-8) when compared to nitrated BSA 
dissolved in KPi (Lanes 9-14).  This is supported by a western blot analysis (Fig. 
5.19(b)) where nitrotyrosine levels of BSA dissolved in KPi shows a dose 
response increase from 5 µM to 100 µM peroxynitrite. BSA dissolved in PBS 
shows the strongest signal at 100 µM peroxynitrite while the rest gave weak 
nitrotyrosine signals. This means that peroxynitrite concentration at 100 µM 
used to nitrate BSA gave an optimal nitration. We then proceeded to the 
nitration of different amounts (20.3, 40.6 and 60.9 µg) of purified resolubilised 
p53 protein after being dialysed in PBS with 100 µM Peroxynitrite in order to 
determine the effects of amounts on the nitrotyrosine signals (see Fig. 5.20). 
However, the experiment was unsuccessful as we could not get any 
nitrotyrosine signals for all the amounts. This shows that p53 protein is not 
easily nitrated. We then attempted to nitrate both purified resolubilised and 
purified soluble p53 protein with 100 µM and 1.5 mM peroxynitrite from 30 mM 
stock (Fig.5.21(a)) but no nitroytrosine signals were detected for both forms of 
p53 protein. BSA which was nitrated at the same time showed strong 
nitrotyrosine signals. Again non-nitrated BSA showed a very weak signal of 
nitrotyrosine indicating that BSA was endogenously nitrated in cow. Both non-
nitrated purified resolubilised p53 and purified soluble p53 protein showed high 
levels of p53 protein as seen in Fig. 5.21(b) Lane 6 and Lane 9, respectively, 
however the p53 protein levels dramatically reduced in nitrated purified soluble 
p53 protein (Fig. 5.21(b), Lanes 10-11) and almost altogether disappeared in 
nitrated purified reolubilised p53 protein (Fig. 5.21(b), Lanes 7-8). 
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Figure 5.19(a). A 10% SDS-PAGE gel showing a comparison of nitration of 
BSA which was incubated with peroxynitrite for 15 min in a rocking water bath at 
37°C. The samples were either dissolved in PBS (pH 7.4) or 50 mM Potassium 
Phosphate Buffer (KPi, pH 8.2). The amount of BSA loaded was 2 µg. The gel 
was stained with Coomassie Blue for 15 mins and then destained overnight. 
 
Lane 1   - prestained protein molecular weight markers (Fermentas) 
Lane 2   - non-nitrated BSA dissolved in PBS 
Lane 3   - 100 µM peroxynitrite previously nitrated BSA dissolved in PBS 
Lane 4   - 5 µM peroxynitrite nitrated BSA dissolved in PBS 
Lane 5   - 10 µM peroxynitrite nitrated BSA dissolved in PBS 
Lane 6   - 25 µM peroxynitrite nitrated BSA dissolved in PBS 
Lane 7   - 50 µM peroxynitrite nitrated BSA dissolved in PBS 
Lane 8   - 100 µM peroxynitrite nitrated BSA dissolved in PBS 
Lane 9   - non-nitrated BSA dissolved in KPi 
Lane 10 - 5 µM peroxynitrite nitrated BSA dissolved in KPi 
Lane 11 - 10 µM peroxynitrite nitrated BSA dissolved in KPi 
Lane 12 - 25 µM peroxynitrite nitrated BSA dissolved in KPi 
Lane 13 - 50 µM peroxynitrite nitrated BSA dissolved in KPi 
Lane 14 - 100 µM peroxynitrite nitrated BSA dissolved in KPi 
 
 
 
47.0 
86.0 
118.0 
BSA 
 MW          1     2    3    4     5     6     7    8    9   10   11   12  13  14 
(kDa)          
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Figure 5.19(b). A western blot analysis showing a comparison of nitration of 
BSA which was incubated with peroxynitrite for 15 min in a rocking water bath at 
37°C. The samples were either dissolved in PBS (pH 7.4) or 50 mM Potassium 
Phosphate Buffer (KPi, pH 8.2). The amount of BSA loaded was 2 µg. The 
primary antibody used was mouse anti-nitrotyrosine monoclonal antibody 
(Upstate Biotechnology) and the secondary antibody was rabbit anti-mouse 
HRP conjugated polyclonal antibody (DAKO Cytomation). 
 
Lane 1   - prestained protein molecular weight markers (Fermentas) 
Lane 2   - non-nitrated BSA dissolved in PBS 
Lane 3   - 5 µM peroxynitrite nitrated BSA dissolved in PBS 
Lane 4   - 10 µM peroxynitrite nitrated BSA dissolved in PBS 
Lane 5   - 25 µM peroxynitrite nitrated BSA dissolved in PBS 
Lane 6   - 50 µM peroxynitrite nitrated BSA dissolved in PBS 
Lane 7   - 100 µM peroxynitrite nitrated BSA dissolved in PBS 
Lane 8   - 100 µM peroxynitrite previously nitrated BSA dissolved in PBS 
Lane 9   - non-nitrated BSA dissolved in KPi 
Lane 10 - 5 µM peroxynitrite nitrated BSA dissolved in KPi 
Lane 11 - 10 µM peroxynitrite nitrated BSA dissolved in KPi 
Lane 12 - 25 µM peroxynitrite nitrated BSA dissolved in KPi 
Lane 13 - 50 µM peroxynitrite nitrated BSA dissolved in KPi 
Lane 14 - 100 µM peroxynitrite nitrated BSA dissolved in KPi 
Lane 15 - 100 µM peroxynitrite previously nitrated BSA dissolved in PBS 
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86.0 
118.0 
Nitro-
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Figure 5.20. A Western blot analysis showing 100 µM peroxynitritre nitration of 
purified resolubilised p53 protein after being dialysed in PBS at different 
amounts which was incubated with peroxynitrite for 15 min in a rocking water 
bath at 37°C. This was in order to determine the effects of volumes/amounts on 
nitrotyrosine signals. The primary antibody used was anti-nitrotyrosine mouse 
monoclonal IgG, Clone 1A6 (Upstate Biotechnology) and the secondary 
antibody was rabbit anti-mouse IgG/HRP conjugated (DAKO Cytomation). Non-
nitrated purified resolubilised p53 protein was used as a negative control. Non-
nitrated and 100 µM peroxynitrite nitrated BSA were also used as controls. The 
amount of BSA loaded was 2 µg. 
 
Lane 1  - prestained protein molecular weight markers (Fermentas) 
Lane 2  - non-nitrated purified resolubilised p53 protein 
Lane 3  - non-nitrated BSA 
Lane 4  - 100 µM peroxynitrite previously nitration of 500 µg BSA as a positive 
control 
Lane 5  - 100 µM peroxynitrite nitration of 60.9 µg purified resolubilised p53 
protein 
Lane 6  - 100 µM peroxynitrite nitration of 40.6 µg purified resolubilised p53 
protein 
Lane 7  - 100 µM peroxynitrite nitration of 20.3 µg purified resolubilised p53 
protein 
 
 
 
 
 
47.0 
86.0 
 MW         1       2       3        4          5         6         7 
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Figure 5.21. Nitration of purified resolubilised and soluble p53 protein with 100 µM 
peroxynitrite directly from 30 mM stock and also 2.5 µl from the stock where the final 
concentration was 1.5 mM which were incubated with peroxynitrite for 15 min in a 
rocking water bath at 37°C. The samples BSA was also nitrated alongside to act as a 
positive control for nitration. The primary antibody used for blot (a) was mouse 
monoclonal anti-nitrotyrosine (Upstate Biotechnology) and DO-1 for blot (b). The 
secondary antibody used for both blots were rabbit anti-mouse polyclonal antibody 
(DAKO Cytomation). 
Lane 1   - prestained protein molecular weight markers (Fermentas) 
Lane 2   - non-nitrated BSA (2 µg) 
Lane 3   - 100 µM peroxynitrite previously nitrated BSA (2 µg) 
Lane 4   - 100 µM peroxynitrite nitrated BSA (2 µg) 
Lane 5   - 2.5 µl peroxynitrite nitrated BSA (2 µg) 
Lane 6   - non-nitrated purified resolubilised p53 protein (2.04 µg) 
Lane 7   - 100 µM peroxynitrite nitrated purified resolubilised p53 protein (2.04 µg) 
Lane 8   - 2.5 µl peroxynitrite nitrated purified resolubilised p53 protein (2.04 µg) 
Lane 9   - non-nitrated purified soluble p53 protein  (1.14 µg) 
Lane 10 -100 µM peroxynitrite nitrated purified soluble p53 protein (1.14 µg) 
Lane 11 - 2.5 µl peroxynitrite nitrated purified soluble p53 protein (1.14 µg) 
26.0 
34.0 
47.0 
118.0 
86.0 
19.0 
26.0 
47.0 
34.0 
118.0 
86.0 
p53 
 MW           1       2      3     4       5     6     7      8      9     10    11 
(kDa) 
 MW           1      2      3     4     5      6     7      8     9      10     11 
(kDa) 
(a) 
(b) 
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5.10 Attempted nitration of purified resolubilised p53 protein 
 
This was the first ever work to nitrate purified recombinant wt p53 protein 
expressed in E. coli. Other works done earlier include nitration of purified 
baculovirus-derived p53 protein (Cobbs et al., 2001), nitration of recombinant 
mwt p53 expressed in cell-free rabbit-reticulocyte lysates (Calmels et al., 1997), 
nitration of cell lysates of cancer cell lines with peroxynitrite (0-100 µM), and an 
endogenous or GSNO-induced (1 mM) NO-production in RAW 264.7. In some 
work, cancer cell lines such as MCF7 human breast cancer cells, HepG2 human 
hepatoma cells, D54MG cancer cells, and HCT 116 colon carcinoma cells (with 
wt p53, null-p53 and null-p21 genes) were treated with NO donors such as 
GSNO, SNAP, SIN-1, NONOate etc. (Calmels et al., 1997; Chazotte-Aubert et 
al., 2000; Cobbs et al., 2001; Hofseth et al., 2003).  
 
We then attempted to nitrate purified resolubilised p53 protein with increasing 
concentrations of peroxynitrite to determine the dose-response effects of 
peroxynitrite on the nitrotyrosine levels of nitrated p53 protein. The basal 
nitrotyrosine signal observed in non-nitrated purified resolubilised p53 protein 
might be due to the p53 protein was endogenously nitrated  E. coli BL21 strain 
where it was being expressed (Fig. 5.22(a), Lane 4). This suggests that the 
recombinant p53 protein was exposed to a nitrating species present in vivo in E. 
coli BL21. Similar basal nitrotyrosine signals were also observed in all nitrated 
purified resolubilised p53 protein samples (Fig. 5.22 (a), Lanes 5-13) when 
compared to a basal nitro-p53 signal in non-nitrated purified resolubilised p53 
protein control (Fig. 5.22(a), Lane 4) except sample in Lane 14 (Fig. 5.22 (a)) 
(nitrated with 3 mM peroxynitrite) where no nitrotyrosine signal was detected. 
From these observations it is clear that there was no dose-response effects of 
peroxynitrite on the nitrotyrosine signals in nitrated purified resolubilised p53 
protein. Fig. 5.22(b) shows that increasing doses of peroxynitrite from 10 µM to 
2 mM  (Lanes 5-13) seemed not to reduce the levels of the nitrated purified 
resolubilised p53 protein where their levels were almost similar compared to the 
p53 protein level in non-nitrated purified resolubilised p53 protein (Lane 4). 
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There was a slight reduction in the p53 protein level in purified resolubilised p53 
protein nitrated with 3 mM peroxynitrite (Fig. 5.22(b), Lane 14) when compared 
to the non-nitrated (Lane 4) and the other nitrated counterparts (nitrated with 10 
µM to 2 mM peroxynitrite) (Lane 5-13). This shows that peroxynitrite at 3 mM 
concentration is quite degrading and did not give any nitrotyrosine signal in 
nitrated purified resolubilised p53 protein.  
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Figure 5.22(a). Western blot analysis showing nitration of 40.6 µg purified 
resolubilised p53 protein with increasing concentrations of peroxynitrite ranging 
from 10 µM to 3 mM which were incubated with peroxynitrite for 15 min in a 
rocking water bath at 37°C. The samples The same amounts of non-nitrated and 
nitrated purified resolubilised p53 protein were loaded onto SDS-PAGE gelS 
(2.04 µg). The primary antibody used was anti-nitrotyrosine monoclonal mouse 
monoclonal IgG, Clone 1A6 (Upstated Biotechnology) and the secondary 
antibody was rabbit polyclonal anti-mouse IgG/HRP conjugated (DAKO 
Cytomation). 
 
Lane 1   - prestained protein molecular weight markers (Fermentas) 
Lane 2   - 100 µM peroxynitrite previously nitrated BSA 
Lane 3   - 100 µM peroxynitrite freshly nitrated BSA 
Lane 4   - non-nitrated purified resolubilised p53 protein  
Lane 5   - 10 µM peroxynitrite nitrated purified resolubilised p53 protein 
Lane 6   - 50 µM peroxynitrite nitrated purified resolubilised p53 protein 
Lane 7   - 100 µM peroxynitrite nitrated purified resolubilised p53 protein 
Lane 8   - 200 µM peroxynitrite nitrated purified resolubilised p53 protein 
Lane 9   - 300 µM peroxynitrite nitrated purified resolubilised p53 protein 
Lane 10 - 400 µM peroxynitrite nitrated purified resolubilised p53 protein 
Lane 11 - 500 µM peroxynitrite nitrated purified resolubilised p53 protein 
Lane 12 - 1 mM peroxynitrite nitrated purified resolubilised p53 protein 
Lane 13 - 2 mM peroxynitrite nitrated purified resolubilised p53 protein 
Lane 14 - 3 mM peroxynitrite nitrated purified resolubilised p53 protein 
 
47.0 
118.0 
 MW          1   2    3    4    5    6   7    8    9   10  11  12   13  14 
(kDa) 
Nitro-
p53 86.0 
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Figure 5.22(b). Western blot analysis showing nitration of 40.6 µg purified 
resolubilised p53 protein with increasing concentrations of peroxynitrite ranging 
from 10 µM to 3 mM which were incubated with peroxynitrite for 15 min in a 
rocking water bath at 37°C. The samples The same amounts of non-nitrated 
and nitrated purified resolubilised p53 protein were loaded onto SDS-PAGE gels 
(2.04 µg). The primary antibody used was anti-p53 mouse monoclonal antibody, 
DO-1. The secondary antibody used was rabbit polyclonal anti-mouse IgG/HRP 
conjugated (DAKO Cytomation). 
 
Lane 1   - prestained protein molecular weight markers (Fermentas) 
Lane 2   - 100 µM peroxynitrite previously nitrated BSA 
Lane 3   - 100 µM peroxynitrite freshly nitrated BSA 
Lane 4   - non-nitrated purified resolubilised p53 protein  
Lane 5   - 10 µM peroxynitrite nitrated purified resolubilised p53 protein 
Lane 6   - 50 µM peroxynitrite nitrated purified resolubilised p53 protein 
Lane 7   - 100 µM peroxynitrite nitrated purified resolubilised p53 protein 
Lane 8   - 200 µM peroxynitrite nitrated purified resolubilised p53 protein 
Lane 9   - 300 µM peroxynitrite nitrated purified resolubilised p53 protein 
Lane 10 - 400 µM peroxynitrite nitrated purified resolubilised p53 protein 
Lane 11 - 500 µM peroxynitrite nitrated purified resolubilised p53 protein 
Lane 12 - 1 mM peroxynitrite nitrated purified resolubilised p53 protein 
Lane 13 - 2 mM peroxynitrite nitrated purified resolubilised p53 protein 
Lane 14 - 3 mM peroxynitrite nitrated purified resolubilised p53 protein 
 
 
 MW          1   2     3    4    5    6   7    8    9  10   11 12  13  14 
(kDa) 
47.0 
86.0 
118.0 
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5.11  Attempted nitration of GST and GST-MDM2 protein 
 
This was the first ever work to nitrate purified GST and purified GST-MDM2 
proteins expressed in E. coli. Our attempts for the nitration of purified GST and 
purified GST-MDM2 proteins were unsuccessful where there were no 
nitrotyrosine signals detected (data not shown). However, Fig. 5.23 shows an 
SDS-polyacrylamide gel stained with Commassie brilliant blue of nitrated and 
non-nitrated purified GST and purified GST-MDM2 proteins. Both GST and 
GST-MDM2 proteins disappeared when nitrated with 500 µM peroxynitrite (Lane 
3 and Lane 4, respectively) when compared to non-nitrated proteins loaded at 
the same amounts (Lane 2 and Lane 5, respectively). We can assume that 
peroxynitrite treatment might cause degradation or loss of the proteins. In Fig. 
5.23, it can be noticed that increasing in the amounts of  purified GST-MDM2 
protein loaded resulted in the increase in the levels of the proteins together with 
its contaminating proteins and/or its degradation products. 
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Figure 5.23. A 10% SDS-PAGE gel of purified GST, 500 µM peroxynitrite 
nitrated purified GST, purified MDM2 and 500 µM peroxynitrite nitrated purified 
MDM2 which were incubated with peroxynitrite for 15 min in a rocking water 
bath at 37°C. The samples loaded at different volumes. The gel was stained 
with Coomassie Blue for 15 minutes and then destained overnight. 
 
Lane 1 - prestained protein molecular weight markers (Fermentas) 
Lane 2 - purified GST (5 µl) 
Lane 3 - 500 µM peroxynitrite nitrated purified GST (5 µl) 
Lane 4 - 500 µM peroxynitrite nitrated purified GST-MDM2 (5 µl) 
Lane 5 - purified GST-MDM2 (5 µl) 
Lane 6 - purified GST-MDM2 (10 µl) 
Lane 7 - purified GST-MDM2 (15 µl) 
Lane 8 - purified GST-MDM2 (20 µl) 
Lane 9 - purified GST-MDM2 (30 µl) 
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34.0 
47.0 
118.0 
86.0 
GST-
MDM2 
 MW          1      2      3      4      5      6       7      8        9 
(kDa)  
GST 
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5.12 Discussion  
The weak nitrotyrosine signal in non-nitrated BSA might be due to BSA was 
endogenously nitrated in cow as it is believed that tyrosine nitration is part of 
normal physiological processes in humans (Moncada et al., 1991; Beckman and 
Koppenol, 1996) and presumably also in other mammals and organisms, with a 
potential role in signal transduction mechanisms, possibly by influencing 
tyrosine phosphorylation or dephosphorylation (Bruckdorfer, 2001). A possible 
explanation for the loss of nitrotyrosine signal at high concentration of 
peroxynitrite used (500 µM) is that due to the degrading properties of 
peroxynitrite on proteins as evident by a study by Ischiropoulos and Al-Mehdi 
which showed that fatty acid-free BSA was fragmented after exposure to 
peroxynitrite (Ischiropoulos and Al-Mehdi, 1995). The incomplete pre-absorbed 
anti-nitrotyrosine antibody could easily pick up the excess nitrated BSA resulting 
in a high level of nitrotyrosine. We cannot see an obvious increasing trend of 
p53 protein degradation products with increasing concentrations of peroxynitrite 
as reported by Cobbs and co-workers (2001 and 2003) where they found that 
tyrosine nitration of purified baculovirus-derived recombinant wt p53 protein and 
of p53 protein in D54MG cells system treated with 0-100 µM peroxynitrite 
caused increased p53 protein degradation.  
 
In summary, there raises a need to improve the yield of the in vitro 
generation of peroxynitrite by either modifying certain steps or by comparing 
several laboratory methods present at the moment which will give sufficient yield 
of peroxynitrite. The most appropriate nitrating method was determined i.e 
vortexing and rocking water bath set 37°C with vigorous speed. Optimisation of 
western blot steps for nitration such as optimal blocking solution used was 
obtained. BSA was readily nitrated especially when dissolved in KPi buffer (pH 
8.2) where nitro-tyrosine was detected at low concentration of peroxynitrite (10 
uM) in comparison to when it was dissolved in PBS (pH 7.4). Attempts to nitrate 
purified resolubilised p53 protein and purified GST-MDM2 protein were 
unsuccessful, indicating these proteins are not readily nitrated which might be 
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due to cryptic location of tyrosine residues in the proteins which made them not 
accessible to nitration. Another factor to take into consideration is that nitration 
is a very selective process where not every tyrosine is nitrated, only certain one 
is susceptible to nitration, possibly those next to glutamate residue as observed 
in neurofilaments, among others (Crow et al., 1997). Peroxynitrite shows 
degrading properties where both nitrated purified resolubilised and soluble p53 
protein and also nitrated purified GST and GST-MDM2 proteins reduced in 
levels or totally loss when compared to their non-nitrated counterparts. 
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RESULTS CHAPTER 6 
 
In this chapter the aim was to isolate and characterise nitrated p53 protein from 
selected cancer cell lines with different p53 status either wild type, mutant or 
null-p53 proteins. These cell lines, either intact or lysed, were untreated or 
treated with peroxynitrite in order to determine whether these p53 proteins and 
their nitro-p53 forms could be successfully immunoprecipitated with anti-p53 
antibodies. In another experiment, a cell line with wt-p53 was incubated with NO 
donor S-Nitrosoglutathione (GSNO) to see its effect on nitro-p53 signal and on 
p53 protein levels. 
 
6.1 Immunoprecipitation studies of p53 and nitro-p53 proteins from 
selected cancer cell lines 
A panel of human cancer cell lines with different p53 status were chosen for 
nitration study using nitrating agent peroxynitrite in the test tubes or incubating 
the cultured cells with nitric oxide donor GSNO at certain concentrations. The 
cells were either lysed or still intact before being nitrated, while the intact cells 
were either first washed with PBS or not before being nitrated. The cell lysates 
were directly nitrated with peroxynitrite before being immunoprecipitated for p53 
protein or nitro-p53 protein and then were subjected to Western blotting by 
probing with the anti-nitrotyrosine and anti-p53 antibodies, respectively. The cell 
lysates were also indirectly nitrated by first immunoprecipitating with the anti-
p53 polyclonal antisera (CM-1) where CM-1 antisera formed complexes with 
p53 protein and protein G beads and then were subjected to Western blotting by 
probing with the anti-nitrotyrosine antibody or vice versa. Table 6.1 shows the 
selected human cancer cell lines used in this study. 
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Table 6.1: Human cancer cell lines used in this study 
Cell lines Description and Characteristics Source 
MCF7 Breast cancer cell line with wild type 
p53 gene. 
ICT, University of 
Bradford 
PANC-1 Pancreatic cancer cell line with 
mutant p53 gene. 
ICT, University of 
Bradford 
SW620 Colorectal cancer cell line with mutant 
p53 gene. 
ICT, University of 
Bradford 
HCT116 p53+/+ Colorectal cancer cell line with wild 
type p53 gene. 
ICT, University of 
Bradford 
HCT116 p53-/- Colorectal cancer cell line with 
deleted p53 gene. 
ICT, University of 
Bradford 
*ICT: The Institute of Cancer Therapeutics 
 
6.2 Pilot nitration study of human cancer cell lines 
SW620 cells were used for our pilot nitration study as the cells have 
accumulated amount of mutant p53 protein. The cells were grown to ~80% 
confluent before being harvested by trypsin and then resuspended in PBS. The 
intact cells were then nitrated with increasing concentrations of peroxynitrite 
ranging from 10 µM to 3 mM. MCF7 cells harbouring wt-p53, which were priorly 
incubated with 500 ng/ml Actinomycin D, an anti-cancer drug commonly used to 
inhibit transcription, for 24 hrs to induce the expression of wt p53 protein (as 
used by Cobbs et al., 2001), were also treated in parallel with 100 µM 
peroxynitrite. Non-nitrated BSA, MCF7 and SW620 were used as negative 
controls for nitration. BSA was also nitrated at the same time with the cells to act 
as a positive control for nitration and also to determine whether the nitration 
process was successful. No nitrotyrosine signal was detected in non-nitrated 
BSA as expected (Fig. 6.1, Lane 2) and very strong signals of nitro-BSA were 
detected in BSA either freshly or previously nitrated with 100 µM (Fig. 6.1, 
Lanes 3 and 4, respectively). 
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Figure 6.1. A Western blot analysis showing nitration of SW620 cells with 
various concentrations of peroxynitrite ranging from 10 µM to 3 mM. The cells 
were grown to ~80% confluent in T75 culture flask before being trypsinised and 
resuspended in PBS and then treated with peroxynitrite and incubated for 15 
min in a rocking water bath at 37°C. 2 mg/ml BSA was nitrated at the same time 
to act as a positive control for nitration. The primary antibody used was anti-
nitrotyrosine mouse monoclonal IgG, Clone 1A6 (Upstate Biotechnology) and 
the secondary antibody was rabbit polyclonal anti-mouse IgG/HRP conjugated 
(DAKO Cytomation).  
 
Lane 1   - prestained protein molecular weight markers (Fermentas) 
Lane 2   - non-nitrated BSA 
Lane 3   - 100 µM peroxynitrite freshly nitrated BSA 
Lane 4   - 100 µM peroxynitrite previously nitrated BSA 
Lane 5   - non-nitrated MCF7 cells 
Lane 6   - 100 µM peroxynitrite nitrated MCF7 cells 
Lane 7   - non-nitrated SW620 cells 
Lane 8   - 10 µM peroxynitrite nitrated SW620 cells 
Lane 9   - 50 µM peroxynitrite nitrated SW620 cells 
Lane 10 - 100 µM peroxynitrite nitrated SW620 cells 
Lane 11 - 300 µM peroxynitrite nitrated SW620 cells 
Lane 12 - 500 µM peroxynitrite nitrated SW620 cells 
Lane 13 - 3 mM peroxynitrite nitrated SW620 cells 
34.0 
47.0 
118.0 
  MW         1  2   3    4    5    6    7   8    9  10  11 12 13 
 (kDa)  
86.0 
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No nitrotyrosine signal was observed in non-nitrated MCF7 cells as expected 
(Fig. 6.1, Lane 5). A moderate signal of nitrotyrosine of proteins in MCF7 cells 
was detected when the cells were treated with 100 µM peroxynitrite (Fig. 6.1, 
Lane 6). This signal was probably nitrated BSA of ~66.4 kDa. No nitrotyrosine 
signals were detected in non-nitrated SW620 cells and also in SW620 cells 
treated with 10 µM peroxynitrite (Fig. 6.1, Lanes 7 and 8). Relatively weak 
nitrotyrosine signals were obtained in SW620 nitrated with 50, 300 and 500 µM 
peroxynitrite (Fig. 6.1, Lanes 9, 11 and 12 respectively) when compared to 
SW620 cells treated with 100 µM peroxynitrite which gave the strongest signal 
among all the concentrations of peroxynitrite used (Fig. 6.1, Lane 10). However, 
no nitrotyrosine signal was detected when SW620 cells were treated with 3 mM 
peroxynitrite (Fig. 6.1, Lane 13). This might suggest that a strong concentration 
of peroxynitrite resulted in the degradation or reduction in the levels of the 
protein. We suspected the nitrated proteins in both PBS resuspended MCF7 
and SW620 cells were residual serum proteins from complete culture media 
used to culture the cells.  
 
As determined above and by Cobbs et al (2001 & 2003),  100 µM peroxynitrite 
used to nitrate cancer cells gave the optimal and strong nitro-tyrosine signals, 
mimicking the concentration in inflamed tissues, we therefore further explored 
the nitration of MCF7 and SW620 cells in various experimental conditions. Non-
nitrated and 100 µM peroxynitrite-nitrated BSA were used as a negative and a 
positive control, respectively. Non-nitrated BSA gave no nitrotyrosine signal as 
expected and 100 µM peroxynitrite-nitrated BSA gave a very strong nitro-
tyrosine signal (Fig. 6.2(a), Lanes 2 and 3, respectively). Whole cells without 
lysing in sample buffer were used in these experiments to see whether 
peroxynitrite could diffuse into whole cells and nitrate p53 protein in comparison 
to direct protein nitration in cell lysates. Also, this is in order to see whether it 
was possible to detect nitrated protein when whole cells which were lysed upon 
boiling in SDS loading buffer were loaded into gels for Western blotting. Both 
non-nitrated unwashed and washed intact MCF7 cells gave negative results 
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where no nitrotyrosine signals were detected as expected (Fig. 6.2(a), Lanes 
4and 6, respectively). 100 µM peroxynitrite-nitrated unwashed intact MCF7 cells 
gave a very weak nitrotyrosine signal whereas no signal observed in 100 µM 
peroxynitrite-nitrated washed intact MCF7 cells (Fig. 6.2(a), Lanes 5 and 7, 
respectively). We suspected the nitrated protein in the unwashed intact MCF7 
cells was a serum protein used in the cell culture media. No nitrotyrosine signals 
were observed in the non-nitrated washed MCF cell lysates as expected (Fig. 
6.2(a), Lane 8). No nitrotyrosine signal was detected in 100 µM peroxynitrite-
nitrated washed MCF7 cell lysates as the serum was washed away when 
preparing the cell lysates (Fig. 6.2(a), Lane 9). Similar results to the MCF7 cells 
were observed in SW620 cells for all the conditions used where no nitrotyrosine 
signals were detected in all the samples except that a very strong nitrotyrosine 
signal was detected in 100 µM peroxynitrite-nitrated unwashed intact SW620 
cells (Fig. 6.2(a), Lane 11) when compared to a weak nitrotyrosine signal in 100 
µM peroxynitrite-nitrated unwashed intact MCF7 cells (Fig. 6.2(a), Lane 5), 
which indicates a higher serum protein level present in unwashed intact SW620 
cells prepared in comparison to a lower level of serum protein in the prepared 
unwashed intact MCF7 cells. In another blot (Fig. 6.2(b)) with the same samples 
loaded as in Fig. 6.2(a) but was probed with  mouse monoclonal anti-p53 
antibody (DO-1), wt p53 protein in MCF7 cells was barely detected (Fig. 6.2(b), 
Lanes 4-9) whereas strong signals of mutant p53 protein were detectable in 
SW620 cells when probed with DO-1 (Fig. 6.2(b), Lanes 10-15). 
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Figure 6.2(a). Western blot analysis showing a pilot nitration study of MCF7 and 
SW620 cells nitrated with 100 µM peroxynitrite and incubated for 15 min in a 
rocking water bath at 37°C. 2 mg/ml BSA was nitrated at the same time to act 
as a positive control for nitration. Non-nitrated BSA, MCF7 cells and SW620 
cells were served as negative controls for nitration. The primary antibody used 
was mouse monoclonal anti-nitrotyrosine (Upstate Biotechnology) and the 
secondary antibody was rabbit polyclonal anti-mouse HRP conjugated (DAKO 
Cytomation). 
 
Lane 1   - prestained protein molecular weight markers (Fermentas) 
Lane 2   - non-nitrated BSA 
Lane 3   - 100 µM peroxynitrite nitrated BSA 
Lane 4   - non-nitrated unwashed intact MCF7 cells 
Lane 5   - 100 µM peroxynitrite nitrated unwashed intact MCF7 cells 
Lane 6   - non-nitrated washed intact MCF7 cells 
Lane 7   - 100 µM peroxynitrite nitrated washed intact MCF7 cells 
Lane 8   - non-nitrated washed MCF7 cell lysates 
Lane 9   - 100 µM peroxynitrite nitrated washed MCF7 cell lysates 
Lane 10 - non-nitrated unwashed intact SW620 cells 
Lane 11 - 100 µM peroxynitrite nitrated unwashed intact SW620 cells 
Lane 12 - non-nitrated washed intact SW620 cells 
Lane 13 - 100 µM peroxynitrite nitrated washed intact SW620 cells 
Lane 14 - non-nitrated washed SW620 cell lysates 
Lane 15 - 100 µM peroxynitrite nitrated washed SW620 cell lysates 
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Figure 6.2(b). Western blot analysis showing a pilot nitration study of MCF7 and 
SW620 cells nitrated with 100 µM peroxynitrite and incubated for 15 min in a 
rocking water bath at 37°C. 2 mg/ml BSA was nitrated at the same time to act 
as a positive control for nitration. Non-nitrated BSA, MCF7 cells and SW620 
cells were served as negative controls for nitration. The primary antibody used 
was mouse monoclonal anti- p53 (DO-1) and the secondary antibody was rabbit 
polyclonal anti-mouse HRP conjugated (DAKO Cytomation). 
 
Lane 1   - prestained protein molecular weight markers (Fermentas) 
Lane 2   - non-nitrated BSA 
Lane 3   - 100 µM peroxynitrite nitrated BSA 
Lane 4   - non-nitrated unwashed intact MCF7 cells 
Lane 5   - 100 µM peroxynitrite nitrated unwashed intact MCF7 cells 
Lane 6   - non-nitrated washed intact MCF7 cells 
Lane 7   - 100 µM peroxynitrite nitrated washed intact MCF7 cells 
Lane 8   - non-nitrated washed MCF7 cell lysates 
Lane 9   - 100 µM peroxynitrite nitrated washed MCF7 cell lysates 
Lane 10 - non-nitrated unwashed intact SW620 cells 
Lane 11 - 100 µM peroxynitrite nitrated unwashed intact SW620 cells 
Lane 12 - non-nitrated washed intact SW620 cells 
Lane 13 - 100 µM peroxynitrite nitrated washed intact SW620 cells 
Lane 14 - non-nitrated washed SW620 cell lysates 
Lane 15 - 100 µM peroxynitrite nitrated washed SW620 cell lysates 
 
47.0 
86.0 
118.0 
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6.3 Nitration of cell lysates of selected cancer cell lines followed by 
immunoprecipitation of p53 protein 
This section is to describe the attempted nitration of MCF7, PANC-1 and 
SW260 cell lysates with different p53 status (wild-type p53 gene for MCF7 cells 
and mutant p53 gene for both PANC-1 and SW260 cells) in order to determine 
whether the p53 protein both wild-type and mutant forms were successfully 
nitrated and to determine the nitration effects on p53 protein levels. 
 
6.3.1 Attempted nitration of MCF7, PANC-1 and SW260 cell lysates (1) 
 
Nitration experiments were then conducted in three cancer cell lines namely 
MCF7, PANC-1 and SW620. The cells were grown until ~80% confluency 
before being harvested by trypsin and then lysed with NET buffer [150 mM 
NaCl, 5 mM EDTA pH 8.0, 50 mM Tris-HCl pH 8.0, 1% (v/v) Igepal s protease 
inhibitors cocktail]. However, MCF7 cells were first incubated with 500 ng/ml 
Actinomycin-D for 24 hr, the purpose of which was to induce wt p53 protein 
expression before being harvested since wt p53 protein is barely detectable in 
MCF7 cells, - see Material & Methods, Section 2.18 for further details of the 
method used. The cell lysates for each cell line were then either directly nitrated 
with 100 µM peroxynitrite or were first immunoprecipitated for p53 protein by 
CM-1 antibody before being nitrated with 100 µM peroxynitrite. In the Western 
blot analyses as shown in Figs. 6.3(a) and (b), just protein G beads bound to the 
three antibodies namely CM-1, DO-1 or the mouse monoclonal anti-nitrotyrosine 
antibody, Clone Clone 16A (Upstate Biotechnology) were loaded onto SDS-
PAGE gels (Lanes 4, 5 and 6) and also the three non-nitrated cell lysates 
(Lanes 7, 8 and 9) to act as negative controls for the experiment. The non-
nitrated and nitrated BSA were run in parallel to act as a negative and a positive 
control for nitration, respectively (Fig. 6.3(a) & (b), Lanes 2 and 3, respectively). 
As can be seen in Fig. 6.3(a) and (b), the rabbit anti-mouse polyclonal 
secondary antibody very weakly recognised the heavy and light chains of the 
rabbit polyclonal CM-1 sera as p53 could be easily be confused with the heavy 
chain of the CM-1 serum (Lane 4). As both DO-1 and the mouse monoclonal 
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anti-tyrosine antibody were both mouse monoclonal antibodies, these antibodies 
were greatly picked up by the secondary anti-mouse antibody and that is why 
the heavy and light chains signals for both the antibodies were very strong 
(Lanes 5 and 6, respectively). No nitro-tyrosine signals were detected in all the 
three cell lysates indicating that p53 protein was not endogenously nitrated in 
these cell lines (Fig. 6.3(a), Lanes 7-9). As PANC-1 and SW620 cells contain 
mutant p53 protein which is stable and at a high level, there were strong signals 
of mutant p53 protein in these two cells (Fig. 6.3(b), Lanes 8 and 9, 
respectively). As wt p53 protein accumulated in MCF7 cells induced with 
Actinomycin-D, we can see quite a strong signal of p53 protein in this cell (Fig. 
6.3(b), Lane 7), nevertheless it was lower than that of mutant p53 proteins in 
both PANC-1 and SW620 (Fig. 6.3(b) Lanes 8 and 9, respectively), which could 
be due to protein load and wavy gel effect (Dr Steven Picksley, personal 
communication). No nitrotyrosine signal of p53 protein was detected in 
Actinomycin-induced MCF7 cell lysates nitrated with 100 µM peroxynitrite which 
was then immunoprecipitated with CM-1 (Fig. 6.3(a), Lane 10). However, very 
weak nitro-tyrosine signals of mutant p53 proteins were detected in PANC-1 and 
SW620 cell lysates nitrated with 100 µM peroxynitrite which were then 
immunoprecipitated with CM-1 (Fig. 6.3(a), Lanes 11 and 12). After 
immunoprecipitation with CM-1, 100 µM peroxynitrite-nitrated MCF7 lysates, 
which were priorly induced with 500 ng/ml Actinomycin D for 24 hr, showed no 
signal of p53 protein (Fig. 6.3(b), Lane 10). This  might be due to quite a lower 
level of the starting wt p53 protein induced in MCF7 cells by Actinomycin D or 
because it did not work. We can also use this evidence of the lower level of 
starting wt p53 protein to reason why there was no nitro-tyrosine signal of this 
sample (Fig. 6.3(a), Lane 10). The levels of mutant p53 protein in PANC-1 and 
SW620 cell lysates nitrated with 100 µM peroxynitrite which were then 
immunoprecipitated with CM-1 were still high (Fig. 6.3(b), Lanes 11 and 12) 
even though their levels were a bit lower than just the lysates (not 
immunoprecipitated) (Fig. 6.3(b), Lanes 8 and 9, respectively). As can be seen 
in Fig. 6.3(a), CM-1- immunoprecipitated p53 protein in MCF7, PANC-1 and 
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SW620 cell lysates nitrated with 100 µM peroxynitrite show strong signals of 
nitrotyrosine (Lanes 13-14) in comparison to their negative control sample (just 
beads bound to CM-1) in Lane 4 in the same Fig. 6.3(a). Stronger signals of 
mutant p53 protein were found in CM1-immunoprecipitated p53 protein in 
PANC-1 and SW620 cell lysates nitrated with 100 µM peroxynitrite (Fig. 6.3(b), 
Lanes 14 and 15, respectively) when compared to their counterpart MCF7 cells 
containing wt p53 protein and a negative control sample (just beads bound to 
CM-1) (Fig. 6.3(b), Lanes 13 and 4, respectively). 
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Figure 6.3(a). Attempted nitration of CM-1 immunoprecipitated p53 proteins 
from Actinomycin D-treated MCF7, PANC-1 or SW620 cell lysates with 100 µM 
peroxynitrite and incubated for 15 min in a rocking water bath at 37°C. The 
primary antibody used was mouse monoclonal anti-nitrotyrosine (Upstate 
Biotechnology) and the secondary antibody was rabbit anti-mouse HRP 
conjugated polyclonal antibody (DAKO Cytomation). 
 
Lane 1   - prestained protein molecular weight markers (Fermentas) 
Lane 2   - non-nitrated BSA (2 µg) 
Lane 3   - 100 µM peroxynitrite nitrated BSA (2 µg) 
Lane 4   - just beads bound to CM-1 
Lane 5   - just beads bound to DO-1 
Lane 6   - just beads bound to mouse monoclonal anti-nitrotyrosine 
Lane 7   - MCF7 cell lysates (10 µg) 
Lane 8   - PANC-1 cell lysates (10 µg) 
Lane 9   - SW620 cell lysates (10 µg) 
Lane 10 - 100 µM peroxynitrite nitrated Actinomycin D-treated MCF7 cell lysates 
immunoprecipitated with CM-1 
Lane 11 - 100 µM peroxynitrite nitrated PANC-1 immunoprecipitated with CM-1 
Lane 12 - 100 µM peroxynitrite nitrated SW620 immunoprecipitated with CM-1 
Lane 13 - CM-1 immunoprecipitated Actinomycin D-treated MCF7 cell lysates 
nitrated with 100 µM peroxynitrite 
Lane 14 - CM-1 immunoprecipitated  PANC-1 cell lysates nitrated with 100 µM 
peroxynitrite 
Lane 15 - CM-1 immunoprecipitated  SW620 cell lysates nitrated with 100 µM 
peroxynitrite 
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Figure 6.3(b). Attempted nitration of CM-1 immunoprecipitated p53 proteins 
from Actinomycin D-treated MCF7, PANC-1 or SW620 cell lysates with 100 µM 
peroxynitrite and incubated for 15 min in a rocking water bath at 37°. The 
primary antibody used was mouse monoclonal anti-p53 (DO-1) and the 
secondary antibody was rabbit anti-mouse HRP conjugated polyclonal antibody 
(DAKO Cytomation). 
 
Lane 1   - prestained protein molecular weight markers (Fermentas) 
Lane 2   - non-nitrated BSA (2 µg) 
Lane 3   - 100 µM peroxynitrite nitrated BSA (2 µg) 
Lane 4   - just beads bound to CM-1 
Lane 5   - just beads bound to DO-1 
Lane 6   - just beads bound to mouse monoclonal anti-nitrotyrosine 
Lane 7   - MCF7 cell lysates (10 µg) 
Lane 8   - PANC-1 cell lysates (10 µg) 
Lane 9   - SW620 cell lysates (10 µg) 
Lane 10 - 100 µM peroxynitrite nitrated Actinomycin D-treated MCF7 cell lysates 
immunoprecipitated with CM-1 
Lane 11 - 100 µM peroxynitrite nitrated PANC-1 immunoprecipitated with CM-1 
Lane 12 - 100 µM peroxynitrite nitrated SW620 immunoprecipitated with CM-1 
Lane 13 - CM-1 immunoprecipitated Actinomycin D-treated MCF7 cell lysates 
nitrated with 100 µM peroxynitrite 
Lane 14 - CM-1 immunoprecipitated  PANC-1 cell lysates nitrated with 100 µM 
peroxynitrite 
Lane 15 - CM-1 immunoprecipitated  SW620 cell lysates nitrated with 100 µM 
peroxynitrite 
26.0 
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6.3.2 Attempted nitration of MCF7, PANC-1 and SW620 cell lysates (2) 
 
In order to confirm and support the experimental results on section 6.3.1, the 
experiments were repeated but with some modifications such that some of the 
samples were not only immunoprecipitated with CM-1 but were also reverse-
order immunoprecipitated i.e. with the mouse monoclonal anti-nitrotyrosine 
antibody. Non-nitrated BSA and 100 µM peroxynitrite-nitrated BSA were served 
as a negative and a positive control for nitration, respectively. No nitrotyrosine 
signal was observed in non-nitrated BSA as expected (Fig. 6.4(a), Lane 2), 
whereas a strong nitrotyrosine signal was detected in BSA nitrated with 100 µM 
peroxynitrite (Fig. 6.4(a), Lane 3). A weak band for the heavy and light chains of 
the rabbit polyclonal CM-1 sera as the anti-mouse secondary antibody weakly 
recognised the two chains (Fig. 6.4(a), Lane 4). Very strong signals for the 
heavy and light chains of DO-1 (the anti-p53 mouse monoclonal antibody) and 
the anti-nitrotyrosine mouse monoclonal antibody as they were greatly picked 
up by the polyclonal anti-mouse secondary antibody (Fig. 6.4(a), lanes 5 and 6, 
respectively). MCF7 cell lysates nitrated with 100 µM peroxynitrite showed a few 
bands corresponding to moderate nitrotyrosine signals (Fig. 6.4(a), Lane 7) 
whereas very weak bands corresponding to very weak nitrotyrosine signals 
observed in both PANC-1 and SW620 cell lysates nitrated with 100 µM 
peroxynitrite (Fig. 6.4(a), Lanes 8 and 9, respectively). The wt p53 protein levels 
were higher in MCF-7 cells incubated 24 hrs with 500 ng/ml Actinomycin D (Fig. 
6.4(b), Lane 7). As expected, very high mutant p53 protein levels were observed 
in PANC-1 and SW620 cell lysates as the mutant p53 proteins are stable and at 
high levels (Fig. 6.4(b), Lanes 8 and 9, respectively). In addition, there were also 
smaller p53 degradation products noticed, which might be due to proteolysis or 
handling of the samples. Samples in Lanes 10 to 12 acted as controls for 
samples in Lanes 13 to 14 in Fig. 6.4. In Fig. 6.4(a) (Lanes 10-12), non-nitrated 
MCF7, PANC-1 and SW620 cell lysates were immunoprecipitated with CM-1 
while the cell lysates were immunoprecipitated with the mouse monoclonal anti-
tyrosine antibody in Fig. 6.4(b) (Lanes 10 to 12) to detect p53 nitrotyrosine and 
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p53 protein, respectively. The blot in Fig. 6.4(a) was probed with the anti-
nitrotyrosine mouse monoclonal antibody while the blot in Fig. 6.4(b) was 
probed with CM-1. Samples in Lanes 13 to 15 were 100 µM peroxynitrite-
nitrated MCF7, PANC-1 and SW620 cell lysates immunoprecipitated with either 
CM-1 (Fig. 6.4(a)) or immunoprecipitated with the mouse monoclonal anti-
tyrosine antibody (Fig. 6.4(b)) to detect p53 nitrotyrosine or p53 protein, 
respectively. As can be seen in Fig. 6.4(a), very weak signals of p53 
nitrotyrosine were detected in both non-nitrated and nitrated MCF7, PANC-1 
and SW620 cell lysates immunoprecipitated with CM-1 (Lanes 10 to 15) with 
sample in Lane 13 showed almost no signal at all.  No p53 protein was 
observed in a sample in Lane 10, Fig. 6.4(b) i.e. non-nitrated MCF7 lysates 
immunoprecipitated with the mouse monoclonal anti-nitrotyrosine antibody and 
also a sample in Lane 13, the same figure i.e. 100 µM peroxynitrite-nitrated 
MCF7 lysates immunoprecipitated with the mouse monoclonal anti-nitrotyrosine. 
Non-nitrated PANC-1 and SW620 cell lysates immunoprecipitated with the 
mouse monoclonal anti-tyrosine antibody showed moderate levels of mutant 
p53 protein (Fig. 6.4(b), Lanes 11 and 12, respectively). However, the mutant 
p53 protein levels in these samples were far lower than their counterparts non-
nitrated lysates (not immunoprecipitated) (Fig. 6.4(b), Lanes 8 and 9, 
respectively). The mutant p53 proteins in 100 µM peroxynitrite-nitrated PANC-1 
and SW620 cell lysates immunoprecipitated with the mouse monoclonal anti-
tyrosine were almost undetected (Fig. 6.4(b), Lanes 14 and 15, respectively). 
This might due to inefficient nitration of p53 protein in these cell lysates as seen 
in Fig. 6.4 (a) where hardly no nitro-p53 signals in samples in Lanes 13-15 or 
could be due to proteolysis of the protein. 
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Figure 6.4(a). Attempted immuniprecipitation study of non-nitrated and nitrated MCF7, 
PANC-1 and SW620 cell lysates. The samples were nitrated with 100 µM peroxynitrite 
and incubated for 15 min in a rocking water bath at 37°C. The nitrated and non-nitrated 
SW620 cell lysates were either immuniprecipitated with CM-1 or  mouse monoclonal 
anti-nitrotyrosine (Upstate Biotechnology). Beads just bound to either CM-1, DO-1 or 
mouse monoclonal anti-nitrotyrosine (Upstate Biotechnology) were used as controls. 
The samples were then subjected to western blot study. The primary antibody used 
was mouse monoclonal anti-nitrotyrosine (Upstate Biotechnology) and the secondary 
antibody was rabbit polyclonal anti-mouse HRP conjugated (DAKO Cytomation). 
Lane 1   - prestained protein molecular weight markers (Fermentas) 
Lane 2   - non-nitrated BSA (2 µg) 
Lane 3   - 100 µM peroxynitrite nitrated BSA (2 µg) 
Lane 4   - just beads bound to CM-1 
Lane 5   - just beads bound to DO-1 
Lane 6   - just beads bound to mouse monoclonal anti-nitrotyrosine 
Lane 7   - 100 µM peroxynitrite nitrated MCF7 lysates  
Lane 8   - 100 µM peroxynitrite nitrated PANC-1 lysates  
Lane 9   - 100µM peroxynitrite nitrated SW620 lysates  
Lane 10 – non-nitrated MCF7 lysates immunoprecipitated with CM-1  
Lane 11 – non-nitrated PANC-1 lysates immunoprecipitated with CM-1  
Lane 12 - non-nitrated SW620 lysates immunoprecipitated with CM-1  
Lane 13 - 100 µM peroxynitrite nitrated MCF7 lysates immunoprecipitated with CM-1  
Lane 14 - 100 µM peroxynitrite nitrated PANC-1 lysates immunoprecipitated with CM-1 
 
Lane 15 - 100 µM peroxynitrite nitrated SW620 lysates immunoprecipitated with CM-1 
 
  MW        1 2   3    4    5     6    7   8   9  10   11 12 13  14 15 
 (kDa) 
34.0 
47.0 
118.0 
86.0 
26.0 
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Figure 6.4(b). Attempted immuniprecipitation study of non-nitrated and nitrated MCF7, 
PANC-1 and SW620 cell lysates. The samples were nitrated with 100 µM peroxynitrite 
and incubated for 15 min in a rocking water bath at 37°C. The nitrated and non-nitrated 
cell lysates were immuniprecipitated mouse monoclonal anti-nitrotyrosine (Upstate 
Biotechnology). Beads just bound to either CM-1, DO-1 or mouse monoclonal anti-
nitrotyrosine (Upstate Biotechnology) were used as controls. The samples were then 
subjected to western blot study. The primary antibody used was anti-p53 polyclonal 
antibody (CM-1) and the secondary antibody was swine polyclonal anti-rabbit HRP 
conjugated. 
Lane 1   - prestained protein molecular weight markers (Fermentas) 
Lane 2   - non-nitrated BSA (2 µg) 
Lane 3   - 100 µM peroxynitrite nitrated BSA (2 µg) 
Lane 4   - just beads bound to CM-1 
Lane 5   - just beads bound to DO-1 
Lane 6   - just beads bound to mouse monoclonal anti-nitrotyrosine 
Lane 7   - just MCF7 lysates  
Lane 8   - just PANC-l lysates (b) 
Lane 9   - just SW620 lysates (b) 
Lane 10 – non-nitrated MCF7 lysates immunoprecipitated with mouse monoclonal anti-
nitrotyrosine  
Lane 11 – non-nitrated PANC-1 lysates immunoprecipitated with mouse monoclonal 
anti-nitrotyrosine  
Lane 12 - non-nitrated SW620 lysates immunoprecipitated with mouse monoclonal anti-
nitrotyrosine  
Lane 13 - 100 µM peroxynitrite nitrated MCF7 lysates immunoprecipitated with mouse 
monoclonal anti-nitrotyrosine  
Lane 14 - 100 µM peroxynitrite nitrated PANC-1 lysates immunoprecipitated with 
mouse monoclonal anti-nitrotyrosine 
Lane 15 - 100 µM peroxynitrite nitrated SW620 lysates immunoprecipitated with mouse 
monoclonal anti-nitrotyrosine 
26.0 
34.0 
47.0 
86.0 
118.0 
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6.3.3 Nitration of HCT116 null-p53 and HCT116 wt-p53 cell lines 
 
HCT116 null-p53 and HCT116 wt-p53 cell lines were used in this next study of 
nitration since null p53 served as a good control for p53 protein as the HCT116 
null- p53 cells do not contain any p53 gene and thus no p53 protein is being 
expressed. In this study, non-nitrated BSA was used as a negative control for 
nitration where a very weak endogenous nitrotyrosine signal was observed (Fig. 
6.5(a), Lane 2). A possible explanation for this observation is that BSA might be 
endogenously nitrated in cow as considerable evidence showed that tyrosine 
nitration is part of both physiological and pathological processes in the human 
body (Moncada et al., 1991; Beckman and Koppenol., 1996) and presumably 
also in other organisms. A very strong nitrotyrosine signal was detected in 100 
µM peroxynitrite-previously nitrated BSA as compared to BSA freshly nitrated 
with 100 µM peroxynitrite where a very weak nitrotyrosine signal was observed 
(Fig. 6.5(a), Lanes 3 and 4, respectively). The anti-mouse secondary antibody 
very weakly recognised the heavy and light chains of the rabbit polyclonal CM-1 
sera (Fig. 6.5(a), Lane 5). Very strong signals for the heavy and light chains of 
DO-1 (the anti-p53 mouse monoclonal antibody) and the anti-nitrotyrosine 
mouse monoclonal antibody as they were greatly picked up by the anti-mouse 
secondary antibody (Fig. 6.5(a), lanes 6 and 7, respectively). A few very weak 
signals of nitrotyrosine were detected throughout the samples in Lanes 8 to 13 
(Fig. 6.5(a)), where non-nitrated HCT116 null-p53 cell lysates and non-nitrated 
Actinomycin D-induced HCT116 wt-p53 cell lysates showed very weak 
nitrotyrosine signals indicating that some of the proteins in both the cell lysates 
were endogenously nitrated (Fig. 6.5(a), Lanes 8 and 9, respectively). There 
was no obvious difference in the nitrotyrosine signals in 100 µM peroxynitrite-
nitrated HCT116 null-p53 cell lysates and 100 µM peroxynitrite-nitrated 
Actinomycin D-induced HCT116 wt-p53 cell lysates (Fig. 6.5(a), Lanes 10 and 
11, respectively) when compared to their non-nitrated counterparts (Fig. 6.5(a), 
Lanes 8 and 9, respectively). No nitrotyrosine signal was detected in 100 µM 
peroxynitrite-nitrated HCT116 null-p53 cell lysates immunoprecipitated with CM-
1 as was expected as no p53 protein present (Fig. 6.5(a), Lane 12). Hardly any 
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nitrotyrosine signal was detected in 100 µM peroxynitrite-nitrated  Actinomycin 
D-treated HCT116 wt-p53 cell lysates immunoprecipitated with CM-1 (Fig. 
6.5(a), Lane 13). CM-1 immunoprecipitated HCT116 null-p53 cell lysates 
nitrated with 100 µM peroxynitrite shows very weak nitrotyrosine signals 
whereas very strong nitrotyrosine signals were observed in CM-1 
immunoprecipitated Actinomycin D-treated HCT116 wt-p53 cell lysates nitrated 
with 100 µM peroxynitrite (Fig. 6.5(a), Lanes 14 and 15, respectively). This, 
therefore, needs to be further studied in other cancer cell lines with different p53 
status (null, wild type or mutant) in order to get full significant insights of the 
experimental findings. 
 
Fig. 6.5(b) was a Western blot analysis of similar samples to Fig. 6.5(a) but was 
probed with DO-1 (the anti-p53 mouse monoclonal antibody) to detect p53 
protein. As can be seen in Lane 5, a very weak signal of the heavy chain of CM-
1 was picked up the anti-mouse secondary antibody. However, very strong 
signals of the heavy and light chains of both DO-1 and the anti-tyrosine mouse 
monoclonal antibody were greatly picked up by the anti-mouse secondary 
antibody (Fig. 6.5(b), Lanes 6 and 7, respectively). As expected, no p53 proteins 
were found in non-nitrated HCT116 null-p53 cell lysates, in 100 µM 
peroxynitrite-nitrated HCT116 null-p53 cell lysates and also in CM-1 
immunoprecipitated HCT116 null-p53 lysates nitrated with 100 µM peroxynitrite 
(Fig. 6.5(b), Lanes 8, 10 and 14, respectively). However, a weak signal of p53 
was observed in 100 µM peroxynitrite-nitrated HCT116 null-p53 cell lysates 
immunoprecipitated with CM-1 (Fig. 6.5(b), Lane 12) which should not be the 
case as the cells did not contain the p53 gene. A reason for this might be due to 
overflow of samples at either side of the well, problems with the secondary 
antibody and/or cross reaction with CM-1 (Dr Steven Picksley, personal 
communication). Strong signals for p53 were observed in non-nitrated 
Actinomycin D-treated HCT116 wt-p53 cell lysates and in 100 µM peroxynitrite-
nitrated  Actinomycin D-treated HCT116 wt-p53 cell lysates (Fig. 6.5(b), Lanes 9 
and 11, respectively) which indicates that Actinomycin D had successfully 
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induced the expression of wt p53 proteins. A p53 signal was observed in 100 
µM peroxynitrite-nitrated Actinomycin D-treated HCT116 wt-p53 cell lysates 
immunoprecipitated with CM-1 (Fig. 6.5(b), Lane 13). A possible explanation for 
this observation is that not all the total p53 proteins bound to CM-1 (the anti-p53 
polyclonal antibody), maybe some percentages of the p53 proteins were 
unbound to CM-1. No signal for p53 protein was observed in CM-1 
immunoprecipitated HCT116 null-p53 cell lysates nitrated with 100 µM 
peroxynitrite (Fig. 6.5(b), Lane 14) whereas a very weak signal for p53 protein 
was found in CM-1 immunoprecipitated Actinomycin D-treated HCT116 wt-p53 
cell lysates nitrated with 100 µM peroxynitrite (Fig. 6.5(b), Lane 15).  
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Figure 6.5(a). Nitration of CM-1 immunoprecipitated p53 proteins from HCT116 null-
p53 and HCT116 wt-p53 cell lysates with 100 µM peroxynitrite and incubated for 15 min 
in a rocking water bath at 37°C. The primary antibody used was mouse monoclonal 
anti-nitrotyrosine (Upstate Biotechnology). The secondary antibody used was rabbit 
anti-mouse HRP conjugated polyclonal antibody (DAKO Cytomation). 
Lane 1   - prestained protein molecular weight markers (Fermentas) 
Lane 2   - non-nitrated BSA (2 µg) 
Lane 3   - previously 100 µM peroxynitrite nitrated BSA (2 µg) 
Lane 4   - 100 µM peroxynitrite nitrated BSA (2 µg) 
Lane 5   - just beads bound to CM-1 
Lane 6   - just beads bound to DO-1 
Lane 7   - just beads bound to mouse monoclonal anti-nitrotyrosine 
Lane 8   - non-nitrated HCT116 null-p53 cell lysates (10 µg) 
Lane 9   - non-nitrated Actinomycin D-treated HCT116 wt-p53 cell lysates (10 µg) 
Lane 10 - 100 µM peroxynitrite nitrated HCT116 null-p53 cell lysates 
Lane 11 - 100 µM peroxynitrite nitrated Actinomycin D-treated HCT116 wt-p53 cell 
lysates 
Lane 12 - 100 µM peroxynitrite nitrated HCT116 null-p53 cell lysate immunoprecipitated 
with CM-1 
Lane 13 - 100 µM peroxynitrite nitrated Actinomycin D-treated HCT116 wt-p53 cell 
lysates immunoprecipitated with CM-1 
Lane 14 - CM-1 immunoprecipitated HCT116 null-p53 cell lysates nitrated with 100 µM 
peroxynitrite 
Lane 15 - CM-1 immunoprecipitated  Actinomycin D-treated HCT116 wt-p53 cell 
lysates nitrated with 100 µM peroxynitrite 
19.0 
26.0 
34.0 
47.0 
86.0 
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Figure 6.5(b). Nitration of CM-1 immunoprecipitated p53 proteins from HCT116 null-
p53 and HCT116 wt-p53 cell lysates with 100 µM peroxynitrite and incubated for 15 min 
in a rocking water bath at 37°C. The primary antibody used was mouse monoclonal 
anti-p53 (DO-1) and  the secondary antibody was rabbit anti-mouse HRP conjugated 
polyclonal antibody (DAKO Cytomation). 
Lane 1   - prestained protein molecular weight markers (Fermentas) 
Lane 2   - non-nitrated BSA (2 µg) 
Lane 3   - previously 100 µM peroxynitrite nitrated BSA (2 µg) 
Lane 4   - 100 µM peroxynitrite nitrated BSA (2 µg) 
Lane 5   - just beads bound to CM-1 
Lane 6   - just beads bound to DO-1 
Lane 7   - just beads bound to mouse monoclonal anti-nitrotyrosine 
Lane 8   - non-nitrated HCT116 null-p53 cell lysates (10 µg) 
Lane 9   - non-nitrated Actinomycin D-treated HCT116 wt-p53 cell lysates (10 µg) 
Lane 10 - 100 µM peroxynitrite nitrated HCT116 null-p53 cell lysates 
Lane 11 - 100 µM peroxynitrite nitrated Actinomycin D-treated HCT116 wt-p53  cell 
lysates 
Lane 12 - 100 µM peroxynitrite nitrated HCT116 null-p53 cell lysate immunoprecipitated 
with CM-1 
Lane 13 - 100 µM peroxynitrite nitrated Actinomycin D-treated HCT116 wt-p53 cell 
lysates immunoprecipitated with CM-1 
Lane 14 - CM-1 immunoprecipitated HCT116 null-p53 cell lysates nitrated with 100 µM 
peroxynitrite 
Lane 15 - CM-1 immunoprecipitated  Actinomycin D-treated HCT116 wt-p53 cell 
lysates nitrated with 100 µM peroxynitrite 
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6.4 Nitration study using NO donor, GSNO, using a model cell line MCF7 
 
In order to look indirectly the effects of nitration on p53-nitro signals and p53 
protein levels, we employed NO donor GSNO (S-Nitrosoglutathione) where in 
the cell NO will be released from GSNO and will react with superoxide to form 
peroxynitrite (Gunther et al., 1997; Goodwin et al., 1998). We attempted a pilot 
nitration study of wt-p53 expressing MCF7 cells incubated with NO donor, 
GSNO, at two selected concentrations namely 0.5 mM and 1.0 mM, optimal 
concentrations for p53 induction (Calmels et al., 1997; Chazotte-Aubert et al., 
2000 & 2001), in culture flasks. Just protein G Sepharose beads bound to 
antibodies namely CM-1, DO-1 and the anti-nitrotyrosine mouse monoclonal 
antibodies were used as experimental controls. The protein G beads were 
added to the antibody and mixed by rotation for 15 minutes before the antibody 
and the beads complex were collected by centrifugation, added SDS loading 
dye and boiled before they were loaded onto SDS-polyacrylamide gel 
electrophoresis followed by Western blotting analyses. Very strong the light and 
heavy chains of DO-1 and the anti-nitrotyrosine mouse monoclonal antibodies 
were observed where they were greatly picked up by the anti-mouse secondary 
antibody (Fig. 6.6(a), Lanes 3 and 4, respectively). 
 
There were strong signals in a sample in Lane 5, Fig. 6.6 (a) where the signals 
seem to be the heavy and light chains of antibody. This must be due to an 
overflow of a sample in Lane 4, in the same figure, i.e. just beads bound to the 
mouse monoclonal anti-nitrotyrosine antibody. Weaker nitrotyrosine signals 
were observed in 0.5 and 1.0 mM GSNO-treated MCF7 cell lysates (Fig. 6.6 (a), 
Lanes 6 and 7). Moderate nitrotyrosine signals were detected in 0.5 mM and 1.0 
mM GSNO-treated MCF7 cell lysates immunoprecipitated with CM-1 (Fig. 
6.6(a), Lanes 8 and 9, respectively).  The levels of p53 protein in the untreated, 
0.5 mM and 1.0 mM GSNO-treated MCF7 cell lysates were about similar (Fig. 
6.6(b), Lanes 5-7) indicating that GSNO did not degrade the p53 protein at 
these 2 concentrations. The 0.5 mM and 1.0 mM GSNO-treated MCF7 cell 
lysates were also reverse-order immunoprecipitated with the mouse monoclonal 
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anti-nitrotyrosine antibody (Fig. 6.6(b), Lanes 8 and 9, respectively) and then 
probed with CM-1 in order to detect p53 protein. However, no p53 protein 
signals were detected in both the samples. A possible reason for this might be 
due to only a small percentage of the nitro-p53 protein had been 
immunoprecipitated as the nitro-p53 protein levels in both 0.5 mM and 1.0 mM 
GSNO-treated MCF7 cell lysates were initially quite low (Fig. 6.6(a), Lanes 6 
and 7, respectively). For this reason, we could not reproduce the results by 
Chazotte-Aubert et al. (2000) which showed moderate signals of nitro-p53 in 
MCF7 cells treated with 1 mM and 2 mM GSNO. There are many possible 
reasons for the discrepancy in the results such as the culture conditions, the 
amounts of protein loaded onto SDS-PAGE gels, the primary and secondary 
antibodies used for immunoprecipitation and Western blotting and also the 
exposure time.  
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Figure 6.6. Western blot analysis of  a pilot nitration study of MCF7 cancer cells 
incubated with the NO donor GSNO for 4 hrs. Nitrated cell lysates were 
immunoprecipitated with either rabbit polyclonal anti-p53 (CM-1) for (a) or 
mouse monoclonal anti-nitrotyrosine (Upstate Biotechnology) for (b) and then 
for Western blot analysis were probed with mouse monoclonal anti-nitrotyrosine 
or CM-1, respectively. The secondary antibody used for blot (a) was rabbit anti-
mouse HRP conjugated polyclonal antibody (DAKO Cytomation) and swine anti-
rabbit HRP conjugated polyclonal antibody for blot (b). 
 
Lane 1  - prestained protein molecular weight markers (Fermentas) 
Lane 2  - just beads bound to CM-1 
Lane 3  - just beads bound to DO-1 
Lane 4  - just beads bound to mouse monoclonal anti-nitrotyrosine 
Lane 5  - untreated MCF7 cell lyates 
Lane 6  - 0.5 mM GSNO treated MCF7 cell lysates (20 µg) 
Lane 7  - 1.0 mM GSNO treated MCF7 cell lysates (20 µg) 
Lane 8  - 0.5 mM GSNO treated MCF7 cell lysates immunoprecipitated with 
CM-1 (a) or immunoprecipitated with mouse monoclonal anti-nitrotyrosine (b) 
Lane 9  - 1.0 mM GSNO treated MCF7 cell lysates immunoprecipitated with 
CM-1 (a) or immunoprecipitated with mouse monoclonal anti-nitrotyrosine (b) 
26.0 
34.0 
47.0 
86.0 
118.0 
p53 
 MW     1    2    3  4    5    6    7   8    9 
(kDa) 
  1    2   3   4    5   6    7   8   9 
 
(a) (b) 
IP: CM-1 
IB: anti-nitrotyrosine 
IP: anti-nitrotyrosine  
IB: CM-1 
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6.5 Discussion 
We suspected the nitrated proteins in both PBS resuspended MCF7 and 
SW620 cells were residual serum proteins from complete culture media used to 
culture the cells. A possible explanation for this observation is that BSA might 
be endogenously nitrated in cow as considerable evidence showed that tyrosine 
nitration is part of both physiological and pathological processes in the human 
body (Moncada et al., 1991; Beckman and Koppenol., 1996) and presumably 
also in other organisms. There are many possible reasons for the discrepancies 
in the results such as the culture conditions, the amounts of protein loaded onto 
SDS-PAGE gels, the primary and secondary antibodies used for 
immunoprecipitation and Western blotting and also the exposure time.  
 
What can be summarised from the findings in this Chapter is that p53 
protein, regardless of either wild type which was induced by Actinomycin-D (in 
MCF7 and HCT116 wt-p53 cells) or mutant (in PANC-1 and SW620 cells), was 
weakly and not efficiently nitrated either treating the cell lysates with 
peroxynitrite or incubating the cells with NO donor GSNO giving a very weak 
signal of nitro-p53 when compared to a readily nitrated BSA and also protein 
serum from residual culture media in unwashed intact cells. This therefore 
poses a question as to whether presumably low levels or undetectable nitro-p53 
protein in the human system does significantly affect the p53-regulated 
pathways especially involving its established functions in cell cycle regulation 
and cell growth as it is famously known as a guardian of the genome, a cellular 
caretaker, a cellular gatekeeper etc. Therefore further insights of p53 nitration 
from cancer patient samples (clinical samples) such as blood, body fluids and 
tissues and also from a large number of various cancer cell lines and animal 
models of cancers need to be established before conclusive data on this 
unestablished type of post-translational modification of p53 protein and its 
effects thereof can be obtained. 
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CHAPTER 7 
DISCUSSION 
 
The main aim of this work was to characterise the effects of nitration on the 
levels and functions of p53 tumour suppressor protein. Initially, it was important 
to obtain a large amount of unmodified p53 protein to work with. Therefore, we 
used an E. coli expression system to express human p53 protein. Heterologous 
protein expression in the Gram-negative bacterium E. coli is the simplest and 
most inexpensive means to produce large amount of the desired product 
(Makrides, 1996; Hannig and Makrides, 1998). Additionally, E. coli has well-
characterized genetics and there is an increasingly large number of cloning 
vectors and mutant host strains (reviewed by Baneyx, 1999). However, the main 
problem caused by E. coli expression of heterologous proteins is  incorrect 
folding which results in the formation of insoluble aggregates known as inclusion 
bodies (Georgiou and Valax, 1996). However, the partially active protein can be 
obtained by in vitro solubilisation and followed by refolding by dialysis. 
Unmodified p53 produced in E. coli provides an excellent source for nitration 
study.  
 
Expression levels of p53 protein were examined in two E. coli host strains 
namely BL21(DE3) and BL21(DE3)Star transformed with the pT7.7 vector 
carrying a full length human p53 gene under similar conditions as described by 
Midgley and coworkers (1992). It has been reported that the presence of 
mutation of the gene encoding RNAse E (rne131) in BL21(DE3)Star increases 
the expression of heterologous protein due to greater stabilization of mRNA with 
concomitant increase in protein translation (Invitrogen). Since no major 
differences in the expression levels of p53 protein between the two transformed 
strains were observed, thus, mRNA stability is not an issue here instead  it is 
most probably due to different codon usage in E. coli and man. The choice of 
codon in both prokaryotes and eukaryotes is not random (Yokota et al, 1980).  A 
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final year project student, Suzanne Camus (unpublished report, 2002), has 
investigated the expression levels of p53 protein in the Rosetta-gami (DE3), 
which supplies tRNAs for the codons AUA, AGG, AGA, CUA, CCC, GGA on a 
compatible chloramphenicol-resistant plasmid (Novagen), relative to the two E. 
coli strains, namely the BL21(DE3) strain and the BL21(DE3) Star strain, used 
in this study. The results showed there was not manifestly any difference in the 
expression levels of p53 in all the three strains. Thus, improved rare codon 
usage in the Rosetta strain does not significantly increase the yield of 
heterologous protein. 
 
In this study, we found that the non-induced BL21(DE3) and 
BL21(DE3)Star transformed with the pT7.7Hup53 construct showed constitutive 
expression of p53 protein. This observation was confirmed by fresh 
transformation of the two strains with the pT7.7Hup53 construct and left 
uninduced. This is probably due to a leaky Ptac promoter where even without 
IPTG the promoter was initiated to transcribe the T7 RNA polymerase gene and 
subsequently resulted in p53 protein production. The leaky production of T7 
RNA polymerase can be controlled by co-transforming E. coli cells with 
additional plasmids namely pLysE and pLysS both of which will constitutively 
produce T7 lysozyme, a natural inhibitor of T7 RNA polymerase (Dubendoff and 
Studier, 1991) but this would not change the overall yield of p53 protein 
produced (Midgley et al., 1992). T7 lysozyme will inactivate the basal level of T7 
RNA polymerase activity which will promote some transcription of heterologous 
gene in the uninduced cells, but will be swamped, and thereby rendered 
ineffective, by the larger amount of T7 RNA polymerase produced during 
induction. T7 lysozyme acts by cutting a specific bond in the peptidoglycan layer 
of the E. coli cell wall and by binding to T7 RNA polymerase and hence 
inhibiting transcription (Studier et al, 1990). Cells carrying pLysE accumulate 
substantial levels of T7 lysozyme than cells carrying pLysS. pLysS has little 
effect on growth rate but pLysE significantly lowers the growth rate of the cells 
carrying it (Studier et al, 1990). 
256 
 
The presence of bands corresponding to p53 protein in non-induced 
BL21(DE3) pT7.7Hup53 and BL21(DE3)Star pT7.7Hup53 was confirmed by 
Western blotting using anti-p53 mouse monoclonal antibody DO-1 which is 
specific for amino acids close to conserved box 1 in the N terminus of human 
p53 protein  (Vojtesek et al., 1992) as a primary antibody for immunodetection 
of p53 protein. Also evident was the absence of bands corresponding to p53 
protein in the two induced strains transformed with the vector pT7.7 alone. The 
two induced strains transformed with the pT7.7Hup53 construct where IPTG 
was added at OD600nm of 0.8-1.0 (late log phase) showed very strong signals 
corresponding to p53 protein. Verification that p53 protein was produced in the 
two induced strains transformed with the pT7.7Hup53 construct therefore led us 
to proceed to a large scale expression of p53 protein and subsequently to purify 
p53 protein through a series of column chromatography purification systems. 
Some p53 protein were not bound to the column and therefore found in the 
flowthroughs (Fig. 3.10(a)) which was most probably due to the fact the protein 
was not completely refolded during dialysis (Dr Picksley, personal 
communication). Overall, the purified p53 protein yield was modest but was 
good enough to do initial work. Therefore, a small scale optimisation of p53 
protein expression in the two E. coli host strains above carrying the pT7.7Hup53 
construct was carried out to get significant amount of p53 protein. The optimum 
conditions for the expression of p53 protein were finally determined as 
described in details in the Results Section 3.5. Therefore, a large scale 
production of p53 protein was carried out using BL21(DE3) pT7.7Hup53 and 12 
litres of cultures of induced BL21(DE3) pT7.7Hup53 were grown using the 
optimum p53 expression conditions obtained earlier. Having established the 
optimisation conditions for p53 expression, a sufficient amount of purified 
resolubilised p53 protein was obtained and therefore sufficient to be used for the 
nitration study. However, in order to get more and improved soluble p53 protein, 
it is worth trying to express human p53 protein in Lemo21(DE3) (New England 
Biolabs, 2013-2014 Catalog & Technical Reference), derivative of BL21(DE23), 
which features tunable T7 expression for potential elimination of inclusion body 
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formation of which ~98% of p53 protein in inclusion bodies when expressed in 
conventional BL21(DE3) system. The p53 protein  expression levels can be 
controlled by varying the level of T7 lysozyme (lysY), the natural inhibitor of T7 
RNA polymerase.  
 
Both resolubilised and soluble p53 protein were separately purified by 
following the methods by Hupp et al. (1992) and Midgley et al. (1992) with slight 
modifications. It was very challenging to purify soluble p53 protein as the protein 
is only present 2% of the total p53 protein, thus a large volume of several 
batches of BL21(DE3) E. coli bacterial culture transformed with pT7.7Hup53 
were needed to be cultivated. After gel purification with Superose 12 column, 
most soluble p53 protein was eluted at fractions 9-14 with calculated masses 
from 340-1100 kDa which were 2-10 fold higher and not in agreement with the 
mass of p53 protein tetramers (172-212 kDa), however two independent studies 
by Hupp et al. and Friedman et al. showed the active p53 fractions were eluted 
at approximately 440 kDa (a multimer larger than a tetramer) (Hupp et al., 1992; 
Friedman et al., 1993), with < 20% of the total protein in the void volume of the 
column (which is around fraction 11 of our results), indicating the presence of 
larger forms of p53 protein (Friedman et al., 1993). The reason for this might be 
due to soluble p53 tetramers formed clumped in the buffer conditions used 
including factors such as pH, ionic strength and temperature but this is not of 
surprise as p53 forms tetramers in solution, both in vitro and in vivo (Friedman 
et al., 1993; Wang et al., 1994; review in Okorokov and Orlova, 2009), but the 
evidence for multi-tetramers is weak as these independent groups did not 
indicate the 2-10 fold increase of p53 tetramers (multiples of tetramers) in their 
studies. Separately, a reasonable amount of purified resolubilised p53 protein 
was obtained for subsequent nitration work. Since preliminary and optimisation 
of nitration had to be done repeatedly, we had to generate a lot of purified p53 
protein both soluble and insoluble by cultivating 12 litres of BL21(DE3) E. coli 
bacterial culture transformed with pT7.7Hup53. The Glutathione S-transferase 
(GST) gene fusion system is a very powerful system to express, purify and 
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detect  fusion proteins produced in E. coli. GST is of a molecular weight  of 26 
kDa. In fusion proteins, GST moiety is at the amino terminus and the protein of 
interest at the carboxyl terminus. The protein accumulates within the cell’s 
cytoplasm. In this work, our GST-fusion protein of interest was GST-MDM2 
protein from the expression construct of Bottger et al. (1996) by which a PCR 
product of human MDM2 cDNA (encompassing a.a. 1-188) was ligated into the 
pGEX-2T plasmid (Pharmacia). GST control protein was also expressed in 
BL21 E. coli and purified along with GST-MDM2 protein with reference to the 
work by Bottger et al. (1996) and Bottger et al. (1997). Both GST and GST-
MDM2 proteins were purified from bacterial lysates by affinity chromatography 
using immobilised Glutathione Sepharose 4B (Amersham Biosciences), which is 
designed for the rapid, single-step purification of GST fusion proteins produced 
using the pGEX series of expression vectors. GST fusion proteins then bound to 
the affinity medium, and impurities or unbound contaminating bacterial proteins 
were removed by washing. The fusion proteins were then eluted under mild, 
non-denaturing conditions using reduced glutathione which preserve protein 
antigenicity and functionality. A lot of relatively pure GST and GST-MDM2 
proteins were obtained in this single-step purification process (Figs. 4.12, 4.13, 
4.14 & 4.15).  
 
We used a simple, most convenient and possibly the cleanest way to 
synthesise peroxynitrite by simultaneously flushing together acidified hydrogen 
peroxide (H2O2) and sodium nitrite (NaNO2) using a Y tubing. The two solutions 
were mixed evenly and rapidly in the Y-connector where the resulting yellow 
solution was immediately passed into alkaline solution 1.5 M NaOH to quench 
peroxynitrous acid ONOOH as peroxynitrite is stable in alkaline solutions. Thus, 
it is noteworthy that optimal conditions to yield higher concentrations of 
peroxynitrite with minimum concentrations of contaminants such as H2O2 and 
nitrite remaining in the resultant peroxynitrite solution, needs further exploration 
such as modifications of certain steps/conditions by varying initial 
concentrations of the reactants, different temperatures (such as at 0°, 20°C and 
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25°C which affects the rate of formation and decay of ONOOH), the flow rate 
where the reactants are efficiently mixed and the reaction is complete i.e. the 
time of quenching, or by comparing several available laboratory methods that 
give higher yield of peroxynitrite such as among others, those using a 
quenched-flow setup with a computerised syringe pump, though it is quite costly  
As a rule of thumb, peroxynitrite free from nitrite can be obtained by using 
slightly higher H2O2 than nitrite and vice versa (Saha et al., 1998). 
 
In this work, fatty acid-free bovine serum albumin (BSA) (Sigma) was 
used as a model nitration substrate since it is easily nitrated and furthermore it 
is 99.8% pure and is available commercially. This is because BSA has 19 
tyrosine residues which are targets for protein nitration. We used BSA for 
determining optimal nitration conditions. First, we had to determine the best 
nitration method by nitrating BSA at various concentrations of peroxynitrite (10 
µM to 500 µM)  by using either aggregometer set at 37ºC or vortexing and 
rocking water bath set at 37ºC (Fig. 5.3) (following Professor Khalid Naseem’s 
suggestion). We found that vortexing and rocking water bath set at 37ºC  gave 
strong nitrotyrosine signals at peroxynitrite concentrations at 100-400 µM when 
compared  to using aggregometer set at 37ºC at the same concentrations of 
peroxynitrite. This is mainly because peroxynitrite reacted very fast and 
instantaneously with proteins and vortexing the mixture of peroxynitrite and BSA 
helped to speed up their reaction and also made the peroxynitrite worked 
effectively to nitrate the tyrosine residues of BSA. A rocking water bath set at 
37ºC supposedly prolonged the reaction between peroxynitrite and BSA. Since 
there was still a lack of expertise for nitration of p53 protein (mostly confined to 
big chemistry groups in the USA), thus we had to start from scratch by first 
optimising nitration conditions by using BSA as a model protein, which had 
taken a lot of time. However, we finally found optimal conditions for Western 
blotting such as optimal conditions for blocking membranes and the best anti-
nitrotyrosine antibody to be used i.e. mouse monoclonal anti-nitrotyrosine IgG 
Clone1A6 (Upstate Biotechnology) for our nitration work. We also used Western 
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blotting steps such as diluent used to dilute primary and secondary antibodies 
and washing steps involved by adapting a method in Dr Picksley’s laboratory 
(see Table 2.8). 
 
Small amounts of BSA used in nitration work did not seem to give 
different nitrotyrosine signals. As BSA was nitrated with 100 µM peroxynitrite at 
different amounts (100, 200, 300 and 500 µg) we could not see any different in 
the levels of nitrotyrosine signals in all the 4 amounts (Fig. 5.13). The possible 
reason to this might be due to almost complete nitration of BSA protein with 100 
µM peroxynitrite when present in small amounts, so the nitrotyrosine signals 
among the different small amounts of BSA were almost similar. However, at 
larger amounts (20 mg), weak nitrotyrosine signals were observed in BSA 
nitrated with 50 µM, 200 µM and 1 mM peroxynitrite whereas a very strong 
signal was detected in BSA nitrated with 3 mM peroxynitrite which was about 
similar to 100 µM peroxynitrite previously nitrated 500 µg BSA (Fig. 5.14). A 
possible explanation to this phenomenon is that when at small amounts, 
peroxynitrite can completely react with all the amounts of BSA, therefore there is 
no difference in nitrotyrosine signals in all the 4 amounts of BSA used. At larger 
amount, only a very high concentration of peroxynitrite reaches and completely 
reacts with all the BSA amounts whereas, lower concentrations of peroxynitrite 
are far too low to completely react with the high amount of BSA. However, it is 
totally different in the case of nitration of purified resolubilised p53 protein at 
small amounts (20.3, 40.6 and 60.9 µg)  with 100 µM. No nitrotyrosine signals 
were obtained in all the 3 amounts. One reason for this is that the starting p53 
protein material was too low and another reason is that p53 protein is not readily 
nitrated when compared to BSA (19 tyrosine residues) as it only contains 9 
tyrosine residues (8 in the DNA binding domain and 1 in the tetramerisation 
domain). The other reason is the tyrosine residues in the p53 protein prepared 
might perhaps be hidden away/cryptic  in or not on the surface of the p53 
protein structure like the Pab240 epitope (where Pab240 reacts with cryptic 
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epitope in wt p53 and exposed in many p53 mutants) (Stephen and Lane, 1992; 
Calmels et al., 1997). 
 
We compared the effects of dissolving BSA in two different buffer 
systems (PBS, pH 7.4 and KPi, pH 8.2) on nitration. While nitrotyrosine signals 
were detected as low as 10 µM up to 100 µM peroxynitrite in BSA dissolved in 
KPi (pH 8.2), detection of nitrotyrosine signals were observed only at 50 µM and 
strongest at 100 µM peroxynitrite when PBS (pH 7.4) was used to dissolve 
peroxynitrite.  Changes in the pH of buffers used to dissolve BSA from 
physiological (PBS, pH 7.4) to alkaline values (KPi, pH 8.2) can increase the 
half-life of peroxynitrite, therefore prolonging peroxynitrite activities towards BSA 
(Cantoni, 2002) and also buffer composition can substantially affect the 
reactivity of peroxynitrite (Beckman et al., 1994). Peroxynitrite is extremely 
short-lived and labile at physiological pH values (pH 7.4) with halflife of ~1 s due 
to its rapid decomposition (Koppenol et al., 1992; Mondoro et al., 1997). Thus, 
we can conclude that peroxynitrite would react more effectively in alkaline 
conditions with slow decomposition rate. Peroxynitrite has a degrading property 
as evident in experiment in Fig. 5.21(b), where both nitrated purified 
resolubilised and nitrated purified soluble p53 protein dramatically reduced in 
levels after they were nitrated with 100 µM and 1.5 mM peroxynitrite (Fig. 
5.21(b), Lanes 7 & 8 and 10 & 11, respectively) when compared to their non-
nitrated counterparts (Fig. 5.21(b), Lanes 6 and 9, respectively). 
 
Very strong nitro-p53 protein signals in purified resolubilised p53 protein 
samples nitrated with 200, 300 and 400 µM peroxynitrite with unreduced high 
molecular weight aggregates (Fig. 5.12(a), Lanes 7-9) which were also seen by 
Calmels et al. (1997) and Cobbs et al. (2001) in  MCF7 and D54MG cells at 0.5-
1 mM and 10-100 µM, peroxynitrite, respectively. This is believed to be due to 
the formation of carbonyl or dityrosine (i.e. tyrosine oxidation by peroxynitrite) or 
loss of zinc from p53 active site (Cobbs et al., 2001), which has been shown 
when p53 protein was treated with zinc chelators or with oxidizing agents 
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(Hainut and Milner, 1993; Hainut et al., 1995). This modification on the p53 
protein might affects p53 structure and functions. Our attempt to nitrate purified 
resolubilised p53 protein resulted in basal levels of nitrotyrosine signals for all 
the samples (10 µM to 2 mM) in correspond to non-nitrated purified resolubilised 
p53 protein (Fig. 5.22(a)). At nitration with 3 mM concentration of peroxynitrite, 
the nitro-p53 protein was undetected (Fig. 5.22(a), Lane 14) when compared to 
the rest of the samples (Lanes 4-13). This might be due to the degrading 
properties of peroxynitrite especially occurs at higher concentration.  However, 
in this work, our attempts to nitrate GST and GST-MDM2 proteins were 
unsuccessful where the nitrotyrosine signals could not be detected in both GST 
and GST-MDM2 proteins nitrated with increasing concentrations of peroxynitrite 
(data not shown). The number of tyrosine residues in MDM2 protein alone is 9 
and GST protein is 4, thus the total number of tyrosines in the GST-MDM2 
fusion protein is 13. However, this did not help in the nitration which might be 
due to the cryptic locations of the tyrosines in the protein which resulted in the 
tyrosine residues not easily accessible to the nitration process. To further 
confirm the degrading properties of peroxynitrite, an SDS-PAGE analysis of 500 
µM peroxynitrite nitrated purified GST and GST-MDM2 protein showed no 
bands corresponding to the proteins (Fig. 5.23, Lanes 3 and  4, respectively) 
when compared to their non-nitrated counterparts (Fig. 5.23, Lanes 2 and 5, 
respectively). This is supported by a study by Ischiropoulos and Al-Mehdi which 
showed that fatty acid-free BSA treated with peroxynitrite resulted in protein 
fragmentation with protein fragments with molecular weight lower than 66 kDa 
(Ischiropoulos and Al-Mehdi, 1995) although no evidence reported in p53 
protein thus far. However, in the culture system it is due to ubiquitin-dependent 
proteolysis by proteasome although evidence for the underlying mechanisms 
are still lacking (Calmels et al., 1997; Cobbs et al., 2003). 
  
A panel of human cancer cell lines with different p53 status were selected 
for nitration study. When the cells reached about ~80% confluent, they were 
harvested and either lysed in cold RIPA lysis buffer or remained intact. The 
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intact cells were either washed with PBS or left unwashed. As determined 
earlier, the concentration of peroxynitrite at 100 µM gave the strongest 
nitrotyrosine signal and also 0-100 µM peroxynitrite are equivalent to its 
concentrations in vivo during oxidative stress and inflammatory conditions 
(Cobbs et al., 2001), therefore we used this concentration, mimicking the 
concentration at oxidative stress and inflammation, in our nitration study on the 
chosen cell lysates and intact cells. We found that BSA in serum in unwashed 
intact cells were readily nitrated. This further confirms that BSA is a readily 
nitrated protein and therefore is very suitable to use as a model protein for 
preliminary nitration work. In all nitration studies on the cell lysates and 
immunprecipitation work we found that at 100 µM peroxynitrite hardly any 
nitrotyrosine signals or just basal signals were obtained. Thus, optimisation for 
nitration conditions for the cell lysates such as using different lysis buffers to 
lyse cells need to be further explored.  
 
We then explored the effects of nitration on p53 protein levels using NO 
donor GSNO in MCF7 cancer cell line. The concentrations of NO that were 
released by GSNO are similar to those formed under intense inflammatory 
conditions (Chazotte-Aubert et al., 2000). GSNO (1 mM) has been shown to 
generate NO at the rate of 1 to 4 µmol/litre/min in culture medium with 10% 
foetal bovine serum (Wink et al., 1996). GSNO is not a strong nitrating agent 
itself in vitro, however, within the cell NO released from GSNO reacts with 
superoxide anion to form peroxynitrite, a strong oxidant and nitrating agent 
(Chazotte-Aubert et al., 2000). We found very weak nitrotyrosine signals in 0.5 
mM and 1.0 mM GSNO treated MCF7 cell lysates while moderate nitrotyrosine 
signals in 0.5 mM and 1.0 mM GSNO treated MCF7 cell lysates 
immunoprecipitated with CM-1. This indicates that p53 protein in MCF7 cells 
were nitrated at tyrosine residues following GSNO treatment. The levels of p53 
protein in 0.5 mM and 1.0 mM GSNO treated MCF7 cell lysates were almost 
similar to that of untreated MCF7 lysates. However, the p53 proteins were 
completely abolished in 0.5 mM and 1.0 mM GSNO treated MCF7 cell lysates 
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immunoprecipitated with mouse monoclonal anti-nitrotyrosine antibody. There 
are two possible reasons for this i) because the starting materials of p53 protein 
immunoprecipitated by CM-1 was low and/or ii) the degrading effect of GSNO 
resulted in the loss of p53 protein. Further studies need to be carried out to see 
the effects of other NO donors on p53 nitration and therefore its protein levels 
and also on p53 functions and activities such as on DNA binding activity of p53 
on its specific consensus sequence using electrophoretic mobility shift assay 
(EMSA), on the expression of p53-target genes such as those involved in cell 
cycle arrest (eg. p21, GADD4), apoptosis (eg. Bax, PUMA, NOXA), DNA repair, 
differentiation and senescence by employing reverse-transcription PCR (RT-
PCR) (expression at RNA levels), western blotting (expression at protein levels), 
or by luciferase reporter assay (co-transfection of a p53 construct with a plasmid 
containing a p53-response element fused with a luciferase gene), the effects on 
apoptosis and cell cycle regulation, protein-protein interactions with cellular 
proteins such as MDM2 and viral proteins by  immunoprecipitation studies and 
ELISA. 
 
Protein tyrosine nitration has been shown to occur under physiological 
conditions by the detection of 3-nitrotyrosine by analytical and immunological 
techniques (reviewed by Greenacre and Ischiropoulos, 2001). Nitration of 
tyrosine residues is a useful marker of the contribution of nitric oxide in oxidative 
damage (reviewed by Alvarez and Radi, 2003). Nitration may interfere with 
signaling cascades, since nitrated tyrosine residues cannot be phosphorylated 
(Gow et al., 1996; Kong et al., 1996). Protein tyrosine nitration is a selective 
process, which depends on the structure of the protein, the abundance of the 
protein and the number of tyrosine residues (Souza et al., 1999). In 
neurofilaments, tyrosine residues next to glutamate in amino acid sequence 
could be easily nitrated (Crow et al., 1997). In human p53 protein three 
tyrosines namely Y 205, Y 220 and Y 327 match these characteristics 
(Chazotte-Aubert et al., 2000). These tyrosine-glutamate sequences are located 
in the central DNA binding domain as well as in the tetramerisation domain of 
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p53 protein. Which tyrosine residues are nitrated in p53 protein and whether 
tyrosine nitration results in the activation or loss of p53 functions and activities 
need further elucidation. p53 tyrosine modification is dependent on the cell 
types, the redox state of the cells, the cell microenvironment which is variable 
and complex, the p53 mutational status, the p53 protein levels and localisation, 
the steady-state concentration and localisation of NO and its derivatives.  
 
On the present Pubmed search under the keywords “p53 nitration”, the 
results showed only 25 publications so far, though some are not directly related 
to our study, versus other modifications such as “p53 phosphorylation” (6180 
papers), “p53 acetylation” (1095 papers), “p53 ubiquitination” (1104 papers), 
“p53 sumoylation” (156 papers), “p53 neddylation” (28 papers), and also “p53 
methylation” (1913 papers) and none papers directly showed “MDM2 nitration”. 
It would seem that nitration work generally has become limited to big chemistry 
groups in the USA etc. (Dr Steven Picksley, personal communication). There 
are two contradictory findings about p53 protein modification by NO and its 
derivatives. Only a handful papers have shown that wt p53 protein was 
inactivated as a transcription factor through being made defective in its DNA 
binding activity as determined by gel shift assays and thereby resulted in 
dysregulation of its downstream pathways (Cobbs et al., 2001 & 2003). 8 of 9 
tyrosine residues of p53 protein are located in the central core DNA-binding 
domain where covalent modifications of these residues by NO possibly causes 
mutant p53 conformation or directly interferes with DNA binding residues. This 
was evident at high concentrations of NO where it inhibited p53 functions by 
altering its conformation and consequently impaired its DNA binding activity in 
vitro, in turn its function as a transcription factor (Ho et al., 1996; Calmels et al., 
1997; Chazotte-Aubert et al., 2000). A study by Salem et al. in the Department 
of Biomedical Sciences, University of Bradford, showed that peroxynitrite, a 
potent oxidising and nitrating derivative of NO, abrogated p53 binding to DNA 
but this effect was counteracted by exposure to hydrogen peroxide (H2O2). They 
confirmed this result by computer simulation which shows that in the native 
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structure of p53 protein there are 7 interacting residues of p53 that bind to DNA 
(Lys120, Ser241, Arg248, Arg271, Ala276, Cys277 and Arg289), however 
Arg248 and Cys277 are lost upon exposure to peroxynitrite, presumably due to 
the conversion of 8 tyrosine residues in the DNA binding domain of p53 to 3-
nitrotyrosine (Tyr103, Tyr107, Tyr126, Tyr163, Tyr205, Tyr220, Tyr234 and 
Tyr236) which causes severe conformational changes in the p53 protein 
structure and thus abrogates its DNA binding capacity. However, after H2O2-
mediated oxidation, a marked increase in DNA binding based on the increase of 
the number of amino acids interacting from 7 to 15 (Salem et al., 2009). On the 
contrary, most papers show that NO treatment of a variety of cells led to p53 
tyrosine nitration and enhanced its DNA binding activity, indicating that NO 
activates wt p53, however, the underlying mechanisms are still not known. It 
was reported that low concentrations of NO and its derivatives activate p53 
protein as a transcription factor due to the induction of DNA damage by NO 
(Forrester et al., 1996; Ho et al., 1996). Upon treatment of various cells with NO, 
either produced endogenously via induction of iNOS or exogenously supplied 
through NO donors, p53 became phosphorylated at serine 15 and accumulated 
in the nucleus due to attenuated nuclear export by NO resulting in the 
stabilisation and activation of p53 protein which as a result affects cell cycle 
progression and/or apoptosis (Schneiderhan et al., 2003). Yakovlev et al. have 
shown that p53 nitrated at tyrosine 327, which is located in the tetramerisation 
domain, promoted p53 oligomerisation, nuclear accumulation and transcriptional 
activity without p53 Ser15 phosphorylation at low NO concentrations (Yakovlev 
et al., 2010). NO has been shown in several different cell types to downregulate 
MDM2 protein levels resulting in the accumulation of p53 protein due to reduced 
p53 ubiquitination but extended NO exposure increased MDM2 protein levels 
due to p53-dependent induction of MDM2 gene (Wang et al., 2002). Activated 
p53 protein by NO in several cell types led to the induction of p53 target genes 
p21 and MDM2, both at mRNA and protein levels (Wang et al., 2002). NO has 
been shown to have both pro- and anti-neoplastic effects (Hussain et al., 2003 & 
2004). Peroxynitrite has been shown to induce apoptosis in HL-60 leukaemia 
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cells through the activation of multiple caspases mainly caspases 2, 3, 6 and 7. 
NO-induced apoptosis was the result of DNA damage and subsequent 
upregulation of p53 protein expression prior to apoptosis (MeBmer et al., 1994). 
NO induced p53 protein upregulation and apoptosis in a dose- and time-
dependent manners in several different cell types (MeBmer et al., 1994; Lee et 
al., 2006; Natal et al., 2008) and NO-treated cells resulted in a decrease in anti-
apoptotic Bcl-2 protein levels and an increase in pro-apoptotic Bax protein levels 
and also an increase in caspase-3 and -9 activities, both playing a major role in 
apoptosis (Natal et al., 2008). The specificity of the NO action was confirmed in 
that NOS inhibitors such as NMMA stopped inducible NO production as well as 
p53 protein expression and apoptosis (MeBmer et al., 1994). There is a close 
relationship, i.e. an autoregulatory feedback loop, between p53 and NO 
whereby upon treatment of cells with NO donors, p53 protein became 
accumulated in the nucleus (Messmer et al., 1994; Forrester et al., 1996; 
Messmer & Brune, 1996; Calmels et al., 1997; Chazotte-Aubert et al., 2000) and 
this was then followed by transrepression of transcription of iNOS mRNA 
expression (Forrester et al. 1996; Ambs et al., 1997; Chazotte-Aubert et al.; 
2000). This is one of the mechanisms whereby p53 safeguards the cells from 
the potential of NO-induced DNA damage other than its well established roles in 
cell cycle arrest and/or apoptosis. In summary, NO inhibits cell proliferation (by 
p53-mediated growth arrest) or induces apoptosis, however, negative and 
positive modulators of apoptosis strongly determine the susceptibility of cells to 
the toxic insult of NO and its derivatives (MeBmer et al., 1994). NO effects 
depend on many factors such as the microenvironment that is variable, complex 
and unpredictable so no firm predictions on how NO will modify a particular 
protein in the cell system (reviewed in Leon et al., 2008). 
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FUTURE STUDIES 
 
Provided that nitration of p53 protein is successful, the following studies should 
be further considered: 
 
i) To map p53 nitration sites by trypsin digestion, 2-D PAGE gels and 
Western blotting with an anti-nitrotyrosine antibody. This is to determine which 
tyrosine residues are nitrated and at which position. To assist mapping, a 
deletion series of the p53 protein will be generated. Separately, whether the 
amino acid analyser can be used to detect nitrated amino acids and whether 
this could be used to extend the range of amino acids beyond nitrotyrosine i.e. 
can we detect nitrophenylalanine and nitrotryptophan. Another indirect method 
of possible detecting nitrated residues is to ask whether nitration of p53 protein 
blocks the binding sites of a range of p53 antibodies. Having detected and 
confirmed nitrated residues on p53 protein, we will mutate these sites by site-
directed mutagenesis and to see whether residues on p53 protein affect its 
latent binding with DNA, and other transcription machinery. 
 
ii) Also to determine whether nitrated p53 protein affects its interaction with 
cellular proteins such as MDM2, viral proteins such as Adenovirus E1B and with 
its transcription machinery proteins by employing immunoprecipitation assay 
followed by Western blotting or by sandwich ELISA. MDM2 and AdE1B proteins 
will be produced as GST fusion proteins  expressed in E. coli. Nitrated p53 
protein and cell extracts containing either MDM2 protein or AdE1B protein is 
mixed. A monoclonal antibody DO-1 raised against human p53 protein is then 
added. If MDM2 protein or AdE1B binds to nitrated p53 protein, they will form an 
immune complex with the monoclonal antibody DO-1 and therefore will be 
pulled down by protein G Sepharose beads upon centrifugation. SDS-PAGE 
and Western blotting will then be carried out. The MDM2-GST or AdE1B-GST 
fusion proteins binding to nitrated p53 protein can also be determined by mixing 
the proteins together with Glutathione Sepharose which then pull down the 
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complex upon centrifugation. This is then followed by SDS-PAGE and Western 
blotting. This can also be done by using Biacore assay (real time, label-free 
detection characterisation and analysis of biomolecular interactions) or failing 
that simply by employing sandwich ELISA. 
 
iii) To check the effects of p53 nitration on its major roles in cell cycle 
regulation and apoptosis by employing flowcytometry and morphological 
detection of apoptotic cells by TUNEL assay, then verified by DNA 
fragmentation assay, and to a lesser extent on its role in DNA repair, 
differentiation and senescence. Apart from these analyses, regulation of genes 
responsible for these activities such as p21, GADD4 (cell cycle checkpoints), 
BAX, PUMA, NOXA (pro-apoptotic genes), Bcl-2, Bcl-xl, survivin (anti-apoptotic) 
and other p53-regulated genes can be determined by RT-PCR (mRNA 
transcript levels) or Western blotting (protein levels). Novel genes 
downregulated or upregulated by p53 protein nitration can be determined by 
employing microarray analysis. Expression or repression of highly significant 
regulated genes having distinct roles will then be verified by Real-Time PCR 
(qPCR). This is also to delineate established as well as novel signalling 
pathways involved in p53 nitration. Apoptosis can also be determined by the 
outer mitochondrial membrane permeability (OMMP) leading to mitochondrial 
dysfunction and collapse resulting in the release of cytochrome c from the 
mitochondria and subsequently the activation of common effector caspases 
such as caspase-3 and caspase-7, determined by using caspase 3/7 assay. 
The cleavage and activated caspases 3 and 7 can also be detected by Western 
blotting. In addition, luciferase reporter assay can also be used to confirm 
transcriptional induction of genes transcribed by nitrated p53 protein compared 
to its native p53 protein counterpart. 
 
iv) Proteomic studies can also be used to detect novel proteins being 
expressed which are associated with p53 protein nitration. Cell lysates from 
untreated control and nitrated samples will be used in order to compare total 
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protein expression profiling between the samples by employing two- 
dimensional gel electrophoresis (2-DE) by first subjecting the cleaned cell 
lysates to immobilised pH gradient (IPG) strips for isoelectric focusing (IEF) 
where the proteins are separated by their isoelectric points (pI) (1st dimension 
separation) and then followed by standard SDS polyacrylamide gel 
electrophoresis by which the proteins are separated according to their molecular 
weights (2nd dimension separation). These combined separations will give 
individual protein spots, also known as 2D map. The gels are stained with 
fluorescent dyes, Commassie Brilliant Blue staining or silver staining (the most 
sensitive staining) and differential in protein expressions and intensities between 
the gels are identified and the selected protein spots are excised and in-gel 
trypsin digested into smaller peptides before being subjected to mass 
spectrometry for peptide mapping or peptide mass fingerprinting by which the 
peptide sequence can be analysed using the protein databases such as 
ExPASY to identify and characterise the protein spots. This advanced 
proteomics technology thus can be used to identify protein biomarkers in 
nitrated samples compared to untreated control samples. In translational 
research, these novel protein biomarkers can be used in the clinical settings as 
early diagnosis and/or treatment response monitoring in human diseases 
particularly in specific types of cancers and inflammatory conditions. In addition, 
uniquely expressed proteins could be potentially useful targeted candidates for 
anti-cancer drug developments. If the main interest is just to look at specific 
tyrosine residues in p53 protein that are nitrated, after 2D electrophoresis, the 
gel is electroblotted and then probed with anti-p53 antibody. The different spots 
of p53 proteins can be processed by mass spectrometry to determine the 
specific amino acids that are modified, in this case nitrated. The Institute of 
Cancer Therapeutics (ICT), University of Bradford, has the facilities for the 
proteomics work. 
 
v) To determine the localisation of nitro-p53 protein compared to non-
nitrated native p53 protein and p53-regulated proteins in the nucleus or 
271 
 
cytoplasm by employing immunofluorescence and then confirmed by cell 
fractionation assay followed by Western blotting. The effects of nitration on p53 
protein stability in cultured cells can be followed temporally by adding protein 
synthesis inhibitor cycloheximide after treatment of cells with NO donors or 
peroxynitrite at certain concentrations or time points. 
 
vi) To check whether NO or its derivatives alone have effects on the cells 
viability by employing MTS assay, which is an improved version of MTT assay. 
Also to check whether NO or its derivatives can sensitise cancer cells to existing 
chemotherapeutic drugs or radiation. 
 
vii) Since we have the baculovirus p53 construct, it is worth to look at human 
p53 protein expressed in baculovirus for nitration study. Insect cells possess 
similar posttranslational modifications to mammalian cells permitting proper 
folding, disulphide bond formation, glycosylation, acylation and phosphorylation. 
p53 protein produced in this system is expected to be soluble, correctly folded 
and biologically active and relatively easy to purify. 
 
From all the above suggested further studies, it is worth noting and bearing in 
mind that, overall, the effects of p53 protein nitration depend on the cell types, 
p53 status, p53 protein levels, types of NO donors, doses of and time of 
exposure to NO and its derivatives.   
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